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Introduction and scope of this thesis 
Nanofilaments as novel artificial antigen-presenting cells: 
A promising approach towards efficient cancer immunotherapy
Loek Eggermont, Leonie Paulis, Jurjen Tel, Carl G. Figdor
Adapted from: Trends in Biotechnology, 2014, 32(9), 456-465
1
CHAPTER 1
8
Abstract
Active anti-cancer immune responses depend on efficient presentation of tumor 
antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with 
autologous natural APCs is costly and time-consuming, and results in variable 
outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has 
attracted significant interest as an alternative. We discuss the characteristics of 
various types of acellular aAPCs, and their clinical potential in cancer immunotherapy. 
The size, shape, and ligand mobility of aAPCs, and their presentation of different 
immunological signals, can all have significant effects on cytotoxic T cell activation. 
Novel optimized aAPCs, combining carefully tuned properties, may lead to efficient 
immunomodulation and improved clinical responses in cancer immunotherapy. 
Semi-flexible nanofilaments based on polyisocyanopeptides may therefore be particularly 
promising scaffolds for development of aAPCs.
Keywords: artificial antigen-presenting cell, synthetic dendritic cell, immunotherapy, 
cancer
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1.1   Towards efficient cancer immunotherapy: advances in 
developing artificial antigen-presenting cells
Advances in cancer immunotherapy
In cancer immunotherapy, the immune system is either passively or actively exploited 
to target and kill cancer cells. In this way, higher specificity for malignant cells may be 
achieved than with conventional cancer therapeutics. This approach thus avoids off- 
target toxicities while still inducing highly potent anti-cancer responses. By targeting 
tumor cells or their microenvironment, passive immunotherapy exploiting monoclonal 
antibodies has proven beneficial clinical effects in several malignancies [1,2]. In active 
immunotherapy, immune cells are stimulated and instructed to actively fight cancer 
and, although more challenging, this approach is extremely promising. Active immuno - 
therapy is highly dependent on efficient stimulation of antigen-specific immune cells, 
such as killer T cells and antibody-producing B cells. In adoptive T cell transfer, isolated 
autologous tumor-specific T cells are expanded ex vivo and, after sufficient stimulation, 
are re-infused into the cancer patient, where these cells are expected to elicit potent 
anti-tumor responses (Figure 1, gray arrows) [3].
 A more recent trend in adoptive T cell transfer exploits molecular biology approaches 
to create more active T cells with higher target affinities and prolonged lifetimes 
(Figure 1, green arrow). For this purpose, T cells have been constructed that express 
transgenic T cell receptors (TCRs) with increased affinity for their peptide-major 
 histocompatibility complex (MHC) complexes, or chimeric antigen receptors that can 
target antigens independent of MHC through antibody-derived ligand binding 
domains. Engineered T cells have been clinically applied and show good results, but 
several issues need to be addressed, including on-target and off-target toxicities, 
undesirable immune responses to chimeric antigen receptors and engineered TCRs, 
and the possibility of transformation, either because of virus-related insertional 
mutagenesis or due to misguided T cell lifetime engineering. Furthermore, engineered 
T cells do not differentiate into memory cells, and therefore no immunological 
memory is created. These fundamental issues need to be resolved before engineered 
T cells can be broadly implemented as anti-cancer therapy [4,5].
 In vivo, induction of T cell responses is highly dependent on interactions with 
professional antigen-presenting cells (APCs), in particular dendritic cells (DCs), which 
present tumor-specific antigens. Therefore, to induce in vivo T cell activation, cancer 
patients are vaccinated with APCs [6]. In contrast to engineered T cells, these 
approaches make use of physiological interactions, which minimizes the risk of 
serious adverse side effects. Natural APCs, in particular DCs, are well equipped to 
induce efficient activation and expansion of tumor antigen-specific naïve T cells, 
which can lead to induction of large populations of T cells, including CD8+ cytotoxic T 
lymphocytes (CTLs) that can kill cancer cells (Figure 1, blue arrows). Several studies 
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now indicate that the use of natural APCs in cancer treatment is associated with a 
beneficial clinical outcome with minor adverse side effects, emphasizing the promise 
of active immunotherapy [3,6–8]. 
 Unfortunately, the use of natural APCs such as DCs over the years has also 
highlighted several serious limitations. Lack of knowledge of the optimal antigen- 
loaded DC combined with deleterious effects of immunosuppressive factors in the 
tumor microenvironment may be responsible for the mixed results that observed 
in clinical trials [9–12]. In addition, isolation and ex vivo stimulation of autologous 
DCs proved time-consuming and expensive, and the quality of ex vivo-generated DCs 
can be variable [9,13,14]. The use of patient-derived, autologous DCs therefore limits 
standardization of DC-based treatment protocols [9,14]. 
Figure 1  Different strategies for active cancer immunotherapy. T cell activation can be induced 
either ex vivo or in vivo by autologous DCs (blue arrows), aAPCs (red arrows), or by engineering 
of T cells through transgenic delivery of TCRs and life-time engineering, for example using 
small molecule inhibitors (green arrow). Ex vivo-activated autologous T cells can be adoptively 
transfered into patients (grey arrows), to specifically kill cancer cells. Alternatively, injection 
of APCs can lead to in vivo aAPC immunotherapy without the need for autologous cell cultures 
(red arrows).
DC 
T T 
T T T 
T T 
aAPC
 
aAPC 
 
DC 
Isolation 
Isolation 
Reinfusion 
Antigen 
loading  
Activation 
and 
expansion 
Reinfusion 
Injection 
T cell 
engineering 
1INTRODUCTION AND SCOPE OF THIS THESIS
11
Artificial APCs for T cell activation
To overcome the disadvantages and difficulties in using autologous APCs, artificial 
APCs  (aAPCs) have been developed as an alternative for both ex vivo and in vivo 
induction of tumor-specific CTLs (Figure 1, red arrows) [15,16]. Whereas natural APCs 
may be influenced by the tumor microenvironment and unknown signaling moieties 
may be present on their surface, artificial presentation of antigens allows for better 
defined systems with more control over the signals presented. Furthermore, the use of 
aAPCs does not require time-consuming and expensive cell-culture strategies and 
can be developed into an off-the-shelf technology [14,15]. However, aAPCs are not 
equipped with a machinery to actively migrate into tissues. In this review, advances 
in aAPC development are discussed for both ex vivo and in vivo application in cancer 
immunotherapy.
Cell-based aAPCs 
Genetically modified xenogeneic or allogeneic cells, such as Drosophila cells, murine 
fibroblasts, and human erythroleukemia cells, have been used as aAPCs [17–19]. These 
cells are easier to handle and are better defined than DCs, allowing for more control 
over the delivered signals. In addition, cellular aAPCs are stable cell lines that can be 
stored for extended times and as such can thus be obtained from a readily accessible 
source [16]. However, a major disadvantage is their allogeneic nature. The use of 
human cell-based aAPCs has recently been extensively reviewed, so this review is 
restricted to the use of acellular aAPCs for active cancer immunotherapy [20].
Acellular synthetic aAPCs for efficient expansion of CTLs
Although cellular aAPCs can induce high expansion rates of CD8+ T cells, they do not 
easily allow for specific control of expression levels of T cell-activating signals. In 
addition, non-tumor antigens and other stimulatory or inhibitory molecules may be 
present on cellular aAPCs [13,21]. To better define the delivery of distinct signals, red 
blood cells have been used as scaffolds to chemically introduce T cell stimulatory 
proteins [22]. To circumvent the use of allogeneic cells altogether, acellular aAPCs have 
been developed. Compared to cellular aAPCs, acellular aAPCs allow for a more 
stringent control over the signals delivered and are attractive tools because of their 
relatively easy preparation. These synthetic entities can be designed to be either 
non-specific or antigen-specific by presenting T cell-activating antibodies (such as 
anti-CD3) or peptide-MHC complexes, respectively. In general, aAPCs approaches have 
focused on induction of CD8+ CTLs through MHC I stimulation, because these cells are 
capable of antigen-specific tumor cell lysis. Other immune cells, such as CD4+ T helper 
cells, can assist in shaping the anti-cancer immune response by helping in the 
activation of CTLs. Therefore, efforts have also been made, albeit to a lesser extent, to 
activate these cells via MHC II. Artificial APCs comprising various sizes, surface ligand 
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distributions, ligand mobilities, and shapes have been developed, and these properties 
can all affect T cell activation. The wide variety of acellular aAPC structures (Figure 2, 
Table S1) reflects different attempts to mimic different aspects of natural DCs.
Rigid spherical microsized aAPCs 
To mimic natural APCs, several cell-sized, rigid, bead-based aAPCs have been developed. 
Because of their homogenous size distribution and straightforward functionalization, 
these beads have been extremely useful in determining the various signals necessary 
for T cell activation. In addition, these more simplistic systems have been used to 
induce T cell activation for clinical purposes [16].
Figure 2  Different types of synthetic aAPCs. (A) rigid spherical particles (1. polystyrene latex 
microbeads, 2. magnetic nano- and microparticles, 3. nanosized quantum dots and 4. PLGA 
microspheres) (B) Non-spherical particles (5. carbon nanotube bundles, 6. ellipsoid PLGA micro- 
particles and 7. nanoworms) and (C) Fluidic lipid bilayer-containing systems (8. 2D-supported lipid 
bilayers (2D-SLBs), 9. liposomes, 10. RAFTsomes/microdomain-liposomes and 11. SLB-particles).
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Latex microbeads
To induce T cell expansion, spherical polystyrene beads can be coated with antibodies 
against CD3 and CD28. It was shown that T cell activation was optimally induced by 
microbeads ranging in size between 4 and 5 µm [23]. Ligand density and bead size, 
rather than the amount of beads, were important parameters for T cell activation. 
However, these non-specific particles could only induce long-term proliferation of 
CD4+ helper T cells, and did not support the growth of CD8+ CTLs for extended culture 
periods, indicating that CD8+ T cells require additional stimulation to maintain their 
effector functions [24]. Furthermore, anti-CD3 stimulation has been associated with a 
loss of antigen specificity when expanding enriched CD8+ T cell populations [19]. 
These reported problems can be avoided by replacing anti-CD3 with specific 
peptide-MHC complexes in combination with co-stimulatory signals [25]. 
 These beads were successfully used to produce large numbers of functional 
antigen- specific CTLs against different targets, including melanoma antigens TRP-2 
and Mart-1 [16,26]. To induce long-term expansion of CD8+ T cells using latex 
microbeads, cells require the presence of IL-2. It was recently demonstrated that IL-2 
may also be replaced by IL-21 or a combination of IL-15 and IL-21, which leads to unique 
functional CTL phenotypes [27,28]. Improved stimulation of T cells can also be achieved 
by coating beads with anti-4-1BB or 4-1BBL, ICAM-1, and CD83 [26,29,30]. 
 A single peptide-MHC complex has a low intrinsic affinity for its specific TCR [31]. 
To enhance this affinity, multimers of MHC complexes have been developed, such as 
human leukocyte antigen (HLA) tetramers [32–34]. In addition, IgG-HLA dimers, 
which consist of IgG molecules containing two MHC complexes that can be easily 
uploaded with any desired antigen, have been developed. In this way, aAPCs can be 
made antigen-specific by uploading IgG-HLA dimers with any desired epitope [35]. 
Dimers have also been applied to synthetic nanoparticles, including dextran-coated 
iron oxide magnetic particles (50-100 nm) and dextran-coated quantum dots (30 nm). 
Although previous research using bead-based systems indicated only very low T cell 
activation below 3 µm [23], these nano-aAPCs showed improved in vivo efficacy 
compared to microsized beads. Although first studies demonstrated that these 
particles exhibited similar or even improved ex vivo T cell activation, the same group 
later showed better activation for micro-aAPCs using this type of particle [36], which 
is in accordance with previous literature [23]. Their ability to stimulate T cells despite 
their small size may be attributed to the use of IgG-MHC, which contains a flexible 
hinge region [37]. In general, it is thought that microbeads are better suited to 
stimulate T cells because, owing to the lower curvature of their surface, a microbead 
can make more interactions with the cell than a nanosized spherical bead. Recently, 
this was demonstrated by directly comparing different nano-and microparticles as 
pMHC/anti-CD28-presenting aAPCs for CD8+ T cell activation. Cell-sized microbeads 
only require 3 pMHC per T-cell for efficient activation, whereas particles of 300 and 
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600 nms need about 200 pMHCs per T-cell, demonstrating that particle concentration 
and ligand density are important parameters for efficient activation. With sufficient 
ligand density, these nanoparticles can stimulate TCR signaling microclusters, whereas 
microbeads can probably trigger multiple clusters simultaneously. At the same time, 
50 nm aAPCs require more than 10.000 pMHCs per T cell and can only efficiently 
stimulate T cells in saturating conditions, owing to the fact that only single TCRs are 
targeted by this type of particle. Thus, 300-nm nanoparticles can be developed into 
efficient nano-aAPCs, but are not as efficient as cell-sized microbeads [38].
Polystyrene-coated magnetic microbeads
Because polystyrene particles are not biodegradable and may be toxic or induce 
embolisms in vivo, they must be removed from the CTL population before ex vivo- 
expanded T cells are infused into patients [9]. For this purpose, microsized magnetic 
latex-coated beads have been developed by coating an iron oxide core with polystyrene, 
which allows for straightforward removal of aAPCs by magnetic depletion before 
reinfusion of CTLs. These beads were initially coated with anti-CD3 and anti-CD28 
for nonspecific CD4+ T cell amplification [39]. Again, replacement of anti-CD3 with 
peptide-MHC complexes results in antigen-specific T cell expansion [32]. Similar to the 
nonmagnetic latex beads, these particles can be easily prepared and are readily 
available [9].
 Importantly, T cells expanded ex vivo using anti-CD3/anti-CD28–coated magnetic 
beads have been applied in Phase I clinical trials in patients with metastatic breast 
cancer, chronic myeloid leukemia and carcinomas. Although infusion of expanded 
CTLs resulted in mixed anti-tumor responses, in some cases bead-expanded cells 
induced tumor regression or even complete remission, indicating that adoptive T cell 
transfer using bead-based aAPC-expanded T cells could be an effective cancer 
treatment. However, these trials also showed a risk of developing non-tumor specific 
cytotoxicity or graft versus host disease [40–43].
Biodegradable poly(lactic-co-glycolic acid) microparticles
Bead-based aAPCs can provide strong proliferative signals to CD8+ T cells. Natural 
APCs provide a third signal (Box 1, Box 2), besides MHC-mediated antigen presentation 
and membrane receptor-based co-stimulation, in the form of soluble secreted 
cytokines. CD8+ T cells require continuous paracrine delivery of cytokines such as IL-2 
during the first few hours for proper activation, and these are initially provided by 
APCs and later by CD4+ helper cells. Besides paracrine delivery, trans-presentation of 
IL-2 on CD25 also plays an important role in initial activation of naïve T cells [44]. 
At later time points, CTLs also require cytokine stimulation to maintain proliferation, 
but high IL-2 concentrations and exposure for extended times may negatively impact 
T cells [45]. When using polystyrene beads, cytokines have to be added to the culture, 
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leading to high overall concentrations and possible side effects due to co-injection of 
IL-2 during reinfusion of T cells into patients [9]. Implementation of mechanisms that 
allow for paracrine cytokine release by aAPCs may therefore further improve their 
potential to activate and differentiate T cells. In particular, cytokine release may be 
essential for the development of functional CD8+ T cells that can generate potent 
immune responses. This may be the one most important characteristic of an aAPC.
Box 1  Signals for T cell activation
Activation signal 1 – antigen recognition
T cell activation occurs after a T cell receptor (TCR) recognizes a specific peptide antigen 
presented on MHC complexes of an antigen-presenting cell. In general, extracellular peptides 
are presented on MHC class II, which is recognized by the TCR in conjunction with the CD4 T 
cell co-receptor, while MHC class I carries peptides derived from intracellular proteins and 
are recognized by the TCR in conjunction with a CD8 T cell co-receptor. Ligation of the TCR by 
a peptide-MHC complex or binding of agonistic antibodies directed towards CD3 leads to 
activation of the CD3 signal-transduction complex, which transduces essential signals 
necessary for activation of the T cell.
Activation signal 2 – Co-stimulation
In order to become fully activated, T cells require a second signal next to TCR-mediated 
antigen recognition. This antigen independent signal is provided in the form of co-stimulatory 
molecules that are upregulated on the antigen-presenting cells when they encounter stress, 
infection or cellular damage. These molecules can interact with receptors on the T cell, of 
which CD28 is the best studied. This receptor interacts with the co-stimulatory molecules 
B7-1 (CD80) or B7-2 (CD86) on the APC, which can also transduce inhibitory signals by ligation 
of CTLA4 on the T cell. Other co-stimulatory receptors on T cells include Inducible 
co-stimulator (ICOS), CD27 and 4-1BB (CD137), which bind to ICOS-L, CD70 and 4-1BBL, 
respectively.
Activation signal 3 - Cytokines
T cell activation and differentiation can be further directed through binding of cytokines to 
cytokine receptors. These cytokines can be produced by either the APC or CD4+ T helper cells 
and, especially for CD8+ T cells, are essential for cell survival and productive immune 
responses. IL-2, the most important cytokine for CD8+ T cell survival, is secreted in low 
amounts by APCs during initial T cell encounter and is produced in larger amounts by 
activated CD4+ T cells. Other cytokines that can assist in T cell activation include IL-12, IL-15, 
IL-21 and type I interferons (IFNα/β). Especially IL-12 and IFNα/β seem to be essential for 
effective T cell function. In addition to immunostimulatory cytokines, immunoinhibitory 
cytokines such as IL-4, IL-5, IL-10 are capable to dampen the immune response or can lead to 
tolerance. Therefore, signal 3 is regarded most important in shaping the immune response.
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Box 2  Signal transmission by APCs
To efficiently induce tumor-specific CTLs, several signals need to be transferred from APCs to 
naïve T cells (Figure I). Antigen recognition represents the first signal, which occurs through 
the interaction of specific T cell receptors (TCRs) with peptide-major histocompatibility 
complexes (MHC) on APCs. APCs can contain two different types of MHC complexes. MHC 
class I molecules present antigens derived from intracellular proteins and bind to T cells 
expressing the CD8 co-receptor, while MHC class II molecules, which present extracellular 
peptides, can bind to CD4+ T cells. Activated CD8+ T cells, or CTLs,  are capable of antigen- 
specific cell lysis, whereas CD4+ T cells, known as T helper cells, release cytokines to stimulate 
CTL activation and antibody production by B cells. In artificial systems, peptide-MHC 
complexes can be replaced by antibodies binding the CD3 subunit of the MHC complex, 
which leads to non-antigen specific T cell activation. Besides signal 1, a second signal, 
co-stimulation by APC cell surface molecules, is passed on to the naïve T cells. This co- 
Figure I  Different signals leading to induction of T cell activation and expansion.
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To facilitate release of cytokines or other soluble factors from aAPCs, biodegradable 
systems have been developed. These biodegradable aAPCs present signals on their 
surface, similar to polystyrene particles, but now this is combined with a slow release 
of IL-2 or other soluble molecules of interest. Particles composed of the biodegradable 
co-polymer PLGA have been extensively applied in slow release systems. Although it 
can be challenging to stably present molecules on the surface of biodegradable PLGA 
particles owing to loss of surface-bound molecules as the particle degrades [15], 
incorporation of avidin-palmitate conjugates facilitated incorporation of all three 
signals in one aAPC [46,47]. Surface ligand presentation of these IL-2 releasing particles 
was stable for 20 days, and they led to significantly higher induction of IFNγ secretion 
by murine and human T cells compared to magnetic beads in the presence of soluble IL-2 
and reached peak activation profiles at lower aAPC concentrations [47]. Furthermore, 
it was shown that this paracrine release by aAPCs, in contrast to exogenous addition, 
can induce local accumulation of IL-2 near the contact area with the T cell, thereby 
significantly altering the activation and proliferation of CD4+ and CD8+ T cells, leading 
to apoptosis of CD4+ T cells and enhanced proliferation of CD8+ killer T cells [45,48]. 
It is likely that the high synaptic concentration that results from paracrine IL-2 
delivery can be detected by the low-affinity IL-2 receptor, which is constitutively 
expressed by T cells. After 24 hours of antigen stimulation, T cells can also express the 
high-affinity IL-2 receptor, and lower amounts of IL-2 may be needed [45]. Similar to 
latex beads, PLGA particles of 6-10 µm in size were most effective inducers of T cell 
activation and expansion ex vivo [47]. Slow release of anti-CTLA4- antibodies together 
with IL-2 further boosts activation of T cells by biodegradable microparticles [49]. 
 Cytokines are essential for induction of potent CD8+ T cells (Box 3), but it is difficult 
to design non-biodegradable aAPCs, such as latex microbeads, capable of releasing 
cytokines for extended periods of time. To circumvent this problem, cytokines may be 
presented by surface receptors similar to CD25, as also occurs on DCs [44]. However, 
It is questionable whether sufficiently high concentrations of cytokines will be 
available. Alternatively, agonistic antibodies may be used, which could also be bound 
stimulation is necessary for proper T cell activation. CD80 and CD86, which bind to CD28 on 
T cells, are the most prominent co-stimulatory signals. Additional co-stimulatory molecules, 
such as 4-1BB and CD83, are also expressed on APCs. Finally, to induce more efficient 
expansion and specific differentiation of T cells, immune cells release cytokines, such as IL-2, 
IL-15 and IL-21, which can be seen as the third signal. Additionally, T-cell-APC interactions are 
guided by adhesion molecules. Important adhesion molecule interactions include those of 
ICAM-1 (CD54) and LFA-3 (CD58) on APCs binding to LFA-1 and LFA-2 on T cells, respectively. 
Similar to natural APCs, the success of aAPCs depends to a great extent on the efficient 
presentation of these different signals to naïve T cells [6,9,15].
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to non-biodegradable aAPC structures. So far, only biodegradable aAPCs have been 
used for cytokine delivery, which may induce a more natural response via paracrine 
delivery. However, it should be noted that because of their biodegradable nature, these 
aAPCs might release their stimulatory surface molecules, which may influence their 
efficacy for T cell activation.
Importance of ligand mobility and pre-clustering for T cell activation
Although rigid spherical beads can be efficiently used for T cell stimulation, the 
membrane of natural APCs is much more dynamic than the outer surface of latex- 
coated and PLGA particles. To more closely mimic natural systems, lipid bilayer 
surfaces and liposomes have been used as aAPC, thereby demonstrating a significant 
effect of membrane fluidity and receptor pre-clustering on T cell activation.
2D surface membrane mimics
The immunological synapse (IS) was originally identified as a membrane structure of 
approximately 70 µm2 that forms upon APC-T cell contact and consists of peptide-MHC 
complexes interacting with TCRs, surrounded by a ring of interacting adhesion 
molecules. More recent research indicates that this is a dynamic structure, which is 
Box 3  Cytokine delivery for T cell activation
Inflammatory cytokines are essential for the survival (in particular IL-2), proliferation and 
functional differentiation of CD8+ T cells. However, most aAPCs are not capable of releasing 
sufficient cytokine levels and require the addition of additional cytokines in cell cultures, 
which may not be as effective as either paracrine delivery or trans-presentation (by CD25) by 
antigen-presenting cells [44]. This underscores the importance in incorporating cytokine 
release systems in aAPC designs. Since IL-2 may also induce regulatory T cells that inhibit 
immune responses, additional cytokines are required to further induce effective T cell 
responses and avoid tolerance (non-responsive T cells). Therefore, development of aAPCs that 
deliver other soluble factors, or can trigger cytokine receptors in different ways (for example 
by using antibodies), could lead to major improvements in T cell survival and function. 
Interesting candidates include IL-12 and type I IFN, usually produced by DCs, which are 
responsible for prolonged T cell survival. These cytokines are necessary for memory T cell 
development and strong effector function of CD8+ T cells. Another interesting combination 
of cytokines is the combination of IL-15 and IL-21. IL-15, which are similar to IL-2, but do not 
lead to CD8+ T cell apoptosis. These cytokines have been used to rescue tumor-reactive CD8+ 
T cells in vivo [120]. In addition, IL-21 was demonstrated to act in synergy with IL-15 [28]. 
Additional cytokines, such as IFNγ and IL-7, can be secreted by the T cell itself or by stromal 
cells in the lymph node and may therefore not be essential for aAPC mediated delivery.
1INTRODUCTION AND SCOPE OF THIS THESIS
19
formed after TCRs cluster together in microclusters that eventually move towards the 
IS centre. It was recently shown that TCR-containing vesicles excreted within the IS 
are also important for signal transmission [50]. In general, efficient CD4+ and CD8+ 
T cell activation is associated with the formation of a functional IS [51]. Synthetic 2D 
cell-surface mimics have played an important role in the elucidation of the structure, 
function, and mechanisms of IS formation [51]. Planar membrane surfaces can easily 
be functionalized with various ligand compositions and allow for the use of high- 
resolution microscopy techniques, making it an attractive tool to study cell membrane 
interactions [52]. 
 To examine the effect of membrane fluidity on synapse formation and T cell 
activation, lipid bilayers can be deposited on glass surfaces to form supported lipid 
bilayers (SLBs). Variation of the membrane fluidity of these lipid bilayers revealed that 
more fluid membranes are better capable of forming ISs, leading to improved CD4+ T 
cell activation compared to more rigid membranes [53]. In addition, 2D surface 
patterning has been used to study the effect of spatial organization of anti-CD3 and 
anti-CD28 on CD4+ T cell activation. Lithographic definition of the positions of proteins 
on a surface revealed that spatial organization is important for efficient IS formation 
and thus for T cell activation [54]. T cell responses were most efficient when co- 
stimulating molecules (anti-CD28) surrounded anti-CD3 compared to other organizations 
[54,55]. Incorporation of protein patterns onto aAPCs may therefore provide a new 
level of control over T cell proliferation [56]. Although there may be small differences 
between ISs of CD4+ and CD8+ T cells, the general organization and dynamics are 
similar between the various T cell subsets [57]. Rigid nanopatterned surfaces have 
also been useful in determining optimal ligand densities  needed for optimal 
stimulation of T cells. In this way, it was established that distances between anti-CD3 
or peptide-MHC ligands need to in the range of 30-100 nm to induce T-cell stimulation, 
with higher densities showing more potent responses [58–60].  
 Although synthetic 2D cell surfaces, and in particular the 2D-supported lipid 
bilayers (2D-SLBs), were useful in clarifying the mechanisms of T cell activation, at 
present they are less suitable as ‘off-the-shelf’ aAPCs owing to their fragility and 
limited lifetime [56]. Furthermore, it should be noted that most cell-surface membrane 
mimics used to date lack organizers, such as a cytoskeleton, which play an important 
role in the distribution of transmembrane molecules, usually resulting in a non- 
random distribution but rather organization into microdomains, whereby groups of 
surface receptors are clustered together. 
Liposomes, RAFTsomes and microdomain-liposomes
To facilitate T cell activation in a more natural context similar to the fluid membrane 
interactions of natural APCs and T cells, MHC-containing liposomes have been 
generated. Phospholipid bilayer vesicles with randomly distributed peptide-MHC 
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complexes have been used mainly to study the physiological mechanisms of CD4+ T 
cell activation [61,62], but have not extensively been used as aAPCs [16,61]. 
 It has been shown that pre-clustering of peptide-MHC complexes in lipid raft 
microdomains on APCs dramatically increases their antigen presentation efficacy 
[63]. It is likely that this allows for better docking to their counterpart TCRs on T cells, 
which are initially also distributed as microdomains. Therefore, liposomes have been 
designed containing lipid raft microdomains with pre-clustered MHC complexes, 
which aids in IS formation. These liposomes, also known as RAFTsomes, can be made 
by incorporating DC-derived lipid rafts in liposomal phospholipid bilayers [64]. 
However, at present these RAFTsomes are not as efficient as natural DCs or other 
aAPCs in stimulating CD4+ T cell proliferation [64], probably because they lack a cyto-
skeleton-mediated surface organization. Another method of pre-clustering molecules 
on liposomes makes use of ganglioside GM1-containing liposomes. A high density of 
ligands can be created by taking advantage of the high affinity of the cholera toxin B 
subunit for GM1, which is a component of lipid rafts. These microdomain aAPCs have 
been used for ex vivo T cell activation studies, and showed improved antigen-specific 
CD4+ T cell stimulation compared to liposomes with randomly distributed MHC 
molecules [65]. Importantly, it has been shown that these aAPCs are better equipped 
to stimulate CD8+ T cells compared to magnetic beads, leading to higher numbers and 
more efficient CTLs specific for MART-1 in melanoma skin cancer [66].
  
3D-supported lipid bilayers (3D-SLB)
Although the fluidity of liposomes is a great advantage for T cell stimulation, they are 
substantially less stable than solid particles. This problem may be solved by using 
solid particles as a scaffold for a lipid bilayer. These SLB-particles combine the fluidity 
of liposomal bilayers with advantageous properties of solid particles, such as their 
high stability [15]. Several 3D-SLBs have been constructed, including lipid bilayers on a 
core of hydrogel, PLGA, or silica [67–69]. Using cell-sized silica beads coated with a 
lipid bilayer, it was shown that 3D-SLBs can boost CTL responses in antigen-primed T 
cells more efficiently than liposomes. By contrast, 3D-SLBs were not able to initiate 
primary T cell expansion, probably due to lack of soluble factors such as IL-2 [70]. In 
another approach, lipid bilayers were isolated from Ag-bearing cells and adsorbed 
onto latex microspheres. Perhaps cytoskeleton-organized microdomains might be 
grafted onto these latex spheres, but no significant change in T cell activation was 
observed when compared to rigid latex beads [23]. Alternatively, tumor-cell derived 
plasma membrane vesicles have been deposited on both silica and latex microbeads, 
leading to large multivalent immunogens, which have an increased immunostimu-
lating activity compared to the nanosized tumor-derived vesicles [71]. Although the 
use of 3D-SLBs is a promising approach, most recent reports have been made on SLBs 
that need membranes extracted from tumor cells for T cell activation. Recently, 
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magnetic nanoparticles coated with fragments from leukocyte membranes and 
chemically modified with stimulatory ligands were established as efficient aAPCs. 
These magnetosomes can efficiently activate T cells, and also for these particles, 
membrane fluidity played an important role, since pre-crosslinking the membrane 
significantly decreases their stimulatory capacity [72].
Solid microbeads
Instead of using complex 3D-SLBs, making aAPCs out of softer materials can be an 
effective alternative to the classic rigid microbeads. T-cell stimulation with anti-CD3- 
and anti-CD28-coated PDMS surfaces or beads can provide an extended proliferative 
phase, especially for scaffolds with lower stiffness [73,74]. In contrast to results obtained 
with PDMS, experiments on polyacrylamide gels show that higher rigidity is beneficial for 
efficient T-cell activation. On these gels it was also demonstrated that TCR signalling is 
mechanoresponsive and that cytoskeletal contractility plays an important role in this 
process [75],  Possibly, local surface shape and nanoscale rigidity of PDMS surfaces 
could account for the different responses observed for these different materials [74].
 As was described above for 2D surfaces, stimulating T cells using surfaces with 
defined ligand orientations can also improve responses. To implement this knowledge 
in an aAPC design, a variety of Janus particles, particles that have two or more surface 
areas with distinct functionalities, have been developed. In this way, the bull’s eye 
pattern of the immune synapse can be mimicked. Interestingly, improved T cell 
responses were observed after stimulation with ‘reversed IS’ patterned beads that 
contain a patch of integrin ligands surrounded by stimulatory anti-CD3 antibodies 
[76]. Furthermore, two-faced magnetic Janus microparticles have also been used to 
remotely control the onset of T-cell stimulation by rotating these particles in a 
magnetic field [77]. In addition, nano-Janus particles have further highlighted the 
importance of high local ligand densities on nanosized aAPCs [78].
Importance of aAPC shape 
Most aAPC systems use spherical particles to stimulate T cells. However, natural APCs, 
especially DCs, are not spherical, and therefore the aAPC shape may be modified to 
increase the contact area with T cells. It will be interesting to design and test differently 
shaped particles and examine nanoclustering of ligands. This may assist in more 
efficient TCR nanoclusters on the T cell surface. As described below, shape appears to 
be an important parameter for T cell activation that should be taken into account 
when designing aAPCs.
Ellipsoid PLGA microparticles
Besides spherical forms, PLGA-based microparticles have also been used as non-spherical 
particles [47]. To closely mimic the natural situation and increase the particle contact area, 
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ellipsoid PLGA-based aAPCs were prepared using film-stretching methods [79,80]. 
Interestingly, particle shape had significant effect on the stimulation of T cells by 
aAPCs. Elongated particles with a more ellipsoid shape were more efficient as aAPCs 
than spherical particles and can induce stronger CD8+ T cell proliferation. These findings 
may be explained by the fact that T cells have more and larger biomimetic interactions 
with these aAPCs, thereby favoring the flatter, longer side of the ellipse, which may 
provide a larger IS-like contact area [80]. Similarly, ellipsoid nano-particles induce 
stronger antigen-specific T cell activation compared to their spherical counterparts. 
In addition, stretched particles exhibit reduced non-specific uptake by macrophages [81].
Carbon nanotube bundles
To both increase the surface area of particles and facilitate more options for surface 
modifications, single-walled carbon nanotubes have been used for efficient T cell 
stimulation [82]. Using anti-CD3-coated tubes, large surface particles evoked higher 
aspecific T cell activation and IL-2 production than polystyrene beads. These 
functionalized nanotubes appear to cluster into large microsized aggregates with a 
high surface area, perhaps mimicking cell-surface microdomains [82]. As already 
demonstrated for fluid membranes and microdomain liposomes, nanopatterning is 
an extremely important issue that deserves further study to improve aAPC-mediated 
T cell activation. Chemical modification of nanotubes might also lead to a local 
clustering of antibodies on their surfaces, with a positive effect on T cell activation. 
Furthermore, this modification causes the nanotubes to have a negative surface 
charge, resembling that of natural APCs, which might also help in interactions with T 
cells [83]. It was recently demonstrated that peptide-MHC complexes can also be 
stably linked to nanotubes, which makes it possible to use these aAPCs for anti-
gen-specific T cell stimulation [84]. By combining a large surface area for interaction, 
pre-clustered antibodies and a negative surface charge, these carbon nanotube 
bundles seem extremely potent for ex vivo T cell activation [82].
Nanofilaments
Lipid bilayer aAPCs have shown that membrane fluidity, which allows ligand motility, 
positively affects T cell activation. In addition, the shape of particles appears to have a 
great influence on this process, resulting in enhanced responses when T cells have a 
larger contact area and can thus better fit onto the aAPCs. A novel promising approach 
incorporates both of these features into an aAPC system exploiting so-called nanoworms, 
composed of semi-flexible filamentous polymers comprising poly(isocyano dipeptides) 
(PICs) with oligoethylene oxide side chains, which can be decorated with molecules 
for antigen presentation and co-stimulation in a highly controlled fashion [85]. In this 
thesis, PIC-protein conjugates are developed to form a potent new class of aAPCs, 
called synthetic Dendritic Cells.
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aAPC development for active in vivo immunotherapy 
Ex vivo expansion and subsequent injection of autologous CTLs is one approach for 
induction of anti-tumor immune responses. However, the survival and function of 
these cells can be highly variable after reinfusion into patients [34,86,87]. In addition, 
the culturing of autologous T cells is a time-consuming, labor-intensive and costly 
procedure [88]. Alternatively, to avoid the use of autologous cells, aAPCs can be 
administered directly into patients to stimulate CD8+ T cell responses in situ, allowing 
for true ‘off-the shelf’ cancer immunotherapy.  
 When considering in vivo T cell targeting through injection of aAPCs, several 
additional properties, besides high T cell stimulation, should be taken into account, 
including the pharmacokinetics and biocompatibiliy of these systems. Therefore, 
optimal size, surface modifications, shape and targeting moieties have been 
extensively investigated for biomaterials used in drug delivery [80,89–92]. 
 Several aAPCs have been tested for in vivo induction of tumor cell killing through 
CD8+ T cell expansion. To the best of our knowledge, one of the first in vivo aAPC 
 immunotherapies was performed in mice using silica microspheres bearing either 
peptide-MHC class I complexes or covered with tumor cell membranes [70]. In mice, 
these aAPCs could not induce immune responses on their own, but were able to 
augment responses in the presence of antigen-bearing stimulator tumor cells, which 
could not be achieved by using liposomes as aAPCs [93]. In combination with the 
 chemotherapeutic agent cyclophosphamide, these particles induced regression of 
established progressing tumors in mice [94]. Variable success was observed for these 
large multivalent immunogens in Phase I and II clinical trials for the treatment of 
melanoma and renal cell carcinoma; in some cases, partial responses were induced 
[95,96]. However, the limited availability of autologous tumor-cell membranes to 
cover the silica beads restricts the wide applicability of this approach. 
 In another strategy, microsized polystyrene beads coated with tumor antigen- 
specific peptide-MHC complexes, anti-CD28 and anti-4-1BB, were injected into tumor- 
bearing mice. These beads efficiently decreased tumor sizes and delayed tumor progression 
[34,97]. Similar results were obtained for magnetic polystyrene microbeads in a mouse 
tumor model [98]. Interestingly, when compared to spherical PLGA microparticles, 
ellipsoid particles were most efficient in reducing tumor sizes and extending survival 
times in melanoma-bearing mice, again emphasizing the importance of size and shape 
[80]. Incorporation of IL-2 into biodegradable particles also improved their efficacy 
reduced tumor growth kinetics in mice engrafted with B16 tumors [9]. IL-2 encapsulation 
can also be combined in SLB particles with small-molecule inhibitors, such as TGF-β 
inhibitors, which increased activity of intratumoral T cells in vivo [99].
 Although no in vivo toxicities were observed, several of the aAPCs used so far are 
non-deformable, large, and in some cases non-biodegradable, which may lead to 
embolisms, making clinical approval for in vivo use difficult [9,16]. 
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Thus, in contrast to microbeads, nanosized particles might be safer and have a better 
chance of obtaining clinical approval. Particle sizes below 100 nm enable easy entry 
into the lymphatic system and allow for transportation to the lymph nodes, where 
particles can gain access to larger numbers of T cells [100]. For example, MHC class 
II-containing RAFTsomes, which are flexible nanoparticles, were able to induce CD4+ T 
cell responses that prevented EG.7 tumor inoculation and reduced tumor sizes in mice 
[64]. Unfortunately, generation of these nanoparticles requires DC-derived lipid rafts, 
and therefore does not completely eliminate the need for isolation and culture of 
autologous APCs. Also leukocyte-membrane coated magnetosomes can efficiently 
activate T cells in vivo. To further improve anti-tumor responses, their magnetic 
properties can be used to guide these particles to tumors [72].Alternatively, completely 
synthetic nanosized aAPCs have also been tested for their in vivo potential in cancer 
immunotherapy. Both dextran-coated iron oxide magnetic particles (50-100 nm) and 
dextran-coated quantum dots (30 nm) can effectively stimulate tumor antigen- 
specific T cells and inhibit tumor growth in vivo. They are also more efficiently distributed 
and better capable of reaching T cell pools in mice than micro-aAPCs [37]. In addition, 
active clustering of magnetic nanoparticle-labelled TCRs by applying a magnetic field 
can further improve T-cell responses and in vivo anti-tumor responses [38,101]. 
 Pharmacokinetics and in vivo T cell responses can be further boosted by making use 
of non-spherical ellipsoid nanoparticles [81].
Future aAPC development for more potent immunotherapy
The efficacy of signal presentation by aAPCs and the resulting T cell activation are 
highly dependent on the properties of the materials used. For future aAPC development, 
the previously discussed properties should be optimally tuned to induce higher 
clinical responses. Ex vivo activation of T cells for subsequent reinfusion into patients 
has proven most effective with large microsized particles. To further improve aAPCs 
for ex vivo T cell activation, current knowledge about the optimal choice of surface 
molecules, cytokine release, particle shape, ligand mobility, and ligand orientation 
should be applied in a microsized system, preferably one that can be quickly separated 
from the T cell population before reinfusion into a patient. The use of 3D-SLB particles 
constitutes a promising, yet rarely applied system that would allow for incorporation 
of these features. For example, future acellular ‘off-the-shelf’ aAPCs could be made 
by coating ellipsoid PLGA microparticles with GM1-microdomain-containing lipid 
bilayers, allowing for more optimally shaped and stable particles with ligands pre- 
clustered in microdomains, high membrane fluidity, and an ability to release paracrine 
cytokines and small-molecule drugs [15,99]. Furthermore, incorporation of magnetic 
nanoparticles may be possible for straightforward separation of particles and cells 
after incubation and expansion. aAPCs that closely mimic features of natural DCs 
should in this way improve the clinical efficiency of ex vivo-generated T cells.
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In vivo, active aAPC immunotherapy, although more challenging, is also particularly 
promising. This approach does not depend on autologous T cells, significantly lowering 
labor and costs. However, injection of microsized aAPCs may be unsafe, and therefore 
biocompatible nanoparticulate constructs are preferred. Nanoparticles in the size 
range of 10-100 nm and with stretched shapes have favorable biodistributions 
[37,81,100]. Therefore, the use of semi-flexible nanofilaments is a promising approach 
for in vivo application. These polymers are small in size and have a high degree of 
flexibility, allowing extensive contacts with the T cell membrane and the dynamic 
interactions that are necessary for potent signal transduction [85]. For in vivo application 
of aAPCs, development of nanosized particles combining these properties may be 
important to boost clinical responses in cancer immunotherapy [15].
Concluding remarks and future perspectives
The development of aAPCs for cancer immunotherapy is a highly promising approach. 
The ex vivo use of these systems for T cell expansion has significant advantages over 
the use of autologous APCs, and initial results from clinical studies are encouraging. 
Therefore, further development of microparticles for this purpose should exploit 
the effects of size, shape, ligand mobility, and ligand distribution. The development 
of nanosized aAPCs with improved flexibility, optimal shape, and efficient signal 
presentation for direct in vivo aAPC immunotherapy is desirable and holds marked 
promise. This approach could eliminate the need for costly and laborious cell culture 
and lead to broadly accessible ‘off-the-shelf’ cancer immunotherapeutics. This high- 
lights the need for research into nano-aAPCs that exhibit more potent in vivo CTL 
responses.
1.2   Water-soluble polyisocyanopeptides for  
biological applications
To induce efficient T cell activation in vivo, aAPCs are preferably small, have a stretched 
shape and should be flexible, at least to a certain degree. Water-soluble polyisocyano-
peptides (PICs), a class of polymers that was mentioned previously, can provide 
scaffolds that combine these properties to form a promising class of aAPCs, called 
‘nanoworms’ or ‘synthetic Dendritic Cells’ (sDCs). Before their application as aAPCs, 
these PICs were studied extensively in the search for new materials with structural 
and mechanical properties resembling natural polymers. Their unique characteristics 
have great potential for application of PICs in catalysis and biomedical applications.
 PICs were developed as derivatives of helical polyisocyanide polymers, which form 
their helical backbone. Helical polyisocyanides can be synthesized from isocyanides 
using a nickel(II)-catalyzed polymerization reaction [102,103]. During polymerization, 
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a helical conformation containing four repeats per turn is formed. This conformation 
can be stabilized when bulky groups are present in the isocyanide side chains. 
By making use of chiral catalysts or monomers, right- and left-handed helices can be 
synthesized in a highly controlled fashion [104]. These helices can also be stabilized 
further through hydrogen bonding by using dipeptide or tripeptide chains in the 
isocyanide side chains [105,106]. Due to this hydrogen bonding, highly stable and 
relatively stiff helices are formed that can only be unfolded by strong acids [107]. 
 Isocyanopeptide polymers synthesized from dialanines or trialanines (polyisocyano-
peptides or PICs), contain peptide side chains that display β-sheet-like packing along 
the isocyanide backbone [108]. This well-defined structure, which has resulted in the 
synthesis of markedly long (100 nm - µm-scale) and rigid polymers, are particularly 
interesting for ordering of electronically or optically active molecules, such as was 
done with chromophores for electronic applications [109,110].
  To make these polymers water-soluble and use them in biological applications, 
oligo(ethylene glycol) tails can be added to the peptide side chains. Incorporation of 
oligo ethylene glycols results in non-ionic water-soluble polymers (Figure 3). By co- 
polymerization of azide-functionalized monomers, azide-PICs are formed that can be 
post modified with biological functionalities through bio-orthogonal strain-promoted 
alkyne-azide cycloaddition (click) reactions When tri- and tetra ethylene glycol- 
containing PICs are used, remarkable thermoresponsive properties are observed [112]. 
For tri-ethylene glycol-modified PICs, short polymers precipitate at temperatures 
above 18 °C, whereas longer polymers do not precipitate, but instead form a hydrogel 
at this temperature. For tetra ethylene glycol-PICs, this transition was seen at 42 °C. 
This thermoresponsive gelation is a result of polymer chain bundling and is completely 
Figure 3  Side chains of PICs important for semi-flexibility and water-solubility. (A) Side chains 
of PICs show a β-sheet-like packing along the polyisocyanide helix (B) Peptides in the side chains 
(red) can form hydrogen bonds to stabilize helix formation of the red polyisocyanide backbone, 
leading to (semi)-rigidity in these polymers. Addition of oligo ethylene glycols (blue) makes 
these polymers water-soluble and thermoresponsive. Adapted with permission from [111].
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reversible when temperatures are lowered again. Interestingly, these hydrogels exhibit 
mechanical properties, in particular nonlinear stress responses, closely resembling 
those of biopolymer networks [111]. Because of this, and because these polymers are in 
gel-form at 37 °C, several possible biological applications have been reported using 
tri-ethyleneglycol-PIC hydrogels as 3D scaffolds [111,113–115]. 
 These PIC hydrogels have possible applications in wound healing, as (immune) 
cell depots and as 3D cell culture scaffolds. For the latter purpose, PICs were recently 
introduced as a novel 3D matrix for culture of stem cells [115]. Because the non-linear 
stress response, or strain-stiffening, is similar to that of biopolymer hydrogels and can 
be easily manipulated, PIC hydrogels were used to assess the effects of strain-stiffening 
on stem cell differentiation. These experiments identified strain-stiffening as a key 
regulator in this process [115]. Instead of physically crosslinking polymers to form 
hydrogels when temperatures are increased, hybridizing strands of DNA can also be 
applied as stimuli-responsive cross-linkers [114]. Also when cross-linked through DNA 
interactions, these hydrogels exhibit mechanical properties similar to biological 
filaments [113]. In chapter 5, we demonstrate that DNA linkers can also be used as 
responsive elements in water-soluble filamentous PICs. Importantly, the various 
applications of PIC hydrogels have led to strategies to functionalize water-soluble 
PICs. Furthermore, the hydrogel-based experiments have demonstrated that these 
polymers are non-toxic and suitable for biological applications. Both the functional-
ization methods and biocompatibility were essential for the development of 
filamentous water-soluble PICs for biological applications.
PICs as synthetic Dendritic Cells – In contrast to tri-ethylene glycol-PICs, tetra-ethylene 
glycol-polymers do not form hydrogels at 37 °C, but instead exist as single filamentous 
semi-flexible nanoworms [111]. Because of their relatively high rigidity (for synthetic 
polymers) and high length, PICs coated with biomolecules, can efficiently mediate 
multivalent interactions with cell surfaces, which can play a role in many biological 
applications [116]. Making use of this multivalency, synthetic Dendritic Cells (sDCs) 
have been developed by conjugating stimulatory anti-CD3 antibodies to PICs. 
Compared to both unbound anti-CD3 or anti-CD3-coated PLGA microparticles, sDCs 
increased IFNy secretion and proliferation of stimulated T cells. In addition, it was 
demonstrated that these ~200 nm long structures were biocompatible and non-toxic 
[117]. To further boost T-cell activation, stimulatory anti-CD28 antibodies were also 
conjugated to PICs (Figure 4). 
 Stimulation of T cells with these anti-CD3/CD28-PICs further increased IFNy 
release and induced robust proliferation of T-cells. In addition, it was established that 
conjugating both these antibodies to a single scaffold is essential for their high 
stimulatory capacity, since stimulation of T-cells with a mixture of anti-CD3-PIC and 
anti-CD28-PIC was not as effective (Figure 5). Stimulation with CD3/CD28-PLGA 
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Figure 4  Synthesis of PIC-based synthetic DCs. Filamentous azide-PICs were synthesized by 
co-polymerization of tetra-ethylene glycol containing isocyanopeptides together with azide- 
functionalized monomers. BCN-functionalized streptavidin was reacted to the azide-PICs through 
strain-promoted alkyne azide cycloaddition (SPAAC). Next, biotinylated anti-CD3 and anti-CD28 
stimulatory antibodies were conjugated to PIC-streptavidin to form the two-signal synthetic 
DCs. Adapted with permission from [118].
Figure 5  Antibody-functionalized PICs are efficient synthetic DCs. Peripheral blood lymphocytes 
were stimulated with different concentrations of stimulatory antibodies against CD3 and CD28. 
Antibodies were either given mixed in unbound form, mixed conjugated on separate PIC scaffolds, 
co-conjugated onto PLGA microparticles or co-conjugated on a single PIC polymer. (A) IFNy 
concentrations in the supernatant after 16 h of stimulation. (B) Proliferation of T cells measured 
by CFSE dilution, depicted as number of divisions, after 4 days of stimulation using 5 ng/ml of 
antibodies. Adapted with permission from [118].
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particles with similar antibody densities could not induce the same level of T cell 
activation. [118]. With this work, tetra-ethylene glycol-PIC-protein conjugates were 
established as promising novel aAPCs. These aAPCs have the potential to become 
highly efficient, off-the-shelf nanovaccines for cancer therapy. Their semi-flexibility, 
high aspect ratio and multivalent binding capacity make them excellent candidates 
for future aAPC-based therapies that can overcome drawbacks of the traditional aAPC 
scaffolds described in the first part of this introduction [117–119].
1.3  Aim and scope of this thesis
The initial papers by our group established proof-of-principle for PIC-antibody 
conjugates as efficient sDCs. To further develop these polymers for immune therapies, 
the mechanisms that govern their effects on T-cells needs to be further investigated. 
In addition, to optimize our sDC designs the impact of different co-stimuli and 
cytokines on T-cell responses needs to be further established. To be able to apply these 
aAPCs for direct in vivo immune therapy, instead of ex vivo activation of T cells, 
polyclonal stimulation of TCRs with anti-CD3 antibodies need to be replaced with an 
antigen-specific approach. The work described in this thesis aims to further understand 
and optimize PIC-based sDCs and their interactions with T-cells. Designs used for 
these PICs are summarized in Figure 6. 
 After the introduction, this thesis continues to further explore how multivalent 
anti-CD3-PICs control the activation of T-cells (chapter 2). Here, the effect of anti-CD3 
antibody density and the role of the length of the scaffold on T-cell signaling and 
activation are described. 
 Up to this point, the use of streptavidin as a linker molecule was sufficient for 
proof-of-principle experiments. However, to increase complexity of linkers and for 
in vivo applicability of the sDC system, in chapter 3 this streptavidin linkage is replaced 
by a more direct approach, making use of only a short PEG spacer. In addition, a novel 
method for PIC-protein conjugate purification is introduced to increase both yield and 
purity of synthetic DCs. It is demonstrated in chapter 4 that this novel design can be 
used to generate potent sDCs. Through incorporation of a wide variety of antibodies, 
the effect of distinct types of co-stimulation could be tested. In addition, the introduction 
of this simple PEG linker was a first step towards introduction of more complex linkers, 
such as the force-responsive DNA linkers described in chapter 5. These linkers were 
used to further study interactions of PIC-antibody conjugates with T cells.
 Increased yields and purity of the affinity-based purification allows for the use of 
PIC-based sDCs to target molecules with widespread biological activity, such as cytokines, 
to T cells. In chapter 6, the stimulatory capacity of purified PICs linked to anti-CD3 and 
cytokines IL-2 and IFNα is explored.
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To translate this knowledge into an antigen-specific PIC-based sDC, chapter 7 describes 
the synthesis of peptide-MHC-presenting PICs. In addition, preliminary data on both 
 in vitro and in vivo T-cell stimulation with these novel antigen-specific sDCs is discussed. 
This thesis finishes with a discussion of possible applications of these novel sDCs and 
possible future directions for application of PIC-conjugates in immunotherapy will be 
considered (Chapter 8). 
Figure 6  Molecular structure, linkers and biomolecules used in PIC-bioconjugates in the work 
presented in this thesis.
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Abstract
Artificial antigen-presenting cells (aAPCs) have recently gained a lot of attention. 
They efficiently activate T cells and serve as powerful replacements for dendritic cells 
in cancer immunotherapy. Focusing on a specific class of polymer-based aAPCs, 
so-called synthetic Dendritic Cells (sDCs), we have investigated the importance of 
multivalent binding on T cell activation. Using antibody-functionalized sDCs, we 
have tested the influence of polymer length and antibody density. Increasing the 
multivalent character of the antibody-functionalized polymer lowered the effective 
concentration required for T cell activation. This was evidenced for both early and late 
stages of activation. The most important effect observed was the significantly 
prolonged activation of the stimulated T cells, indicating that multivalent sDCs 
sustain T cell signaling. Our results highlight the importance of multivalency for the 
design of aAPCs and will ultimately allow for better mimics of natural dendritic cells 
that can be used as vaccines in cancer treatment.
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Introduction
One important goal of cancer immunotherapy is the replacement of costly dendritic 
cell (DC) vaccines with synthetic variants, thereby overcoming the need of generating 
a customized vaccine for every individual patient.[1] These synthetic variants, called 
artificial antigen presenting cells (aAPCs), are designed to prime T cells against cancer 
specific antigens. These aAPCs can be produced in a straight forward manner from 
synthetic building blocks, opening up the possibility for standardized “off-the-shelf” 
protocols2 and circumventing elaborate and expensive personalized medicine. Different 
aAPC designs have been synthesized over the last years with scaffolds varying from 
polymer beads,[3-4] carbon nanotubes,[5] liposomes[6] and many others.[7] In general, 
the design of aAPCs is inspired by the natural DC and its interaction with the T cell. 
DC binding to T cells involves three main signals that are all required to fully activate the 
T cell: antigen-loaded major histocompatibility complexes (pMHC) of the DC bind to 
specific T cell receptors (TCR; signal 1). At the same time, co-stimulatory molecules on 
the DC surface interact with their T cell binding partners (signal 2). In addition to 
these receptor interactions, also soluble factors (cytokines) are involved in T cell 
activation (signal 3). In the first stage of activation, signal 1 interactions trigger the 
TCR, which is pre-arranged in nanoclusters in the T cell membrane (up to 20 TCRs per 
cluster).[8-12] In the next step, triggered TCR molecules re-arrange together with 
signal 2 interactions, to form larger signaling microclusters containing around 20-300 
TCRs.[9,11,13-16] These contact areas between both cells are stabilized by a number of 
different adhesion molecules. After the initial stimulation, triggered microclusters 
move towards the so-called supramolecular adhesion complex (SMAC) where 
receptors and adhesion molecules are rearranged to form a ‘bulls eye’ pattern of 
micrometer size.[17] This process clearly involves the dynamic multivalent binding of 
many (different) binding partners.
 Multivalent interactions generally form at the interface between two objects 
that carry multiple, complementary functionalities.[18-19] The simultaneous inter- 
action between these functionalities enhances the binding strength (avidity), 
sometimes by several orders of magnitude compared to the affinity of the monovalent 
interaction.[20] This enhancement mainly originates from an increase in the effective 
concentration of identical binding partners. Once the first ligand is bound, the ‘search 
volume’ is reduced and the following binding events occur with a higher probability.[21] 
We have recently introduced a new multivalent aAPC design for activating T cells: 
synthetic Dendritic Cells (sDCs).[22-23] In this design, anti-CD3 antibodies (αCD3), 
which are known to trigger the TCR (signal 1), were bound to a semi-flexible and linear 
polyisocyanopeptide scaffold with a length of ~200 nm. Using these novel sDCs, T cell 
activation occurred at much lower doses of antibody compared to freely soluble αCD3. 
This is a direct consequence of the unique physical properties of the polymer scaffold. 
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Its high aspect ratio allows the efficient simultaneous binding of all αCD3 effector 
molecules to the T cell. At the same time, its nanometer size combined with its semi- 
flexibility promote the dynamic spatial rearrangement of polymer-bound effector 
molecules, mimicking the fluidity of the natural cell membrane and supporting 
receptor mobility. Coupling of additional anti-CD28 antibodies (αCD28; signal 2) to the 
sDC shaped the immunoresponse towards the induction of helper and killer T cells, 
without activating the regulatory T cell population.[23] Remarkably, this effect was 
only seen when both signals were bound to one and the same polyisocyano peptide 
backbone, indicating that activation requires both signals to bind in close spatial 
proximity. These results already provided a first indication that multivalent binding of 
these sDCs does not only increase the binding strength of the interaction. The polymer 
concentrates the effector molecules in a locally confined area. It may therefore affect 
T cell signaling pathways and directly influence the strength and specificity of the 
T cell response.
 Focusing on sDCs functionalized with only anti-CD3 antibodies (αCD3-sDC), we 
have now designed a series of experiments to investigate the effect and importance of 
multivalent binding of our sDCs. We have synthesized a library of αCD3-sDCs with 
different polymer lengths and αCD3 densities and investigated the influence of these 
parameters on T cell activation. Incubating T cells with the αCD3-sDCs, we show that 
an increase in polymer length and/or effector molecule density boosts both early 
(Ca2+-signaling) and late (interferon γ release) stages of T cell activation and provide 
evidence that this effect goes beyond a simple avidity increase. A positive effect on T cell 
signaling is further demonstrated after removal of the αCD3-sDCs. T cell activation is 
sustained for extended periods of time (days), as confirmed by prolonged Ca2+-
signaling, expression of the early activation marker CD69 and the release of interferon 
γ (IFNγ).
Results and discussion
Synthesis of αCD3-sDCs. All polymer-αCD3 conjugates (i.e. the αCD3-sDCs) were 
synthesized according to previously published methods[22-23] (Fig. 1). The sDC scaffold 
is based on a water-soluble polyisocyanopeptide co-polymer bearing non-functional 
methoxy and functional azide groups. The corresponding methoxy and azide isocyanide 
monomers were polymerized using a nickel catalyst to obtain azide- functionalized 
polyisocyanopeptide polymers. The azide groups were subsequently utilized in a 
strain-promoted azide-alkyne cycloaddition (SPAAC) reaction with bicyclononyne- 
functionalized streptavidin (BCN-SAv).[24] The SAv molecules allow for the binding 
of biotinylated αCD3 antibodies to yield the αCD3-sDCs (Fig. 1a). In all experiments, 
the ratio between SAv and αCD3 was tuned to be 1:1.
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Influence of αCD3-sDC length on T cell activation. Polyisocyanopeptides of different 
length were synthesized using different catalyst-to-monomer ratios during the 
polymerization reaction. Two polymers of different average lengths (P1’ = 175 nm and 
P2’ = 350 nm; azide:methoxy = 1:100) were synthesized using this strategy (Table S1; 
Figs. S1-S2). The density of SAv per polymer chain was determined using atomic force 
microscopy (AFM imaging; Table S2; Figs. S1 and S3). The P1-SAv and P2-SAv conjugates 
possess an average density of 1 SAv molecule per 110 nm and 120 nm, respectively. For 
the synthetic protocol used, we have shown earlier that one αCD3 antibody is bound 
per SAv molecule.22-23 It can therefore be assumed that these values also represent the 
densities of αCD3 molecules on the αCD3-sDC conjugates P1 and P2 (Fig. 1b). This means 
that P1 carries 1-2 αCD3 molecules per polymer, whereas the total number of αCD3 
molecules on P2 is ~3.
 P1 and P2 were compared to free αCD3 in a single-cell Ca2+-signaling experiment 
(Fig. 2a). Ca2+-release from the endoplasmic reticulum is one of the earliest activation 
events when triggering T cells at the TCR level. The subsequent complex interplay 
between Ca2+-release from the endoplasmic reticulum and calcium influx across the 
plasma membrane via Ca2+-release activated Ca2+ (CRAC) channels leads to oscillations 
of cytoplasmic calcium.25 These calcium oscillations, which have a direct influence on 
T cell gene expression, were monitored using peripheral blood lymphocytes (PBLs) 
loaded with the Ca2+-sensitive fluorescent dye Fura-2 (Table S3; Fig. S4 and movies 
Figure 1  Schematic overview of the sDC library. (A) Experimental design for sDC synthesis. 
(B) Schematic overview of the sDCs used in this study (P1-P3) showing the corresponding 
polymer lengths and αCD3 densities.
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M1-M2).26 Determination of the number of Ca2+-signaling cells during the first hour of 
treatment with P1, P2 or free αCD3 (5 ng/ml and 25 ng/ml) revealed that the two 
αCD3-sDCs as well as free αCD3 caused a marked increase in the number of Ca2+-signaling 
cells (above the 30 % background level of Ca2+-signaling cells observed in the absence 
of any stimulant27). At 0.5 ng/ml this effect was only seen for P2 and not for P1 or 
free αCD3.
 To probe the effect of the two αCD3-sDCs on a late and more robust event in 
T cell activation, we stimulated PBLs for 16 hours with P1, P2 and αCD3 and measured 
the release of IFNγ. Both αCD3-sDCs stimulated the production of IFNγ over a range of 
concentrations from 0.05 to 100 ng/ml (Fig. 2b). At all concentrations tested, the effect of 
P2 was most pronounced. Considering that P1 and P2 possess approximately the same 
αCD3 density, these results suggest that polymer length is a crucial design parameter. 
It increases the total number of αCD3 molecules per αCD3-sDC, thereby causing a 
stronger T cell stimulating effect.
Influence of αCD3 density on T cell activation. The previous experiment has shown 
that a density of one αCD3 antibody in 110-120 nm combined with a polymer length of 
maximally 350 nm (P2) leads to a small but clearly detectable increase in T cell 
activation. We therefore decided to increase both the polymer length and the αCD3 
density to investigate the multivalency effect over a larger dynamic range. Increasing 
the number of azide functional groups (azide:methoxy = 1:70), polymer P3’ with an 
average length of 400-450 nm was synthesized (Table S1; Figs. S1-S2). This polymer was 
then functionalized with a different number of SAv molecules per polymer, using 
different ratios of BCN-SAv:azide in the coupling reaction (0.5, 1 and 5 equivalents of 
BCN-SAv). Using AFM imaging, the average SAv density on these polymer conjugates 
was determined to be 1 SAv molecule in every ~130 nm (P3a-SAv, 0.5 eq.), ~90 nm 
(P3b-SAv, 1 eq.) and ~40 nm (P3c-SAv, 5 eq.) (Fig. 1b, Table S2; Fig. S1 and Fig. S3). Again, 
it was assumed that these values correspond to the density of αCD3 antibodies so 
that the αCD3-sDCs carry an average of 3-4 (P3a-SAv), 5 (P3b-SAv) or 10-11 (P3c-SAv) 
antibodies per polymer.
 The single-cell Ca2+-signaling assay shows a marked increase already at the 
lowest tested concentration of P3c (0.005 ng/ml; Fig. 2c). In sharp contrast, P3a and P3b 
displayed the same dose-dependency as free αCD3. Also for these αCD3-sDCs a more clear 
difference was observed in the IFNγ release assay. All three αCD3-sDCs were shown to 
be more effective than free αCD3 (Fig. 2d). Most importantly, a positive correlation 
was observed between αCD3 density and IFNγ release over the full range of tested 
concentrations (0.05-50 ng/ml). At the highest αCD3 concentration of 50 ng/ml, P3a, 
P3b and P3c induced a 2.4-, 3.5- and 6.1-fold increase of secreted IFNγ compared to free 
αCD3, respectively. Clearly, in addition to polymer length, αCD3 density is an important 
determinant for T cell activation by αCD3-sDCs.
2CONTROLLING T CELL ACTIVATION WITH MULTIVALENT SDCS
43
Figure 2  T cell activation using sDCs of different length and αCD3 density. (A) Fraction of 
activated PBLs as determined from single-cell Ca2+-signaling measurements performed 
during the first hour of stimulation with P1, P2 and free αCD3. (B) Relative increase in the 
concentration of IFNγ secreted by PBLs treated with P1, P2 and free αCD3 for 16 hours. 
Untreated PBLs were used as a reference. (C) Fraction of activated PBLs as determined from 
single-cell Ca2+-signaling measurements performed during the first hour of stimulation 
with P3a, P3b, P3c and free αCD3. (D) Relative increase in the concentration of IFNγ secreted 
by PBLs treated with P3a, P3b, P3c and free αCD3 for 16 hours. Untreated PBLs were used as a 
reference. For (a)-(c) the data represents the mean ± SEM of 3 independent experiments 
performed with T cells from different donors. For (d) the data represents the mean ± SEM of 2 
independent experiments performed with T cells from different donors. The number of cells 
analyzed in the single-cell Ca2+-signaling experiments (a, c) is summarized in Table S4.
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Quantification of the multivalent enhancement factor. The above results show that 
both polymer length and αCD3 density are crucial design parameters for our sDC 
design. Together, these parameters determine the number of interactions that can 
form between the polymer and the T cell. To quantify the enhancement of the 
multivalent binding strength, dose-response curves were established for both free 
αCD3 and the best performing αCD3-sDC (P3c). The dose-response curves provide the 
basis for determining the EC50 values and allow for calculating an enhancement 
factor for the multivalent interaction. To construct these dose- response curves, 
single-cell Ca2+-signaling experiments were performed over an extended range of 
αCD3 concentrations (0.001-100 ng/ml). Even though T cell activation was more 
difficult to quantify in the Ca2+-signaling experiment, we have chosen this readout 
parameter as it corresponds to a very early activation event. We believe that an early 
readout parameter is more relevant for quantifying the multivalent binding strength 
than downstream parameters when signal amplification may have taken place.
 When PBLs were treated with P3c, the smallest concentration that caused a 
detectable effect on the number of Ca2+-signaling cells was a factor ~200-300 fold 
lower than for free αCD3 (Fig. 3), which is in line with previously reported results.[22] 
For free αCD3 an EC50 value of 16 ng/ml was found, whereas an EC50 value of 0.24 ng/
ml was obtained for the multivalent P3c. This yields an enhancement factor of ~67 for 
the multivalent system (Fig. 3).[28] This remarkable enhancement clearly indicates 
that multivalency is one of the key parameters responsible for the increased potency 
of αCD3-sDCs. It is worth mentioning that the slope of the dose-response curve does 
usually contain additional information, e.g. about positive or negative cooperativity. 
The sDC polymers are heterogeneous, however, when considering both their length 
and the αCD3 density. It is therefore highly likely that the more gradual response to 
increasing the concentration of P3c is a direct result of this heterogeneity. We further 
note that it would be interesting to increase the αCD3 density on the polymer to 
determine if this multivalent system is characterized by an optimum loading. Despite 
several attempts, we have not been able to attach more αCD3 antibodies to the 
polymer, possibly due to steric hindrance.
Assuming that the enhancement factor purely characterizes the avidity increase of 
the multivalent interaction, the question remains if enhanced binding of the 
αCD3-sDC is the only parameter that determines T cell activation or if T cell signaling 
is also affected. The polymer linkage between several αCD3 antibodies efficiently 
directs these polymer-attached αCD3 antibodies to the same spatially confined area 
even if the overall αCD3 concentration is very low. It further enhances the probability 
of rebinding after dissociation (koff = 0.39 s-1)[29] for individual polymer-attached αCD3 
antibodies, thereby triggering a higher number of TCRs in close proximity. Considering 
the sequence of events occurring during T cell activation, this may directly lower the 
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threshold concentration for T cell activation. A first indication for this can be obtained 
when re-considering the potency of the αCD3-sDCs P3a, P3b and P3c (Fig. 2c,d) that all 
bind in a multivalent fashion. During all experiments, the data was normalized to 
the αCD3 concentration so that the polymer concentration (i.e. the concentration of 
T cell stimulating entities; αCD3-sDCs) varies between the different samples. When 
normalizing the data with respect to the αCD3-sDC concentration, it becomes evident 
that a 1000-fold lower concentration of P3c is sufficient to obtain the same effect as 
with P3a (Fig. S5). This value is considerably larger than the multivalent enhancement 
factor determined above and may suggest that the co-localization of a certain number 
of αCD3 antibodies in a small area on the cell surface is a key factor for T cell activation. 
Interestingly, a total number of ~10 αCD3 antibodies (P3c carries ~10 antibodies) 
distributed over an area of several tens of nanometers matches with the predicted size 
of TCR nanoclusters that are pre-formed on the T cell surface.[8-10] It may therefore be 
speculated that αCD3-sDCs form a highly specific and dynamic multivalent interaction 
with these nanoclusters and that T cell fate is already determined at this very early 
stage of forming the initial contact with the T cell.[11]
Long-term effect of αCD3-sDC binding on T cell signaling. To investigate the effect of 
the αCD3-sDCs on T cell signaling in more detail, we designed a new series of 
experiments to obtain information about sustained T cell activation. Instead of 
measuring T cell activation in the continuous presence of the αCD3-sDCs or free 
antibodies, excess stimulant was washed off after 1 hour of treatment and T cell 
Figure 3  Dose-response curves for PBLs treated with P3c and free αCD3 as determined from 
single-cell Ca2+-signaling experiments. EC50 values were determined using a four-parameter 
fit. The multivalent enhancement factor is calculated by dividing the EC50 of free αCD3 by 
the EC50 of P3c. The data represents the mean ± SEM of 3 independent experiments performed 
with PBLs from different donors. The number of cells analyzed is summarized in Table S4.
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activation was analyzed at several time points after removal of the stimulant. 
This allowed for determining the long-term effect of the initial stimulation, as no 
free stimulant was available for binding to the T cells after the medium was replaced. 
To quantify the effect, we have again performed single-cell Ca2+-signaling experiments 
and determined the secretion of IFNγ. In addition, the expression of the surface 
activation marker CD69 was measured, which is another indicator of early T cell 
activation.
 For the single-cell Ca2+-signaling measurements, PBLs were treated with free 
αCD3 or P3c (12.5 ng/ml) for 1 hour. The stimulant was then removed, fresh medium 
was added and the cells were incubated without stimulant for another 15 or 23 hours. 
Fura-2 was added in the last 20 min of this extended incubation period and the 
fraction of Ca2+-signaling cells was determined during the following hour (starting at 
15 or 23 h after the initial addition of the stimulant; see Fig. S6 for a detailed timeline). 
A reference sample was imaged for 1 hour in the presence stimulant (0 h; Fig. S6). 
In agreement with the results presented above (Figs. 2c and 3) both free αCD3 and P3c 
(12.5 ng/ml) readily increased the number of Ca2+-signaling T cells during the first 
hour of stimulation (Fig. 4a). In samples treated with free αCD3 the fraction of 
Ca2+-signaling PBLs was significantly reduced at both post-stimulation time points 
(Fig. S7). In sharp contrast, the vast majority of P3c-treated PBLs remained active after 
removal of the stimulant. Even at 24 h hours after the initial stimulation with P3c, the 
fraction of Ca2+-signaling T cells was still ~75%, indicating that the multivalent sDC 
causes a sustained stimulation of the intracellular pathways involved in Ca2+-
responses. Negative controls involving an isotope control (mIgG2a antibody), polymers 
with SAv but no αCD3 and non-treated cells did not show high amounts of activated 
T cells before and after removal of the stimulant (Fig. S7).
 To support the results from the single-cell Ca2+-signaling experiments, FACS 
analysis was performed to determine the expression of the surface marker CD69. 
T cells were treated with P3c or free αCD3 (1, 5 and 50 ng/ml) for 8 hours before placing 
the PBLs into fresh medium. At the time of removal of the stimulant higher numbers 
of CD69 expressing T cells were observed when the PBLs were treated with 50 ng/ml 
P3c than when they were treated with the same concentration of free αCD3 (Fig. 4b, 
Fig. S8). Based on the multivalent enhancement factor of 67 (Fig. 3) one would expect a 
similar level of activation for PBLs treated with 1 ng/ml of P3c or with 50 ng/ml of free 
αCD3. When comparing the initial time point at 8 hours, the P3c treated sample indeed 
contains approximately the same number of CD69 expressing cells. This amount 
increases during the next 40 h for the P3c treated sample, whereas it decreases for the 
sample treated with free αCD3.
 To further confirm that T cells were showing sustained and robust activation for 
an extended period of time, IFNγ release assays were performed. PBLs were treated 
with 5 ng/ml P3c or free αCD3 for 16 hours, after which the cells where washed and 
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Figure 4  Analysis of sustained T cell activation. (A) Long-term Ca2+-signaling after treating 
PBLs with 12.5 ng/ml P3c or free αCD3 for 1 hour. The first measurement (0 h) was performed 
directly on the microscope during 1 hour of incubation with the stimulant. The other time 
points represent the total time of the experiment (i.e. 1 hour incubation with the stimulant + 
incubation time after removal of the stimulant). For all experiments the data represents the 
mean ± SEM of 3 independent experiments performed with PBLs from different donors. 
The number of cells analyzed is summarized in Table S5. (B) Fraction of T cells expressing 
CD69 after treatment with P3c or free αCD3 for 8 hours. For P3c concentrations of 1 ng/ml and 
50 ng/ml are shown. For αCD3 a concentration of 50 ng/ml is shown. The first measurement was 
performed directly before the stimulant was removed (8 hours). The following time points 
represent the total time of the experiment. For all experiments the data represents the 
mean ± SEM of 3 independent experiments performed with PBLs from different donors. 
(C) Concentration of secreted IFNγ after treating PBLs with 5 ng/ml P3c or αCD3 for 16 hours. 
The first measurement was performed directly before the stimulant was removed (16 hours). 
The following time points represent the total time of the experiment. Untreated PBLs were 
used as a reference. For all experiments, the data represents the mean ± SEM of 3 independent 
experiments performed with PBLs from different donors.
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new medium was added. The supernatant was tested for IFNγ directly before the 
removal of the stimulant (16 hours) and a high concentration of IFNγ was determined 
for both treatment conditions as expected. At all subsequent time points (24, 48, 72, 96 
and 120 hours after the initial stimulation), a clear difference was seen between 
T cells treated with P3c or free αCD3 (Fig. 4c). PBLs treated with free αCD3 do not seem 
to produce new IFNγ and a decrease in the IFNγ level is seen over time. In contrast, PBLs 
stimulated with P3c produced new IFNγ. Until the 96 hour time point an approximately 
constant level of IFNγ was maintained before a decrease of the IFNγ concentration 
was observed. Taken together, these results show that sDCs stimulate T cells over 
much longer periods of time compared to free αCD3 and this effect is observed for both 
early and late T cell activation markers.
 Overall, these results show that αCD3-sDCs efficiently activate T cells, combining the 
benefits of multivalent binding with a spatially confined interaction with several 
TCRs. The equilibrium binding constant of the αCD3 antibody used is KD = 680 µM[29] 
so that an overall increase in the multivalent binding strength is seen (enhancement 
factor of 67). At the same time, the antibody possesses a relatively fast kinetic off-rate 
koff = 0.39 s-1 so that dissociation and immediate re-binding of individual polymer- 
attached αCD3 molecules is highly likely to occur while the sDC is bound to the cell 
surface. It has been proposed that such dynamic interactions are important factors 
contributing to T cell activation.[30] In addition to these thermodynamic and kinetic 
effects, the sDC polymers keep up to 10 individual effector molecule in close spatial 
proximity. It appears likely that one sDC binds within one nanocluster, where this 
proximity effect may have direct consequences for its signaling activity.[12] All together, 
these factors ensure efficient and long-lasting T cell activation. Even though this 
appears to be the most likely mechanism, other factors such as altered TCR endocytosis 
and exocytosis[16,31-32] or changes in membrane properties may contribute to the 
observed activation. Investigating these additional factors will be the subject of 
further study. Clearly, our sDC design is a powerful new tool that allows for studying 
the initial steps of T cell activation in more detail, incl. the role of TCR nanoclusters. 
As another important next step, the αCD3 antibody will be replaced with pMHC 
complexes. Natural pMHC complexes bind to the TCR with a slightly higher KD, 
but similar off-rates when compared to the αCD3 antibody used.[33] The established 
sDC design principles can therefore be applied directly for the development of clinically 
relevant sDCs.
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Conclusion
In summary, we have shown that polymer length and effector molecule density are 
key design parameters for the development of sDCs. These parameters have a direct 
effect on the valency of the sDC and, consequently, on the effective concentration 
required for T cell activation. In addition to this enhancement of the binding strength, 
robust and sustained T cell activation was observed that goes beyond a pure avidity 
effect. Our results show that the multivalent scaffold also affects T cell signaling 
pathways. Co-localization of several effector molecules in the same nano- or 
micro cluster leads to a long lasting activation that cannot be achieved with non- 
polymer-bound antibodies. Future studies, using natural pMHCs as effector molecules, 
will be directed at elucidating the mechanistic origin of this sustained T cell response.
Experimental section
Polymer synthesis (P1’-P3’). Water-soluble polyisocyanopeptides were synthesized as 
described using our previously published method.22 For the synthesis of P1’ and P2’, 
the functional azide monomer (N3) and the non-functional methoxy monomer (OMe) 
were polymerized in a 1:100 ratio. For P3’, a 1:70 N3:OMe ratio was used to increase the 
number of possible coupling sites. The polymer length was controlled by the amount 
of nickel catalyst added in the polymerization reaction. A 1:200 ratio of catalyst: 
monomer was used for the synthesis of P1’. For P2’ and P3’ the catalyst:monomer ratio 
was 1:10000. The molecular weight of the polymers was determined from viscosity 
measurements (Table S1) as described previously.22
Synthesis of polymer-streptavidin conjugates. Streptavidin (SAv, Thermo Fisher 
Scientific) was functionalized with BCN-POE3-NH-C(O)CH2CH2CH2C(O)OSu (BCN- 
NHS; Synaffix) to couple it to the azide-groups on the polymer in a strain-promoted 
azide-alkyne cycloaddition (SPAAC) reaction.[24] The reaction was performed in borate 
buffer (10 mM, pH 8.5) using a 5 to 6-fold excess of BCN-NHS. Following incubation 
for 1.5 hours at room temperature, the mixture was purified by ultrafiltration (10 kDa 
cut-off) and gel filtration (PD-10 desalting column; GE Healthcare) to remove 
non-reacted BCN-NHS. During purification, the buffer was exchanged to phosphate 
buffered saline (PBS, pH 7.4). Mass spectrometry analysis (ESI-TOF) revealed that 1-4 
BCN moieties were coupled per streptavidin molecule (BCN-SAv).
 BCN-SAv was subsequently reacted with azide-bearing polyisocyanopeptide 
polymers. A 1:1 molar ratio of N3:BCN-SAv was used for the synthesis of P1-SAv and 
P2-SAv. N3:BCN-SAv ratios of 1:0.5, 1:1 and 1:5 were used for the synthesis of P3a-SAv, 
P3b-SAv and P3c-SAv, respectively. All reactions were performed in PBS. The reaction 
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mixtures were first incubated at room temperature for 1 hour and subsequently stirred 
at 4° C for 2.5 days. The resulting polymer-SAv conjugates were purified by ultrafiltration 
(100 kDa cut-off).
Characterization of polymer-streptavidin conjugates. The average polymer length 
and SAv density were determined with atomic force microscopy (AFM) using the 
method described earlier[22] (Fig. S1). The resulting histograms, displaying the 
distribution of polymer length and SAv distance of at least 41 individual polymers, 
are shown in Fig. S2 and Fig. S3. The results are summarized in Table S2.
Synthesis of sDCs (P1, P2, P3a-c). The polymer-SAv conjugates were incubated with 
biotinylated, monoclonal mouse anti-human CD3 antibodies (αCD3; clone OKT3; 
purified in house from the hybridoma cell line) to obtain the αCD3- functionalized 
polymers P1, P2, P3a, P3b and P3c. The polymer-SAv conjugates were incubated with 
the biotinylated antibodies in a 4:1 αCD3/SAv molar ratio. As previously described,[22] 
this 4:1 αCD3/SAv molar loading ratio yields a 1:1 binding ratio of αCD3 and SAv on the 
polymer backbone (αCD3-sDC).
Cell preparation and cell culture. Peripheral blood lymphocytes (PBLs) were obtained 
from buffy-coats of healthy individuals in accordance with institutional guidelines.[22] 
Briefly, peripheral blood mononuclear cells were obtained from Ficoll density 
centrifugation. Monocytes were removed using the plastic flask adherence method. 
The non-adherent PBLs were then maintained at 37 °C and 5 % CO2 in complete medium: 
RPMI-1640 (Lonza), containing 10 % (v/v) fetal bovine serum (FBS, Gibco), 1 % (w/v) 
glutamine (Lonza), and 1x Antibiotic-Antimycotic (Gibco).
Single-cell Ca2+-signaling. The fraction of PBLs responding to the αCD3-sDC treatment 
was determined in a single-cell Ca2+-signaling assay using the ratiometric Ca2+- 
indicator Fura-2. PBLs (105 cells) were loaded with 3 µM Fura-2 AM (Thermo Fisher) in 
complete medium for 1 hour at 37 °C and 5 % CO2. Fura-2 loaded PBLs were washed 
twice with HEPES buffered saline (20 mM HEPES pH 7.4, 115 mM NaCl, 5.4 mM KCl, 1 
mM CaCl2, 0.8 mM MgCl2, 13.8 mM glucose) and allowed to adhere to poly-D-L-lysine-
coated (0.05 mg/ml; Sigma-Aldrich) glass bottom dishes (Nunc) at room temperature. 
Single-cell Ca2+-measurements were performed as described before.[34] Dishes were 
placed on the stage of an inverted microscope (Axiovert 200M; Zeiss) equipped with 
a temperature-controlled CO2 stage incubator (37 °C and 5 % CO2) and a 63x, 1.25 NA 
objective (Plan NeoFluar). Fura-2 was excited at 340 nm and 380 nm alternatingly, 
using a monochromator (Polychrome IV; TILL Photonics). The emitted light was 
directed through a 415 DCLP dichroic mirror (Omega Optical) and a 510WB40 emission 
filter (Omega) onto a CoolSNAP HQ monochrome CCD camera (Roper Scientific). 
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The camera exposure time was 30 ms and the time between two ratio images was 2-4 s. 
All hardware was controlled with Metafluor 6.0 software (Universal Imaging). 
The images obtained were analyzed using Image-Pro Plus software (Media Cybernetics). 
Regions of interest (ROIs), corresponding to individual PBLs, were selected together 
with a cell-free ROI for background correction. For each ROI, the average pixel intensity 
was calculated for each excitation wavelength. After subtraction of the corresponding 
background value, the 340 nm/380 nm fluorescence emission ratio was calculated as a 
measure of the cytosolic Ca2+-concentration. Increases in cytosolic Ca2+-concentration 
were identified with GraphPad Prism 5 (GraphPad Software), using as criterion that 
the increase in the 340 nm signal is mirrored by a decrease in the 380 nm signal.
 To investigate the early effects of different αCD3-sDCs on Ca2+-signaling, a series 
of experiments was performed. These experiments include measurements to compare 
the effect of different αCD3-sDCs (experiments 1 and 2 in Table S3) and the dose 
dependences of P3c and freely soluble αCD3 (experiment 3 in Table S3). For these 
experiments, the dishes with the Fura-2 loaded T cells were placed onto the microscope 
and imaging was started. The different stimulants were added 5 min after the onset 
of imaging. After 1 h of imaging, 1 µg/ml of ionomycin was added to test for cell 
viability. The number of cells analyzed for every experimental condition tested is 
summarized in Table S4. Typical raw data of PBLs stimulated with αCD3-sDC or free 
αCD3 are shown in Fig. S4 and movies M1 and M2. The movies (60x speed) show Fura-2 
loaded PBLs treated with free αCD3 (M1) or with the sDC-αCD3 P3c (M2). Each movie 
shows 5 min of baseline imaging and 1 h of imaging in the presence of stimulant. 
The last 5 min of each movie show the cells in the presence of ionomycin. The movies 
were captured with a frame rate of 0.25 s-1. The data shows that PBLs display different 
patterns of Ca2+ signaling. In this study, we restricted ourselves to determining the 
fraction of Ca2+ signaling cells.
 To establish the long-term effect of P3c on single-cell Ca2+-signaling, PBLs were 
treated with the respective stimulant for 1 h, followed by incubation without stimulant 
for an extended period of time. The following conditions were tested: untreated, P3c, 
free αCD3, P3-mIgG2a (isotype control; 40 nm mIgG2a spacing) and P3c-SAv (lacking 
αCD3). In more detail, PBLs (105 cells) were incubated with the respective stimulant 
(12.5 ng/ml) for 1 hour at 37 °C and 5 % CO2. At the end of this stimulation period, the 
cells were washed with RPMI-1640 medium without serum and antibiotics to remove 
the stimulant. The cells were resuspended in fresh complete medium and maintained 
at 37 °C and 5 % CO2 for another 15 h or 23 h (Fig. S6). During the last 20 min of this 
post-stimulation period, the cells were loaded with Fura-2. The Fura-2-loaded cells 
were washed twice with PBS + 1 % BSA (PBA) and imaged under the microscope for 1 h. 
Cell viability was assessed at the end of the measurement as described above 
(treatment with ionomycin for 5 min). To be able to compare these post-stimulation 
results with the previously obtained data, a ‘0 h’ time point was taken where the PBLs 
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(105 cells) were first loaded with Fura-2 for 20 min and imaged exactly as described 
above.
Enzyme-linked immunosorbent assay (ELISA; IFNγ secretion). To investigate the 
effect of the different αCD3-sDCs on IFNγ secretion, PBLs (105 cells/well) were seeded 
in 96 well plates and treated with P1, P2, P3a, P3b and P3c or free antibodies (αCD3) 
at different concentrations (0.05, 0.5, 5, 50 and 100 ng/ml) for 16 h at 37 °C and 5 % CO2. 
To determine the effect of polymer length, the treatment variables were P1, P2 and 
free αCD3 along with an untreated control. The experiment was performed with PBLs 
from 3 different donors, each measured in duplicate. P3a, P3b, P3c were used to 
investigate the effect of αCD3 density (again using free αCD3 and untreated cells as a 
control). This experiment was performed with PBLs from 2 different donors (measured 
in duplicate). The concentration of secreted IFNγ was determined using a sandwich 
ELISA as described in our earlier publications.[22-23] Briefly, 96 well plates (Nunc 
Immunomodules) were coated with mouse anti- human IFNγ antibody (Thermo 
Fisher). After incubation at 4 °C overnight, the plates were washed and blocked with 
PBS/Tween (0.05 %) and PBS + 1 % BSA (PBA), respectively. IFNγ standards (Thermo Fisher) 
and supernatants (from treated and untreated cells) were added into the respective 
wells and incubated for 1 h at room temperature. After washing 3x with PBA, the 
concentration of IFNγ was detected using a biotinylated mouse anti-human IFNγ 
antibody (Thermo Fisher) and a streptavidin-horseradish peroxidase (HRP) conjugate 
(Life Technologies). HRP activity was detected using tetramethyl benzidine (TMB; 
Sigma Aldrich). Absorption at 450 nm was measured using an iMark Microplate 
Reader (Bio-Rad).
 To measure the long-term effect of the αCD3-sDC treatment, PBLs (105 cells/well) 
were seeded in 96 well plates and treated with the respective stimulant at 5 ng/ml. 
The cells were incubated with the stimulant for 16 h at 37 °C and 5 % CO2. After this 
incubation time, the cells were washed with RPMI-1640 medium without serum and 
antibiotics. They were then resuspended in fresh complete medium with serum to 
observe the activation state of the cells after the treatment was removed. The IFNγ 
concentration was determined directly before the medium was removed (16 hours) 
and at the following time points after the initial stimulation: 24, 48, 72, 96 and 120 h.
Flow cytometry (CD69 expression). To measure the long-term effect of the αCD3-sDC 
treatment on CD69 expression, PBLs (105 cells/well) were seeded in 96 well plates and 
treated with the respective stimulant (1, 5 and 50 ng/ml). The cells were incubated 
with the stimulant for 8 h at 37 °C and 5 % CO2. After this incubation time, a sample 
was taken for analysis. The remaining cells were washed with RPMI-1640 medium 
without serum and antibiotics. They were then resuspended with fresh complete 
medium with serum to observe the activation state of the cells after the treatment 
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was removed. The cell suspensions were collected at the respective time points (24, 48, 
72, 96 and 120 h after the initial stimulation) and used for flow cytometric analysis 
(CyAn ADP; Beckman Coulter) following the same methodology as described in our 
previous publications.[22-23]
 Briefly, PBLs (treated or untreated) were washed twice with PBA to remove 
unbound sDCs or antibodies. PBLs were stained with antibodies specific for the CD4/8+ 
T cell subpopulations (APC-labeled mouse anti-human CD4/8 mAb; T cell marker; BD 
Pharmingen) and with PE-labeled mouse anti-human CD69 (eBioSciences). After 1 hour 
of incubation, the cells were again washed twice with PBA before performing flow 
cytometric analysis. The data obtained were analyzed using FlowJo ver. 9.2 Software 
(TreeStar Inc.). The gating strategy is shown in Fig. S9.
Associated content
Supporting Information. Characterization data for the polymer conjugates, experimental 
details of the single-cell Ca2+-signaling experiments as well as additional control 
experiments are described in the supporting information. Movies M1 and M2 show 
representative data of the single-cell Ca2+-signaling experiments. This material is 
available free of charge via the Internet at http://pubs.acs.org
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Supplementary tables and figures
Figure S1  Representative AFM images of the polymer-SAv conjugates (P1-P3c) drop-casted on 
polylysine treated mica. Scale bar: 200 nm for (a)-(e).
Table S1  Characteristics of the polymers.
Polymer Catalyst ratio N3 ratio Mv (kg/mol)a
P1’ 1:200 1:100 200
P2’ 1:10,000 1:100 628
P3’ 1:10,000 1:70 577
a Determined from viscosity measurements.
P1 P2
P3a P3b P3c
a b
c d e
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Figure S2  Length distribution of the different polymer-SAv conjugates as determined from 
AFM images. Each histogram contains at least 41 polymers: (A) P1-SAv, n = 48; (B) P2-SAv, 
n = 74; (C) P3a-SAv, n = 72; (D) P3b-SAv, n = 68; (E) P3c-SAv, n = 41.
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Figure S3  Average distance between SAv molecules determined from the AFM images. 
Each histogram contains at least 41 polymers: (A) P1-SAv, n = 48; (B) P2-SAv, n = 74; (C) P3a-SAv, 
n = 72; (D) P3b-SAv, n = 68; (E) P3c-SAv, n = 41.
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Table S2  Characteristics of the polymer-SAv conjugates.
Polymer SAv equivalents Mean length (nm)a Mean SAv distance (nm)a
P1 1 175 110
P2 1 350 120
P3a 0.5 400 134
P3b 1 442 85
P3c 5 438 43
a Determined with AFM imaging.
Table S3  Treatment conditions for the single-cell Ca2+-signaling experiments.
Experiment Stimulant Imaging time αCD3 concentrationa
1. sDC length i. P1
ii. P2
iii. free αCD3
iv. untreated
5 min baseline Ca2+
1 h treatment
5 min ionomycin
0.005, 0.5, 5, 25 ng/ml
2. αCD3 density i. P3a
ii. P3b
iii. P3c
iv. free αCD3
v. untreated
5 min baseline Ca2+
1 h treatment
5 min ionomycin
0.005, 0.5, 5, 25 ng/ml
3.  dose-response 
curves
i. P3c
ii. free αCD3
iii. untreated
5 min baseline Ca2+
1 h treatment
5 min ionomycin
0.001, 0.01, 0.1, 5, 10, 25, 50, 
100 ng/ml
a  The concentration always refers to the amount of αCD3 bound to the αCD3-sDCs or present in freely 
 soluble form (free αCD3).
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Table S4  Number of cells analyzed for the single-cell Ca2+-signaling experiments.
Experiment Stimulant c(αCD3) Number of cells analyzed
Donor 1 Donor 2 Donor 3
1. sDC length i. P1
ii. P2
iii. αCD3
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
12
12
11
6
12
12
12
7
7
6
5
7
7
5
5
7
6
5
7
8
5
3
8
7
5
6
6
6
6
6
6
5
4
6
5
6
2. αCD3 density i. P3a
ii. P3b
iii. P3c
iv. αCD3
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
0.005 ng/ml
0.5 ng/ml
5 ng/ml
25 ng/ml
4
2
4
12
6
5
8
6
6
10
8
14
6
7
5
7
4
4
4
6
6
5
5
5
6
10
8
10
5
4
8
7
4
6
4
5
5
8
7
6
6
6
5
5
4
6
5
6
3.  dose-response 
curves
i. P3c
ii. αCD3
0.001 ng/ml
0.01 ng/ml
0.1 ng/ml
5 ng/ml
10 ng/ml
25 ng/ml
50 ng/ml
100 ng/ml
0.001 ng/ml
0.01 ng/ml
0.1 ng/ml
5 ng/ml
10 ng/ml
25 ng/ml
50 ng/ml
100 ng/ml
44
17
22
22
23
13
14
21
10
24
14
17
13
8
12
11
31
39
21
17
14
12
24
26
30
26
33
16
42
21
20
25
33
19
22
18
22
25
24
31
23
26
33
15
26
15
31
21
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Figure S4  Single-cell Ca2+-signaling experiments. Representative time traces (340 nm/380 
nm ratio) for PBLs treated with free αCD3 (A) or P3c (B).
Figure S5  IFNγ secretion of PBLs treated with P3a, P3b or P3c normalized to polymer 
concentration.
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Figure S6  Timeline of the post-stimulation single-cell Ca2+-signaling experiments. To obtain 
the ‘0 h’ time point, the Fura-2 loaded cells were treated with the stimulant directly under the 
microscope and imaged for 1 h. For the ’16 h’ and ’24 h’ time points the cells were first treated 
with the respective stimulant for 1 h, washed to remove the stimulant and then incubated 
without stimulant for 15 h or 23 h, respectively. During the last 20 min of this incubation 
period, the cells were loaded with Fura-2. Imaging was started at the indicated time point. At 
the end of the 1 h imaging period, the cells were treated with ionomycin to determine cell 
viability. In this post-stimulation experiment, the ‘5 min’ baseline was only determined for 
the ‘0 h’ time point.
2CONTROLLING T CELL ACTIVATION WITH MULTIVALENT SDCS
63
Figure S7  Results of the post-stimulation single-cell Ca2+-signaling experiments. PBLs were 
treated with 12.5 ng/ml P3c or free αCD3 for 1 h. The stimulant was removed and the cells were 
incubated in fresh medium. Ca2+-imaging was performed 16 h or 24 h after starting the 
treatment (15 h or 23 h after removal of the stimulant). As a reference, PBLs were also imaged 
under the microscope while the stimulant was added (0 h). The graph further shows data 
obtained for PBLs treated with the following controls: P3-SAv, P3-mIgG2a (isotype control) or 
medium (untreated). For all experiments the data represents the mean ± SEM of 3 independent 
experiments performed with PBLs from different donors. The number of cells analyzed is 
summarized in Table S5. The asterisks represent the statistical significance at ‘p’ values of 
0.001 (***). A clear difference is observed between the post-stimulation signaling of αCD3-sDC 
treated cells and the cells treated with the free αCD3 antibody or any of the controls. Of note, 
the untreated control shows a small fraction of PBLs (~30 %) that display spontaneous 
increases in the cytosolic Ca2+-concentration (white bars). A similar percentage of PBLs (~26%) 
showing spontaneous Ca2+ oscillations (Ca2+ oscillations that occur in the absence of added 
stimulant) has been reported before (Donnadieu, E; Bismuth, G; Trautmann, A. The intracellular 
Ca2+ concentration optimal for T cell activation is quite different after ionomycin or CD3 
stimulation. Pfluegers Arch. – Eur. J. Physiol. 1995, 429 (4), 546-554).
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Table S5  Number of cells analyzed for the post-stimulation Ca2+-signaling experiments.
Stimulant Incubation time Number of cells analyzed
Donor 1 Donor 2 Donor 3
i. P3c
ii. αCD3
iii. P3-mIgG2a
iv. P3-SAv
v. untreated
0 h
16 h
24 h
0 h
16 h
24 h
0 h
16 h
24 h
0 h
16 h
24 h
0 h
16 h
24 h
15
7
10
14
9
10
10
10
10
10
11
9
9
9
9
14
8
7
9
9
9
9
8
9
14
11
9
7
7
9
11
6
7
8
7
7
6
6
5
7
5
6
8
5
7
Figure S8  Post-stimulation analysis of CD69 expression. Percentage of CD69 expressing 
T cells after treatment with different concentrations of P3c or αCD3.
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Figure S9  Post-stimulation analysis of CD69 expression. Percentage of CD69 expressing 
T cells after treatment with different concentrations of P3c or αCD3.
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Abstract
Water-soluble poly(isocyanopeptides) (PICs) are a new class of synthetic polymers 
that mimic natural protein-based filaments. Their unique semi-flexible properties 
combined with a length of several hundred nanometers have recently enabled a 
number of biomedical applications, ranging from tissue engineering to cancer 
immunotherapy. One crucial step toward the further development of PICs for these 
applications is the efficient and controlled synthesis and purification of PIC-
biomolecule conjugates. Considering the large size of PICs and the biomolecules to be 
conjugated, conjugations reactions do usually not proceed to completion due to steric 
effects. As a consequence, purification of the reaction mixture is necessary to separate 
the obtained bioconjugates from unreacted biomolecules. As a direct result of the 
semi-flexible nature of PICs, standard polymer and/or protein purification methods 
based on molecular weight have not been successful. Here, we introduce a new 
affinity-based purification method utilizing biotin as an affinity tag. PICs decorated 
with a controlled and tunable density of biotin molecules (biotinPICs) were efficiently 
bound to and eluted from a mono-avidin resin in buffered aqueous solution. Using 
these biotinPICs, two different protein conjugates were synthesized, one carrying 
the enzyme alkaline phosphatase (PhoA) and the other T-cell activating anti-CD3 
antibodies. The resulting biotinPIC-protein conjugates were successfully obtained in 
high purity (>90 %) and without any loss of protein activity. The high purity greatly 
simplifies the analysis of biotinPIC-bioconjugates, such as the determination of the 
average number of biomolecules conjugated per biotinPIC chain. Most importantly, it 
allows for the direct and straightforward application of the obtained bioconjugates in 
the desired applications. The new method developed may further be adapted for the 
purification of other advanced bioconjugates that are difficult to obtain in high purity 
with available standard methods.
Keywords
polymer bioconjugate, polyisocyanopeptide, streptavidin, avidin, biotin, affinity 
chromatography
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Introduction
Following the synthesis of the first polymer-protein conjugate approximately 
40 years ago,[1] the range of applications of these functional bioconjugates has grown 
enormously. The first and still most common motivation for the synthesis of polymer- 
protein conjugates is to improve the properties of therapeutic proteins. Nowadays, the 
conjugation of poly(ethylene glycol) (PEG) is a frequently employed strategy to 
increase protein solubility and stability, to reduce immunogenicity and to alter 
circulation half-life.[2-4] With continuous improvements in polymer synthesis and 
bioconjugation methods,[5-8] the range of applications has expanded and new classes 
of polymers have been utilized. For example, conjugation with stimuli-responsive 
polymers such as poly(N-isopropylacrylamide) (PNIPAAm) introduces additional 
functionality into the protein.[5,8,9] Making use of the  temperature-sensitive 
behavior of PNIPAAm, the protein-polymer conjugate reversibly precipitates when 
increasing the temperature above the lower critical solution temperature (LCST) of 
PNIPAAm,[5] allowing for the development of advanced purification methods and 
diagnostic assays.[8,9] Linear or branched polymers with multiple reactive groups 
have been used as scaffolds for the synthesis of multivalent bioconjugates with 
increased binding strength[10-14] or of multifunctional entities that combine 
different activities.[12,13,15] The latter is of particular interest for engineering enzyme 
cascades where reaction intermediates need to be efficiently transferred between 
enzyme active sites.[15-17] Polymer-bioconjugates further find application for the 
synthesis of biocompatible hydrogels for tissue engineering applications[18-21] as well 
as for the synthesis of self-assembled nanostructures, where the biomolecules are 
used as functional material building blocks.[22,23]
 Over the last years we have introduced water-soluble poly(isocyanopeptides) 
(PICs) as novel and versatile polymer scaffolds for biological applications.[24-26] PICs 
are long (100-1000 nm) and semi-flexible polymers that mimic the properties 
of many protein-based filaments found in nature, e.g. in the cytoskeleton and 
the extracellular matrix. Their semi-flexibility is a direct result of their helical 
secondary structure and represents a unique feature for synthetic polymers.[27,28] 
PICs are polymerized from isocyanide monomers that carry a short di-alanine peptide 
in every monomer. Upon folding into a helix, hydrogen bonds between the peptide 
amides stabilize the helical structure. PIC monomers are further functionalized with 
oligoethylene glycol chains to provide water solubility. When carrying a tri-ethylene 
glycol chain (EG3), the corresponding PIC undergoes a sol-to-gel transition at a 
temperature of ~19 °C.[27,29] Consequently, EG3-functionalized PICs form a hydrogel at 
room temperature. This hydrogel has been used in cell culture[21] and for sensing the 
binding of short oligonucleotides to their complementary sequence.[30]. In contrast, 
tetra-ethylene glycol (EG4) functionalized polymers undergo a sol-to-gel transition at 
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40-45 °C.[27] These PICs are therefore fully dissolved at physiologically relevant 
temperatures, making them excellent scaffolds for the synthesis of polymer 
conjugates. As a first application, we have attached T cell stimulating antibodies to 
EG4-functionalized PICs and used these PIC-antibody conjugates as novel artificial 
antigen presenting cells in immunotherapeutic applications.[11,12,14]
 All these applications have in common that the PICs have to be functionalized 
with biomolecules. For the cell culture application, a short integrin-binding GRGDS 
peptide was grafted onto PICs to provide cell adhesion sites in the hydrogel.[21] In the 
sensing application, short DNA oligonucleotides were coupled to the PICs. These DNA 
sequences were subsequently cross-linked upon binding of an analyte.[30] For the 
 immunotherapeutic application, the PICs were functionalized with streptavidin to 
allow for the subsequent binding of biotinylated antibodies.[11,12,14]
 As a direct result of their unique physical properties, these semi-flexible PICs do 
not form a typical random coil structure in solution. This complicates the separation 
of polymer-biomolecule conjugates from non-reacted biomolecules, following a 
conjugation reaction. Despite careful optimization, neither dialysis nor size exclusion 
chromatography nor field flow fractionation methods were found to be successful. 
Ultrafiltration was identified as the only possible method for the purification of freshly 
synthesized PIC-bioconjugates, but more than 99% of the material was lost during the 
process.[11,12,14] As an alternative, the reaction between PICs and biomolecules was 
carefully optimized so that an almost quantitative coupling of biomolecules was 
achieved and no purification was needed. For small molecules, such as short peptides[21] 
and DNA oligonucleotides,30 this method was successful. For large proteins, e.g. 
antibodies, the reaction with the PIC is not quantitative,[11,12,14] however, as steric 
effects limit the kinetics and the yield of the reaction. Clearly, an alternative and 
efficient purification method is needed to obtain pure PIC-bioconjugates in good yield.
 Affinity tags such as the hexahistidine tag,[31] the strep-tag[32] or biotin[33] are 
frequently used for the purification of recombinantly expressed proteins from crude 
cell extracts. To the best of our knowledge, such a purification strategy has never been 
used for the purification of bioconjugates that contain a synthetic polymer. Inspired 
by the affinity tag method, a PIC polymer carrying biotin as an affinity tag was 
designed. Using this biotin-functionalized PIC (biotinPIC), affinity purification on a 
mono-avidin resin can potentially be used to remove unreacted biomolecules. 
Mono-avidin is a monomeric derivative of avidin that possesses a highly reduced 
affinity for biotin.[34] It has been shown that biotinylated molecules bind to 
mono-avidin agarose in a reversible manner and can be eluted competitively when 
adding high concentrations of free biotin.[35] Here, we describe the synthesis and 
 characterization of biotinPIC polymers. We show that these biotinPICs reversibly bind 
to a mono-avidin resin and that this affinity purification method can be used for the 
purification of  biotinPIC-bioconjugates. The versatility of this new purification method 
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is demonstrated using two different model proteins, an antibody and an enzyme. 
The enzyme (alkaline phosphatase from E. coli; PhoA) was chosen as it allows for 
the straightforward determination of the activity of the conjugated biomolecule. 
The antibody of choice is the same anti-CD3 antibody (αCD3) that has been used earlier 
for the synthesis of PIC-antibody conjugates for stimulating T cells.[11,12,14]
Results and discussion
Synthesis and characterization of biotin-functionalized polyisocyanopeptides. To 
investigate if the biotin affinity tag can be used for the purification of PIC-bioconjugates, 
biotin-functionalized polymers were synthesized (Figure 1) and used in a series of 
purification experiments. For this purpose, PICs containing azide-functionalized side 
chains in a pre-defined density were synthesized using the same method as described 
in our previous publications.[11,12,14,21,30] In short, functional azide monomers were 
copolymerized with monomers containing non-functional methoxy groups, using a 
nickel catalyst. The ratio of azide:methoxy monomers was chosen to be 1:30, yielding 
a statistical average distance between azides of 3 nm. Subsequently, the azide- 
functionalized PIC was reacted with different relative amounts of biotin-azadibenzo-
Figure 1  Conjugation strategy for the synthesis of biotin-functionalized polyisocyano-
peptides that can be used for the subsequent coupling of DBCO-containing biomolecules. 
In this work, the biomolecule is either an antibody (αCD3) or an enzyme (PhoA).
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cyclooctyne (biotin-EG4-DBCO) in a strain-promoted azide-alkyne cycloaddition 
(SPAAC) reaction.[36] Assuming a quantitative yield of the reaction, biotinPICs with 
an average biotin spacing of 5, 7.5, 10 and 40 nm were prepared. Using this strategy, 
the remaining azide groups are available for a second SPAAC reaction that allows 
for the coupling of DBCO-functionalized biomolecules.
 To optimize the biotin density necessary to bind and elute the biotinPICs from 
mono-avidin containing beads in a batch purification process, an incubation and 
elution protocol was developed. The polymers were diluted to 0.1-0.2 mg ml-1 in 
phosphate buffered saline (PBS) and mixed with a 50 % slurry of mono-avidin beads 
in a 1:1 (v/v) ratio. The binding of the biotinPICs to the beads was determined 
by measuring the concentration of unbound biotinPIC in the supernatant using 
circular dichroism (CD) spectroscopy. Due to the helical conformation of the PICs, this 
technique provides an indication of the polymer concentration, assuming that the 
polymer conformation is not altered during the experiment.[25,26,37] The CD spectrum 
of the PIC is characterized by a negative peak at λ = 360 nm and a larger positive peak 
with a maximum at λ = 272 nm (Figure S1). Calibration curves of the azide-functionalized 
PIC were determined at both wavelengths, showing that the corresponding peak 
heights scale linearly with polymer concentration (Figure S1). The analysis of the 
supernatants after 4 hours of incubation shows that the biotinPICs are able to bind to 
the mono-avidin beads. When comparing the samples with different biotin densities, 
clear differences are seen in the fraction of bound biotinPICs (Figure 2a). Polymers 
with the lowest biotin density (spacing of 1 biotin per 40 nm) showed little binding 
(~12%) and the majority of biotinPICs remained in the supernatant. Decreasing the 
biotin spacing to 10 nm already increased the fraction of bound biotinPICs to ~30%. 
A further decrease in the biotin spacing to 7.5 nm and 5 nm allowed for binding ~65-70% 
of the biotinPICsto the mono-avidin beads. The biotin spacing was not decreased 
further as a sufficient amount of free azides is required for further bioconjugation.
 After having confirmed binding of the biotinPICs to mono-avidin beads, the 
elution protocol was optimized. The beads were first washed with PBS containing 0.1% 
Tween 20 (PBS-T, 2x) and PBS (4x) to remove any non-specifically bound polymers. 
During this extensive washing protocol, ~30% of the beads were lost, which reduces 
the total yield of eluted polymers. Following washing, PBS containing 2 mM biotin 
was added to the beads to elute the bound biotinPICs competitively. In the last step, 
the eluate was filtered over a frit with 20 µm pore size to remove residual mono-avidin 
beads. The CD spectrum of the eluted fractions was not altered when compared to the 
original polymer samples before purification, which indicates that the helical 
structure is not affected during the binding and elution process (Figure 2b). The 
fraction of eluted biotinPICs clearly correlates with the relative amount of biotinPIC 
initially bound to the beads and, consequently, also with the density of biotin coupled 
to the polymer. Only a small fraction (4 % of the original amount) was obtained for the 
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polymer with a biotin spacing of 40 nm. Higher fractions of 17, 34 and 35 % were 
obtained for the other polymers with a biotin spacing of 10, 7.5 and 5 nm, respectively 
(Figure 2a). Considering the loss of beads during the washing steps and the fraction of 
polymer that did not bind to the beads, elution with 2 mM biotin is sufficient to elute 
more than 50 % of the bound biotinPIC polymers.
Figure 2  Binding and elution of biotinPICs to and from mono-avidin beads. (A) Binding and 
elution profiles for biotinPICs containing a different biotin density (EG4 linker). Shown is 
the relative amount of biotinPIC in the supernatant after binding or elution. (B) CD spectrum 
of the supernatant after 4 hours of incubation. In addition, the eluted fraction is shown 
(data shown for 1 biotin in 7.5 nm. (C) Binding and elution profile of biotinPICs prepared with 
the long (3000 Da) PEG linker and a biotin spacing of 7.5 nm. Shown is again the relative 
amount of biotinPIC in the supernatant after binding and elution.
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In addition to the biotin density, also the linker length between biotin and the PIC 
polymer backbone was investigated. To test for possible steric hindrance, the length of 
the PEG spacer between the biotin moiety and the DBCO functional group was 
increased. Using a PEG linker with a molecular weight of 3000 Da, biotinPIC polymers 
were prepared with an average biotin spacing of 7.5 nm. Binding of this polymer to the 
beads was considerably slower when compared to the previously used biotinPICs 
containing only the EG4 linker. Only after 15 hours of incubation more than 90% of the 
polymer was bound. Unfortunately, elution of this polymer recovered only 15 % of the 
original amount (Figure 2c). Overall, it appears that the longer linker does not reduce, 
but instead increases steric hindrance thereby affecting both the kinetics of the 
interaction as well as the yield of the purification protocol.
 Taken together, these results show that the biotinPIC with a biotin spacing of 7.5 
nm coupled via the short linker performs best when considering both the requirements 
for an efficient purification as well as its future application. It shows good binding 
and a reasonable amount is eluted from the mono-avidin beads. At the same time, 
a sufficient number of azides is left for further conjugation. This biotinPIC was 
therefore selected as a model system to test whether this purification method can be 
used for the purification of biotinPIC-bioconjugates.
Synthesis and purification of alkaline phosphatase (PhoA) biotinPIC-bioconjugates. 
To investigate if biotinPIC-bioconjugates can be purified with the newly developed 
affinity-based method, biotinPICs were first functionalized with the enzyme PhoA. 
This was motivated by the availability of a large number of chromogenic and 
fluorogenic phosphoester substrates, which facilitate a straightforward comparison 
of enzyme activity before and after conjugation. To complement this sensitive activity 
readout, the enzyme was labeled with a fluorophore so that also the enzyme 
concentration can be determined easily during all steps of the experiment. PhoA was 
therefore reacted with the N-Hydroxysuccinimide (NHS) esters of DBCO- and 
AlexaFluor647 in a one-pot reaction. To determine the degree of labeling, the PhoA 
concentration was estimated with a BCA assay and the DBCO and AlexaFluor647 
concentrations were determined with UV/VIS spectro -scopy. On average, 1.1 
fluorophore molecules and 2.4 DBCO functional groups were coupled to the PhoA 
dimer. DBCO- and AlexaFluor647-labeled PhoA was then reacted with the biotinPIC 
polymer possessing a biotin spacing of 7.5 nm. Three different ratios of PhoA:azide 
were used for coupling the enzyme to the polymer (0.1, 0.2 and 0.5 eq. of PhoA with 
respect to azide groups). Assuming a quantitative reaction, this would result in an 
average PhoA spacing of 50, 25 and 10 nm.
 The PIC-PhoA bioconjugates were then purified over mono-avidin beads, using the 
optimized method described earlier for biotinPICs. The purified PIC-PhoA conjugates 
were analyzed with atomic force microscopy (AFM). The AFM images were used to 
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count the number of enzymes attached to every individual polymer chain (Figure 3a 
and b, Figure S2) and the average spacing between PhoA molecules was determined to 
be 55 nm (PIC 0.2 eq PhoA) and 100 nm (PIC 0.1 eq PhoA). In parallel, the polymer 
concentration was determined in a CD measurement at a wavelength of 360 nm and 
the PhoA concentration was determined with a BCA assay. This measurement yielded 
a spacing of 70 nm for the biotinPIC functionalized with 0.2 eq. PhoA and of 155 nm for 
the biotinPIC functionalized with 0.1 eq PhoA (Figure 3c). Considering the error in the 
AFM-based estimation, these values agree very well. This proves that unreacted 
enzymes have been efficiently separated from the bioconjugates during the 
Figure 3  Synthesis and purification of biotinPIC-PhoA bioconjugates. (A-B) AFM images of 
biotinPICs reacted with 0.1 eq. PhoA or 0.2 eq. PhoA drop-casted on mica. The bright ‘dots’ 
correspond to the enzyme while the ‘connecting line’ represents the polymer. (C) Calculated 
PhoA distances on the biotinPIC backbone, determined either from the measured bulk 
concentrations (BCA) or the AFM measurement. (D) Enzyme activity measurements of the 
PIC-PhoA conjugates in comparison to non-conjugated PhoA. The curves display the mean of 
three independent measurements.
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purification process. Unfortunately, no polymer bioconjugates were found on the mica 
surface for the biotinPIC functionalized with 0.5 eq PhoA, but the spacing determined 
from the bulk concentration assay was 34 nm. On average, the determined PhoA 
spacing is a factor 3 larger than the distances expected for a quantitative reaction, 
indicating a coupling efficiency of 30 %. This low coupling efficiency is expected for a 
reaction between two macro- molecules and again highlights the importance of a 
good purification method.
 In the next step, it was examined if the biotinPIC-conjugated PhoA was still 
catalytically active (Figure 3d). The activity of the enzyme was tested using the 
fluorogenic substrate 9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl) phosphate 
(DDAO-phosphate).[38] PhoA dephosphorylates the DDAO fluorophore, thereby 
altering its photophysical properties (Figure S3). Enzymatic activity results in an 
increase in product fluorescence allowing for a straightforward kinetic measurement. 
The increase in product fluorescence was determined for the three PIC-PhoA conjugates 
and for a control sample containing non-conjugated enzyme of the same concentration 
(determined via the fluorescence intensity of the AlexaFluor647 label before the 
kinetic measurement was started). All samples show very similar enzyme activities 
(Figure 3d), indicating that the coupling and purification process does not inactivate 
the enzyme. Taken together, these results show that the new purification protocol is a 
highly powerful method for the purification of PIC-enzyme conjugates. In the next 
step, these conjugates could be used for forming enzyme-functionalized hydrogels for 
a number of different applications. Such nature-like hydrogels represent an interesting 
new method for enzyme immobilization, as their large pore size[27] allows for free 
substrate and product diffusion. PIC polymers are further highly versatile scaffolds for 
the co-conjugation of different functional entities[12] so that they represent an 
interesting new platform for the assembly of cascade reactions.
Synthesis and purification of anti-CD3 biotinPIC-bioconjugates. Having established 
that the new purification protocol can be used to purify PIC-bioconjugates, an antibody 
was conjugated to the biotinPIC in the next step to investigate the general applicability 
of the method. This was further motivated by our earlier experiments with anti-CD3 
(αCD3) functionalized PICs that were shown to be highly effective as synthetic 
dendritic cells.[11,12,14] To obtain PIC-αCD3 of sufficient purity, the polymer conjugates 
had to be purified extensively using ultrafiltration, which resulted in a huge loss of 
both polymer and antibody (<1 % yield). Therefore, using the previously utilized αCD3 
antibody, it was tested if the new affinity-based purification method can overcome 
these problems and yield PIC-αCD3 bioconjugates with increased yield and purity. 
In the earlier experiments, αCD3 was biotinylated and bound to a streptavidin- 
functionalized PIC polymer. As biotin is now used as the affinity tag for purification, 
the original design had to be adjusted to allow for a direct conjugation of αCD3 to the 
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azide-functionalized biotinPIC. To achieve this, αCD3 was functionalized with the 
DBCO-NHS ester, allowing for a direct conjugation to the biotinPIC. The degree of 
labeling, as determined by UV/VIS spectroscopy,[39] was between 2 and 2.5 DBCO 
molecules per antibody.
 To investigate the influence of the antibody density on the performance of 
the biotin-tag based purification method, 4 different PIC-αCD3 bioconjugates were 
synthesized. DBCO-αCD3 was reacted with biotinPIC in PBS using 0.1, 0.3, 0.5 and 
1 equivalents of antibody relative to azide groups. The resulting reaction mixtures 
were then incubated with mono-avidin beads. The ability of the PIC-αCD3 bioconjugates 
to bind to the resin was estimated by analyzing the supernatant with CD (Figure 4a, 
Figure S1). The binding efficiency of the PIC-αCD3 to the mono-avidin beads was 
typically in the range of 35-55 %, which was lower than for the biotinPIC without αCD3 
Figure 4  Purification of PIC-αCD3 bioconjugates using a biotin affinity tag. (A) Binding and 
elution profile of PIC-αCD3 to and from mono-avidin agarose beads. Shown is the relative 
amount of PIC-αCD3 in the supernatant, determined using CD measurements. (B) Non- 
reducing SDS-PAGE of the PIC-αCD3 sample (1 eq. of antibody with respect to azide groups) 
in comparison to different concentrations of αCD3. Shown are relative concentrations with 
respect to the amount of αCD3 used in the reaction mixture. (C)Calculated average distances 
between αCD3 on the biotinPIC backbone obtained for different equivalents of DBCO-αCD3 
during the reaction.
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(65-70 %). After extensive washing (2x PBS-T, 4x PBS), typically 10-25 % of the original 
amount of PIC-αCD3 could be eluted (Figure 4a). Compared to biotinPIC without αCD3 
these yields are slightly lower, which is a direct result of a less efficient capture of the 
bioconjugate. This may originate from steric effects resulting from the large antibody 
or less favorable charge interactions between the antibody and mono-avidin.[40] 
In the case of unfavorable charge interactions, optimizing the buffer conditions in 
the capture and/or release step may lead to increased yields in future experiments. 
Still, the yields are significantly better than the yields obtained with the ultrafiltration 
protocol used before (<1 % yield).
 In addition to the yield, also the purity of the PIC-αCD3 is a crucial aspect for 
the further optimization and applicability of these bioconjugates. A combination of 
methods was used to determine the remaining amount of non-conjugated αCD3 in 
the samples after affinity purification. Gel electrophoresis (SDS-PAGE) was performed 
under non-reducing conditions to keep the disulfide bonds of the antibody intact 
(Figure 4c). As the polymer bioconjugate is too large to enter the SDS-PAGE gel (Figure 
S4), it can be directly concluded that any protein of the size of ~150 kDa represents 
non-conjugated antibody. A comparison of the PIC-αCD3 sample (1 eq. of antibody with 
respect to azide groups) with different concentrations of free αCD3 shows that more 
than 92 % of the antibody in the affinity purified sample was conjugated to the 
polymer. This result is in line with the results obtained for the PIC-PhoA conjugates, 
where only a very small amount of non-conjugated PhoA was observed in the AFM 
images (Figure 3). This high purity of the PIC-αCD3 conjugates allows for a simple 
determination of the number and the statistical spacing of αCD3 on the polymer 
backbone. Knowing the molar concentrations of both the antibody and the biotinPIC, 
the number of αCD3 per polymer can simply be determined by dividing the two values 
(Figure 4c). The biotinPIC concentration was again determined by CD measurements 
and the αCD3 concentration was obtained from a BCA assay. For 0.1, 0.3, 0.5 and 
1 equivalents of αCD3, an average antibody spacing of approximately 70, 40, 30 and 
20 nm was found, respectively. When compared to the average antibody spacing 
calculated for a coupling efficiency of 100 % (50 nm, 17 nm, 10 nm and 5 nm), it can be 
concluded that between 25-70 % of αCD3 antibodies have coupled to the polymer, 
with a lower coupling efficiency being observed for larger equivalents of αCD3. 
This may directly result from the altered DBCO-αCD3:azide ratio or originate from 
steric hindrance, which prohibits access of αCD3 molecules to remaining coupling 
sites (Figure 4c).
 Overall, our results clearly show that the purification of PIC-bioconjugates with 
an affinity tag is a powerful method for obtaining pure bioconjugates in high yield, 
which can be easily analyzed with standard spectroscopic methods. The affinity-based 
purification method developed now opens the way toward the synthesis of multi-
functional conjugates. The greatly increased yield and purity allow for a step-wise 
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functionalization with different molecules, providing unprecedented control over the 
number and stoichiometry of functional entities. This method, therefore, represents a 
highly promising starting point for the further development of PIC-bioconjugates for 
immunotherapeutic applications as well as for designing enzyme cascade reactions, 
which both require the conjugation of multiple different biomolecules to a polymer 
scaffold.
Conclusion
In this study, an affinity-based purification method was developed that increases 
both the total yield as well as the purity of PIC-bioconjugates. PIC polymers were equipped 
with biotin tags that allow for the reversible binding of the resulting biotinPIC 
polymers to mono-avidin beads. For optimal binding, a minimum statistical spacing 
between individual biotin moieties of at least 7.5 nm was required. To demonstrate 
the application potential of this new purification method, two different biotinPIC- 
bioconjugates were successfully synthesized and purified. Although the final yield of 
the purification was only 10-25 %, it was significantly better than the previously used 
ultrafiltration method where the yield was below 1 %. The yields of the binding and 
elution steps may be further optimized when re-applying the supernatant to the mono- 
avidin beads or when using (strept)avidin mutants[41,42] or biotin derivatives[43,44] 
with different affinity. Alternatively, the strong biotin-streptavidin interaction may 
be utilized when integrating a cleavable linker[45] between the PIC and the biotin 
moiety. More importantly, the new method allowed for removing non-reacted bio- 
molecules nearly quantitatively (>90 %), leading to highly pure biotinPIC-bioconju-
gates. As a consequence of this high purity, the analysis of these constructs was 
straightforward and the spacing of the conjugated biomolecules could be calculated 
from simply dividing the concentration of polymer by the concentration of the 
respective biomolecule. The densities calculated from bulk concentrations were in 
good agreement with the results from AFM imaging, where every individual 
biomolecule coupled to the polymer was visualized and counted. Furthermore, the 
developed purification method preserved the activity of the coupled biomolecule as 
was demonstrated with activity measurements for alkaline phosphatase. Altogether, 
a new versatile protocol was developed for the synthesis and purification of biotin-
PIC-bioconjugates. This protocol will not only be highly useful for further developing 
these molecules toward applications, but also for the preparation of other complex 
and multifunctional bioconjugates.
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Experimental procedures
Polymer synthesis. The PIC polymer used in this study was synthesized according to 
the procedure described in the literature.[11,12,14,21,30] In short, a 30:1 ratio of methoxy- 
terminated (1.124 g, 3.12 mmol) and azide-terminated (0.0038 g, 0.104 mmol) isocyano-
peptide monomers were mixed in toluene (50 mg ml-1) in a round bottom flask and 
stirred for 2 days until IR measurements showed the complete disappearance of 
 the isocyanide peak. The solution was diluted with dichloromethane and precipitated 
in diisopropyl ether three times, resulting in an off-white solid (0.937 g, 82%). 
The resulting polymer contains a statistical density of 1 azide per 3 nm. The polymer 
was analyzed using viscometry as described previously (Mv= 490 kg mol-1).[11]
Biotin-functionalization of PICs. The PIC polymer was dissolved in PBS (10 mM 
Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) in a concentration of 1 mg 
ml-1. Biotin-EG4-DBCO (Click Chemistry Tools) dissolved in DMSO or DBCO-PEG3000Da-
biotin (Nanocs) dissolved in DMSO was added to this solution in the required amount 
(less than 5% of the total volume, see below). The mixture was stirred overnight and 
subsequently used for testing the mono-avidin purification protocol or for the 
conjugation of biomolecules. Four different biotinPIC polymers were prepared with a 
different density of biotin. To achieve this, the molar ratio of biotin-EG4-DBCO:mono-
mer was varied from 1:75, 1:100 and 1:400. Assuming a quantitative reaction, this 
yields an average biotin distance of 7.5, 10 and 40 nm, respectively. During the 
synthesis of the fourth polymer with a 1:50 molar ratio (5 nm biotin spacing) DIBO-
AlexaFluor647 (Thermo Fisher Scientific) was added in a 1:500 ratio of dye:monomer to 
obtain a fluorescently labeled biotinPIC polymer for testing the migration of biotinPEG 
in SDS-PAGE (Figure S4). After stirring overnight, the mixture was precipitated in 
diisopropyl ether and dried in air. The dried material was dissolved in a concentration 
of 1 mg ml-1 in PBS.
Expression and purification of PhoA. The phoA gene was cloned from the plasmid 
pET-22b-phoA[46] into a vector of the pAK[47]/pKB[48] series, where the original lac 
promotor was replaced by the arabinose inducible PBAD promotor. The sequence of the 
pelB signal peptide was replaced with the signal peptide of PhoA. The resulting 
plasmid pKB5-PhoA-His allows for the periplasmic expression of PhoA with a 
C-terminal His-tag. For protein expression, the plasmid was transformed into the 
E. coli K12 strain TB1 (New England Biolabs). The cultures were grown in SB medium 
(20 g l-1 tryptone, 10 g l-1 yeast extract, 5 g l-1 Nacl, 50 mM K2HPO4) at 25 °C and induced 
with 0.02 % (w/v) arabinose at an OD600 between 0.5-1. After 3 hours, the cells were 
harvested by centrifugation at 5000 rpm and 4 °C for 15 min. The cells were resuspended 
in 50 mM tricine pH 8.0, 300 mM NaCl (loading buffer) and lysed using sonication. 
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The lysate was cleared by centrifugation and the resulting supernatant was incubated 
at 80 °C for 10 min to denature proteins other than the heat stable PhoA-His. Denatured 
proteins were removed by centrifugation (2x 30 min, 20000 g) at 4°C and filtration 
through a 0.22 µm syringe filter. The resulting supernatant was loaded onto a Zn2+-NTA 
column (His Gravi Trap equilibrated with ZnCl2 instead of NiCl2; GE Healthcare Life 
Sciences). Following a washing step with loading buffer (30 column volumes), the 
column was washed with 5 column volumes of loading buffer supplemented with 10 
mM imidazole. The protein was eluted from the column with 50 mM tricine pH 8.0, 
300 mM NaCl, 200 mM imidazole. The eluted protein was concentrated using ultra-
filtration (10 kDa cut-off; Amicon Ultra-15 Centrifugal Filter Units; Merck Millipore). 
Lastly, the buffer was exchanged to 50 mM sodium borate pH 8.5 using a PD-10 
desalting column (GE Healthcare Life Sciences). The purity was verified using 
SDS-PAGE and the correct molecular weight was confirmed with mass spectrometry 
(ESI-TOF). The protein concentration was determined from its absorbance at 280 nm (ε 
= 63260 M-1 cm-1 for the PhoA dimer) and confirmed using a BCA assay. The purified 
protein was stored in aliquots at -80 °C.
BCA assay. To determine the protein concentration, a micro BCA Protein Assay Kit 
(Thermo Fisher Scientific) was used. The assay was performed using the protocol 
supplied by the manufacturer. When determining the αCD3 or PhoA-His concentration, 
non-reacted αCD3 was used as the standard, spanning a concentration range from 
7.8 μg ml-1 to 1 mg ml-1. PIC-αCD3 samples were freeze-dried before the BCA assay and 
re-dissolved in PBS, to increase the sample concentration by a factor of 5-6.
Synthesis of AlexaFluor647-DBCO-PhoA. PhoA-His (~15 µM) was labeled with 
AlexaFluor647-NHS (Thermo Fisher Scientific) and DBCO-EG4-NHS simultaneously 
(Click Chemistry Tools). Using DMSO stock solutions, 4 equivalents of AlexaFluor647-
NHS and 4 equivalents of DBCO-EG4-NHS were added, yielding a final concentration of 
60 µM for both reagents. The DMSO content was ~10 % of the total volume. The reaction 
was incubated for 3-4 hours at 4 °C, followed by ultrafiltration with a 10 kDa cut-off. 
During ultrafiltration, the buffer was exchanged to 50 mM HEPES, pH 8.0. To determine 
the degree of labeling of the resulting AlexaFluor647-DBCO-PhoA-His, the protein 
concentration was first determined with a BCA assay. The DBCO and AlexaFluor647 
concentrations were determined from UV/VIS measurements using an extinction 
coefficient of 12,000 M-1 cm-1 for DBCO (309 nm) and of 270,000 M-1 cm-1 for 
AlexaFluor647 (650 nm). This analysis yielded a degree of labeling of 2.5 DBCO and 1.1 
AlexaFluor647 molecules per PhoA-His dimer.
Synthesis of αCD3-DBCO. The αCD3 antibodies (monoclonal mouse anti-human αCD3 
clone OKT3; bioXcell) were dissolved in PBS. DBCO-EG4-NHS (3.5 equivalents in DMSO) 
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was added to the antibody solution. The final concentration of αCD3 in the reaction 
mixture was 4 mg ml-1. The mixture was stirred for 2 hours at 4 °C and subsequently 
purified using ultrafiltration (30 kDa cut-off; Amicon Ultra-15 Centrifugal Filter Units) 
to remove non-reacted DBCO-EG4-NHS. The degree of labeling was determined from 
absorption measurements at 309 nm (DBCO) and 280 nm (αCD3). The signal at 280 nm 
was corrected for the absorption of DBCO using the following equation: Corrected 
absorption (280 nm) = absorption at 280 nm – (1.089 * absorption at 309 nm).[39] 
The DBCO concentration was calculated from the absorption at 309 nm (ε = 12,000 M-1 
cm-1). To obtain the αCD3 concentration, the corrected absorption at 280 nm (ε = 
210,000 M-1 cm-1) was used. Typically, this reaction yields a degree of labeling of 2-2.5 
DBCO molecules per antibody.
Synthesis of biotinPIC-bioconjugates. All biotinPIC-bioconjugates were prepared 
using a similar protocol. A solution of biotinPIC (1 mg ml-1 stock solution in PBS) was 
added to the DBCO-functionalized biomolecules to obtain the desired ratios. The reaction 
mixture was stirred overnight at 4 °C and directly used for purification over 
mono-avidin beads (agarose-based; Thermo Fisher Scientific). PBS was used for the 
coupling and purification of αCD3-DBCO. HEPES was used for AlexaFluor647-DBCO-
PhoA-His.
Circular Dichroism (CD) measurements. To prepare the CD standard curves, the 
azide-functionalized PIC was dissolved in a concentration of 1 mg ml-1 in PBS (Figure S1). 
This stock solution was used to prepare the following concentrations of the polymer: 
0.025, 0.05, 0.1, 0.2 and 0.3 mg ml-1. The CD spectrum of these samples was measured 
and corrected using a PBS blank. Standard curves were constructed for the CD signals 
measured at 272 nm or 360 nm, yielding calibration factors of ε272nm= 525.6 mdeg mg-1 
ml-1 and ε360nm= -121.1 mdeg mg-1 ml-1.
Purification using mono-avidin agarose. All buffers were freshly prepared and 
filtered before use. In general, 500-800 μl of a 50 % slurry containing regenerated and 
blocked mono-avidin beads was spun down in a Eppendorf tube and the supernatant 
was removed. The PIC-biomolecule mixture was added (250-400 μl) and the beads 
were incubated for 4 hours. Following incubation, the beads were spun down, the 
supernatant was removed and the remaining beads were washed with PBS containing 
0.1% (v/v) Tween 20 (PBS-T, 2x) and with PBS (4x). The beads were then incubated with 
PBS containing 2 mM biotin for 1-2 hours to release the purified biotinPIC-bioconju-
gate. After completing affinity purification, the eluted samples were filtered to remove 
a small portion of remaining beads in the elution fraction. Filtering the samples with 
standard filters of 0.2-0.45 μm pore size did result in a huge loss of polymer so that a 1 
ml column with a frit of 20 μm pore size (Screening Devices) was used instead. Using 
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this larger pore size, the loss of polymer during filtration was reduced to 10 %. During 
all steps of the purification, PBS was used for the PIC-αCD3 bioconjugate, while HEPES 
was used for the PIC-PhoA samples.
AFM measurements. The mono-avidin purified and filtered PIC-PhoA samples were 
drop casted (20 μl) onto freshly cleaved mica. After incubation on the surface for 20 
seconds, the samples were removed and the surface was dried in a nitrogen stream. 
The samples were imaged with tapping mode in air, using a Nanoscope IV instrument 
(Bruker) and NSG-10 tapping mode tips (NT-MDT). The images were analyzed with 
ImageJ software.[49] The average spacing of PhoA molecules was calculated from the 
number of enzymes counted on a polymer of given length (Figure S2).
PhoA activity measurements. The fluorogenic substrate DDAO-phosphate (9H- (1,3- 
Dichloro-9,9-Dimethylacridin-2-One-7-yl) phosphate, diammonium salt; Thermo 
Fisher Scientific) was used for measuring the activity of the biotinPIC-PhoA bio-
conjugates. The substrate was dissolved in dry DMSO at a concentration of 40 µM. 
The biotinPIC-PhoA conjugates were diluted in activity buffer (50 mM HEPES pH 8.0, 
100 mM KCl, 20 mM MgCl2, 100 µM ZnCl2) to obtain a PhoA concentration of 500 pM. 
DDAO-phosphate was added to a final concentration of 2 µM to start the measurement. 
The release of the fluorophore DDAO was followed in a micro- plate reader (λex = 
620 nm; λem = 660 nm; Tecan Infinite M200 PRO). The measurement was performed 
at 37 °C for 40 min (30 s intervals). All measurements were performed in triplicate. 
The data was corrected for auto-hydrolysis of the substrate.
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Supplementary figures
Figure S1  Calibration curves for determining the PIC polymer concentration from CD 
spectroscopy. (A) CD spectra of the PIC polymer measured at different concentrations. (B) 
Standard curve determined at 272 nm using a path length of 1 cm (slope: 525.6 mdeg ml mg-1). 
(C) Standard curve determined at 360 nm using a path length of 1 cm (slope: -121.1 mdeg ml 
mg-1).
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Figure S2  Average distance between PhoA molecules as determined from AFM imaging. 
(A) PIC-PhoA conjugate prepared with 0.1 eq. PhoA. (B) PIC-PhoA conjugate prepared with 
0.2 eq. PhoA.
Figure S3  Enzymatic reaction converting DDAO-phosphate into DDAO.
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Figure S4  SDS-PAGE (non-reducing conditions) of a mono-avidin purified PIC-αCD3 
bioconjugate (biotinPIC, 1 biotin in 50 nm). The αCD3 antibody was fluorescently labelled 
with AlexaFluor647. The fluorescence in the gel was scanned at an excitation wavelength of 
633 nm. This result clearly shows that the PIC-αCD3 bioconjugate does not enter the gel.
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Abstract
Immunotherapies are highly dependent on T cell function, which may be controlled 
by distinct co-stimulatory signaling pathways. Therefore, triggering of co-stimulatory 
signaling in T cells is an attractive approach to induce anti-cancer responses. Anti- 
bodies that stimulate co-stimulatory molecules have induced potent immune 
responses, but can also lead to serious side effects due to off-target immune responses. 
Combined stimulation of specific T cell receptors (TCRs) and co-stimulatory molecules 
is an attractive approach to avoid these side effects. This can be achieved using 
synthetic mimics of immune cells, called synthetic Dendritic Cells (sDCs). These sDCs 
can provide efficient TCR signaling, using antibodies against CD3, and CD28 co- 
stimulation in close proximity on a filamentous nanosized scaffold. Stimulation of 
other co-stimulatory molecules with sDCs may lead to more control over T cell differ-
entiation and functionality. Here, set out to develop a wide variety of co-stim-sDCs to 
obtain control over T cell function. For this, the co-stimulatory capacity of several 
antibodies was first tested when bound to a plate, which demonstrated that distinct 
co-stimulatory pathways can control the speed of T cell differentiation. To incorporate 
a wide variety of co-stimulatory molecules onto sDCs, a highly modular strategy is 
developed for their synthesis in which antibodies are conjugated to polyiscyano-
peptides (PICs) through short PEG linkers. We demonstrate that the pH of antibody 
functionalization greatly affects the capacity of the synthesized αCD3-sDCs to 
stimulate T cells. Furthermore, providing αCD3 and co-stimulatory antibodies on one 
and the same scaffold results in highly enhanced activation of T cells. In the future, 
optimized co-stim-sDCs can be used to study co-stimulatory mechanisms and may be 
applied to induce distinct T cell functions.
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Introduction
Over the last decade, immunotherapy has revolutionized cancer treatments for several 
malignancies. In particular, immune checkpoint blockade antibodies targeting co- 
inhibitory receptors CTLA-4 and PD-1 have shown impressive clinical responses, 
leading to marked increases in survival rates for advanced cancers [1,2]. Stimulation of 
CTLA-4 and PD-1 leads to inhibition of T cell activation. Blockade of these receptors 
releases this inhibition and can therefore boost anti-tumor immune responses [3]. 
Alternatively, instead of blocking co-inhibitory pathways, anti-tumor immunity can 
be evoked through stimulation of co-stimulatory pathways. Therefore, there is 
increasing attention for agonist antibodies against co-stimulatory receptors that can 
trigger these pathways [4]. These antibodies have induced potent anti-cancer 
responses in pre-clinical models and clinical trials, but have also led to toxic side 
effects in several cases [5]. In addition, development and application of agonist 
co-stimulatory antibodies has contributed to our understanding of the role of 
co-stimulation in the induction of T cell responses [6].
 These clinical observations highlight the essential role that co-stimulation and 
co-inhibition play in T cell biology. TCR triggering (signal 1) in absence of co-stimulation 
(signal 2) leads to T cell anergy, which causes unresponsiveness towards the recognized 
antigens [7,8]. During T-cell activation, co-stimulatory molecules provide a second 
signal that determines the functional outcome of TCR signaling. Classically, CD28 was 
postulated as the co-stimulatory receptor in this two-signal model [6,9]. Indeed, CD28 
is required in most antigen-dependent T cell responses, and is especially important for 
priming of naïve T cells [10,11]. Triggering of CD28 by B7 ligands expressed on dendritic 
cells (DCs) leads to enhanced and prolonged T-cell responses, characterized in 
particular by increased IL-2 secretion, cell survival and proliferation [9,12]. CD28 
signaling is counteracted by upregulation of CTLA-4, which binds B7 ligands with 
high affinity and blocks TCR signaling [13]. 
 Besides CD28, co-stimulation can also be provided through alternative pathways. 
For priming of naïve T cells, CD27 supports CD28 signals or prime T cells when the 
CD28 pathways is blocked [14,15]. Triggering of CD27 by CD70 or agonist antibodies 
promotes T cell proliferation, mainly by promoting survival of proliferating T cells 
[16]. Other co-stimulatory molecules are not expressed on naïve T cells, but upregulated 
after activation. These receptors include TNFR superfamily members 4-1BB, OX40, 
CD30 and GITR [17], SLAM-receptor CD150 [18], and Notch family member Notch2 [19]. 
The different signaling pathways of these groups of receptors can all synergize with 
TCR signaling to promote cytokine release and proliferation of T cells. For example, 
TNFR family proteins do this through binding of different TNF receptor-associated 
factor (TRAF) adaptors, that interact with downstream signaling molecules [6]. 
Conversely, CD28 does not bind to TRAFs, although signaling between CD28 and 
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TNFRs can overlap downstream [6]. For many co-stimulatory receptors it is not 
completely understood how distal signaling leads to downstream functions in 
T cells [17].
 Nonetheless, it is becoming increasingly clear that the different co-stimulatory 
receptors each have distinct roles in regulating effector function in T cells [6,17]. In 
addition, it has been suggested that different co-stimulatory molecules may affect 
memory formation and effector differentiation of CD8+ T cells [6,20]. For clinical 
translation, this is especially important in application of adoptively transferred T cells 
[21]. Traditionally, T cells isolated from cancer patients are cultured ex vivo with 
anti-CD3 and anti-CD28 antibodies. However, making use of cytokines or alternative 
co-stimulatory molecules could have great impact on the clinical efficacy of these T 
cells [22,23]. In particular, the differentiation status of these cells seems to correlate 
with clinical responses [24,25]. Furthermore, in chimeric antigen receptor (CAR) T cells 
4-1BB and OX40 signaling seem to counteract T cell exhaustion and induce increased 
T cell persistence compared to CD28 co-stimulation [26–28], which further highlights 
the distinct functions of co-stimulatory signaling. It is important to note that 
functional outcomes of co-stimulation are generally context-dependent. Because 
costimulatory receptors provide signaling together with TCR signaling, it remains 
a difficult task to dissect intracellular pathways and isolate their functional 
outcomes [17].
 Synthetic mimics of immune cells, called artificial antigen-presenting cells 
(aAPCs), allow for a high level of control of the exact signals that are given to T cells. In 
this way, aAPCs provide a method to study signaling and functions for co-stimulatory 
molecule in the context of TCR signaling [29]. In addition, development of aAPCs that 
trigger various co-stimulatory molecules may lead to T cells with a variety of 
functions, which is interesting from a clinical point of view. Clinical application of 
agonist antibodies against co-stimulatory molecules in the context of TCR signaling, 
which could limit autoimmunity and toxic side effects of these antibodies, can be 
done using aAPCs. At this point, a variety of aAPCs have been developed that can 
induce co-stimulation through CD28. In addition, microbead-based aAPCs that 
incorporate 4-1BB have been developed [30,31], but other co-stimulatory molecules 
have not yet been applied in cell-free aAPC designs. Thus, there is a need for the 
development of highly modular aAPCs capable of ligating a variety of co-stimulatory 
molecules, which can provide a way to distinguish the distinct effects of each receptor 
on T cell function.
 Previously, we developed filamentous PICs as a cell-free aAPC scaffolds, called 
synthetic Dendritic Cells (sDCs) [32–34]. These sDCs were synthesized by binding 
biotinylated antibodies to conjugates of polyisocyanopeptides (PICs) and streptavidin. 
Due to their semi-flexibility and high aspect ratio, PIC-antibody scaffolds were 
established as highly efficient sDCs capable of inducing robust T cell activation. It was 
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demonstrated that combining signal 1 and 2 on one and the same polymer leads to 
highly synergistic T cell responses [33]. This synergy of semi-flexible PICs can be used 
to study the effect of various co-stimulatory molecules in the context of TCR signaling. 
To test the wide variety of co-stimulatory molecules requires synthesis of a high 
number of different sDCs. This number increases even further when considering the 
large number of possible combinations of different co-stimulatory molecules, PIC- 
bound antibody densities or possible combinations with cytokines. Therefore, a highly 
modular synthetic strategy is essential to efficiently study co-stim-sDCs. This strategy 
requires a straightforward method to produce sDCs in a high yield and a straight-
forward method to adequately characterize the produced PIC-protein conjugates.
 Although the previously used streptavidin-linked αCD3/CD28-PICs could efficiently 
stimulate T cells, their synthesis, purification and characterization is inefficient. 
Because of this, it is difficult to make a large variety of co-stimulatory sDCs using the 
previously described method. In chapter 3, the synthetic design of sDCs was optimized 
by replacing streptavidin with a short PEG linker, which allows for more straightfor-
ward analysis of PIC-protein conjugates. In addition, an affinity-based purification 
method was developed to obtain purified PIC-protein conjugates in higher yields [35]. 
This novel synthetic strategy was used to produce purified αCD3-PIC conjugates, but to 
this point these sDCs have not been applied to stimulate T cells. 
 Here, the concept of purified PIC-antibody conjugates, linked through PEG instead 
of streptavidin, is further optimized to obtain highly modular sDCs that can be 
efficiently synthesized and provide strong stimulatory signals. This modular strategy 
is used to synthesize sDCs containing agonistic antibodies against a variety of 
co-stimulatory molecules. 
Results and discussion
Co-stimulation with plate-bound anti-CD27 accelerates T cell differentiation. CD28 
has been widely studied as co-stimulatory molecule, which demonstrated that a 
second signal is essential for full-blown T cell activation. However, apart from CD28, 
T cells can express a variety of additional co-stimulatory molecules. Some of these 
receptors, CD28 and CD27 being the best known examples, are already expressed on 
naïve T cells, while others are upregulated after T cell activation [6]. The different 
co-stimulatory molecules may each have varying roles in T cell activation and 
stimulation of these receptors may each play a role in inducing unique phenotypes 
and functionalities of T cells [12,17]. Incorporation of additional co-stimulatory 
antibodies onto sDCs allows us to study the exact role of these molecules and could 
give rise to distinct subsets of T cells with interesting properties for clinical application. 
The small size of sDCs may allow control over T cell differentiation in vivo. Therefore, 
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we selected a variety of co-stimulatory antibodies and tested their (co-)stimulatory 
potential. For this, agonist antibodies were obtained that trigger CD27, 4-1BB, OX40, 
CD150, CD30, Notch2 and GITR. These co-stimulatory molecules were selected because 
they have been reported to influence memory or effector responses in CD8+ T cells, 
and because of the availability of agonistic antibodies that can trigger signaling when 
bound to these co-stimuli.
 Synthesis of PIC-protein conjugates requires relatively high amounts of protein. 
However, most of the co-stimulatory antibodies are available in low quantities and 
production of large amounts of antibody is costly. Therefore, the stimulatory capacity 
of these antibodies was first screened when bound onto ELISA plates together with 
αCD3. In this way antibodies could be selected for co-stim-sDC synthesis. To establish 
the effect of αCD27 stimulation, naïve CD8 T cells were added to ELISA plates coated 
with αCD3, αCD3 and αCD28 or αCD3 and αCD27 (Figure 1a). After 6 days, T cell 
proliferation and survival was assessed by CFSE dilution (Figure 1b). Limited numbers 
of naïve CD8 T cells stimulated with only αCD3 survived up to this time point, and no 
proliferation of T cells was observed. In contrast, when also CD28 or CD27 was 
stimulated, high levels of proliferation were induced, demonstrating the high 
co-stimulatory capacity of the CD27 antibody. CD3/CD28-stimulated cells showed a 
further increased proliferation compared to CD3/CD27-coated plates. However, it 
should be noted that these experiments were performed at optimized CD3:CD28 
ratios, whereas the CD3:CD27 ratio was not optimized.
 To elucidate whether CD27 co-stimulation can induce distinct phenotypes from 
naïve CD8 T cells, cells were stained for CCR7 and CD45RA after 0, 6 and 
13 days of plate-bound stimulation (Figure 1c). Before stimulation, cells mostly showed 
the CCR7+CD45RA+ naïve T cell phenotype. After 6 days of CD3/CD28 stimulation, a 
large population of T cells were CCR7+CD45RA-, which is consistent with a central 
memory phenotype. After 13 days, T cells were differentiated further into a 
CCR7-CD45RA- effector memory phenotype. Interestingly, CD3/CD27 stimulation 
leads to a decreased expression of CCR7 after 6 days compared to CD3/CD28 stimulation, 
indicating that they are already moving towards an effector memory phenotype. 
In addition, some of the CD3/CD27-stimulated cells have gained CD45RA expression 
after 13 days, which points towards development of an effector T cell phenotype. CD127 
expression is also lost faster after CD3/CD27 stimulation, which is also consistent with 
effector memory formation (Figure S1a) [41]. Furthermore, loss of co-stimulatory 
molecule (CD28 or CD27) expression, which is indicative of differentiation towards a 
terminal effector phenotype, is increased after CD3/CD27 stimulation. These results 
demonstrate that CD27-induced co-stimulation leads to an increased speed of 
 differentiation compared to CD28 co-stimulation. With regard to CD27-induced 
terminal differentiation, in vivo studies have shown conflicting results, suggesting 
that the outcome of co-stimulation-induced differentiation is highly context- 
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dependent [42–45]. Possibly, CD27 can only induce memory formation when high 
levels of IL-12 are present [44], or effector differentiation is a result of constitutive CD27 
co-stimulation [43]. In addition, signal strength appears to be highly correlated 
to CD8 T cell differentiation and the progressive effector differentiation observed for 
both CD3/CD28 and CD3/CD27 stimulation is therefore likely to be a result of the 
strong and continued high-affinity signals given to the T cells [46].  
 T cell activation also leads to expression of additional co-stimulatory molecules, 
including 4-1BB, OX40 and CD150. To establish whether cell surface expression of these 
molecules is increased by our plate-bound stimulations, naïve CD8 T cells were again 
incubated on CD3/CD28 and CD3/CD27-coated ELISA plates and stained for inducible 
co-stimulatory molecules at different time points (Figure 1d). For both stimulations, 
expression of 4-1BB, OX40 and CD150 peaked after 3 days of stimulation, which is 
consistent with previous reports that report peaks of co-stimulatory molecules 
between 3-6 days [47,48]. CD3/CD27-stimulation led to increased upregulation of 
co-stimulatory molecules compared to CD3/CD28. In each case, 4-1BB was first 
expressed, followed by OX40 and finally CD150. Additionally, 4-1BB expression was 
higher compared to the other co-stimuli. Stimulation of naïve CD8 T cells using only 
αCD3 did not result in high expression of most inducible co-stimulatory molecules 
(Figure S1b). In fact, when only signal 1 was used, only a high Notch2 expression was 
induced after 3 days. After stimulation with CD3/CD28 and CD3/CD27, also Notch2, 
CD30 and GITR were induced after 3 days (Figure S1c). Similar to the other inducible 
costimulatory molecules, CD30 and GITR expression was reduced at later time points. 
However, Notch2 expression was retained at similar levels. Taken together, these 
experiments demonstrate that co-stimulation with both αCD28 and αCD27 lead to 
strong T cell activation, expression of additional co-stimuli and differentiation 
towards an effector phenotype, which is especially accelerated by stimulation of CD27.
Plate-bound anti-4-1BB accelerates differentiation of pre-activated T cells. After 
having established that the αCD27 antibody can provide strong co-stimulatory 
signals, the effect of inducible receptor stimulation was determined. CD3/CD28 and 
CD3/CD27 stimulation leads to high expression of a variety of additional co-stimulatory 
receptors after 3 days that are absent before stimulation. Therefore, naïve CD8 T cells 
were stimulated with plate-bound antibodies for 3 days, after which they were 
removed from these plates and added to a plate coated with αCD3 and antibodies 
against co-stimulatory molecules (Figure 2a). After 3 subsequent days of stimulation 
with these antibodies, cells were counted to assess the strength of stimulation of each 
condition. Re-stimulation of both CD3/CD28- or CD3/CD27-primed T cells with 
antibodies against CD28, CD27, 4-1BB, OX40 and CD150 increased cell numbers compared 
to αCD3 stimulation (Figure 2b). These results indicate a strong co-stimulatory capacity 
of these antibodies, making them interesting candidates for incorporation into sDCs. 
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Figure 1  Screening of antibodies for CD28 and CD27 stimulation by plate-bound antibody 
stimulations of naïve CD8+ T cells. (A) Experimental strategy for screening of stimulatory 
capacity of co-stimulatory antibodies. Naïve CD8+ T cells were incubated on CD3/Co-stimulatory 
antibody-coated ELISA plates. At various time points, cells were removed from the wells 
and analyzed. (B) Proliferation of naïve CD8+ T cells as determined by CFSE dilution after 
3 days of stimulation. Representative histogram of stimulations of two donors is depicted. 
(C) Expression of CCR7 and CD45RA as determined by flow cytometry after 6 days and 
13 days of stimulation with plate-bound antibodies. Dot plots show representative example 
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In contrast to these co-stimuli, stimulation of GITR, Notch2 or CD30 induced modest 
levels of proliferation or gave variable results (Figure S2a). 
 Next, the effect of triggering inducible co-stimulators on T cell differentiation 
was established. For this, T cells were first stimulated with plate-bound CD3/CD28 for 
3 days, then stimulated with plate-bound CD3/CD27, CD3/4-1BB, CD3/OX40 or CD3/
CD150. 6 days and 13 days after initial stimulation (or at day 3 and 10 of secondary 
stimulation), cells were stained for CCR7, CD45RA, CD27 and CD127. At day 6, T cells 
were generally CD45RA+CCR7+, indicating that the transfer step slightly slowed down 
differentiation. Interestingly, T cells stimulated with 4-1BB showed lower expression 
of both CD45RA and CCR7, which corresponds to a more differentiated memory 
phenotype. After 13 days, T cells had lost CD45RA expression and partially lost CCR7, 
pointing towards a late central memory phenotype (in transition to effector memory). 
For 4-1BB-stimulated T cells, CCR7 expression was again decreased compared to the 
other co-stimuli. In addition, 4-1BB-stimulated T cells showed a lower expression of 
CD127 and CD27 (Figure S2b), which is also associated with a more differentiated 
effector memory phenotype. Possibly, the accelerated and enhanced upregulation of 
4-1BB compared to the other co-stimulators could account for the faster differentiation 
of 4-1BB-stimulated T cells [49]. Contrastingly, some in vivo experiments and CAR T 
cells with 4-1BB signaling domains have associated 4-1BB with memory formation, 
although 4-1BB signaling may also enhance survival of effector cells [42,50,51]. This 
enhanced survival, combined with the high signal strength of the plate-bound 
antibodies, may explain the observed high number of more differentiated cells. 
 Taken together, plate-bound antibody stimulations with CD3 combined with 
CD28, CD27, 4-1BB, OX40 or CD150 results in strong stimulation of T cells. Under 
continued stimulation, these cells progressively differentiate towards effector 
memory/effector T cells. Probably, this is a result of the strong CD3 signaling induced 
in this plate-bound system [46]. Priming with CD27 or re-stimulation after 3 days with 
4-1BB appears to accelerate this differentiation process. Because T cell differentiation 
is highly context-dependent, these observations do not exclude a role of CD27 and 
4-1BB in memory formation, which has been demonstrated by various research groups 
[42,43,45]. Because of the strong signals given to T cells in this system, mostly small 
differences in differentiation were observed. In addition, these co-stimulatory 
molecules could also have distinct roles in inducing other functionalities in T cells, 
including cytotoxicity or production of inflammatory cytokines. This still needs to be 
addressed in future experiments. 
of three independent observations. (D) Expression of co-stimulatory molecules CD27, CD28, 
4-1BB, OX40 and CD150 after stimulation with plate-bound CD3/CD28 (left) or CD3/CD28 
(right) antibodies. Average percentage of co-stimulus-expressing T cells after duplicate 
stimulations of two donors is depicted.
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Figure 2  Stimulation of inducible co-stimulatory molecules on pre-activated CD8 T cells by 
plate-bound antibodies. (A) Experimental strategy for screening of stimulatory capacity of 
co-stimulatory antibodies. Naïve CD8+ T cells were incubated on αCD3/CD28 or αCD3/
CD27-coated ELISA plates to induce expression of inducible co-stimulatory molecules. 
After 3 days, cells were transferred to plates coated with antibodies against inducible CD3 
and co-stimulatory molecules. (B) Normalized cell counts at day 6 (or 3 days after second 
stimulation). Naïve CD8+ T cells were pre-stimulated with αCD3/CD28 (top) or αCD3/CD27 
(bottom). After 3 days, cells were stimulated with antibodies depicted on x-axis. Values 
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Modular synthesis of PEG-linked PIC-antibody conjugates. Experiments using plate- 
bound antibodies revealed a selection of antibodies that can provide strong co- 
stimulatory signaling. Next, we aimed to incorporate these antibodies into a nanosized 
sDC system. These sDCs need to be highly modular in order to study a wide variety of 
antibodies and combinations thereof. To achieve this, straightforward characterization 
and high yields are essential during sDC synthesis. 
 In chapter 2, multivalent streptavidin-linked PIC-antibody conjugates were 
established as potent sDCs [33]. However, the use of streptavidin as a linker complicates 
characterization of these conjugates and using this method to produce streptavi-
din-linked PIC-protein conjugates with both high purity and decent yield is 
challenging. Therefore, in chapter 3 a method for affinity-based purification of 
PIC-protein conjugates was developed [35]. Using this method purified PIC-αCD3 
conjugates were developed with covalently bound antibodies linked through only a 
short polyethylene glycol (PEG) linker. Although characterization and purity of 
PIC-αCD3 conjugates were optimized, they were not applied as sDCs. Here, the modular 
method developed in chapter 3 was applied to synthesize a variety of PIC-antibody 
conjugates to optimize their activity in T cell activation assays and elucidate essential 
design parameters in PIC-based sDC synthesis.
 PIC-antibody conjugates were synthesized as depicted in Figure 3a. First, 
antibodies were functionalized using DBCO-PEG-NHS esters. To determine the effect 
of linker length on sDC synthesis and activity, PEG linkers were used containing 4, 16 
and 68 ethylene glycol (EG) units. Reactions were performed at pH 7.4, 8.3 and 9. At 
higher pH, amines on antibodies are increasingly deprotonated, which is necessary 
for efficient reactions with NHS esters. Functionalized antibodies were purified using 
spin filtration after which DBCO content could be characterized using UV-Vis spectro-
photometry (Figure 3b). DBCO functionalization reactions were optimized to obtain 
an average degree of labeling (DOL) of 2-3 DBCO per antibody. While reactions with the 
short 4EG-linker where relatively efficient, reactions with the longer linkers required 
high amounts of DBCO-NHS esters in the reaction mixture to obtain the preferred 
DOL.
 Functionalized antibodies were conjugated to biotin-containing azide- 
functionalized PICs. The resulting PIC-protein conjugates were purified over 
mono avidin beads as described in chapter 3. After this, antibody and PIC concentrations 
were measured using a BCA protein assay and circular dichroism (CD), respectively. 
were normalized to CD3/CD28-stimulated cell count and the average values + SEM from 
stimulation of two donors were plotted. (C) Expression of CCR7 and CD45RA as determined 
by flow cytometry after 6 days and 13 days of stimulation with plate-bound antibodies. 
Dot plots show representative example of three independent observations.
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These concentrations were used to calculate the antibody density, or relative antibody 
spacing, conjugated to the PICs (Figure 3c). Relative ligand distance is essential for 
proper T cell activation, as has been demonstrated for protein-coated surfaces. In 
chapter 2 it was established that also for PIC-based sDCs antibody density is essential 
to induce potent T cell responses. Therefore, to study additional design parameters of 
sDCs, PIC-protein conjugates with similar antibody densities (or amounts of antibody 
per polymer chain) were selected. This allows for a fair comparison of the effect of pH 
and linker length. PIC-αCD3 (P-αCD3) conjugates where DBCO-functionalization was 
performed at different pH contained one antibody every 75-95 nm. Since the average 
PIC length was ~400 nm, these polymers contained ~4-6 antibodies per chain. 
For PIC-protein conjugates with different PEG linker lengths antibodies were spaced 
at 70-80 nm (~5-6 antibodies per polymer). To obtain PIC-antibody conjugates with 
similar densities, for DBCO-αCD3 with long PEG linkers approximately twice as much 
functionalized antibody had to be added to the reaction mixture, probably due to 
steric effects of the long PEG chains. αCD28-containing polymers were synthesized 
Figure 3  Synthesis and characterization of PEG-linked PIC-antibody conjugates. (A) Synthetic 
strategy for the development of PEG-linked PIC-antibody conjugates. Antibodies against 
CD3 or CD28 were functionalized with DBCO-PEG-NHS esters with different PEG linker 
lengths (#EG) and at different pH. The resulting DBCO-functionalized antibodies were 
purified using spin filtration and reacted to azide- and biotin-containing PICs. The resulting 
PIC-antibody conjugates were purified over monovalent avidin beads. (B) Degree of DBCO 
labelling (DOL) for the different functionalized antibodies used for synthesis of PIC-antibody 
conjugates. (C) Analysis of antibody densities conjugated onto sDCs.
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with antibodies spaced at ~90-120 nm (~3-5 antibodies per polymer). αCD3 density of 
polymers used in this experiment was slightly higher (spacing of ~55 nm, 7-8 
antibodies per polymer). 
T cell stimulation with PIC-αCD3 conjugates. To test the effect of pH during antibody 
DBCO functionalization, peripheral blood lymphocytes (PBLs) were incubated with 
different concentrations of unbound αCD3 and 4EG -linked polymers P-αCD3(pH7.4), 
P-αCD3(pH8.3) or P-αCD3(pH9) for 18 h (Figure 4a). After this, IFNy concentrations in 
the supernatant were measured using ELISA. DBCO functionalization at pH 7.4 and 
subsequent PIC conjugation resulted in a reduction of the stimulatory capacity of 
αCD3. The activity of DBCO-PEG-NHS-functionalized antibodies that were not bound 
to PICs was comparable to non-functionalized αCD3 (Figure S3), indicating that PICs 
hamper antibody activity. However, at higher pH of functionalization, P-αCD3 
stimulation induces a markedly increased IFNy production compared to stimulation 
with unbound antibodies (Figure 4a). Probably, the increased pH leads to availability 
of additional amines on antibodies (by deprotonation) that can participate in reactions 
with NHS esters. In particular, the low pKa (8.9) of N-terminal amines are likely to 
allow functionalization at lower pH, while amines in lysine side chains with a pKa of 
10.5 need a higher pH to be functionalized [36]. Functionalization of alternative 
amines may lead to DBCO conjugation at a different site on the antibody, which could 
cause a different orientation of antibodies when conjugated to PICs. Thus, this different 
orientation might liberate the antibodies from the steric effects that blocks the 
activity of P-αCD3(pH7.4).
Furthermore, the role of PEG linker length was established in similar experiments. 
PBLs were stimulated with different concentrations of unbound αCD3, P-4EG-αCD3, 
P-16EG-αCD3 and P-68EG-αCD3, and IFNy secretion was measured (Figure 4b). Again, 
P-4EG-αCD3 induced significantly increased IFNy secretion compared to unbound 
anti-CD3. P-αCD3 conjugates with longer PEG linkers induced slightly higher IFNy 
production compared to P-4EG-αCD3. Possibly, the linkers generate a sDC scaffold with 
higher flexibility, which is an important parameter for aAPC development [37,38]. 
Alternatively, the longer linkers could allow for a further reduced obstruction of αCD3 
activity by the PIC. However, these linkers do not give rise to functional sDCs when 
conjugated to αCD3 at pH 7.4 (Figure S3b), indicating that these linkers do not greatly 
affect the blocking effect of PICs. In the next chapter it is demonstrated that a more 
rigid double-stranded DNA-linker can be included in PIC-αCD3 conjugates using pH 7.4 
functionalization without affecting αCD3 activity. Possibly, random coil formation 
due to the flexibility of PEG linkers only provide minimal spacing between antibodies 
and PICs and are therefore not able to relieve the blocking effect [39].
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T cell stimulation with αCD28-containing PIC-protein conjugates. After having 
established the effect of antibody functionalization pH and PEG linker length for 
conjugation of signal 1 onto our sDCs, we tested the stimulatory capacity of sDCs 
containing both signal-1 and signal-2. Therefore, PBLs were labeled with CFSE, 
incubated with unbound αCD3 and αCD28, P-68EG-αCD3 and P-4/68EG-αCD28, or 
P-4/68EG-αCD3/68EG-CD28. After 18 hours, IFNy concentrations in the supernatant 
were determined (Figure 5a) and after 3 days, proliferation was assessed through CFSE 
dilution (Figure 5b). Combined stimulation with P-αCD3 and P-αCD28 induced a 
marked increase in IFNy secretion compared to unbound antibody stimulation. IFNy 
levels were further increased by combining αCD3 and αCD28 on one and the same 
polymer chain. These co-conjugated αCD3/αCD28-sDCs also induced strong 
proliferation of T cells, which was also increased compared to stimulation with the 
mixture of P-αCD3 and P-αCD28. PEG linker length for P-αCD28 does not affect its 
stimulatory capacity. In addition, there is no difference in stimulation when linker 
length of αCD3 in P-αCD3/CD28 is changed. Thus, similar to the streptavidin-linked 
Figure 4  IFNy secretion by T cells after different P-αCD3 stimulations of PBLs. (A) Normalized 
IFNy concentrations in supernatant after stimulation of PBLs with P-αCD3 synthesized 
from CD3 antibodies that were functionalized with DBCO-4EG-NHS at different pH. 
(B) IFNy concentrations in supernatant after stimulation of PBLs with P-αCD3 synthesized 
from CD3 antibodies that were functionalized with DBCO-PEG-NHS with different linker 
lengths at pH 8,3. IFNy concentrations from duplicate stimulations of PBLs from two donors 
were normalized to the concentration induced by 200 ng/mL αCD3 stimulation and the 
mean concentrations ± SEM were depicted.
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PIC-αCD3/CD28 conjugates [33], there is a great synergy when αCD3 and αCD28 are 
linked to one and the same polymer chain using a purified PEG-linked sDC. Because of 
the simplified design of our polymers, we demonstrate that this synergistic effect is 
caused through co-conjugation on PICs, and not co-conjugation on streptavidin. PEG 
linker length slightly affects T cell activation for P-αCD3, but not for P-αCD28 or 
P-αCD3/CD28. As CD3, and not CD28, can act as a mechanosensor [40], this receptor 
may detect differences in PEG linker length as differences in substrate flexibility on 
P-αCD3, but not on P-αCD28. Because synthesis with the 4EG linker is more efficient 
and therefore requires lower amounts of protein to be used in conjugation reactions, 
DBCO-4EG-NHS was chosen for development of future sDCs.
Small scale synthesis of sDCs containing αCD27, α4-1BB, αOX40 and αCD150. Having 
established a successful synthetic strategy to conjugate αCD3 and αCD28 to PICs, we 
aimed to incorporate additional co-stimulatory molecules into our sDC design and 
test their stimulatory capacity. To allow for development of a larger variety of sDCs, 
synthesis of these complexes was done at a smaller scale. Furthermore, to differentiate 
Figure 5  PBL stimulation with αCD28-containing PICs. (A) IFNy secretion after 18 h and (A)
proliferation after 3 days of stimulation of PBLs with αCD3 + αCD28, P-αCD28 with different 
PEG linker lengths + P-αCD3, and P-αCD3/CD28 with different PEG linker lengths. IFNy 
concentrations and mean number of proliferation cycles from duplicate stimulations of 
PBLs from two donors were normalized to the concentration induced by 200 ng/mL αCD3 
stimulation and the mean concentrations ± SEM were depicted.
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between different co-stimuli conjugated to PICs, antibodies were labelled with a 
fluorophore during DBCO functionalization (Figure 6a). Because fluorophores can 
interact with filter membranes, spin filtration of fluorophore-labelled antibodies 
results in loss of proteins during spin filtration and therefore requires high amounts 
of starting materials. For a more cost-effective approach, antibodies were instead 
purified using size exclusion spin columns, resulting in quantitative yields after 
purification. Directly after purification, the degree of DBCO and fluorophore labelling 
was again assessed using UV/Vis spectrophotometry (Figure S4a). The resulting 
functionalized antibodies were used to develop sDCs using the strategy described 
before (Figure 3a). 
 After purification of PIC-protein conjugates, antibody concentration was 
determined using fluorescence measurements and protein density was calculated for 
each conjugate (Figure 6b). Unfortunately, when working with antibodies purified 
over spin columns we did not have the high level of control over this synthetic strategy 
as reported for the earlier CD3- and CD3/CD28-polymers. This resulted in relatively low 
amounts of αCD3 and high amounts of co-stimuli being conjugated to most of the 
PICs. αCD3 spacing was generally between 100-150 nm (~2-4 antibodies per polymer), 
except for P-CD3/CD150, which had a spacing of ~40 nm (~10 antibodies per polymer). 
Spacing of co-stimuli was between 5-25 nm (~15-80 antibodies per polymer). 
sDC stimulation of inducible co-stimulatory molecules. Although these sDCs 
should be further optimized, their stimulatory potential was tested on isolated T cells. 
Similar to the results described before, CD28-containing sDCs induced strong 
proliferation of T cells (Figure 6c). Again, stimulation with P-αCD3/CD28 resulted in an 
enhanced effect compared to a combination of P-αCD3 and P-αCD28. Separately, 
P-αCD3 and P-αCD28 do not induce proliferation (Figure S6b). While PBL stimulation 
with unbound αCD3 and αCD28 is able to induce a low level of T cell proliferation, 
no proliferation is observed for stimulation of purified T cells.
 To determine the effect of the other sDCs, expression of co-stimuli was induced 
by stimulation of purified T cells with CD3/CD28-T cell activator Dynabeads for 3 days. 
Because these beads are magnetic, they can be easily removed from T cells after 
stimulation. Next, 3-day-activated T cells were stimulated with a mix of unbound 
αCD3 and co-stimulatory antibody, mixed P-αCD3 and co-stimulatory PIC or with 
corresponding concentrations of PICs containing both αCD3 and co-stimulatory 
antibody. Measurement of IFNy production after 24 h revealed a similar trend 
compared to the αCD28-containing PICs (Figure 6d). Irrespective of the co-stimulus 
used, when both signal 1 and 2 are conjugated to one and the same polymer, IFNy 
concentrations were increased compared to stimulation with a mixture of signal-1-PIC 
and signal-2-PIC. However, IFNy concentrations were relatively low compared to 
re-stimulations with αCD28-containing PICs (Figure 6e). Thus, we could not induce 
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strong T-cell activation with co-stimulatory sDCs, and to achieve this more 
optimization of the sDC design is required. 
 The sDCs described here contain low densities of αCD3 and high densities of 
co-stimulatory antibodies, which could contribute to their low stimulatory capacity. 
To optimize conjugation of co-stimulatory molecules, a lower degree of DBCO labeling 
(of around 2-3 DBCO per antibody would be better suitable. For functionalized αCD3, 
DBCO content was in this desired range. Unexpectedly, when this functionalized 
antibody was purified using size exclusion columns, as was done for the sDCs described 
in Figure 6, conjugation efficiency to PICs was low. To determine whether the size 
exclusion columns affected the stability of DBCO-functionalized antibodies, αCD3 
functionalization with DBCO and ATTO488 was repeated and degree of DBCO labeling 
was re-assessed immediately after and 24 h after purification (Figure S4d). These 
measurements demonstrated that functional DBCO was lost 24 h after purification 
over size exclusion columns. At the same time, DBCO content was stabile when 
antibodies were purified using spin filtrations or when columns were washed at least 
5 times (instead of 3) before use. Probably, antibodies used to develop sDCs depicted in 
figure 6 were contaminated with small amounts of sodium azide present in the size 
exclusion columns used for purification. This contamination competes for DBCO with 
PIC-bound azides. Further optimization to remove these contaminations should give 
us more control over small scale PIC-protein synthesis.
Conclusions and outlook
In this chapter, a highly modular strategy was developed to produce sDCs with a wide 
variety of co-stimulatory molecules. Co-stimulatory molecules can be used to control 
the speed of T cell differentiation. In plate-bound assays antibodies against CD27 
induced strong naive T cell proliferation and CD3/CD27-stimulated T cells exhibits a 
faster differentiation compared to CD3/CD28-stimulated T cells. In pre-activated 
T cells, 4-1BB induces a more differentiated phenotype compared to CD27, OX40, and 
CD150. Incorporation of these antibodies onto co-stim-sDCs may therefore lead to 
powerful nanosized tools to direct T cell functionality.
 For the development of modular sDCs PEG-linked PIC-antibody conjugates were 
successfully synthesized and applied in T cell activation experiments. To synthesize 
sDCs with high stimulatory capacity towards T cells, αCD3 functionalization with DBCO 
should be done at pH 8.3 or higher, since functionalization at lower pH results in 
diminished T cell stimulation. Making use of longer PEG linkers between αCD3 and PICs 
slightly increases IFNy secretion, but not when αCD28-containing polymers are used. 
Using the optimized and purified sDC design it was demonstrated that conjugating 
αCD3 and αCD28 to one and the same PIC results in highly enhanced T cell activation.
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Figure 6  Development of sDCs that can trigger a wide variety of co-stimulatory molecules. 
(A) Functionalization of antibodies with DBCO and fluorophores. Antibodies were incubated 
in Borate Buffer with pH 8.5, after which DBCO-4EG-NHS ester and ATTO488-NHS (for αCD3) 
or AF350 (for co-stimulatory antibodies) were added. After 2 h, functionalized antibodies 
were purified using size exclusion spin columns. (B) Analysis of antibody densities 
conjugated onto sDCs. Mean values ± SD of two independent measurements. (C) Proliferation 
as determined by Celltrace Violet dilution of CD4+ (top) and CD8+ (bottom) T cells after 3 
days of stimulation with αCD3 and αCD28 at a concentration of 100 ng/mL. Bar graphs show 
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Modularity of the novel 4EG-linked sDC design was further increased by improving 
yields of functionalization during small scale antibody functionalization, which was 
done through use of size exclusion spin columns. However, DBCO-functionalized 
antibodies showed variable stability due to spin column contaminations, which 
resulted in PIC-antibody conjugates with sub-optimal antibody densities. Although 
these co-stim-sDCs only induced low levels of T cell activation, co-conjugation of 
co-stimulatory antibodies together with αCD3 on one and the same polymer showed 
a trend towards higher stimulatory capacity. Nonetheless, only αCD28 co-stimulation 
is capable of inducing high levels of IFNy secretion at these sub-optimal αCD3 densities.
 To fully understand this synergistic effect of co-conjugation of signal 1 and 2, and 
use co-stimulatory polymers to control T cell differentiation and function, the small 
scale sDC synthesis should be further optimized. The PICs with optimized antibody 
densities can be used to induce strong T cell responses with a wide variety of 
co-stimulatory molecules. It is expected that αCD27 and/or a4-1BB-presenting sDCs 
should be able to speed up T cell differentiation. Due to the modular synthesis, testing 
the effect of additional co-stimulatory molecules and cytokines can be done in a 
highly straightforward fashion. This novel synthetic strategy can then be exploited to 
gain a high level of control over T cell differentiation and functionality. Due to their 
bio-compatibility, the resulting co-stim-sDCs could eventually be applied to induce 
these functions in T cells used in a clinical setting.  
Experimental section
Materials. Zeba™ Spin Desalting Columns (40K MWCO), Celltrace Violet and CFSE Cell 
proliferation kit, Dynabeads human T-activator CD3/CD28 and AlexaFluor 350-NHS 
ester (AF350) were purchased from ThermoFisher. Magnetic mono-avidin beads were 
from Bioclone. Anti-CD3 (Clone OKT3) and Anti-CD28 (Clone 9.3) was from BioXCell. 
Human Pan T cell isolation kit, naïve CD8+ T cell isolation kit and propidium iodide 
solution were obtained from Miltenyi. Antibodies anti-OX40 (Clone L106) and anti-
CD4-APC-H7 were from BD Biosciences, and antibodies anti-4-1BB (Clone 4B4-1), 
anti-Notch2 (Clone MHN2-25), anti-GITR (Clone 621), anti-CD30 (BY88), anti-CD28-
PECy7, anti-CD45RA-BV510, anti-CD27-PE, anti-Notch2-APC, anti-OX40-FITC, anti-
mean values ± SEM of mean number of proliferation cycles from two donors, normalized to 
mean cycles of CD8+ T cells stimulated by P-CD3/CD28. (D) Normalized IFNy secretion 24 h 
after re-stimulation of Dynabead-primed pan T cells with co-stimulatory antibodies αCD27, 
a4-1BB, aOX40, αCD150 and (E) αCD28. Data is shown of duplicate stimulation of T cells from 
one donor representative for observations from three independent experiments.
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CD30-FITC, anti-4-1BB-APC and anti-CD127- PerCP-Cy5.5 were from Biolegend. eFluor 
780 live-dead cell marker was from eBioscience. Anti-CD27 (Clone 1A4CD27) was from 
Beckman Coultier. DBCO- 4EG-NHS was purchased from Jena Bioscience. DBCO-16EG- 
NHS and DBCO- 68EG-NHS were obtained from Biochempeg. Atto488-NHS ester 
(A488) was obtained from Atto-TEC GmbH. 30 kDa Amicon Ultra-15 ultrafiltration 
membranes were from Merck Millipore. X-vivo medium was purchased from Lonza. 
Antibody functionalization. For functionalization, around 1-5 mg of αCD3 or αCD28 
antibodies was diluted in PBS or Borate buffer to a concentration ~1 mg/mL to adjust 
the pH. DBCO-PEG-NHS ester, and in some cases ATTO488-NHS ester or AF350-NHS 
ester, was added and the reaction mixture was incubated for 2 h at 4 °C on a rotator. 
After this, functionalized antibodies were purified by washing four times with 15 mL 
PBS using Amicon ultrafiltration membranes (30 kD MWCO). Antibodies that were 
also labelled with a fluorophore were purified over Zebaspin size exclusion columns 
(40 kD MWCO). Before use, size exclusion columns were washed with PBS three times 
according to the manufacturer’s protocol.
Analysis of functionalized antibodies. To determine the degree of DBCO and 
fluorophore functionalization, the functionalized antibodies were analyzed with UV/
Vis spectrophotometry using a Nanodrop 2000c spectrophotometer. Absorbance at 
280, 309, 350 and 501 nm were measured to calculate the concentrations of protein, 
DBCO, AF350 and ATTO488. Overlap of the spectra of the individual molecules was 
corrected using the formulas:
A280c=A280–c1A309+c1c4A501–c2A5011–c1c3
A309c=A309–c3A280c–c4A501
A280c: Corrected absorbance at 280 nm
A309c: Corrected absorbance at 309 nm
A280: Absorbance signal measured at 280 nm
A309:  Absorbance signal measured at 309 nm
A501:  Absorbance signal measured at 501 nm
c1:    Correction factor DBCO on A280, determined as A280/A309 of 
DBCO-PEG-NHS
c2:   Correction factor ATTO488 on A280, determined as A280/A501 of 
ATTO488-NHS
c3:   Correction factor antibody on A309, determined as A309/A280 of non-func-
tionalized antibody
c4:   Correction factor ATTO488 on A309, determined as A309/A501 of 
ATTO488-NHS
4CO-STIMULATORY CONTROL OVER T CELL DIFFERENTIATION
111
The respective concentrations were calculate using molar extinction coefficients of 
the individual molecules: 210000 M-1 cm-1 for antibodies, 12000 M-1 cm-1 for DBCO, 
90000 M-1 cm-1 for ATTO488 and 19000 M-1 cm-1 for AF350.
PIC-antibody conjugate synthesis. To synthesize PIC-antibody conjugates, DBCO -
functionalized antibodies (Generally 0.2 equivalents with respect to the reactive 
azide groups on the polymer for 4EG-DBCO and 0.4 equivalents for longer PEG chains) 
were added to azide-biotin-PIC in (1 mg/mL in PBS). αCD3 and co-stimuli were added in 
a 1:1 ratio. The reaction mixture was incubated at 4 °C on a rotator overnight. After 
conjugation, the PIC-antibody conjugates were purified using magnetic mono-avidin 
beads as described in chapter 3 [35]. The conjugates were incubated with magnetic 
mono-avidin beads for 2h at 4 °C. The polymer-bound beads were then washed 
extensively with PBS+0.1% Tween-20 (2x) and PBS (4x), on a Dynal MPC-L Magnetic 
Particle Concentrator. After this, the conjugates were eluted from the beads using PBS 
containing 2 mM biotin (biotin elution buffer) on a rotator for 2h at 4 °C.
Analysis of PIC-antibody conjugates. For non-fluorescent antibodies, concentrations 
on PIC-antibody conjugates were determined using a micro BCA assay. Unbound DB-
CO-functionalized antibodies were used as a standard. For fluorophore-labeled 
antibodies, concentrations on PIC conjugates were determined using a Tecan Spark 
10M fluorescence microplate reader. Unbound functionalized antibodies were used as 
standard for each measurement. The PIC-antibody conjugate samples (100 µl) were 
pipetted into black, flat-bottom non-binding 96-well microplates (Greiner Bio-One). 
A488 and A350 were excited at 490 nm and 360 nm, and detected 
at 535 nm and 442 nm, respectively. The PIC concentrations was measured using 
circular dichroism (CD) (JASCO J-810). 100 µl of each PIC-antibody conjugate was 
pipetted into a 1 cm cuvette and the CD spectrum was measured using biotin elution 
buffer as a blank. The peak value at 272 nm was used to determine the polymer 
concentration, using an extinction coefficient of 547.8 mdeg ml cm-1, which was 
determined with a standard curve of different polymer concentrations 
as described previously [35].
Human T cell stimulation assays. Peripheral blood mononuclear cells (PBMCs) were 
isolated from buffy coats, obtained from healthy donors, using Ficoll density 
centrifugation. To isolate peripheral blood lymphocytes (PBLs), PBMCs were adhered 
to culture plates for 1 h, after which non-adherent cells were taken. PBLs were either 
used directly for T cell activation assays, or used for isolation of T cells with the 
Miltenyi Pan T cell isolation kit or naïve CD8+ T cells with the Miltenyi naïve CD8+ T 
cell isolation kit. To follow T cell proliferation, for some experiments T cells were 
labeled with CFSE or Celltrace Violet. For this, the dye was added to the cells at a final 
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concentration of 2.5 µM in PBS and cells were incubated in the dark at RT for 15 minutes. 
The reaction was quenched by addition of 3 reaction volumes of cold Fetal Bovine 
Serum (FBS), followed by washing the cells 3 times. PIC-protein conjugates were added 
to 100.000 PBLs or 50.000 T cells in round-bottom 96-well cell culture plates, with 
final volumes of 100 µl per well. For plate-bound antibody stimulations, 50 uL PBS 
containing 1 µg/mL αCD3 and 5 µg/mL co-stimulatory antibody was added to ELISA 
plates and incubated at 4 °C overnight. Plates were washed with PBS twice and naïve 
CD8+ T cells were added. For stimulation of inducible co-stimulatory molecules, T cells 
were stimulated for three days using plate-bound antibodies or CD3/CD28 T cell 
activator Dynabeads. After these three days, cells were removed from the plate or 
beads, washed 3x and re-stimulated. Cell culture was performed at 37 °C using X-Vivo 
medium containing 4% human serum.
Analysis of early T cell activation. After 18 h of stimulation, supernatant from the 
stimulated cells was collected to determine the concentration of IFNy secreted. These 
concentrations were determined by ELISA measurements (human IFNy ELISA, Thermo 
Scientific). For detection, absorbance was measured at 450 nm on a Bio-rad iMark plate 
reader. IFNy concentrations were determined using 4-paramer fits in Microplate 
Manager 6 software. After 3 days of stimulation, cells were stained for CD4 and CD8 
and the dilution of CFSE or Celltrace Violet label was determined using FACS (BD 
FACSVerse). The mean number of cycles (i.e. the average number of cell divisions) was 
determined as 2log of the ratio of the mean fluorescence intensity (MFI) of non-divided 
cells (as determined using FlowJo) divided by the MFI of all cells. To determine 
expression kinetics of co-stimulatory molecules after activation, at various time 
points after stimulation cells were split in three groups that were stained with either 
anti-CD27-PE, anti-CD28-PECy7 and anti-4-1BB-APC, or anti-OX40-FITC and 
anti-GITR-APC, or anti-CD150-AF568, anti-CD30-FITC and anti-Notch2-APC. Expression 
of the different co-stimulatory molecules was determined using FACS (BD FACSVerse).
Analysis of late T cell activation and differentiation. To determine proliferation after 
6 days of stimulation, cells were stained for CD4 and CD8 (if necessary) and counted 
using a Miltenyi MACSQuant Analyzer 10. Propidium iodide staining of dead cells was 
done using the MACSQuant before flow cytometry measurement. To analyze the dif-
ferentiation of naïve CD8+ T cells, cells were stained with eFluor 780 live-dead cell 
marker and anti-CD28-PECy7, anti-CD45RA-BV510, anti-CD27-PE, anti-CD127-PerCP-
Cy5.5, anti-CCR7-AF647 and anti-CD4-APC-H7. Expression of the different makers was 
determined using FACS (BD FACSVerse).
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Supplementary figures
Figure S1  Screening of αCD28 and αCD27 by plate-bound antibody stimulations of naïve 
CD8+ T cells. (A) Expression of CD127 and CD27 or CD28 as determined by flow cytometry 
after 6 days and 13 days of stimulation with plate-bound antibodies. Because the stimulating 
antibodies block the receptor for staining antibodies, CD27 expression is shown for CD3/
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CD28-stimulation and CD28 expression is shown for CD3/CD27 stimulation. Dot plots show 
representative example of three independent observations. (B) Expression of co-stimulatory 
molecules after stimulation with plate-coated αCD3 only. (C) Expression of co-stimulatory 
molecules CD30, Notch2 and GITR after stimulation with plate-coated αCD3/CD28 (right) 
or CD3/CD27 (left). Average percentage of co-stimulati-expressing T cells after duplicate 
stimulations of two donors is depicted.
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Figure S2  Stimulation of inducible co-stimulatory molecules on pre-activated CD8 T cells 
by plate-bound antibodies. (A) Normalized cell counts at day 6 (or 3 days after second 
stimulation). Naïve CD8+ T cells were pre-stimulated with αCD3/CD28 (left) or αCD3/CD27 
(right). After 3 days, cells were stimulated with antibodies depicted on x-axis. Values were 
normalized to CD3/CD28-stimulated cell count and the average values + SEM from 
stimulation of two donors were plotted. (B) Expression of CD127 and CD45RA as determined 
αC
D3
αC
D3
/C
D2
8
αC
D3
/G
ITR
αC
D3
/C
D3
0
αC
D3
/N
otc
h2
0
1
2
3
N
or
m
al
iz
ed
 c
el
l c
ou
nt
αC
D3
αC
D3
/C
D2
8
αC
D3
/G
ITR
αC
D3
/C
D3
0
αC
D3
/N
otc
h2
0.0
0.4
0.8
1.2
N
or
m
al
iz
ed
 c
el
l c
ou
nt
CD3/CD28 CD3/CD27
CD3/CD28 CD3/4-1BB
CD3/CD28 CD3/OX40
CD3/CD28 CD3/CD150
CD3/CD28 CD3/CD27
Day 6 Day 13
C
D
12
7-
Pe
rC
PC
y5
.5
104
103
102
101
105
C
D
12
7-
Pe
rC
PC
y5
.5
104
103
102
101
105
C
D
12
7-
Pe
rC
PC
y5
.5
104
103
102
101
105
C
D
12
7-
Pe
rC
PC
y5
.5
104
103
102
101
105
CD27-PE
105104103102101
CD27-PE
105104103102101
A
B
4CO-STIMULATORY CONTROL OVER T CELL DIFFERENTIATION
119
Figure S3  T cell stimulation with DBCO-αCD3 and P-αCD3 functionalized at pH 7.4. 
(A) Normalized IFNy concentrations in supernatant after stimulation of PBLs with unbound 
αCD3, unbound DBCO-4EG-αCD3 and unbound DBCO-68EG-αCD3. Antibodies were 
functionalized at pH 7.4. (B) Normalized IFNy concentrations in supernatant after 
stimulation of PBLs with P-αCD3 synthesized from CD3 antibodies that were functionalized 
with DBCO-PEG-NHS at pH 7.4. For P-4EG-αCD3 and P-68EG-αCD3 antibodies had a relative 
spacing of 45 and 68 nm, respectively. IFNy concentrations from duplicate stimulations of 
PBLs from three donors were normalized to the concentration induced by 200 ng/mL αCD3 
stimulation and the mean concentrations ± SEM were depicted.
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by flow cytometry after 6 days and 13 days of stimulation with plate-bound antibodies. 
Naïve CD8 T cells were pre-stimulated with plate-bound αCD3/CD28 and transferred to a 
new antibody-coated plate after 3 days. Dot plots show representative example of three 
independent observations.
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Figure S4  Development of sDCs that can trigger a wide variety of co-stimulatory molecules. 
(A) Degree of DBCO and Dye labeling for antibodies used to make the PIC-antibody 
conjugates depicted in figure 6. (B) IFNy secretion as determined by ELISA of T cells 
stimulated with 500 ng/mL (left) and 100 ng/mL (right) of αCD3 for 24 h. Bar graphs show 
mean values ± SEM of IFNy secreted into the supernatant by T cells from two donors, 
normalized to T cells stimulated with 500 ng/mL P-αCD3/CD28. (C) Proliferation as 
determined by Celltrace Violet dilution of CD4+ (left) and CD8+ (right) T cells after 3 days of 
stimulation with αCD3 and αCD28 at a concentration of 100 ng/mL. Bar graphs show mean 
values ± SEM of mean number of proliferation cycles from duplicate stimulation of two 
donors, normalized to mean cycles of CD8+ T cells stimulated by P-CD3/CD28. (D) Stability 
of antibody-functionalized DBCO during storage. Degree of DBCO labeling after antibody 
functionalization and purification (Day 0), and stability after 1 and 2 days are depicted as 
measured by UV/Vis spectrophotometry.
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Abstract
TCR triggering is initiated after binding to specific pMHC complexes on both antigen 
presenting cells or synthetic mimics thereof, so-called artificial Antigen-Presenting 
Cells (aAPCs). It is becoming increasingly clear that force generation is important in 
TCR stimulation, but it is not always evident how aAPCs can generate these forces 
necessary for T cell activation. Importantly, better understanding of the role of force in 
artificial stimulations could be exploited to develop both improved aAPC designs and 
force-responsive systems. To generate force-responsive aAPCs, DNA duplexes that 
rupture under specific pN-range tensions can be exploited. In this chapter, DNA 
duplexes were incorporated as linkers into filamentous nanosized aAPCs to develop a 
force- sensitive material that may be used to study and manipulate receptor cluster 
movement on the T cell surface. For this, filamentous polyisocyanopeptides (PICs) 
were stably linked to antibodies through DNA hybridization. Importantly, these 
constructs induced strong activation when incubated with T cells. Furthermore, 
a DNA duplex was introduced into PIC-antibody conjugates in two different geometries, 
which could either unzip or shear upon force application. Fluorescence of fluoro-
phore-quencher or FRET pairs allowed for assessment of force-induced DNA duplex 
rupture. In addition to DNA-linked anti-CD3, the PIC-antibody conjugates contained 
antibodies against CD28 or CD45. These molecules could possibly provide anchoring 
points on the T cell surface that can be used to study relative forces and manipulate 
clustering between moving receptors. A preliminary experiment indicated that 
incubation of these conjugates with T cells led to unexpected shearing, rather than 
unzipping of linkers. Additional experiments are required to fully understand how 
this high force DNA duplex shearing is induced and to establish whether these 
force-sensitive sDCs can be used to manipulate receptor clustering and T cell activation.
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Introduction
Adaptive immunity against cancer cells and invading pathogens is driven by 
activation of T cells. In the past decade, anti-cancer T cell responses induced by 
immunotherapy have led to a marked increase in clinical responses, but also gave rise 
to dangerous side effects as a result of non-specific immune activation [1,2]. To improve 
our understanding of T cell triggering and fully harness the potential of T-cell-based 
immunotherapy, methods for precise manipulation of T cell activation are essential. 
It is now increasingly recognized that force generation plays an important role in TCR 
stimulation, which could give novel opportunities to control T cell stimulation. 
Artificial antigen-presenting cells (aAPCs), are specifically designed to initiate and 
control activation of T cells [3,4], because the use of cell-free synthetic scaffolds allows 
controlled presentation of signals [4,5]. In the previous chapters, we developed a 
promising aAPC that is based on polyisocyanopeptide (PIC)-antibody conjugates, 
called synthetic Dendritic Cells (sDCs). Their filamentous shape combined with their 
small size allow for straightforward characterization and should accommodate 
application in vivo [6–9]. Increased understanding of sDC force generation may be 
exploited for the development of force-responsive scaffolds that allow for additional 
control over T cell stimulation. Although sDCs can induce robust T cell activation, it is 
not clear how they generate forces at the T cell surface necessary for TCR triggering. 
 In nature, stimulation of T cells starts with binding of T cell receptors (TCRs) to 
peptides presented on mature antigen-presenting cells (APCs) in the context of MHC 
molecules. During this process, TCRs need to distinguish between foreign and 
self-derived antigens based on interactions with short peptides presented on MHC 
complexes. Remarkably, T cells are able to recognize foreign ligands in a sea of 
self-derived peptides that have only minimal differences in affinity for their TCR 
[10,11]. To achieve this high level of selectivity and sensitivity, several mechanisms for 
TCR triggering by pMHC have evolved. TCRs are clustered on the membrane of T cells 
and stimulation of TCRs leads to increased clustering, which allows for rapid release 
and rebinding of pMHCs [12,13]. Sensitivity of this process is enhanced through spatial 
segregation of clustered TCRs from phosphatases such as CD45 [14]. In addition, the 
close contacts formed between T-cells and antigen-presenting cells lead to application 
of 10-50 pN forces on TCRs. Force is essential for signal transduction in T cell activation 
and enhances the specificity of TCR-pMHC interactions [15–17].
 Forces on TCRs are generated through the formation of close contacts and relative 
receptor movements between T cells and APCs. To establish these TCR-pMHC 
interactions in close contacts, a thick layer of glycocalyx and large membrane-bound 
proteins needs to be pushed away or compressed, leading to tension on the TCR-pMHC 
complexes [18–20]. Forces may also be generated when T cells and APC membranes are 
moving relative to each other. Furthermore, the cytoskeleton of T cells is essential for 
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signal transduction by TCRs [21]. When activation is initiated, clusters of TCRs are 
moved over the membrane by myosin-II and actin retrograde flow-dependent 
processes [22,23]. During movement of clusters, which can ultimately lead to immune 
synapse formation, binding of TCRs to immobilized ligands leads to generation of 
forces that are directly correlated to proximal signaling events [17]. Ultimately, these 
processes combined lead to tension between TCRs and pMHCs. A different type of 
force may be generated to initiate segregation of TCRs from other receptors, such as 
CD28.
 Direct evidence that established T cells as force sensors was given by experiments 
where forces were directly applied to the TCR-CD3 complex. Micropipette manipulation 
of T cells immobilized through non-stimulatory anti-CD3 antibodies is able to induce 
robust Ca2+ responses [24]. Similarly, forces exerted on non-stimulatory anti-CD3-beads 
by optical tweezers can initiate signaling in T cells [25,26]. When the same forces are 
applied to other receptors, such as CD28, no effect on activation is observed [27,28]. 
Studies using biomolecular force probes, micropipettes with a probe bead attached, 
have further defined the TCR-intrinsic forces necessary for efficient signal transduction. 
Using these probes it was demonstrated that 10 pN forces applied to a single OT-1 TCR 
induced the highest Ca2+-responses. Interestingly, bond lifetimes also peaked at 10 pN, 
indicating catch bond behavior of TCR-pMHC interactions [29]. Thus, exerting force on 
a TCR does not just lead to enhanced signaling, but may also prolong interaction (via 
catch bonds) instead of breaking it [17]. A role for catch bond formation is further 
backed up by structural analysis of the TCR complex, which indicates that bond 
lifetimes can be prolonged through a force-driven conformation change [30]. However, 
it is unclear whether catch bonds are important for every agonist pMHC-TCR pair 
[17,31].
 To further probe the exact tensions applied to TCRs during activation, DNA-based 
tension sensors have been developed [32]. These DNAs contain a hairpin loop that 
dehybridizes at defined force thresholds, which leads to unquenching of a fluorophore. 
In this way, these sensors allow for highly sensitive detection of tension generated by 
specific TCRs. Using these tension sensors, it has been demonstrated that 19-pN forces 
are generated in a defined pattern before the onset of Ca2+-signaling [32]. A similar 
approach that also allows for physical modulation of TCR forces makes use of DNA 
tension gauge tethers (TGTs). These tethers consist of DNA duplexes that rupture when 
a tension greater than a certain threshold is applied [33]. In particular, force thresholds 
can be set by changing the geometry in which TGTs are attached to a surface via one 
DNA strand and to a ligand via the complementary strand. This leads to double-strand-
ed DNA that needs to be either unzipped to rupture, which requires low force, or 
sheared, which requires a higher force [33,34]. These TGTs, which act as force-respon-
sive linkers, have demonstrated that TCR signaling is stronger when higher amounts 
of force can be applied on TCRs [32]. Therefore, incorporation of TGTs into sDCs may 
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lead to development of force-responsive aAPCs, which may allow for additional control 
over T cell activation. 
 Besides forces between TCRs and pMHCs, forces need to be generated during T cell 
activation to cluster and separate receptors in the membrane. Early during T cell 
activation, CD45 is excluded from TCR-CD28 microclusters due to its large size. CD28 is 
separated later on, when the clusters are moving into the cSMAC of the immune 
synapse. In chapter 4 it was demonstrated that triggering TCRs and CD28 with one 
and the same polymer greatly enhances T cell activation. However, it is unclear 
whether keeping these receptors in close proximity is still needed after cSMAC 
formation. Until now, forces needed for separation of these receptors have not been 
analyzed. The use of force-responsive nanosized sDCs that move along with TCR 
microclusters makes it possible to study and manipulate this process. Manipulation of 
receptor clustering may be used to precisely control T cell responses.
 Here, PIC-antibody conjugates that are stably linked through double-stranded 
DNA (dsDNA) TGTs are developed. In the second part of this chapter these PIC-dsD-
NA-antibody conjugates are developed into force-sensitive sDCs using the DNA-based 
TGTs previously described in [32]. These TGTs are incorporated into this sDC design 
together with anti-CD28 or anti-CD45 antibodies as anchoring points, which may 
allow for examination of relative receptor movement and the forces involved. The 
force-responsive dsDNA-linked sDCs developed here can be used to study the role of 
mechanical force and membrane receptor movements in sDC-induced T cell activation. 
Through manipulation of force-induced receptor segregation, the force-sensitive sDCs 
may allow for additional control over T cell activation.
Results and discussion
Synthesis and analysis of PICs with dsDNA-linked antibodies. Before introduction of 
force-sensitive linkers, it was first established whether sDCs could be synthesized by 
using DNA hybridization as linker between PICs and antibodies. To develop these 
stable double-stranded DNA (dsDNA)-linked PIC-antibody conjugates, clickable 
dsDNAs were synthesized (Figure 1a). Complementary DNA strands functionalized 
with an amine at the 5’ end or 3’ end were functionalized using NHS esters, such that 
one strand contained a trans-cyclooctene (TCO) group at the 5’ end and the other 
strand had a dibenzocyclooctyne (DBCO) moiety at the 3’ end. Depending on the 
synthetic strategy, the functionalized DNA strands were either used as single strands 
or hybridized before application in biorthogonal click reactions with antibodies. Two 
different strategies were applied to synthesize sDCs using the clickable DNAs: the 
dsDNA and ssDNA Click strategies (Figure 1b). For both methods, anti-CD3 antibodies 
were first functionalized with tetrazine using NHS ester chemistry as described in 
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Figure 1  Synthesis and characterization of dsDNA-linked PIC-antibody conjugates. (A) DNA 
functionalization with DBCO and TCO. Two complementary DNA strands were functionalized 
with either TCO-4EG-NHS esters or DBCO-4EG-NHS esters. The resulting DNA strands were 
hybridized to form a TCO- and DBCO-functionalized duplex. (B) Synthetic strategies used 
for the development of dsDNA-linked PIC-antibody conjugates. Antibodies were either 
reacted with single stranded DNA (lower transparent route, ssDNA click strategy) or 
 DBCO-containing double-stranded DNA (upper route, dsDNA click strategy). (C) Picogreen 
staining of ssDNA-αCD3 before (ssDNA-αCD3) and after (dsDNA-αCD3) formation of a DNA 
TCO-4EG-NHS
Tetrazine
-4EG-NHS
αCD3
NH2
N
N
N
N
N
N
TT TTT TTC AAC ATC AGT ACT ATA AH2N
TT TTT TTT ATA GTA CTG ATG TTG AH2N
N
DBCO-4EG-NHS
N
P-αCD3
P-αCD3/CD28
P-αCD3
Sample       αCD3        αCD28    Used in 
name                Spacing (nm)  Spacing (nm)   Figure
       P-4EG-αCD3        75         2a
P-DNA-αCD3        89         1d, 2a
P-4EG-αCD3/CD28   57 ± 12    16 ± 4    2b
P-DNA-αCD3/CD28   98 ± 4      11 ± 2         2b, S2b   
P-4EG-αCD3/CD28      10    28     2c
P-DNA-αCD3/CD28      74        252     2c
ss
DN
A-
aC
D3
ds
DN
A-
aC
D3
0
50
100
150
200
250
 d
sD
N
A 
(n
g/
m
l)
PIC
ss
DN
A-
aC
D3
P-
ds
DN
A-
aC
D3
0
20
40
60
80
 d
sD
N
A 
(n
g/
m
l)
A488
-NHS
dsDNA Click
Strategy
ssDNA Click
Strategy
A
B
C D E
5DNA-LINKED PIC-ANTIBODY CONJUGATES
129
chapter 4 for DBCO-NHS esters. In the dsDNA click strategy, tetrazine-functionalized 
αCD3 was reacted with TCO/DBCO-functionalized dsDNA via reverse-electron 
demand Diels Alder reactions to give antibodies functionalized with DBCO through 
dsDNA hybridization. Subsequently, this complex was reacted with azide- and bio-
tin-functionalized PICs. To provide additional signals important for T cell activation, 
αCD28-containing sDCs were synthesized through addition of DBCO-functionalized 
anti-CD28 antibodies to the reaction mixture. The resulting PIC-dsDNA-αCD3 
conjugates were purified over monovalent avidin beads as described in chapter 3 [7]. 
 As alternative synthetic method, the ssDNA click strategy, was applied to assess 
the dsDNA-linkage of the newly synthesized sDCs. For this, tetrazine-αCD3 was 
reacted to single-stranded TCO-DNA to give antibodies functionalized with single- 
stranded DNA (ssDNA). By adding a complementary DNA strand to these antibodies, 
DNA hybridization was measured using the dsDNA-sensitive fluorophore picogreen 
(Figure 1c). Picogreen fluorescence was highly increased when dsDNA- αCD3 was 
compared to ssDNA, which demonstrated that stabile dsDNA-αCD3 conjugates were 
formed. Furthermore, ssDNA-αCD3 was also efficiently hybridized with complementary 
ssDNA-functionalized PICs (Figure 1d). For PICs and ssDNA- αCD3, low background 
levels of picogreen staining were observed, whereas PIC-dsDNA-αCD3 showed a strong 
signal. These measurements demonstrated that dsDNA hybridization can be used as 
linkage between PICs and antibodies. Because this second strategy leads to a final 
product that potentially contains non-hybridized ssDNA, the first method was used to 
develop sDCs for functional experiments.
 Anti-CD3 concentrations of PIC-αCD3 conjugates were determined using BCA 
assays, and PIC concentrations were determined using circular dichroism (Figure 1e). 
Antibodies on P-DNA-αCD3 were spaced around 90 nm on average (~4-5 αCD3/PIC). 
As a control, covalently linked conjugates were synthesized as described in chapter 4. 
This sDC had a similar antibody spacing of ~80 nm. When both αCD3 and αCD28 were 
used in PIC-antibody conjugates, antibodies were fluorescently labeled to determine 
antibody concentrations. Also for these sDCs, two controls were synthesized with 
4EG-linked αCD3, which contained one αCD3 every 60 nm or 10 nm and a αCD28 every 
15 nm or 30 nm (~7 αCD3 and 26 αCD28, or ~40 αCD3 and 13 αCD28 per polymer 
respectively). The DNA-linked PIC-antibody conjugates contained one αCD3 every 100 
or 75 nm and an αCD28 every 10 or 250 nm (~4 αCD3 and 40 αCD28 per polymer, or 40 
αCD3 and 2 αCD28 per polymer). It is important to note that there are marked 
duplex. (D) Picogreen staining of polymer, ssDNA-αCD3 and P-αCD3 showing presence of 
dsDNA in the synthesized sDC. Picogreen measurements were done relative to a dsDNA 
standard to show the amount of DNA hybridization. (E) Analysis of antibody densities 
conjugated onto sDCs.
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differences in densities between the different DNA-linked PICs and between 
DNA-linked and 4EG-linked sDCs. As discussed in chapter 4, this is probably a result of 
small sodium azide contamination that renders DBCO unreactive towards polymer- 
bound azides. As a result, antibody conjugations to PICs could not be fully controlled 
and antibody densities were not consistent. In the future, this problem can be 
circumvented by extensive pre-treatment of the purification columns. Nonetheless, 
antibody densities on the synthesized conjugates are sufficiently high to allow for 
T cell activation.
sDCs with agonistic antibodies stably linked through dsDNA efficiently stimulate 
T cells. In chapter 2 and 4, it was shown that streptavidin and PEG-linkers can be used 
to conjugate PICs and αCD3 to form efficient sDCs. To ensure that PIC-dsDNA-antibody 
conjugates may be used as force-responsive stimulant in the future, it is essential to 
demonstrate that DNA hybridization also can yield potent sDCs. To establish this, PBLs 
were stimulated with the synthesized PIC-dsDNA-αCD3 conjugates. Similar to cells 
stimulated with PEG-linked αCD3 (P-4EG-αCD3), IFNγ secretion by PBLs stimulated 
with the novel dsDNA-linked sDCs was increased compared to unbound antibodies 
(Figure 2a). Because stimulation with unbound dsDNA-αCD3 induced comparable 
IFNγ secretion to non-functionalized αCD3, presence of the short double-stranded 
DNA strand is not responsible for the observed increase in IFNγ secretion (Figure S1a). 
In chapter 4 it was demonstrated that αCD3 functionalization with DBCO-PEG-NHS 
esters at pH 7.4 did not result in functional sDCs. Interestingly, when dsDNA linkers 
are used, αCD3 functionalization at low pH results in sDCs that can induce markedly 
increased levels of IFNγ secretion (Figure S1a). Possibly, the rigidity of dsDNA linkers 
diminishes steric blocking of αCD3 activity by the PICs compared to the highly flexible 
PEG linkers.
Also for αCD28-containing sDCs it was shown that PICs with dsDNA-linked αCD3 
induce strong activation of T cells. For this, IFNγ secretion was measured from purified 
T cells stimulated with PICs containing dsDNA-linked αCD3 and 4EG-linked αCD28 
(Figure 2b). As a positive control, P-4EG-αCD3/CD28 was also used. Because the αCD3 
density of P-DNA-αCD3/CD28 is lower than that of P-4EG-αCD3/CD28, their stimulatory 
capacity cannot be directly compared. Nonetheless, stimulation with dsDNA-linked 
PICs resulted in high levels of IFNγ secretion. To further demonstrate the strong 
stimulatory capacity of DNA-linked P-αCD3/CD28, celltrace violet-labeled purified T 
cells were stimulated with dsDNA-αCD3 + αCD28, P-dsDNA-αCD3/CD28 and 
P-4EG-αCD3/CD28 for 3 days (Figure 2c). P-dsDNA-αCD3/CD28 induced a strong 
proliferative T cell response, similar to that of P-4EG-αCD3/CD28. Stimulation with 
P-dsDNA-αCD3/CD28 conjugates with low αCD3 densities did not induce activation of 
T cells (Figure S1b), which is in agreement with results presented in chapter 2 and 
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chapter 4 for streptavidin-linked and PEG-linked PIC-antibody conjugates. Taken 
together, these results demonstrate that DNA hybridization can be used as stable 
linkage in PIC-antibody conjugates to obtain sDCs that efficiently stimulate T cells, 
which is essential for the development of force-sensitive sDCs.
Development of force-sensitive sDCs through different TGT DNA geometries. After 
having demonstrated that dsDNA-linked sDCs induce strong T cell activation, we 
made use of the dsDNA-linkage to develop force-sensitive PIC-antibody conjugates. 
To introduce force sensitivity, dsDNA linkers that are ruptured under defined pN-range 
forces can be used. In pioneering work by the group of Liu et al., two identical dsDNA 
sequences were used to immobilize ligands in two different ways, as such that rupturing 
these TGT DNAs would require different amounts of force [32]. By immobilizing 
ligands at the same end of the dsDNA where it was immobilized, dsDNA could be 
ruptured using a low 12 pN force by ‘unzipping’ of the helix. Alternatively, ligands 
were immobilized on the opposing end of the dsDNA, which required a 56 pN force to 
‘shear’ the two DNA strands. Using this calibrated system, it was demonstrated that 
T cells exert forces on pMHCs or αCD3 that can rupture dsDNA in the unzipping 
geometry, but not when the shearing geometry was used. The forces generated by 
T cells were demonstrated to be essential for downstream signaling. Because the 
thermal stability, rupture force and compatibility with T cell stimulation of these 
DNA sequences and geometries are already optimized by Liu et al., we applied the 
same sequences in PIC-antibody conjugates to develop force-sensitive sDCs and 
measure rupture forces in the nanosized sDC with CD28 or CD45 as anchoring points. 
Early (CD45) and later (CD28) after TCR triggering, these receptors move away from 
the TCR-CD3 complex. Using these molecules as anchoring points in sDCs may allow 
us to study this process in more detail. In this way, forces necessary for these receptor 
movements may be determined and receptor clustering can be manipulated to further 
control T cell activation.
 To synthesize force-sensitive sDCs with both an unzipping or a shearing DNA 
rupture geometry (Figure 3a), the same DNA sequences were used. For both geometries, 
the same 5’-DBCO modified DNA strand was used, whereas the complementary strand 
was functionalized with TCO at either the 5’ or 3’ end (Figure 3b). Hybridization of 
these strands gave a DNA duplex with DBCO and TCO at either the same end or 
opposing ends to obtain dsDNA in an unzipping or shearing geometry, respectively. 
A Cy5 dye and a quencher were used on the opposing strands to measure rupturing of 
DNA. Alternatively, Cy3 was used instead of a quencher to obtain dsDNA linkers where 
FRET could be used as additional method to measure duplex stability (Figure S2a). 
 The unzipping and shearing dsDNAs were used to synthesize a variety of P-αCD3/
CD28 conjugates with comparable 4EG-linked αCD28 spacing of ~120-150 nm (~3 αCD28 
per polymer; Figure 3c). Since CD28 could be used as an anchoring point to rupture 
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αCD3-bound dsDNA, sDCs with low αCD3 and high αCD28 densities may lead to an 
increased unquenched signal because a larger part of DNA strands can be separated as 
a result of stronger multivalent sDC binding to CD28. To be able to test this hypothesis 
for the unzipping geometry, conjugates were generated with two different αCD3 
Figure 2  T cell activation after stimulation with dsDNA-linked sDCs. (A) Normalized IFNγ 
concentrations in supernatant 18 h after stimulation of PBLs with unbound dsDNA-αCD3, 
P-dsDNA-αCD3 and P-4EG-αCD3. IFNγ concentrations from stimulation of PBLs from two 
donors were normalized to the concentration induced by 250 ng/mL dsDNA-αCD3 
stimulation and the mean concentrations ± SEM were depicted. (B) Normalized IFNγ 
concentrations in supernatant 18 h and (C) proliferation 3 days after stimulation of purified 
T cells with 500 ng/ml dsDNA-αCD3 + αCD28, P-dsDNA-αCD3/CD28 and P-4EG-αCD3/CD28. 
Two different batches of conjugates were used for IFNγ secretion and proliferation 
experiments (Figure 1e). Measurement values from stimulation of PBLs from two donors 
were normalized to the IFNγ concentration or mean value induced by P-4EG-CD3/CD28 
stimulation and the mean values ± SEM were depicted.
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densities, containing either one αCD3 every 175 nm (~2-3 αCD3 per polymer) or one 
αCD3 every 500 nm (<1 αCD3 per polymer). P-αCD3/CD28 with DNA in shearing 
geometry was made with a similar αCD3 density (1 αCD3 every 440 nm, <1 per 
polymer). Furthermore, FRET-based P-αCD3/CD28 conjugates with low αCD3 densities 
were made with Cy3 instead of a quencher. These PICs also contained less than 1 αCD3 
per polymer. During TCR stimulation, CD45 is separated from CD3 further than CD28. 
Therefore, CD45 could be an interesting anchoring point to induce αCD3-linked dsDNA 
rupture. Two different conjugates containing 4EG-linked αCD45 were synthesized, 
containing either αCD3 attached in the unzipping geometry or shearing geometry. 
As was demonstrated for P-4EG-αCD3/CD45, αCD45 does not block activation of 
T cells, and may even lead to increased IFNγ secretion compared to P-αCD3 conjugates 
(Figure S2d). 
 To test whether the DNA-linked Cy5 fluorophore is sufficiently quenched after 
formation of DNA duplexes, Cy5 fluorescence of unreacted dsDNA, αCD3-bound dsDNA 
and P-dsDNA-antibody conjugates was measured (Figure 3d). In each case, only low 
background levels of Cy5 fluorescence were observed, which was increased more than 
100-fold by releasing DNA hybridization using sodium hydroxide. A very low 
background signal was observed for the shearing geometry DNA, which was slightly 
higher than the low background observed for the unzipping geometry. This is probably 
caused by the different position of the fluorophore on the DNA strand, which results in 
a slight difference in distance between Cy5 and BHQ in the corresponding dsDNA. The 
efficient hybridization of the two dsDNAs was further confirmed using FRET of 
Cy3-containing DNAs (Figure S2b) Additionally, the stability of the DNA duplexes was 
analyzed by incubation of dsDNA-bound antibodies and dsDNA-containing conjugates 
at 37 °C (Figure 3d). No significant decrease in DNA hybridization was observed over 
two days, demonstrating that the produced sDCs are thermally stabile and suitable for 
use in biological assays.
sDCs containing dsDNA linkers show increased Cy5 fluorescence after incubation 
with T cells. Although it is known that unzipping, but not shearing dsDNA linker 
geometries can be ruptured by T cells when immobilized on a surface, they have not 
yet been tested in nanosized aAPC designs. Therefore, we measured Cy5 fluorescence 
of purified T cells after overnight incubation with the synthesized P-dsDNA-αCD3/
CD28 using flow cytometry. Although this dsDNA rupture is expected to occur much 
earlier during T cell activation, this late time point was chosen as a first test to allow 
for the Cy5-signal to be amplified by binding of multiple sDCs to each T cell. T cells 
were first incubated with P-αCD3/CD28 conjugates with different αCD3 densities, 
linked through dsDNA in unzipping geometry, to determine the effect of αCD3 density 
on dsDNA rupture (Figure 4a). Cy5 fluorescence from the two sDCs was compared 
with the background levels of the corresponding unconjugated dsDNA-αCD3s. 
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Figure 3  Synthesis and characterization of unzipping and shearing TGT-dsDNA-contain-
ing sDCs. (A) The different dsDNA geometries are ruptured by either unzipping or shearing, 
which requires a different direction of applied forces. (B) Sequences and structure of 
clickable dsDNA linkers that can be ruptured by unzipping or shearing. DNA duplex 
stability can be followed due to presence of a Cy5 fluorophore and Black Hole Quencher 
(BHQ) on both strands. (C) Analysis of densities of TGT-linked antibodies conjugated onto 
sDCs. (D) Stability and quenching efficiency of TGT-linked sDCs. Background Cy5 signal was 
measured after 0 h (before), 24 h and 48 h of incubation of PIC-dsDNA-antibody conjugates 
at 37 °C. After measurement, dsDNA strands were separated by addition of NaOH, allowing 
for measurement of 100% dequenched cy5 signals.
Sample       αCD3    αCD28/CD45  Used in 
name                Spacing (nm)  Spacing (nm)   Figure
       P-αCD3/CD28
 Unzip Quench HD  176 ± 1    115 ± 2  S4a
 Unzip Quench   501 ± 43    113 ± 27    S4a, 4a
 Shear Quench   438 ± 4    148 ± 2    4a
 Unzip FRET    705 ± 40    130 ± 10  S4b
 Shear FRET    748 ± 45    140 ± 10  S4b
P-αCD3/CD45
 Unzip Quench   69 ± 1     174 ± 3      S4c-d
 Shear Quench   96 ± 4       88 ± 2      S4c-d
GT GTC GTG CCT CCG TGC TGT G
TGT GTC GTG CCT CCG TGC TGT G
N TT TTT TTT CAC AGC ACG GAG GCA CGA CAC 
N
N
F
F
Unzip
Quench
Shear
Quench
Unzipping force Shearing force
Cy5
BHQ
%
 D
eq
ue
nc
he
d
0h 24
h
48
h
Na
OH 0h 24
h
48
h
Na
OH
0.0
0.5
1.0
20
60
100
P-αCD3/CD28 Unzip Quench
P-αCD3/CD28 Shear Quench
A
B
C D
5DNA-LINKED PIC-ANTIBODY CONJUGATES
135
P-αCD3/CD28 high density (HD) incubation with T cells did not lead to an increase in 
fluorescence, whereas fluorescence was slightly increased for the conjugates with 
lower density. This result indicates that αCD3 multivalency reduces DNA duplex 
rupture. Because no signal was observed for conjugates with higher densities, 
conjugates with low αCD3 densities were used to further study the differences 
between the unzipping and shearing dsDNA linker geometries. Because of the low 
antibody densities, T cell activation was not yet assessed at this point.
 Next, Cy5 fluorescence of T cells incubated with P-αCD3/CD28 with unzipping and 
shearing linker geometries were compared (Figure 4b). As earlier, P-αCD3/CD28 
unzipping showed a slight increase in Cy5 fluorescence. Remarkably, baseline-correct-
ed P-αCD3/CD28 dsDNA shearing showed a three-fold increase in Cy5 signal compared 
to unzipped dsDNA. No fluorescent signal was observed when these conjugates were 
incubated with T cells at 4 °C (Figure S3a) and comparable amounts of αCD3 were 
bound to T cells for both unzipping and shearing conjugates, as could be determined 
from the αCD3-bound A488 fluorescence (Figure S3b). This indicates that the observed 
signal is a result of duplex rupture. However, it needs to be further investigated 
whether this is a result of Cy5 quenching, since a similar trend was observed when 
measuring the Cy5 signal in FRET-based DNA duplexes. For these conjugates, Cy5 
signals also increased after incubation with T cells, indicating that the increased Cy5 
signals may not be the result of unquenching (Figure S3c). Also in this case αCD3 
binding was similar for both of the conjugates (Figure S3d). At this point, the Cy5-Cy3 
FRET signal was not exploited. Measurement of FRET signals could be done to confirm 
whether shearing is more efficient than dsDNA unzipping in our PIC-based sDCs. 
Similarly, αCD45-containing PICs also showed increased unquenched Cy5 signals in 
the shearing mode (Figure S3e), although it should be noted that antibody densities 
for these two conjugates are not comparable, which could significantly influence the 
results of T cell stimulation. 
 If significant, these results seem to contradict the work of Liu et al., which 
demonstrated that T cells can rupture DNA strands when dsDNA is used to immobilize 
ligands to a surface in unzipping, but not in shearing geometry [32]. As surface bound 
tension probes, the unzipping geometry was calibrated with a 12 pN rupture force, 
while the shearing geometry requires 56 pN to rupture. Since identical DNA sequences 
were used for the linkers developed in this chapter, it is unexpected that there is an 
increased T-cell induced rupture of the shearing geometry dsDNA used in our sDCs. 
Liu et al. did not include a dye in their design. In the designs presented here, the 
location of the Cy5 fluorophore slightly differs between the two geometries. It is 
possible that the Cy5 dye at the end of the unzipping sequence could slightly stabilize 
the DNA duplex, although this should only lead to a minimal increase in stability [35]. 
More importantly, the dsDNAs are not immobilized on a rigid surface, but on a small 
and semi-flexible scaffold. When immobilized on a surface, immobilized ligands 
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Figure 4  DNA duplex rupture of TGT-linkers after incubation with T cells. (A) Representative 
histograms depicting Cy5 and A488 signal of dsDNA-αCD3 control (red lines) and P-αCD3/
CD28 conjugates (black lines) with low (left) and high (HD, right) αCD3 density bound to 
CD4+ (top) and CD8+ (bottom) T cells after 18 h of incubation. (B) Normalized mean Cy5 
fluorescence intensity (MFI) from TGTs bound to CD4+ (top) and CD8+ (bottom) of duplicate 
measurements performed on two donors. (C) Representative histograms depicting Cy5 and 
A488 signal of dsDNA-αCD3 control (red lines) and P-αCD3/CD28 conjugates (black lines) 
with unzipping (left) and shearing (right) dsDNA geometries bound to CD4+ (top) and CD8+ 
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cannot traffic to the center of the immune synapse together with moving TCR 
microclusters. The size of PIC-based sDCs matches that of the moving microclusters, 
which could result in the movement of sDCs together with these clusters. This leads to 
lower forces that are applied to the dsDNAs at this point, and these forces are more 
likely to be the result of receptor movement, rather than TCR pulling. Forces that are 
exerted onto the TGT linkers could be further reduced by the semi-flexible scaffold, 
which may partly absorb some of the applied force. The effects of scaffold flexibility 
and aAPC size could be further explored by repeating these experiments using 
 surface-immobilized PICs or PICs with different rigidities. Nonetheless, the size and 
semi-flexibility of the scaffold might explain why only low levels of unzipping 
are observed, but do not provide an explanation for the relatively high shearing of 
dsDNA linkers.
 Although CD3 and CD28 are clustered together in TCR microclusters, they separate 
in the immune synapse [36]. Since Cy5 signals are mostly observed when conjugates 
have low αCD3 density combined with higher αCD28 densities, CD28 might act as an 
anchor point for dsDNA rupture at low αCD3 densities. The dependence of dsDNA 
duplex rupture on αCD3 and anchor point densities needs to be further explored to 
pinpoint whether this is indeed a result of relative receptor movements. Possibly, the 
different direction of these forces, compared to movement of CD3-receptors alone, 
could provide an explanation for the enhanced shearing of dsDNA linkers. The results 
presented here are a first step towards force-responsive sDCs that could manipulate 
this process, but more experiments are needed to confirm this.
Conclusions and outlook
DNA hybridization was successfully exploited to stably link antibodies to PICs, which 
allowed for the development of functional and potentially force-sensitive sDCs. 
DNA-linked PIC-antibody conjugates were synthesized by using a combination of 
biorthogonal click reactions. Complementary DNA strands clicked onto PICs and αCD3 
can form stabile DNA duplexes and these PIC-dsDNA-αCD3 conjugates were 
demonstrated to induce efficient T cell activation, which was further increased when 
αCD28 was co-conjugated to these PICs.
(bottom) T cells after 18 h of incubation. (D) Normalized and background (dsDNA-Ab)-cor-
rected mean Cy5 fluorescence intensity (MFI) from TGTs bound to CD4+ (top) and CD8+ 
(bottom) of duplicate measurements performed on two donors. Fluoresence was normalized 
to fluorescence measured on CD8+ T cells after incubation of P-αCD3/CD28 shear.
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To develop sDCs that exhibit force sensitivity, PIC-antibody conjugates containing 
αCD3 linked through two previously reported TGT dsDNA geometries were 
synthesized. To follow strand rupture of the TGT linkers, conjugates were made 
containing either a fluorophore and quencher, or a FRET pair. The synthesized sDCs 
were highly stabile and showed only low background fluorescence. Compared to the 
unzipping geometry DNA linker, the shearing dsDNA geometry unexpectedly showed 
more strand separation during stimulation of T cells. Further experimentation is 
needed to explain the observed differences in dsDNA rupture. Nonetheless, the sDC 
design presented here may be used in the future to measure and manipulate forces 
associated with receptor clustering on the T cell surface.
 In the initial experiments with TGT-sDCs, Cy5 signals were measured after 
overnight incubation with T cells. To determine which events are responsible for 
rupturing the dsDNA linkers, signals from these sDCs could be determined in the first 
minutes or hours after stimulation. Confocal imaging of the interactions could also 
contribute to a better understanding of the location of the forces that are being applied 
on the sDCs. Our PIC-antibody conjugates contained covalently linked αCD28 or αCD45 
that could be used as anchoring points on the T cell surfaces. This may potentiate 
measurement of forces required for the relative movements of receptors in the T cell 
membrane. To fully assess the types of forces applied on sDCs by T cells, and whether 
these forces are responsible for strand rupture of dsDNA linkers, the exact timing and 
localization of dsDNA separation should be studied in more detail. Furthermore, the 
effect of anchoring points on force application could be studied further by using 
anchor points that do not separate from CD3 or study TGT dsDNA linkers in sDCs 
without anchor points. This could lead to a better understanding of the relative 
movement of membrane receptors. In addition, the dependence of T cells on the linker 
rupture force can be studied. After optimizing the force threshold of dsDNA linkers, 
future sDCs may be developed that use force application as a trigger. This trigger may 
then be exploited to either visualize ongoing immune responses or release stimulatory 
molecules, allowing for additional levels of control over T cell activation. 
Experimental section
Materials. Zeba™ Spin Desalting Columns (40K MWCO), Celltrace Violet Cell 
proliferation kit, AlexaFluor350-NHS ester (AF350), Quant-iT Picogreen dsDNA assay 
kit and mono-avidin beads were purchased from ThermoFisher. Anti-CD3 (Clone 
OKT3) and Anti-CD28 (Clone 9.3) was from BioXCell. Anti-CD45 (Clone HI30) and 
anti-CD8-PECy7 were obtained from Biolegend. Human Pan T cell isolation kit, naïve 
CD8+ T cell isolation kit and propidium iodide solution were obtained from Miltenyi. 
Anti-CD4-APC-H7 was from BD Biosciences. eFluor 780 live-dead cell marker was from 
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eBioscience. DBCO-4EG-NHS, TCO-4EG-NHS and Tetrazine-5EG-NHS were purchased 
from Jena Bioscience. Atto488-NHS ester (A488) was obtained from Atto-TEC GmbH. 
30 kDa Amicon Ultra-15 ultrafiltration membranes were from Merck Millipore. X-vivo 
medium was purchased from Lonza. G25 spin columns were from GE. Amine-func-
tionalized DNAs were purchased from Integrated DNA technologies Inc.
DNA functionalization. The amine DNAs were functionalized with DBCO or TCO 
using a previously described protocol [37].  Briefly, 50 µl of 100 mM borate buffer (pH 
8.5) was added to 50 µl of a 1mM stock of amine-DNA. To this 2.5 equivalents of the TCO 
or DBCO-NHS ester was added (12.5 µl of a 10 mM stock in DMSO). After mixing for 2 h 
at room temperature the functionalized DNAs were purified over G25 spin columns 
and the concentration of DNA was determined by Nanodrop. 
Antibody functionalization with clickable moieties. Before functionalization, buffer 
exchange to 50 mM Borate Buffer (pH 8.5) was done using Amicon ultrafiltration 
membranes (30 kD MWCO). After this, NHS esters were added to a ~1 mg/mL 
concentration of antibodies in borate buffer and the reaction mixture was incubated 
for 2 h at 4 °C on a rotator. For functionalization of αCD3, 5 equivalents of tetrazine-
5EG-NHS ester was used. When αCD3 antibodies needed a fluorescent label, 2.5 
equivalents of ATTO488 (A488)-NHS ester was added at the same time. For αCD28 and 
αCD45, 5 equivalents of DBCO-4EG-NHS and 2.5 equivalents of AlexaFluor350 
(AF350)-NHS ester were added. Antibodies were purified over Zebaspin size exclusion 
colums (40 kD MWCO) according to the manufacturer’s protocol. Degree of DBCO and 
fluorophore labeling, and concentration were determined using UV/Vis spectropho-
tometry with a Nanodrop 2000c spectrophotometer. After correcting for the overlap 
of the spectra of the individual molecules, the concentrations of the individual 
molecules were calculated using their molar extinction coefficients (210000 M-1 cm-1 
for antibodies, 12000 M-1 cm-1 for DBCO, 90000 M-1 cm-1 for ATTO488 and 19000 M-1 
cm-1 for AF350).
Antibody-DNA conjugation. Tetrazine-functionalized αCD3 antibodies were reacted 
to either single stranded or double-stranded TCO-functionalized DNA. For this, 1 
equivalent of ssDNA or 1.5 equivalents of dsDNA was added to ~1 mg/mL αCD3 in PBS. 
DNA labeling of antibodies was analyzed using UV/Vis spectrophotometry with a 
Nanodrop 2000c spectrophotometer, using the absorption of the antibody-conjugated 
fluorophore to determine antibody concentrations.
Synthesis of synthetic DCs. Synthetic DCs were synthesized using two different 
strategies. For the first strategy, azide- and biotin-containing PICs were reacted with 1 
eq (with respect to PIC-bound azides) of a DBCO-functionalized DNA strand. After this, 
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0.6 equivalents of αCD3 functionalized with the complementary ssDNA strand was 
added to the ssDNA-PICs. The mixture was incubated overnight at 4 °C on a rotator. In 
the second strategy, 0.4-0.6 equivalents of dsDNA-containing αCD3 was reacted to 
azide-and biotin-containing PICs. When required, 0.2 equivalents of DBCO-αCD28 or 
DBCO-αCD45 were also added at this step. The reaction mixtures were incubated 
overnight at 4 °C on a rotator. The synthesized PIC-antibody conjugates were purified 
over monovalent avidin beads as described in chapter 3. The conjugates were incubated 
with mono-avidin beads for 2 h at 4 °C. The polymer-bound beads were washed 
extensively using PBS+0.1% Tween-20 (2x) and PBS (4x). The conjugates were eluted 
from the beads by incubation with PBS+2mM biotin (biotin elution buffer) on a rotator 
for 2 h at 4 °C.
Analysis of PIC-antibody conjugates. Concentrations of P-αCD3 conjugates were 
determined with a micro BCA assay, using the corresponding unbound DBCO- or 
DNA-functionalized antibodies as a standard. For P-αCD3/CD28 and P-αCD3/CD45 
conjugates, that contain fluorescently labeled antibodies, concentrations were 
determined using a Tecan Spark 10M fluorescence microplate reader. Again, the 
corresponding unbound functionalized antibodies were used as a standard for each 
measurement. The PIC-antibody conjugate samples (100 µl) were pipetted into black, 
flat-bottom non-binding 96-well microplates (Greiner Bio-One). A488 and A350 were 
excited at 490 nm and 360 nm, and detected at 535 nm and 442 nm, respectively. To 
determine antibody densities, PIC concentrations were determined using circular 
dichroism (CD) (JASCO J-810). 100 µl of each PIC-antibody conjugate was pipetted into 
a 1 cm cuvette and the CD spectrum was measured using biotin elution buffer as a 
blank. The peak value at 272 nm was used to determine the polymer concentration, 
using an extinction coefficient of 547.8 mdeg ml cm-1, which was determined with a 
standard curve of different polymer concentrations as described in chapter 3.
Analysis of DNA hybridization. To analyze whether antibodies were bound to the 
PICs via DNA hybridization, a picogreen assay was performed using the protocol 
supplied by the manufacturer. The dsDNA linker without antibody and polymer was 
used as standard to determine the apparent dsDNA concentrations. Both duplex 
stability as well as the efficiency of the quencher and FRET of the antibody dsDNA-PICs, 
antibody dsDNA and dsDNA was analyzed by measuring the fluorescence over time. 
The samples (100 µl) were pipetted in a black flat bottom 96-well plate and measured 
on the indicated times. The Cy5-ssDNAs used for unzipping and shearing geometries 
were used as the standard. To measure the effect of dequenching the samples and 
standards were treated with 25 µl of a 1 M NaOH solution, which leads to dsDNA dehy-
bridization.   
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Human T cell assays. Ficoll density centrifugation was used to isolate Peripheral blood 
mononuclear cells (PBMCs) from buffy coats obtained from healthy donors using. 
After this, peripheral blood lymphocytes (PBLs) were obtained by adhering PBMCs to 
culture plates for 1 h, after which non-adherent cells were taken. For stimulation with 
P-αCD3, PBLs were used directly for T cell activation assays. In the other assays, T cells 
were first purified with the Miltenyi Pan T cell isolation kit. When T cell proliferation 
needed to be measured, cells were labeled with Celltrace Violet. For this, Celltrace 
Violet was added to the cells at a final concentration of 2.5 µM in PBS and cells were 
incubated for 15 minutes in the dark at RT. The reaction was quenched with 3 reaction 
volumes of cold Fetal Bovine Serum (FBS), and washed 3 times. For stimulation of PBLs 
and isolated T cells, 100.000 and 50.000 cells per condition were used, respectively. 
sDCs were incubated at indicated concentrations of αCD3 in round-bottom 96-well cell 
culture plates with final volumes of 100 µl per well. Cell culture was performed at 37 
°C using X-Vivo medium containing 4% human serum.
Analysis of stimulated T cells. Supernatants from stimulated T cells were collected 
after 18 h of stimulation to determine their level of IFNγ secretion using ELISA (human 
IFNγ ELISA, Thermo Scientific). For detection, absorbance was measured at 450 nm on 
a Bio-rad iMark plate reader. IFNγ concentrations were determined using 4-paramer 
fits in Microplate Manager 6 software. To measure fluorescent signals from the bound 
PIC-antibody conjugates, cells were collected after 24 h, stained for CD4 and CD8, and 
measured using FACS (BD FACSVerse). To determine T cell proliferation, cells were 
stimulated for 3 days, stained for CD4 and CD8, and Celltrace Violet dilution was 
determined using FACS (BD FACSVerse). The mean number of cycles (i.e. the average 
number of cell divisions) was determined as 2log of the ratio of the mean fluorescence 
intensity (MFI) of non-divided cells (as determined using FlowJo) divided by the MFI 
of all cells.
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Supplementary figures
Figure S1  IFNγ secretion after stimulation with dsDNA-linked sDCs. (A) Normalized IFNγ 
concentrations in supernatant 18 h after stimulation of PBLs with αCD3, dsDNA-αCD3, 
P-4EG-αCD3 (αCD3 spacing of 24 nm) and P-dsDNA-αCD3 (αCD3 spacing of 17 nm). In each 
condition, αCD3 that was functionalized at pH 7.4 was used. IFNγ concentrations from 
stimulation of PBLs from two donors were normalized to the concentration induced by 100 
ng/mL αCD3 stimulation and the mean concentrations ± SEM were depicted. (B) Normalized 
IFNγ concentrations in supernatant 18 h after stimulation of purified T cells with 500 ng/mL 
dsDNA-αCD3 + αCD28, P-dsDNA-αCD3/CD28 and P-dsDNA-αCD3/CD28 LD (αCD3 spacing of 
445 ± 1 nm, αCD28 spacing of 69 ± 3 nm), which contains a lower density of αCD3. IFNγ 
concentrations from stimulation of T cells from two donors were normalized to the 
concentration induced P-4EG-αCD3/CD28 stimulation and the mean concentrations ± SEM 
were depicted.
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Figure S2  Synthesis and characterization of unzipping and shearing TGT-dsDNA-contain-
ing sDCs that can be analyzed with FRET. (A) Sequences and structure of clickable dsDNA 
linkers that can be ruptured by unzipping or shearing. DNA duplex stability can be followed 
due to presence of a Cy5 fluorophore and Cy3 fluorophore on the opposing strands. 
(B) Stability and FRET efficiency of TGT-linked sDCs. FRET ratio was determined as Cy5 
signal divided by the Cy3 signal after 0 h (before), 24 h and 48 h of incubation of PIC-dsDNA- 
antibody conjugates at 37 °C. After measurement, dsDNA strands were separated by 
addition of NaOH, allowing for measurement of background signals in absence of FRET. 
(C) Stability and quenching efficiency of TGT-linked sDCs. Background Cy5 signal was 
measured after 0 h (before), 24 h and 48 h of incubation of PIC-dsDNA-antibody conjugates 
at 37 °C. After measurement, dsDNA strands were separated by addition of NaOH, allowing 
for measurement of cy5 signal after strand separation. (D). IFNγ secretion induced from 
purified T cells after stimulation with P-4EG-αCD3 (αCD3 spacing 153 ± 1 nm) and 
P-4EG-αCD3/CD45 (αCD3 spacing 222 ± 7 nm and αCD45 spacing 232 ± 6 nm) with and 
without addition of IL-2.
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Figure S3  Binding and duplex rupture of sDCs with TGT linkers after incubation with T 
cells. (A) Normalized mean fluorescence intensities (MFI) of A488 signal from αCD3 bound 
to T cells. MFIs of duplicate treatment of T cells from two donors were normalized to the 
signal of P-αCD3/CD28 shear bound to CD8+ T cells and the mean values ± SEM were 
depicted. (B) Histograms showing A488 and Cy5 signal of P-αCD3/CD28 shear (black lines) 
and dsDNA-αCD3 (red lines) bound to CD4+ and CD8+ T cells after incubation at 4°C. Bar 
graphs depict normalized mean Cy5 fluorescence intensity (MFI) of P-αCD3/CD28 shear 
after overnight incubation with CD4+ (top) and CD8+ (bottom) T cells at 4 °C and 37 °C. 
Duplicate measurements were performed on two donors. (C) Representative histograms 
depicting Cy5 and A488 signal of dsDNA-αCD3 control (red lines) and P-αCD3/CD28 FRET 
conjugates (black lines) with unzipping (left) and shearing (right) dsDNA geometries bound 
to CD4+ (top) and CD8+ (bottom) T cells after 18 h of incubation. Bar graphs show normalized 
mean Cy5 fluorescence intensity (MFI) from TGTs bound to CD4+ (top) and CD8+ (bottom) of 
duplicate measurements performed on two donors. (D) Normalized mean fluorescence 
intensities (MFI) of A488 signal from αCD3 bound to T cells after 18 h incubation of 
αCD45-containing conjugates. MFIs of duplicate treatment of T cells from two donors were 
normalized to the signal of P-αCD3/CD45 shear bound to CD8+ T cells and the mean values 
± SEM were depicted. (E) Representative histograms depicting Cy5 and A488 signal of 
dsDNA-αCD3 control (red lines) and P-αCD3/CD45 conjugates (black lines) with unzipping 
(left) and shearing (right) dsDNA geometries bound to CD4+ (top) and CD8+ (bottom) T cells 
after 18 h of incubation. Bar graphs show normalized mean Cy5 fluorescence intensity (MFI) 
from TGTs bound to CD4+ (top) and CD8+ (bottom) of duplicate measurements performed 
on two donors.
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Abstract
Widespread application of cytokine-based therapies is hampered by severe toxic side 
effects, resulting from off-target (immune) cell stimulation. This emphasizes the need 
for more precise targeting of cytokines to immune cells. While cytokines are generally 
active as soluble proteins, we now demonstrate that synthetic mimics of immune 
cells based on polyiscocyanopeptides (PICs), called synthetic Dendritic Cells (sDCs) 
can efficiently present immobilized cytokines to T cells, when targeted by anti-CD3 
antibodies. Anti-CD3/IL-2-functionalized PICs induce strong T cell activation and 
proliferation, when compared to PICs functionalized with IL-2 alone. In contrast to the 
semi-flexible PICs, immobilization of IL-2 on a rigid micro-sized scaffold results in 
significant loss of IL-2 activity, signifying the importance of molecular flexibility on 
the PIC polymers to maintain function. Similarly, anti-CD3/IFNα-functionalized PICs 
support long-term proliferation of T cells. IFNα-containing sDCs additionally promote 
the development of cytotoxic effector functions of T cells with limited upregulation of 
the inhibitory immune checkpoint PD-1. This high cytolytic activity and low PD-1 
expression are essential to maintain effective anti-cancer activity. Together, these 
results demonstrate that PICs form unique nano-sized scaffolds that efficiently 
present immobilized cytokines to T cells, thus creating a powerful tool to improve 
cytokine-based immunotherapies without concomitant off target toxicity. 
KEYWORDS:  Immunotherapy, artificial antigen-presenting cell, synthetic dendritic 
cell, cytokines, polyisocyanopeptides
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Introduction
Cytokines are small soluble proteins that mediate immune responses and 
communication between immune cells. For almost three decades, high-dose cytokine 
treatment regimens have been applied as cancer immune therapies to treat different 
malignancies.[1–4] High doses of interleukin-2 (IL-2) have induced cancer regression in 
a small portion of patients, and even led to complete remission of the disease in rare 
cases.[2,5,6] Besides being used as a mono-therapy, bolus IL-2 injections are also used 
to support the survival of adoptively transferred T cells. However, tumor reduction 
requires cytokine doses that induce severe IL-2-related toxicities. The most common 
side effects include capillary leak syndrome, which is caused by the direct binding of 
IL-2 to CD25-positive endothelial cells combined with high concentrations of secondary 
cytokines, and multi-organ failure, originating from the infiltration of lymphocytes 
and direct IL-2 stimulation of endothelial cells.[7,8] Similarly, interferon-α (IFNα) 
has been used in clinical trials with varying success. It has mostly been applied in 
hematological malignancies and as a post-surgery treatment option for solid tumors.
[9] For this cytokine, patients often experience severe flu-like symptoms, induced 
by the broad immunological activity of IFNα.[10] These dose-dependent side effects 
pose one of the biggest challenges for the widespread and safe clinical application 
of cytokines. Due to the need for close monitoring, this frequently results in the 
 hospitalization of patients. Regardless of their clinical efficacy, many clinicians are 
still hesitant to systemically apply cytokine-based immunotherapies because of their 
severe side effects.[8]
 In many cases, these cytokine-based therapies directly stimulate T cells, resulting 
in increased proliferation, survival and functionality of tumor-reactive T cells.[2,11] 
When applying IL-2 and IFNα, these cytokines can also trigger many other (immune) 
cell types.[12,13] Reducing off-target stimulation is, therefore, of key importance to 
diminish the observed dose-related side effects so that higher therapeutic efficacy of 
cytokine-based therapies can be achieved. For IL-2 and IFNα, these strategies have 
focused on improving their circulation times, reducing non-specific binding, localizing 
delivery and direct targeting to infected or tumor cells.[14–24] Although these 
approaches have indeed shown reduced side effects compared to high-dose injections 
of native cytokines, off-target activation of immune cells can still remain. Clearly, 
specific targeting of IL-2 and IFNα to T cells is expected to greatly improve the efficacy 
of cytokine based therapies.
 One promising strategy to warrant such specific targeting of cytokines to T cells 
is the use of artificial antigen-presenting cells (aAPCs). These synthetic mimics of 
immune cells allow for the highly controlled activation of T cells, based on the 
multivalent presentation of antigens (signal 1) and co-stimulatory molecules (signal 2) 
as a cell-free system.[25] Several aAPC designs have incorporated the presentation or 
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release of IL-2 as a third signal to stimulate T cell activation. Importantly, aAPC-based 
T cell stimulation leads to an increase in the surface expression of IL-2 receptors.[12] 
Using IL-2-functionalized poly (lactic-co-glycolic acid) (PLGA) microparticles, it was 
demonstrated that the slow release of IL-2 in close proximity to T cells significantly 
increases proliferation of T cells, compared to exogenous non-encapsulated cytokine 
administration.[26,27] However, the size of these micro-aAPCs limits their potential 
for in vivo application. Alternatively, IL-2-presenting nano-aAPCs with a size of 500 nm 
have been generated from endoplasmic reticulum membranes of a bioengineered B 
cell line.[28] Considering the proven potential of cytokine targeting, nano-sized and 
synthetic aAPCs are needed for the specific delivery of cytokines to T cells.
 Recently, we have developed a new aAPC scaffold based on polyisocyano peptides 
(PICs): synthetic Dendritic Cells (sDCs).[29,30] These long (100-1000 nm), helical and 
semi-flexible polymers appeared ideal candidates for multivalent presentation of 
signals to T cells.[31,32] Previous studies demonstrated that combining multiple 
different molecules on these polymers markedly enhanced the activation and 
proliferation of T cells.[33] Importantly, these nanoworm-shaped PICs are cell-free and 
nano-sized scaffolds that can be applied as efficient sDCs. Because of their semi-flexible 
nature,[32] which allows for dynamic rearrangement of receptor-bound ligands, 
which is essential during T cell activation, we hypothesized that they may be ideal for 
the presentation of cytokines.
 Here, we introduce cytokine-functionalized PIC-based sDCs as a new platform for 
T cell targeted cytokine-based immunotherapies. These sDCs co-present two T cell 
activating signals: T cell stimulating anti-CD3 antibodies in combination with either 
IL-2 or IFNα. Comparing co-presentation of anti-CD3 and cytokines on the same 
scaffold with the presentation of these signals on separate scaffolds, we show how 
different delivery methods impact T cell responses. We show that the presented and 
CD3-targeted cytokines efficiently exert their function on human T cells, and that 
targeting to CD3 is essential for enhanced cytokine activity. Overall, we demonstrate 
that PIC-based sDCs are the first cell-free, nano-sized aAPC design that allows for the 
efficient presentation of functional IL-2. Moreover, for the first time, IFNα is 
incorporated into an aAPC design and is shown to be functional, enhancing cytotoxic 
T cell functions.
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Results
Synthesis and Characterization of IL-2-functionalized sDCs. To create PIC-based sDCs, 
an azide-functionalized PIC-polymer was synthesized first (Figure S1a). Following 
previously described protocols, an azide-terminated monomer was co-polymerized 
with a non-functional methoxy-terminated monomer in a ratio chosen such that the 
polymer statistically yielded an azide group every 3.5 nm.[31–33] The obtained polymers 
had a length of ~400 nm, as measured by atomic force microscopy (AFM) (Figure S1b 
and c). To facilitate purification of the PIC-protein conjugates with a recently introduced 
affinity-based method, 50 % of the azide groups were converted to biotin.[34] 
The remaining azide handles were utilized to couple anti-CD3 (αCD3) and IL-2. For this 
purpose, αCD3 and IL-2 were functionalized with dibenzocyclooctyne (DBCO)-PEG4-
NHS esters and NHS esters of Atto488 (A488) or AlexaFluor647 (AF647), respectively. 
(Figure S2a). Subsequently, the PIC-protein conjugates were synthesized using 
strain-promoted azide alkyne cycloaddition (SPAAC) of the fluorescent and 
DBCO-labeled proteins to the biotin-functionalized azido-PIC polymers (Figure 1a). 
The fluorescent dyes coupled to both antibody and IL-2, as well as the circular dichroism 
signal of the PIC polymers (a consequence of the helical polymer backbone), allowed 
for the straightforward quantification and characterization of the purified sDCs, 
including their degree of functionalization with αCD3 and IL-2. Figure 1b summarizes 
the main characteristics of the PIC-protein conjugates used in this study. On average, 
all synthesized conjugates contain one αCD3 antibody every 140-200 nm (~3 antibodies 
per polymer). While similar amounts of αCD3 are present, the IL-2 densities vary, 
depending on the amount of DBCO-IL-2 added to the reaction mixture. In total, sDCs 
with three different IL-2 densities were synthesized: P-αCD3/IL2low, P-αCD3/IL2med 
and P-αCD3/IL2high. These sDCs contain one molecule of IL-2 within every 190, 130 
and 40 nm, respectively. Thus, on average, P-αCD3/IL-2low is functionalized with ~2 
molecules of IL-2, whereas P-αCD3/IL-2med contains ~4 and P-αCD3/IL-2high carries 
~10 IL-2 molecules. In addition, two polymers containing only IL-2 were synthesized: 
P-IL-2low and P-IL-2high. P-IL-2low carries one IL-2 within every 400 nm (on average ~1 
IL-2 per polymer) and P-IL-2high contains one IL-2 every 40 nm (on average ~9 IL-2 per 
polymer). Furthermore, sDCs were synthesized that contained only αCD3 in a density 
similar to that of P-αCD3/IL-2 sDCs: P-αCD3. As demonstrated previously,[34] bio-
tin-functionalized PIC-protein conjugates can be efficiently purified over monovalent 
avidin beads, which was verified for the PIC-IL-2 conjugates using SDS-PAGE (Figure 1c). 
For the PIC-IL-2 conjugates tested, no protein band is visible in the gel. Due to their 
large size, PIC-protein conjugates cannot enter the gel so that the absence of IL-2 
demonstrates the high purity of the sDC samples.
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Figure 1  Synthesis, characterization and functionality of filamentous, semi-flexible IL-2- 
presenting sDCs. (A) DBCO- and dye-functionalized IL-2 and αCD3 antibodies were covalently 
coupled to biotin- and azide-functionalized polyisocyanopeptides (PICs) via strain-promoted 
azide alkyne cycloaddition. The resulting PIC-protein conjugates were purified over magnetic 
mono-avidin beads. Schematic structures of P-αCD3, P-αCD3/IL-2low, P-αCD3/IL-2med, 
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PIC-bound IL-2 induces efficient T cell activation. In natural immune responses, IL-2 
is mostly active as a soluble cytokine, whereas immobilization of this cytokine onto a 
more rigid aAPC surface impedes activity.[27] To analyze the binding and stimulatory 
capacity of IL-2 when immobilized on PIC-based sDCs, the newly synthesized P-αCD3/
IL-2 polymers were tested with human T cells. T cells were isolated from peripheral 
blood of healthy donors, reacted with the dye CellTrace Violet for tracking cell 
proliferation and stimulated with P-αCD3/IL-2 polymers functionalized with varying 
IL-2 densities. For all IL-2 densities, IFNγ secretion by T cells was increased at least 
two-fold after 16 h, compared to the control polymer, functionalized with αCD3 only 
(P-αCD3). The optimal αCD3/IL-2-ratio was found on P-αCD3/IL-2med, which increased 
IFNγ secretion 5-fold (Figure 1d). In addition, incubation with P-αCD3/IL-2 lead to 
 activation-induced expression of the IL-2 receptor (CD25). Expression was significantly 
increased and followed a similar dependence on IL-2 density (Figure S3c). Furthermore, 
T cell proliferation was increased after three subsequent days of incubation with 
P-αCD3/IL-2 (Figure 1e and S3d), also demonstrating that IL-2 is active when bound 
to PICs. As demonstrated using A488-labeled-αCD3 (Figure S3a) and AF647-labeled IL-2 
(Figure S3b), the amount of αCD3 bound to T cells was not significantly affected when 
comparing the different sDCs, while the amount of bound IL-2 showed the expected 
increase when using sDCs with higher IL-2 densities. Together, these measurements 
P-αCD3/IL-2high, P-IL-2low and P-IL-2high are depicted on the right. (B) Analysis of 
PIC-protein conjugates. To calculate the average spacing between proteins, the protein 
concentration was determined using the fluorescence intensity of the labeled proteins and 
the PIC concentration was determined from the circular dichroism (CD) signal at 272 nm. 
The standard error of the mean (SEM) is depicted next to the mean values of duplicate 
measurements. (C) SDS-PAGE of purified P-IL-2 conjugates (lanes 5-9). Lanes 1-4 were loaded 
with unbound IL-2 as a standard. The IL-2 concentrations of P-IL-2 conjugates correspond to 
100% IL-2 (lane 1), except for lane 5 (loading of 63%, due to a lower concentration of the 
purified polymer conjugate). (D) IFNγ secretion into the supernatant after stimulation of 
T cells for 16 h with αCD3-functionalized sDCs containing different amounts of IL-2. 
The cells were stimulated using 500 ng/ml αCD3 or 100 ng/ml αCD3. (E) Proliferation of 
T cells after 72 h of stimulation with αCD3-functionalized sDCs containing different 
amounts of IL-2. Proliferation was determined using flow cytometry analysis, measuring 
the dilution of Celltrace Violet (x-axis of histograms). The histograms show one 
representative experiment of duplicate stimulation of T cells from three healthy donors 
for CD4+ T cells (upper panel) and CD8+ T cells (lower panel). The mean number of cycles 
was calculated for each experiment. After T cell stimulation, the values were normalized, 
using the stimulation with 500 ng/ml of P-αCD3/IL-2med (CD8+ T cells) as the reference. 
The normalized values of duplicate stimulations of three donors were pooled to obtain 
mean and SEM values as depicted in the bar graphs. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2  The role of sDC scaffolds in T cell stimulation by cytokines. (A) IFNγ secretion into 
the supernatant after stimulating T cells with P-αCD3 mixed with unbound IL-2 or P-IL-2, or 
P-αCD3/IL-2med for 16 h. In each stimulation, the same amount of IL-2 was used. The cells 
were stimulated using 500 ng/ml or 100 ng/ml αCD3. (B) Proliferation of T cells after 72 h of 
stimulation with 500 ng/ml P-αCD3 mixed with unbound IL-2 or P-IL-2, or P-αCD3/IL-2med. 
Proliferation was determined by flow cytometry analysis, measuring the dilution of 
Celltrace Violet (x-axis of histograms). (C) Amount of IL-2 bound to T cells after 16 h of 
incubation with 500 ng/ml P-αCD3 mixed with unbound IL-2 or P-IL-2, or P-αCD3/IL-2med. 
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indicate that IL-2 is active when coupled to PICs and that the binding of P-αCD3/IL-2 to 
T cells is predominantly αCD3-dependent. P-αCD3/IL-2med contained the most potent 
ratio of αCD3 and IL-2 and was, therefore, selected for further studies.  
CD3-targeting of PIC-IL-2 conjugates significantly increases cytokine activity. 
Having established that IL-2-functionalized PICs induce strong T cell responses, 
we analyzed the exact role of the polymer scaffold in IL-2 presentation. Purified 
human T cells were stimulated with P-αCD3/IL-2med and, alternatively, with the 
corresponding concentrations (as determined through AF647 fluorescence) of P-IL-2 or 
unbound IL-2 in the presence of P-αCD3. Although IFNγ secretion induced by P-IL-2 + 
P-αCD3 was two-fold lower compared to the same concentration of unbound IL-2 + 
P-αCD3, targeting P-IL-2 to CD3 by co-conjugation of αCD3 on one and the same PIC 
(P-αCD3/IL-2med) restored IFNγ levels to those that can be achieved with unbound IL-2 
+ P-αCD3 (Figure 2a). A comparable trend was observed for the secretion of TNFα 
(Figure S4a). Along the same way, when compared to unbound IL-2 + P-αCD3, the 
induction of CD25 expression (Figure S4e) and T cell proliferation (Figure 2b and S4d) 
was significantly reduced for P-IL-2 + P-αCD3-stimulated CD8+ T cells, but was again 
increased to higher levels for P-αCD3/IL-2med. This increase points towards a 
synergistic effect when co-delivering αCD3 and IL-2 on one and the same polymer. To 
explain this phenomenon, we quantified the amount of IL-2 bound to T cells exploiting 
the AF647 signal. Indeed, binding of P-IL-2 is greatly reduced compared to that of 
unbound IL-2 when used in combination with P-αCD3, probably due to steric hindrance. 
This reduced binding, which explains the lower stimulatory capacity, can be restored 
by CD3+ T cell-targeting using P-αCD3/IL-2med (Figure 2c and S4c). For each condition, 
comparable levels of αCD3 were bound to the stimulated T cells (Figure S4b).
 T cells can bind IL-2 through either the high affinity trimeric αβγ-receptor, or, as 
happens in the absence of IL-2Rα (CD25), via the low affinity dimeric βγ-receptor.[12] 
While non-activated T cells only express the low affinity receptor, CD25 is upregulated 
upon TCR stimulation and the affinity towards IL-2 increases. CD25 is also expressed on 
other (immune) cells, including endothelial cells that are thought to be responsible 
Bound IL-2 was determined by flow cytometry analysis of AF647 signals (x-axis of 
histograms). For both proliferation and binding analysis, the histograms show one 
representative experiment of duplicate stimulation of T cells from three healthy donors for 
CD4+ T cells (upper panel) and CD8+ T cells (lower panel). After T cell stimulation, the values 
were normalized, using the stimulation with 500 ng/ml of P-αCD3/IL-2med (CD8+ T cells) 
as the reference. The normalized values of duplicate stimulations of three donors were 
pooled to obtain mean and SEM values, as depicted in the bar graphs. *p < 0.05, **p < 0.01, 
***p < 0.001.
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for part of the side effects of IL-2. To investigate the response of CD25-positive cells 
when stimulated under different IL-2 treatment regiments, T cells were first activated 
with the commonly used CD3/CD28 Dynabeads to activate T cellsand induce CD25 
expression. Next, these CD25 high T cells were incubated with unbound IL-2 + P-αCD3, 
P-IL-2 + P-αCD3 or P-αCD3/IL-2med. Binding of IL-2 to activated T cells was increased in 
all three cases, indicating that binding to CD25-positive T cells is not exclusively 
dependent on αCD3 (Figure S4f-g). Importantly, P-IL-2 treatment showed the lowest 
amount of bound IL-2, also for CD25-high T cells. Therefore, decreased P-IL-2 binding 
may reduce off-target effects of PIC-cytokine conjugates in future therapeutic 
applications, even though a possible effect on other cells still needs to be investigated. 
Together, the synergistic effect of co-targeting IL-2 and αCD3 shows that IL-2 exerts its 
highest activity on cells that are simultaneously triggered via αCD3. These results, 
therefore, clearly demonstrate the potential of PICs as a scaffold for IL-2 immobilization 
and T cell targeting. 
IL-2 activity is abrogated when presented on solid microbeads. Having determined 
that IL-2 can be efficiently presented to T cells on PIC-based sDCs, we investigated 
whether IL-2 is also active on more conventional microbead-based aAPCs. Such rigid 
microparticles, coated with antibodies against CD3 and CD28, are routinely used for 
in vitro T cell expansion.[35] To synthesize αCD3 and IL-2-coated beads, tosyl-actived 
microbeads were reacted with NH2-PEG5-azide. The resulting azide-functionalized 
beads were then mixed with DBCO-labeled αCD3 to yield αCD3-functionalized 
microbeads B-αCD3. Following this step, one fraction of these αCD3-beads was reacted 
with DBCO- and AF647-labeled IL-2 to obtain B-αCD3/IL-2. Flow cytometry analysis 
demonstrated that microbeads were positive for fluorescently labeled αCD3 and IL-2 
(Figure S4h). Bead-conjugated αCD3 and IL-2 concentrations were determined, 
measuring A488 and AF647 fluorescence of unreacted proteins in the supernatant. 
Stimulation of T cells with unbound IL-2 + B-αCD3 induced modest secretion of IFNγ, 
which was absent when the same amount of IL-2 was conjugated onto these aAPCs 
(B-αCD3/IL-2; Figure 3a). Additionally, some proliferation of CD8+ T cells was observed 
when the T cells were stimulated with unbound IL-2 + B-αCD3, while B-αCD3/
IL-2-stimulated T cells did not proliferate at all (Figure 3b). These experiments 
demonstrate that IL-2 presentation is not effective on conventional aAPCs, while it 
induces strong T cell activation when similar concentrations of IL-2 are presented on 
the more flexible sDCs. 
Synthesis and characterization of IFNα-functionalized PICs. Having demonstrated 
the suitability of PIC scaffolds for IL-2 presentation, we next determined whether this 
sDC design can also be used for targeting other types of cytokines. IFNα is known to 
play an important role in anti-viral immune responses and is produced in large 
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quantities by plasmacytoid dendritic cells. As a signal 3 cytokine, IFNα stimulates 
T cells in combination with CD3-stimulation and co-stimulation to promote the 
acquisition of effector functions and to enhance cell proliferation.[36] In this way, 
IFNα stimulation contributes to the differentiation of CD4+ T cells into type 1 helper 
cells (Th1), increases IFNγ secretion and induces the expression of cytotoxic molecules 
in CD8+ T cell.[37] However, when stimulation of IFNα is not combined with a TCR 
trigger, T cell proliferation is inhibited.[38,39] Thus, combining this cytokine on an 
sDC scaffold could both target this cytokine to T cells and at the same time link these 
two signals, thereby avoiding inhibition of T cell proliferation. 
 P-αCD3/IFNα conjugates were synthesized according to the same method as 
described above for P-αCD3/IL-2 conjugates. In the first step, DBCO-PEG4-NHS ester and 
Figure 3  Low IL-2 activity on αCD3/IL-2-functionalized microbeads. (A) IFNγ secretion into 
the supernatant after stimulating T cells with B-αCD3, B-αCD3 mixed with unbound IL-2 
and B-αCD3/IL-2 for 16 h. Cells were stimulated using 2 beads per cell or 0.4 beads per cell. 
(B) Proliferation of T cells after 72 h of stimulation with B-αCD3, B-αCD3 mixed with 
unbound IL-2 and B-αCD3/IL-2 determined by flow cytometry analysis, measuring the 
dilution of Celltrace Violet (x-axis of histograms). Histograms show one representative 
experiment of duplicate stimulation of T cells from three healthy donors for CD4+ T cells 
(upper panel) and CD8+ T cells (lower panel). After T cell stimulation, the values were 
normalized, using the stimulation with 2 beads per cell of B-αCD3+IL-2 (CD8+ T cells) as the 
reference. The normalized values of duplicate stimulations of three donors were pooled to 
obtain mean and SEM values, as depicted in the bar graphs. *p < 0.05, **p < 0.01, ***p < 0.001.
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AF647-NHS ester were conjugated to IFNα (Figure S2b). The biological activity of 
the resulting DBCO- and AF647-functionalized IFNα was equally effective as the 
unconjugated cytokine, as determined in a T cell proliferation assay using in 
 Dynabead-stimulated human T cells (Figure S5a). Subsequently, the functionalized 
cytokine was reacted with the azide-biotin-PICs. The resulting IFNα-PIC conjugates 
were purified over magnetic mono-avidin beads. After purification, the protein 
concentration on the PIC-protein conjugates was analyzed, using fluorescence and 
circular dichroism as described before. Again, different sDCs with different IFNα 
densities were prepared and characterized with fluorescence and circular dichroism 
measurements. The spacings between IFNα molecules were 190 nm (P-αCD3/IFNαlow), 
90 nm (P-αCD3/IFNαmed) and 40 nm (P-αCD3/IFNαhigh). This corresponds to 2, 4 and 
10 molecules of IFNα per polymer. For the different samples with varying IFNα 
densities, the average αCD3 spacing varied between 90-130 nm (Figure 4a). On average, 
these conjugates contained ~4 antibodies per polymer. Also, PICs containing only IFNα 
were synthesized with two different densities. P-IFNαlow contained ~2 proteins per 
PIC (spacing of 200 nm) and P-IFNαhigh carried ~8 proteins (spacing of 50 nm). 
SDS-PAGE revealed that only low amounts of unconjugated cytokine were present in 
the purified samples (Figure 4b). 
PIC-conjugated IFNα induces T cell activation and proliferation. Stimulation of 
T cells with P-αCD3/IFNα with varying cytokine densities induced the increased 
secretion of IFNγ compared to the P-αCD3 control, demonstrating that also this 
cytokine is functional when conjugated to PICs (Figure 4c). Surprisingly, P-αCD3/IFNα 
samples seem to inhibit the release of TNFα and IL-2 by T cells (Figure S5d-e). 
In contrast to P-αCD3/IL-2, no clear pattern emerges when investigating the binding of 
P-αCD3/IFNα with different IFNα densities, possibly because this interaction does not 
dependent on CD3 (figure S5b-c). To establish how PIC-conjugated IFNα affects T cells, 
the cells were stimulated with unbound IFNα + P-αCD3, P-IFNα + P-αCD3 and P-αCD3/
IFNαhigh. For these three conditions, little differences were observed when comparing 
the amount of IFNα bound to T cells. All three conditions also induced comparable 
amounts of IFNγsecretion (after 16 h; Figure 4d), demonstrating that IFNα conjugation 
to PICs does not reduce its initial activity. 
 When analyzing T cells 3 days after stimulation, no significant influence of IFNα 
on T cell proliferation could be detected (Figure S5f-g). Since IFNα is known to support 
T cell proliferation at later stages after TCR stimulation,[36] cell numbers were assessed 
7 days after stimulation. At this time point, P-αCD3/IFNα stimulation increased CD8+ 
T cell numbers more than four-fold compared to P-αCD3-stimulated cells, both in 
the presence or absence of unbound IFNα (Figure 4e). These results clearly illustrate 
that PIC-conjugated IFNα can stimulate T cells to induce IFNγ secretion and (late) 
proliferation. While PIC-conjugation of IL-2 in the absence of CD3-targeting antibodies 
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Figure 4  Synthesis, characterization and biological activity of PIC-IFNα conjugates. 
(A) Characteristics of PIC-protein conjugates. To calculate the average spacing between 
proteins, the protein concentration was determined using the fluorescence intensity of the 
labeled proteins and the PIC concentration was determined from the circular dichroism 
(CD) signal at 272 nm. The standard error of the mean (SEM) is depicted next to the mean 
values of duplicate measurements. (B) SDS-PAGE of purified PIC-IFNα conjugates (lanes 5-9). 
Lanes 1-4 were loaded with an IFNα standard. The amount of IFNα conjugated to the 
PIC-IFNα samples corresponds to 100% (lane 1). (C) IFNγ secretion into the supernatant after 
stimulating T cells with αCD3-functionalized sDCs containing different amounts of IFNα 
for 16 h. The cells were stimulated using 500 ng/ml αCD3 or 100 ng/ml αCD3. (D) IFNγ 
secretion into the supernatant after 16 h of T cell stimulation with P-αCD3 mixed with 
unbound IFNα or P-IFNα, or P-αCD3/IFNαhigh. In each stimulation, the same amount of 
IFNα was used. The cells were stimulated using 500 ng/ml αCD3 or 100 ng/ml αCD3. (E) Cell 
counts after 7 days of T cell stimulation with 100 ng/ml P-αCD3, P-αCD3 mixed with 
unbound IFNα or P-αCD3/IFNαhigh. After T cell stimulation, the values were normalized 
using the stimulation with P-αCD3/IFNαhigh (CD8+ T cells) as the reference. The normalized 
values of duplicate stimulations of three donors were pooled to obtain mean and SEM 
values, as depicted in the bar graphs. *p < 0.05, **p < 0.01.
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resulted in a significant loss of binding and activity, IFNα can be readily conjugated to 
PICs without losing its stimulatory capacity. Importantly, stimulation with P-αCD3/
IFNα leads to a significant increase in the CD8+ T cell number after 7 days.
T cells stimulated with PIC-conjugated cytokines develop multiple effector functions. 
After having confirmed that P-αCD3/IL-2 and P-αCD3/IFNα are capable of targeting 
cytokines to T cells and of inducing potent T cell responses, we investigated the 
functionality of the stimulated T cells after 14 days. Different functionalities of T cells, 
such as cytokine production and cytotoxicity, determine their capacity to induce a 
potent immune response. Expression of pro-inflammatory cytokines IL-2, IFNγ and 
TNFα can be essential in anti-tumor immunity, especially when produced in 
combination, each having their own role in orchestrating an immune response.[40] 
Cytokines are known to be important for equipping T cells with these functionalities. 
To ensure that the desired immune response is not affected when stimulating T cells 
with our sDCs, it is essential that these functions are also preserved after stimulation 
with cytokine-functionalized sDCs.
 To determine these functionalities, T cells were stimulated with cytokine- 
functionalized sDCs (or Dynabeads as a positive control for long-term T cell expansion) 
and re-stimulated after 7 days. After 14 days, intracellular staining for IL-2, IFNγ and 
TNFα was performed to determine the percentage of cells capable of producing these 
cytokines. Long-term stimulation resulted in T cells capable of producing multiple 
cytokines, demonstrating the presence of functional T cells. Stimulation with P-αCD3/
IFNα induced high numbers of IFNγ-producing T cells, but led to a decrease in 
TNFα-producing cells. For IL-2-stimulated cells, a decrease in IL-2 production was 
observed (Figure 5a-b). In general, the stimulation with cytokine-functionalized sDCs 
resulted in cytokine expression profiles comparable to stimulation with unconjugated 
cytokines (Figure S6a-b), further demonstrating that IL-2 and IFNα are still fully 
capable of exerting their function after conjugation to PICs.
 One of the most important functions of T cells, especially for CD8+ cells, is to kill 
pathogen infected cells or cancer cells through the release of granules that contain 
cytotoxic molecules, such as Granzyme B. As the release of cytotoxic molecules from 
these vesicles exposes CD107a on the cell surface, this can be used as a surrogate 
marker for cytotoxic activity and measured by flow cytometry.[41] After 14 days of 
stimulation, T cells expressed high levels of CD107a and Granzyme B, demonstrating 
their capacity of killing target cells (Figure 4c-d). Especially after stimulation with 
IFNα, expression of the degranulation marker CD107a was significantly increased, 
while degranulation in IL-2-stimulated cells was much lower. Degranulation was not 
dependent on whether IL-2 and IFNα were conjugated to PICs during stimulation 
(Figure S6c), whereas Granzyme B levels were somewhat increased when using 
PIC-cytokine conjugates for stimulation (Figure S6d). These findings demonstrate that 
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Figure 5  Functional consequences of 14-day T cell stimulation with cytokine-PIC conjugates. 
T cells were stimulated with 500 ng/ml P-αCD3/IL-2, P-αCD3/IFNα and Dynabeads and 
re-stimulated after 7 days. After 14 days, the cytokine production capacity of these T cells 
was determined after 6 h PMA + ionomycin stimulation in the presence of Brefeldin A and 
monensin. Using intracellular staining and flow cytometry analysis, the cytokine 
expression profiles for IL-2, IFNγ and TNFα were determined for (A) CD4+ T cells and (B) 
CD8+ T cells. (C-E) Expression of (C) CD107a, (D) Granzyme B and (E) PD-1. T cells stimulated 
for 14 days were re-stimulated with PMA + ionomycin in the presence of Brefeldin A and 
monensin. An anti-CD107a-PECy5 antibody was used to determine the expression of the 
degranulation marker CD107a (C, x-axis of histograms) using flow cytometry analysis. 
Intracellular staining for Granzyme B and cell surface staining for PD-1 were performed to 
determine the expression of these molecules. The histograms show one representative 
experiment of duplicate stimulation of T cells from three healthy donors for CD4+ T cells 
(upper panel) and CD8+ T cells (lower panel). Pooled mean fluorescence intensities (MFI) ± 
SEM are depicted in the bar graph. *p < 0.05, **p < 0.01.
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IL-2- and IFNα- induced cytotoxic T cell functions are retained or slightly increased 
upon P-αCD3/cytokine stimulation. Complying with their cytotoxic function, CD8+ 
T cells were the main producers of Granzyme B, although CD4+ T cells also showed 
degranulation and some Granzyme B production. Indeed, similar to CD8+ T cells, CD4+ 
T cells have recently been found to be capable of antigen-specific cytotoxicity in some 
cases.[42]
 Besides showing expression of cytotoxic markers, cell surface expression of PD-1 
was determined after 14 days. Interaction of PD-1 with its ligand, PD-L1, restrains T cell 
activity and can inhibit T cell function. Expression levels of PD-1 are therefore an 
indication of the ability of a T cell to be functional within immunosuppressive 
environments, including many tumors.[43] After stimulation with P-αCD3/IFNα, 
T cells expressed relatively low levels of PD-1, while the PD-1 expression level for 
P-αCD3/IL-2-stimulated cells was higher and more comparable to the expression level 
of Dynabead-stimulated T cells (Figure 5e). Stimulation of T cells with unbound 
cytokines resulted in comparable PD-1 expression (Figure S6e). The relatively low 
expression of PD-1 on IFNα-stimulated cells might make T cells less susceptible to 
PD-L1-expressing tumor cells or APCs, and is thus beneficial for their functionality. 
Contrary to our findings, increased PD-1 expression has been reported for mouse T cells 
stimulated with IFNα, although these measurements were done at an earlier time 
point after stimulation.[44]
 Together, these experiments demonstrate that T cells stimulated with cytokine- 
functionalized PICs are capable of producing multiple cytokines and of expressing 
cytotoxic markers. Although IFNα-stimulated T cells exhibit lower proliferation than 
IL-2 treated cells, they are potentially more capable of killing their target cells. On top 
of this, their relatively low PD-1 expression makes them less susceptible for inhibition 
by PD-L1. Taken together, co-conjugation of αCD3 and cytokines to PIC-based sDCs 
increases the early activation and proliferation of T cells, while retaining the capacity 
of these cytokines to bring about important functional characteristics in these T cells.
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Discussion
Lack of specificity seriously hampers widespread clinical application of cytokine-based 
 immunotherapies. Therefore, more precise targeting of cytokines to T cells would 
greatly reduce the off-target side effects of these therapies. To accomplish this, there is 
a great need for cytokine-functionalized aAPCs that allow antigen specific targeting 
of T cells, that could be applied directly in vivo in an off-the-shelf approach. However, 
to this point no nanosized cell-free aAPCs capable of cytokine delivery have been 
developed.
 In this study, cytokine-functionalized PIC-based sDCs, containing αCD3 antibodies 
combined with IL-2 or IFNα, were successfully synthesized and applied in T cell 
activation experiments. Although IL-2 and IFNα are cytokines with distinct functional 
and structural characteristics, both of them could be efficiently conjugated to PICs and 
remain biologically active. For both cytokines, proliferation was enhanced when cells 
were stimulated with PICs that were functionalized with both αCD3 and cytokines. 
Whereas PIC-conjugation of IL-2 alone diminished binding and reduced cytokine 
activity, co-conjugation of αCD3 targeted these IL-2 conjugates to the CD3 receptor and 
greatly increased all aspects of T cell activation. PIC-based sDCs are therefore a unique 
scaffold for the presentation of IL-2 to T cells. PIC-conjugation of IFNα did not alter 
biological activity in early activation assays and was mostly beneficial for the 
induction of late T cell proliferation as well as for the induction of potent cytotoxic 
functionality. Thus, these experiments demonstrate that IL-2-presenting sDCs can 
efficiently enhance T cell proliferation, while IFNα-functionalized PICs can be used to 
induce more potent T cells.
 Comparing T cell activation of cells stimulated with unbound IL-2, P-IL-2 and 
P-αCD3/IL-2med we found a synergistic effect when combining αCD3 and IL-2 on one 
and the same polymer chain. This enhanced activation may partially be explained by 
the increased amount of bound IL-2 when using P-αCD3/IL-2med. On top of this, the 
observed synergistic effect could be the result of co-localized TCR (CD3) and IL-2 
signaling, especially since components of the IL-2 receptor complex can be present in 
clusters together with (co-receptors of) TCRs.[45] In addition, localized paracrine 
delivery can greatly enhance stimulatory capacity of IL-2, as was reported for 
IL-2-releasing micro-aAPCs.[27] Also in natural DC-T cell or T-T cell interactions, 
synapses formed where TCR clusters are present may facilitate polarized IL-2 release.
[46] Similarly, we previously observed that after sDC stimulation, TCRs polarize and 
form immune synapse-like structures on one side of the T cell.[32] Thus, polarization 
of IL-2 signaling complexes to these synapses could allow for more efficient IL-2-induced 
signaling and explain the synergistic effect of closely spaced αCD3 and IL-2.[46] 
Similar to the enhanced proliferation observed after stimulation with P-αCD3/IL-2, 
the enhanced effect of P-αCD3/IFNα could be the result of co-triggering IFNα receptors 
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in close proximity to CD3. Indeed, TCRs and IFNα share similar early signaling 
complexes and functional TCRs are required for efficient IFNα signaling,[47] which 
could indicate co-localization of both receptors. In addition, for IFNγ receptors, which 
are related to IFNα receptors, inclusion within immune synapses in CD4+ T cells has 
been described as a mechanism to enhance signal transduction.[48]
 Importantly, we demonstrated here that IL-2 activity is abrogated when 
immobilized on classical rigid (dynabead-based) aAPCs. Similarly, IL-2 presentation on 
αCD3/αCD28-coated PLGA particles is known to be inefficient and requires high IL-2 
densities for stimulating T cells.[27] In contrast to rigid particles, liposome-conjugated 
IL-2 retain their activity towards T cells, which could result from the mobility of lipo-
some-anchored molecules, although the use of Fc-bound IL-2 could also play a role 
here.[20] In addition, no negative effect of IL-2 surface conjugation was reported when 
using hydroxyethyl starch nanocapsules.[22] As rigid microparticles are not able to 
present active IL-2, size and/or nano-scale flexibility seem to be essential for the 
activity of immobilized IL-2. This observation is also in line with our result that the 
amount of T cell bound P-IL-2 is low. By contrast, for our semi-flexible PICs T cell 
responses greatly increase when IL2 is co-conjugated with αCD3 to the same polymer. 
In addition, the multivalent presentation of both αCD3 and IL-2 seems to play an 
important role in this synergistic effect, since αCD3-IL-2 fusion proteins did not show 
the same synergy.[49] Probably, flexible scaffolds that can dynamically rearrange, 
appear to be better mimics of natural DC surfaces, facilitating a more efficient 
interaction of multiple ligands with T cells. Semi-flexible PIC scaffolds consequently 
allow for presenting IL-2 in close spatial proximity with a TCR trigger, resembling the 
trans-presentation observed in natural immune synapses formed between DCs and 
T cells. In this case, IL-2 can be presented on the DC surface by CD25, which is located 
in close proximity to peptide-MHC complexes, leading to robust T cell responses.[50] 
Taken together, our results demonstrate that classical solid microparticles are less 
suitable as scaffolds for IL-2-presentation, while IL-2-conjugation to PIC-based sDCs 
can induce excellent T cell responses. For IFNα-functionalized sDCs retention of 
biological activity was demonstrated when measuring early T cell activation markers. 
A similar retention of biological activity after scaffold conjugation has also been 
observed when stimulating other cell types with IFNα-functionalized scaffolds, such 
as the stimulation of B-lymphoblasts with gold nanoparticles.[17]
 The biological activity of these novel cytokine-functionalized sDCs may be 
further optimized when combining these two different cytokines on a single 
CD3-targeting PIC. This approach may allow for more substantial T cell proliferation 
combined with the induction of strong cytotoxic effector function, leading to high 
numbers of highly effective cytotoxic T cells. In this proof of concept study, cytokines 
were targeted to T cells using αCD3 antibodies, which bind closely to the TCR and 
generically trigger all CD3 expressing T cells. Having demonstrated synergistic effects 
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of simultaneous triggering of TCRs and cytokine receptors in close proximity, it is 
possible to transform this approach towards antigen-specific cytokine delivery, by 
replacing αCD3 antibodies with peptide-MHC complexes. Furthermore, in vivo tumor 
models will have to be used to further validate the benefit of cytokine presentation on 
PIC-based sDCs. Here, to the best of our knowledge, we demonstrate for the first time 
that the cytokines IL-2 and IFNα are capable of inducing potent T cell responses when 
presented on synthetic nano-sized aAPCs. Thus, the results of the presented study 
establish PIC-based sDCs as highly suitable vehicles for the delivery and presentation 
of otherwise soluble cytokines to T cells. The small size and straightforward synthesis of 
these conjugates makes them particularly promising for future off-the-shelf immune 
therapies. 
Experimental Section
Materials. Zeba™ Spin Desalting Columns (7K and 40K MWCO), Celltrace Violet Cell 
proliferation kit, tosyl-activated Dynabeads M450, Dynabeads human T-activator 
CD3/CD28 and AlexaFluorF647-NHS ester (AF647) were purchased from ThermoFisher. 
Magnetic mono-avidin beads were from Bioclone. Azide-PEG5-NH2 (O-(2-Aminoeth-
yl)-O′-(2-azidoethyl)pentaethylene glycol) was obtained from Sigma-Aldrich, anti-CD3 
(Clone OKT3) was from BioXCell. Recombinant human IL-2 and IFNα were purchased 
from Cell Sciences, IL-2 and TNFα ELISA Ready-set go kits were from eBioscience. 
Pan T cell isolation kit and propidium iodide solution were obtained from Miltenyi. 
Antibodies anti-CD4-APC-Cy7, anti-PD-1-BV510, anti-CD107a-PECy5, anti-CD25-PE, 
anti-CD4-BV421, anti-CD8-BV510 and anti-IFNγ-BV421 were from BD Biosciences, and 
antibodies anti-Granzyme B-PE, anti-CD8-PECy7 and anti-CD4-PECy7 were from 
Biolegend. Antibodies anti-TNFα-PerCPCy5.5 and anti-IL-2-PE were from eBioscience. 
DBCO-PEG4-NHS was purchased from Jena Bioscience. Atto488-NHS ester (A488) was 
obtained from Atto-TEC GmbH. 30 kDa Amicon Ultra-15 ultrafiltration membranes 
were from Merck Millipore. X-vivo medium was purchased from Lonza. Cytoperm/
cytofix buffer kit was purchased from BD Biosciences.
Synthesis of polyisocyanopeptides. The polyisocyanopeptides (PICs) used in this 
study were synthesized according to literature procedures.[32,33] Briefly, non-functional 
methoxy- and functional azide-terminated monomers were reacted in a 30:1 ratio 
using a nickel catalyst (Figure S1a), statistically yielding a polymer with a functional 
azide group every 3.5 nm. Next, 50 % of the azides were converted to biotin using DB-
CO-PEG4-biotin as described in the literature[34]. The resulting azide-biotin-PICs were 
analyzed with atomic force microscopy (Nanoscope III, Digital Instruments), operating in 
tapping mode in air, using NSG10 tips. For these experiments, the polymer (10 µg/ml) 
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was drop-casted onto freshly cleaved mica and incubated for 5 min. After removing 
the liquid, the substrate was dried under nitrogen flow (Figure S1b). These AFM images 
were used to determine the polymer length with ImageJ, yielding an average length 
of 383 nm (figure S1c).   
Protein functionalization. In order to functionalize αCD3 antibodies, the storage 
buffer was exchanged to 50 mM borate buffer pH 8.5, using Amicon ultrafiltration 
membranes (30 kD MWCO). For αCD3, IL-2 and IFNα functionalization between 1-5 mg 
of protein was used at concentrations between 1-3 mg/ml. For αCD3, 5 equivalents of 
DBCO-PEG4-NHS ester and 2.5 equivalents of A488-NHS ester was added. IL-2 and IFNα 
were reacted with 4 equivalents of DBCO-PEG4-NHS ester and 2 equivalents of 
AF647-NHS ester. After incubation for 2 h at 4 °C on a rotator, functionalized αCD3 was 
purified over a 5 ml 40K Zeba spin desalting column, while the cytokines were purified 
over a 2 ml 7K Zeba spin desalting column.
Analysis of functionalized proteins. To determine the degree of DBCO and dye 
labeling, the proteins were analyzed using a Nanodrop 2000c spectrophotometer. 
Absorbance at 280, 309, 501 and 650 nm was used to calculate the concentrations of 
proteins, DBCO and dye. After correcting for the overlap in the absorbance spectra of 
the individual molecules, the respective concentrations were calculated using the 
molar extinction coefficients of the proteins used: 210000 M-1 cm-1 for αCD3, 11900 M-1 
cm-1 for IL-2 and 18700 M-1 cm-1 for IFNα. This yielded ratios of 1:3.6:2 for αCD3:DBCO:A488, 
1:2:0.5 for IL-2:DBCO:AF647 and 1:2:0.5 for IFNα:DBCO:AF647. Protein yields were 
typically between 60-80%. The degrees of labeling were confirmed for IL-2 and IFNα 
using MALDI-ToF (Bruker microflex) with sinapinic acid as the matrix (Figure S2a-b).
PIC-protein conjugate synthesis. To obtain the PIC-αCD3/cytokine conjugates, DB-
CO-functionalized αCD3 (0.25 equivalents with respect to the reactive azide groups on 
the polymer) was added to the azide-biotin-PIC (100 µg, 1 mg/ml in Phosphate Buffered 
Saline; PBS) and incubated. After 2 h, IL-2 or IFNα was added to the reaction mixture 
and incubated at 4 °C on a rotator overnight. To obtain the low, medium and high 
density samples, 0.1, 0.2 or 0.5 equivalents of cytokine (with respect to azide) were 
used. After coupling, the protein-functionalized PICs were purified over magnetic 
mono-avidin beads as described in.[34] The PIC-protein conjugates were incubated 
with magnetic mono-avidin beads (1 ml bead solution for each polymer sample) for 2 
h at 4 °C, after which they were washed extensively with PBS+0.1% Tween-20 (2x) and 
PBS (4x), making use of a Dynal MPC-L Magnetic Particle Concentrator. To elute the 
conjugates from the beads, they were incubated in PBS containing 2 mM biotin (biotin 
elution buffer) on a rotator for 2 h at 4 °C.
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Analysis of PIC-protein conjugates. The protein concentrations in all PIC-protein 
conjugate samples were determined using a Tecan Spark 10M fluorescence microplate 
reader. Unbound DBCO/dye-functionalized proteins were used as standard for each 
measurement. The samples (100 µl) were pipetted into black, flat-bottom non-binding 
96-well microplates (Greiner Bio-One). A488 and AF647 were exited at 490 nm and 635 
nm, and detected at 535 nm and 680 nm, respectively. The polymer concentration was 
measured using circular dichroism (CD) (JASCO J-810). 100 µl of each PIC-protein 
conjugate was filled into a 1 cm cuvette and the CD spectrum was measured using 
biotin elution buffer as a blank. The peak value at 272 nm was used to determine the 
polymer concentration, using an extinction coefficient of 547.8 mdeg ml cm-1, which 
was determined with a standard curve of different polymer concentrations as 
described previously.[34] To confirm the absence of unbound proteins after purification, 
the PIC-protein conjugates were further analyzed with SDS-PAGE. A standard of 
unbound protein was loaded onto these gels for quantifying the amount of protein 
that was not fully removed during purification. After electrophoresis, the gels were 
scanned with a Typhoon trio+ gel scanner to detect the AF647 dye coupled to the 
cytokines.
Microbead-protein conjugation. To synthesize microbead-based aAPCs, tosyl-activat-
ed Dynabeads were reacted with 1000 equivalents of azide-PEG5-NH2 in 50 mM borate 
buffer (pH 8.5) overnight at room temperature. The beads were washed 4x with PBS to 
remove excess azide-PEG5-NH2. The beads were incubated with the previously 
synthesized DBCO- and Atto488-labeled αCD3 antibodies. Following overnight 
reaction at 4 °C, the beads were again washed with PBS (4x) to remove excess αCD3 
and DBCO- and AF647-labeled IL-2 was added to one part of the αCD3-labeled beads. 
Again, the beads were reacted overnight at 4 °C and washed with PBS containing 0.1 % 
BSA and 2 mM EDTA (2x) and PBS (4x) to remove excess IL-2. αCD3-functionalized and 
αCD3/IL-2-functionalized beads were analyzed using a BD FACSverse flow cytometer. 
The αCD3 and IL-2 concentrations were measured in the supernatants of the reaction 
mixtures to determine the amount of proteins coupled to the different microbeads. 
For this measurement, the samples were analyzed in a Tecan Spark 10M fluorescence 
microplate reader, relative to a standard of the unbound and fluorescently labeled 
proteins. Bead-coupled αCD3 and IL-2 densities were 43 and 58 ng/106 beads, 
respectively.
Human T cell activation assays. Peripheral blood lymphocytes were isolated from 
buffy coats, obtained from healthy donors using Ficoll density centrifugation. T cells 
were isolated from peripheral blood lymphocytes with the Miltenyi Pan T cell isolation kit. 
To follow T cell proliferation, Celltrace Violet was added to the cells at a final 
concentration of 2.5 µM. The labeling reaction was performed for 15 min at room 
CHAPTER 6
172
temperature. The reaction was quenched upon addition of 3 reaction volumes of cold 
Fetal Bovine Serum (FBS), followed by washing the cells 3 times. The PIC-protein 
conjugates were added to Celltrace Violet labeled T cells (50.000) to obtain a final 
concentrations of 100 ng/ml or 500 ng/ml of PIC-conjugated αCD3. Incubation was 
performed in round-bottom 96-well cell culture plates, with final volumes of 100 µl 
per well. Cell culture was performed at 37 °C using X-Vivo medium, containing 4% 
human serum.
Analysis of T cell stimulation. After 16 h of stimulation, a fraction of the cells was 
collected for analysis. The supernatants were collected for ELISA measurements to 
determine the concentrations of IFNγ (human IFNγ ELISA, Thermo Scientific), IL-2 
(ready-set go IL-2 ELISA kit, eBioscience) and TNFα (ready-set go TNFα ELISA kit, 
eBioscience). For detection, absorbance was measured at 450 nm on a Bio-rad iMark 
plate reader. The respective cytokine concentrations were determined using 
4-paramater fits in Microplate Manager 6 software. In addition, to assess binding of 
the conjugates and the T cell activation status, T cells were stained for CD4, CD8 and 
CD25 expression and measured using a BD FACSverse flow cytometer. 
Analysis of T cell proliferation. After 3 days, the supernatants were collected for IL-2 
and TNFα ELISAs, and the cells were stained for CD4 and CD8. CD4 and CD8 expression 
as well as the dilution of the Celltrace Violet label was determined using FACS (BD 
FACSVerse). The mean number of cycles (i.e. the average number of cell divisions) was 
determined as 2log of the ratio of the mean fluorescence intensity (MFI) of non-divided 
cells (as determined using FlowJo) divided by the MFI of all cells. To determine 
long-term T cell proliferation (7 days), T cells were stimulated with 100 ng/ml of the 
respective PIC-protein conjugates or with CD3/CD28 T cell activator Dynabeads in a 2:1 
bead:cell ratio. After 7 days, the cells were stained for CD4 and CD8 and counted using 
a Miltenyi MACSQuant Analyzer 10. Propidium iodide staining (1:1000 dilution) of 
dead cells was done using MACSQuant before flow cytometry measurements.
Binding analysis using activated T cells. To determine binding to activated 
CD25-positive cells, T cells were stimulated with CD3/CD28 T cell activator Dynabeads 
in a 1:1 bead:cell ratio at 37°C in X-vivo medium, containing 4% human serum. After 24 
h, the beads were removed over a Dynal MPC-L Magnetic Particle Concentrator (2x). 
After this step, the PIC-protein conjugates were added to 50.000 of activated T cells 
and cultured at 37°C. After 16 h, the cells were collected, stained for CD4, CD8 and CD25. 
Binding of IL-2 was analyzed on the BD FACSverse flow cytometer.
Long-term T cell functionality assay. Pan T cells were isolated from healthy peripheral 
blood lymphocytes using a Miltenyi Pan T cell isolation kit. The cells were stimulated 
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with the PIC-protein conjugates, using an αCD3-concentration of 500 ng/ml and CD3/
CD28 human T cell activator Dynabeads in a 2:1 bead:cell ratio in X-vivo medium, 
containing 4% human serum at 37 °C. After 7 days, the cells were washed with X-vivo 
medium and a fraction of the cells was re-stimulated with the same concentration of 
stimulant. After 14 days, a portion of the T cells was stimulated with PMA and 
ionomycin for 6 h to induce cytokine production in the presence of Brefeldin A and 
monensin to trap the cytokines in the cells.[51] The cells were fixed and permeabilized 
with the BD cytofix/cytoperm kit, and stained for intracellular IL-2, IFNγ and TNFα. 
In addition, 14-day-stimulated T cells were incubated with PMA and ionomycin for 6 h 
(to induce degranulation of cytotoxic granules) in the presence of brefeldin A, 
monensin and anti-CD107a-PECy5 antibody. After stimulation, intracellular staining 
for Granzyme B was performed. Additionally, surface staining for PD-1 was done 
(14-day-stimulated T cells). All stained T cells were measured using the BD FACSverse 
flow cytometer. 
Data Analysis. Flow cytometry data were analyzed using FlowJo software. 
Gating was done as depicted in Figure S7. Each experiment was performed with 
T cells from 3 different donors. Each donor was measured in duplicate and the 
corresponding values were averaged. To account for variations between donors, all 
conditions measured with samples from the same donor were first normalized by 
dividing each value by that of the most important condition. After this step, the mean 
and the standard error of the mean (SEM) were calculated, using the normalized 
values of the different donors. Statistical analysis was performed using GraphPad 
Prism (5.03) software. Statistical significances were calculated with one-way ANOVA 
and Bonferroni post tests. P values of 0.05 or less were considered significant. Bar 
graphs show the mean ± SEM of calculated values.
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Supplementary figures
Figure S1  Polymer synthesis and characterization. (A) Polymerization reaction of non- 
functional methoxy- and functional azide-terminated monomers. (B) Representative AFM 
image showing the filamentous polymer structure, scale bar 400 nm (C) Histogram of 
polymer length analysis, fitted with a Gaussian distribution.
Figure S2  Degree of labeling of IL-2 and IFNα with DBCO and dye. (A) Maldi-ToF spectra of 
functionalized IL-2. (B) Maldi-ToF spectra of functionalized IFNα. Red circles are assigned 
when the mass of DBCO was added to the cytokine, blue stars are assigned for AF647.
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Figure S3  Biological activity of filamentous semi-flexible IL-2-presenting sDCs. (A) Amount 
of αCD3 bound to T cells after 16 h of incubation with 500 ng/ml and 100 ng/ml P-αCD3 
conjugates, functionalized with different IL-2 densities. Bound αCD3 was determined by flow 
cytometry analysis of A488 signals (x-axis of histograms). (B) Amount of IL-2 bound to T cells 
after 16 h of incubation with 500 ng/ml and 100 ng/ml P-αCD3 conjugates, functionalized 
with different IL-2 densities. Bound IL-2 was determined by flow cytometry analysis of AF647 
signals (x-axis of histograms). (C) CD25 expression of T cells after 16 h of incubation with 500 
ng/ml and 100 ng/ml P-αCD3 conjugates, functionalized with different IL-2 densities. To 
determine CD25 expression, the cell surface was stained using an anti-CD25-PE antibody, 
followed by flow cytometry analysis. (D) Proliferation of T cells after 72 h of stimulation with 
100 ng/ml P-αCD3, functionalized with different IL-2 densities. Proliferation was analyzed 
using flow cytometry analysis, measuring the dilution of Celltrace Violet (x-axis of histograms). 
The histograms show one representative experiment of duplicate stimulation of T cells from 
three healthy donors for CD4+ T cells (upper panels) and CD8+ T cells (lower panels). The mean 
number of cycles was calculated for each experiment. After T cell stimulation, the values were 
normalized using the stimulation with 500 ng/ml of P-αCD3/IL-2med (CD8+ T cells) as the 
reference. The normalized values of duplicate stimulations of three donors were pooled to 
obtain mean and SEM values, as depicted in the bar graphs. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure S4  The role of sDC scaffolds in T cell stimulation by cytokines. (A) TNFα secretion into 
supernatant after 16 h of T cell stimulation with P-αCD3 mixed with unbound IL-2 or P-IL-2, or 
P-αCD3/IL-2med. In each stimulation, the same amount of IL-2 was used. The cells were 
stimulated using 500 ng/ml αCD3 or 100 ng/ml αCD3. (B) Amount of αCD3 bound to T cells 
after 16 h of incubation with 500 ng/ml and 100 ng/ml P-αCD3 mixed with unbound IL-2 or 
P-IL-2, or P-αCD3/IL-2med. Bound αCD3 was determined by flow cytometry analysis of A488 
signals (x-axis of histograms). (C) Amount of IL-2 bound to T cells after 16 h of incubation 
with 100 ng/ml P-αCD3 mixed with unbound IL-2 or P-IL-2, or P-αCD3/IL-2med. Bound IL-2 
was determined by flow cytometry analysis of AF647 signals (x-axis of histograms). 
(D) Proliferation of T cells after 72 h of stimulation with 100 ng/ml P-αCD3 mixed with 
unbound IL-2 or P-IL-2, or P-αCD3/IL-2med determined by flow cytometry analysis, measuring 
the dilution of Celltrace Violet (x-axis of histograms). The mean number of cycles was 
calculated for each experiment. (E) CD25 expression of T cells after 16 hours of incubation with 
500 ng/ml and 100 ng/ml of P-αCD3 mixed with unbound IL-2 or P-IL-2, or P-αCD3/IL-2med. 
To determine CD25 expression, the cell surface was stained using an anti-CD25-PE antibody, 
followed by flow cytometry analysis. (F) Amount of IL-2 bound to non-activated and activated 
CD4+ T cells and (G) CD8+ T cells after 16 hours of incubation with 500 ng/ml of P-αCD3 mixed 
with unbound IL-2 or P-IL-2, or P-αCD3/IL-2. To obtain activated CD25+ T cells, the cells were 
stimulated with αCD3/aCD28-functionalized Dynabeads for 24 h. Bound IL-2 was determined 
by flow cytometry analysis of AF647 signals (x-axis of histograms). The histograms show one 
representative experiment of duplicate stimulation of T cells from three healthy donors for 
non-activated (top/white box) and activated (bottom/grey box) T cells. After T cell stimulation, 
the values were normalized to the stimulation with 500 ng/ml of P-αCD3/IL-2med (non- 
activated CD8+ T cells). The normalized values of duplicate stimulations of three donors were 
pooled to obtain mean and SEM values, as depicted in the bar graphs. (H) Dot plot of flow 
cytometry measurements of αCD3-coated and αCD3/IL-2-coated microbeads to show successful 
coating with αCD3 and IL-2. Samples used in the T cell stimulation experiments are depicted 
in green (B-αCD3) and red (B-αCD3/IL-2). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure S5  Biological activity of PIC-IFNα conjugates (A) IFNγ secretion of T cells treated with 
Dynabeads alone, or together with IFNα or DBCO- and dye-functionalized IFNα (D-IFNα). 
 The cells were stimulated using 2 beads/cell and 33 ng/ml IFNα (left) or 0.4 beads/cell with 
6.6 ng/ml IFNα (right). (B) Amount of αCD3 bound to T cells after 16 h of incubation with 
500 ng/ml and 100 ng/ml P-αCD3, functionalized with different IFNα densities. Bound αCD3 
was determined by flow cytometry analysis of A488 signals (x-axis of histograms). (C) 
Amount of IFNα bound to T cells after 16 h of incubation with 500 ng/ml and 100 ng/ml 
P-αCD3, functionalized with different IFNα densities. Bound IFNα was determined by flow 
cytometry analysis of AF647 signals (x-axis of histograms). (D) IL-2 secretion and (E) TNFα 
secretion into the supernatant after 16 h of stimulation of T cells with P-αCD3, functionalized with 
different IFNα densities. The cells were stimulated using 500 ng/ml αCD3 or 100 ng/ml αCD3. 
(F) Proliferation of T cells after 72 h of stimulation with 500 ng/ml P-αCD3, functionalized 
with different IFNα densities. Proliferation was determined using flow cytometry analysis, 
measuring the dilution of Celltrace Violet (x-axis of histograms). The mean number of cycles 
was calculated for each experiment. (G) Proliferation of T cells after 72 h of stimulation with 
500 ng/ml P-αCD3 mixed with unbound IFNα or P-IFNα, or P-αCD3/IFNαhigh. Proliferation 
was determined by flow cytometry analysis, measuring the dilution of Celltrace Violet (x-axis of 
histograms). The mean number of cycles was calculated for each experiment. The histograms 
show one representative experiment of duplicate stimulation of T cells from three healthy 
donors for CD4+ T cells (upper panel) and CD8+ T cells (lower panel). After T cell stimulation, 
the values were normalized using the value obtained from stimulation with Dynabeads (A) as 
the reference or, alternatively, the stimulation with 500 ng/ml of P-αCD3/IFNαhigh (CD8+ 
T cells). The normalized values of duplicate stimulations of three donors were pooled to obtain 
mean and SEM values, as depicted in the bar graphs. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure S6  Functional consequences of 14-day T cell stimulation with PIC-cytokine conjugates. 
(A, B) T cells were stimulated with 500 ng/ml P-αCD3 mixed with IL-2, P-αCD3/IL-2, P-αCD3 
mixed with IFNα, P-αCD3/IFNα or Dynabeads and re-stimulated after 7 days. After 14 days, the 
cytokine production capacity of these T cells was determined after 6 h PMA + ionomycin 
stimulation in the presence of Brefeldin A and monensin, after which intracellular staining 
and flow cytometry analysis revealed cytokine expression profiles for IL-2, IFNγ and TNFα 
of (A) CD4+ T cells and (B) CD8+ T cells. (C-E) Expression of (C) CD107a, (D) Granzyme B and 
(E) PD-1. 14-day-stimulated T cells were re-stimulated with PMA + ionomycin in the presence 
of Brefeldin A and monensin. An anti-CD107a-PECy5 antibody was used to determine the 
expression of the degranulation marker CD107a (C, x-axis of histograms) by flow cytometry 
analysis. Intracellular staining for Granzyme B and cell surface staining for PD-1 were performed 
to determine the expression of these molecules. The histograms show one representative 
experiment of duplicate stimulation of T cells from three healthy donors for CD4+ T cells 
(upper panel) and CD8+ T cells (lower panel). Pooled mean fluorescence intensities (MFI) ± 
SEM are depicted in the bar graphs. *p < 0.05, **p < 0.01.
Figure S7  Gating strategy for flow cytometry experiments. Lymphocytes were first gated 
using forward (FSC-A) and side scatter (SSC-A). Subsequently, CD4 and CD8 T cells were gated 
using APC-H7 and PECy7 signals, respectively. Non-proliferated T cells were gated as Celltrace 
Violet (CTV)-positive cells and proliferating T cells as CTV-negative.
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Abstract
Artificial antigen-presenting cells (aAPCs) are powerful tools that can be used to 
deliver stimulatory signals to T cells for active antigen-specific immunotherapy. In 
particular, polyisocyanopeptide (PIC)-based synthetic Dendritic Cells (sDCs) are a 
potent class of aAPCs due to their semi-flexible and filamentous structure. Previous 
work demonstrated that sDCs can induce strong polyclonal T cell responses. However, 
they have not been used for antigen-specific activation of T cells to this point. In this 
chapter, antigen-specific sDCs are developed through conjugation of different 
peptide-MHC complexes to PICs. We demonstrate that these novel structures are 
capable of inducing specific activation of human T cells transfected with TCRs 
recognizing the NY-ESO-I cancer antigen. In addition, sDCs can specifically stimulate 
mouse OT-1 cells both in vitro and in vivo. These preliminary results demonstrate that 
in addition to their capacity to induce polyclonal T cell stimulation, PICs are also 
promising sDC scaffolds for antigen—specific immunotherapy.
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Introduction
Since the introduction of cancer immunotherapy, treatment options for advanced 
cancers such as metastatic melanoma have greatly increased [1,2]. The application of 
cytokines (such as IL-2 and IFN-α2b) and checkpoint inhibitors (CTLA-4 and PD-1) have 
led to significant improvement of survival rates in melanoma patients over the 
past decades. Cytokine therapies can stimulate immune cells to enhance immune 
responses, whereas checkpoint blockade releases the brakes on immune cells. 
This induces anti-tumor immunity in immunologically active cancers [3–6]. However, 
since these therapies are not antigen-specific, in many cases they can also lead to 
dangerous side effects due to overstimulation of the immune system [7,8]. This puts 
limitations on the applicable therapeutic doses of im mune-stimulating agents, which 
has inspired the development of antigen-specific anti- cancer therapies. For these 
treatments, immune responses are specifically induced against antigens expressed on 
cancer cells, thereby greatly decreasing off-target side effects [9].
 In general, this specific anti-tumor immunity relies on generation of antigen- 
specific T cells. These cells specifically recognize antigens expressed on tumor cells 
and subsequently eliminate these cells. In advanced melanoma, presence of functional 
tumor antigen-specific T cells is correlated with a better prognosis [10]. A successful 
method to amplify numbers of antigen-specific T cells makes use of Adoptive Cell 
transfer (ACT) of T cells. Generally, ACT-based therapies exploit tumor infiltrating T 
lymphocytes isolated from tumor biopsies that specifically recognize tumor antigens 
[11–14]. These T cells are expanded to large numbers before being re-injected into the 
patient, which in some successful cases leads to marked tumor regression. The efficacy 
of these therapies is dependent on the expansion and generation of functional anti-
gen-specific T cells, as was demonstrated by injection of specific T-cell clones [15]. 
Interestingly, tumor-infiltrated T cells with a wide variety of additional tumor-antigen 
specificities have been identified [16]. In melanoma, antigens targeted by the infused 
T cells include cancer-testis antigens, cell-type specific (melanocyte) antigens and 
neo-antigens. Cancer- germline antigens (e.g. NY-ESO-I) are antigens derived from 
genes that are not expressed in healthy adult tissue, while melanocyte antigens, (e.g. 
gp100, tyrosinase and MART-1) are generally also present on healthy melanocytes. 
Both these types of antigens are often shared between patients [16]. In contrast, 
neo-antigens are the direct result of cancer-specific somatic mutations, and are 
therefore often unique peptides. Although more complicated to incorporate into other 
therapeutic strategies, these peptides have proven to be even more potent targets [17].
 Experiments with T cells that express transgenic T cell receptors (TCRs) further 
demonstrate the potency of (high-affinity) antigen-specific T cells in cancer therapies. 
Using this approach, T cells transduced with engineered TCRs against MART-1, gp100 
and NY-ESO-1 have shown clinical responses after adoptive transfer into cancer 
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patients [18,19]. Engineering approaches to increase TCR affinity also lead to augmented 
anti-tumor immunity, but can induce lysis of healthy cells expressing low levels of 
these antigens [20,21]. Thus, application of antigen-specific T cells can lead to highly 
potent cancer immunotherapies with lower toxicity.
 Alternatively, ex vivo generated antigen-loaded antigen-presenting cells, most 
prominently dendritic cells (DCs), are widely used for antigen-specific immunotherapy 
[22]. For this, DCs are isolated from cancer patients, after which they are cultured ex 
vivo with adjuvants and loaded with tumor antigens. After DCs are properly matured 
and present anti-cancer antigens, they are re-injected back into cancer patients to 
stimulate specific T cell clones and evoke an antigen- specific response [22]. This form 
of cell-based immunotherapy induces considerable clinical responses in a small 
portion of patients with metastatic cancer. Also for this therapy, anti-tumor immune 
responses are mainly mediated by CD8+ T cells. These cells are activated through 
peptide-MHC complexes that are expressed on the infused DCs [23]. In this way, 
long-lasting clinical responses were induced against gp100, tyrosinase, MART-1 and 
NY-ESO-1 [24,25]. These trials clearly demonstrate objective clinical efficacy through 
in vivo activation of antigen- specific CD8+ T cells with antigens presented on class I 
MHC complexes.
 Although cell-based therapies with T cells and DCs hold great promise of  antigen- 
specific immunotherapies, these approaches are highly laborious and expensive. 
The need for large investments in infrastructure and tailor-made vaccines that require 
ex vivo cell culture for each patient hampers wide-spread application of ACT. 
A promising alternative approach towards an off-the-shelf vaccine instead makes use 
of artificial Antigen-Presenting Cells (aAPCs) [26]. These synthetic mimics of immune 
cells allow for highly controlled activation of T cells through multivalent binding 
to TCRs and co-stimulatory molecules [27,28]. We have developed a novel class of 
aAPCs based on polyisocyanopeptides (PICs) scaffolds. When these semi-flexible 
filamentous 100-1000 nm-long polymers are modified with biomolecules they can 
accommodate efficient multivalent interactions with T cells. Previously, we demonstrated 
that stimulatory anti-CD3 antibodies, that bind and trigger TCR co-receptor CD3, 
induce potent polyclonal activation of T cells when conjugated to PICs [29,30]. 
Through conjugation of co-stimulatory antibodies and cytokines to the same polymer 
chains, T-cell responses can be further enhanced to give full-blown activation and 
proliferation, as was demonstrated in chapters 4 and 6 [31]. These aAPCs are especially 
attractive due to their small size and straightforward characterization. Although it 
was established that PICs are highly suitable scaffolds for aAPCs, the use of anti-CD3 
hampers their application in therapeutic settings because of its polyclonal mode of 
stimulation.
 Here, we develop antigen-specific PIC-based aAPC through conjugation of pMHC 
complexes and establish a modular approach for synthesis of pMHC-PICs. For induction 
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of T cells against human cancer antigens, peptides derived from NY-ESO-I and MART-1 
loaded in class I MHC (HLA*0201) are conjugated to PICs. To further boost T-cell responses, 
anti-CD28 antibodies and IL-2 are also conjugated to these scaffolds. Additionally, 
 ovalbumin-specific aAPCs were generated and assessed their capacity towards both 
in vitro and in vivo stimulation of mouse T cells. Taken together, we here demonstrate 
the feasibility of producing pMHC-PIC conjugates and establish their potential for 
in vivo antigen-specific immuno therapy.
Results and discussion
Production and characterization of peptide-MHC complexes. Polyisocyano peptide 
(PIC)-protein conjugates have been established as efficient synthetic DCs for polyclonal 
stimulation of human T-cells. For these polyclonal stimulations, anti-CD3 antibodies 
were used in chapters 2-6 to stimulate the CD3 co-receptor of TCRs, which induces 
non-specific activation of all human T cells [29–31]. To create PIC-based sDCs that can 
induce antigen-specific monoclonal T-cell activation, anti-CD3 antibodies need to be 
replaced by specific peptide-MHC (pMHC) complexes. For this, peptide-MHC-complexes 
were produced according to a protocol adapted from Toebes et al. [32,33]. Genes 
encoding for human β2m, human class I HLA-A2 heavy chain and mouse class I H2-Kb 
heavy chain (Figure S1) were each expressed separately in BL21 bacteria. Inclusion 
bodies were isolated containing the desired proteins and denatured using urea. 
To produce the complexes, heavy chain and β2m were refolded in the presence of short 
peptide antigens (Figure 1a). In this way, human HLA-A*0201 pMHC complexes and 
mouse pH2-Kb-complexes were developed. Human pMHC was made presenting short 
immunogenic peptides derived from NY-ESO-1 and MART-1, and mouse pMHC 
contained an OVA-derived short peptide. Refolded complexes were concentrated and 
size exclusion chromatography was performed to both purify pMHC complexes and 
analyze complex formation. SDS-PAGE gel electrophoresis revealed protein bands at 34 
kDa and 13 kDa, corresponding with molecular weights of MHC heavy chain and β2m, 
present in the first protein-containing fractions eluted after size exclusion. This 
indicates the presence of refolded pMHC, since only completely refolded pMHC 
complexes are stable [33](Figure 1b).
 To determine biological activity of human NY-ESO-I-MHC complexes and their 
compatibility with aAPCs, NY-ESO-I-MHC was reacted to microbeads to obtain beads 
with two different pMHC densities. These pMHC-microbeads could be used to 
determine whether pMHC is active when immobilized. To assess this, human CD8+ 
T cells were transfected with a TCR specific for the produced NY-ESO-I-presenting 
HLA-A2 complex. These NY-ESO-I-specific T-cells were then stimulated with 
pMHC-microbead conjugates and unbound pMHC in presence of IL-2, and IFNy 
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concentrations in supernatant were measured after 24 and 72 hours (Figure 1c). After 
24 hours, secretion of IFNy was detected for high density pMHC-beads, while after 72 
hours, also low density-pMHC beads had induced IFNy secretion in a concentration- 
dependent fashion. Importantly, with this it was demonstrated that functional 
pMHC complexes were produced and that these complexes can retain functionality 
when conjugated onto a rigid aAPC scaffold. In contrast to anti-CD3 stimulations 
reported in previous chapters, unbound pMHC was able to induce high IFNy secretion 
levels. Although microbead aAPCs have been reported to induce increased T-cell 
activation compared to unbound pMHC, unbound HLA molecules are known to have 
some stimulatory capacity as well [34–37]. Although not determined exactly for 
dynabeads, pMHC concentrations in both experiments are likely in a similar range. 
Additional concentrations of beads and pMHC should be tested to see whether 
stimulation of dynabeads at higher concentrations also induce similar IFNy secretion. 
Further increasing pMHC density and co-conjugation of costimulatory ligands on 
these beads will probably also increase T-cell responses beyond levels of unbound 
pMHC [38,39]. Taken together, it was demonstrated that functional pMHC complexes 
were produced and that these complexes can retain their functionality when used on 
microbead aAPCs.
Figure 1  Production and characterization of pMHC-PIC conjugates (A) Schematic depiction 
of synthetic strategy for the development of antigen-specific PIC aAPCs. MHC class I heavy 
chain and β2m were refolded with short peptides and purified using size exclusion 
chromatography. Refolded pMHC complexes were functionalized with DBCO-4EG NHS 
ester and Atto488-NHS ester, after which they were conjugated to azide- and biotin-func-
tionalized PICs. The resulting PIC-protein complexes were purified over magnetic 
mono-avidin beads. (B) Trace of Absorbance at 280 nm (top) and SDS-PAGE gel electrophore-
sis (bottom) of peptide-MHC complex size exclusion purification for MART-1 and NY-ESO-I 
antigens refolded in HLA-A*0201 complexes. Fractions corresponding with pMHC complex 
peak are depicted in the red boxes (C) IFNy secretion 24h and 72h after stimulation of NY-
ESO-I-specific transfected CD8+ T cells. CD8+ T cells were transfected with an NY-ESO-I-spe-
cific TCR and stimulated with low (LD)- and high (HD)-density pMHC beads at 1 bead/cell 
and 0.5 bead/cell (left bar graph), or with 100 ng/mL unbound pMHC (Right bar graph). 
After 24 hours and 72 hours, supernatant was collected and IFNy secretion was determined 
by ELISA. (D) Degree of DBCO and dye labelling after functionalization and purification of 
peptide-MHC complexes as determined by spectrophotometry measurements (E) Protein 
densities of PIC-conjugated proteins after purification. Fluorescence of protein-conjugated 
dyes was used to determine concentrations of the different proteins conjugated to PICs. PIC 
concentration could be determined using circular dichroism. For both fluorescence and CD 
signals, duplicate measurements were done.
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Synthesis of pMHC-containing sDCs. After successfully producing peptide-MHC 
complexes and having established their biological activity, pMHCs were functionalized 
to prepare them for further conjugation to PICs. For this, complexes were reacted to 
DBCO-4EG-NHS ester and Atto488-NHS ester as described for other proteins used in 
chapters 3-6 of this thesis [40]. Spectrophotometry of functionalized complexes 
revealed successful reactions of NHS-esters (Figure 1d). While aiming for two 
functional groups per protein complex, NY-ESO-I-MHC, MART-1-MHC and OVA-Kb had 
protein:DBCO:dye ratios of 1:2:2, 1:4.1:3.7 and 1:3.3:2.4, respectively. These data 
demonstrate that, similar to antibodies and cytokines used before, pMHC-complexes 
were also efficiently reacted to NHS esters to introduce a dye and DBCO functionality.
 Having demonstrated that pMHC-complexes were properly labelled with DBCO 
and dye, they were conjugated to azide- and biotin-containing PICs. Functionalized 
pMHCs were mixed with polymers and PIC-pMHC conjugates were purified over 
magnetic mono-avidin beads using the biotin tag as described in chapter 3 [40]. To 
synthesize NY-ESO-I-specific PICs, polymers were reacted to either pMHC alone, or 
NY-ESO-I MHC together with a DBCO-functionalized  AlexaFluor350-labelled anti-CD28 
antibody using the approach described in chapter 4. For MART-1, polymers were made 
containing MART-1-MHC alone, MART-1-MHC/anti-CD28 and MART-1/IL-2 (as 
described in chapter 6). Mouse H2-Kb-OVA polymers were made with only this 
complex, or combined with IL-2. Protein concentrations were determined using their 
respective fluorescent signals and polymer concentration was assessed using circular 
dichroism. Combining these methods, protein densities conjugated to PICs were 
calculated for human MHC-containing samples (Figure 1e). With one pMHC every 240 
nm for NY-ESO-I-MHC and a spacing of 180 nm for MART-1-MHC (approximately 2 
NY-ESO-1-MHC or MART-1-MHC complexes per polymer), pMHC densities were 
comparable for the different samples. Anti-CD28-containing polymers contained 
similar amounts of pMHC and anti-CD28. Although pMHC and IL-2 densities were in a 
similar range as anti-CD3 and IL-2 densities reported in chapter 6, pMHC/IL-2-PICs 
contained 6.5-fold more IL-2 than pMHC, which is markedly higher than the optimal 
IL-2/anti-CD3 ratios used in chapter 6. Using lower IL-2 densities may result in 
conjugates with more optimal T-cell stimulatory capacity. In addition, H2-Kb-OVA 
polymers were produced using the same method, but no circular dichroism was done 
to determine the PIC/protein ratios to avoid contamination that could affect in vivo 
experiments later on. Compared to conjugation of antibodies and cytokines to PICs, 
conjugation reactions with functionalized pMHC were less efficient, since twice the 
amount of pMHC was needed to obtain similar PIC-bound densities. Probably, the 
lowered reactivity is a result of unavailable DBCO functionalities due to sodium azide 
contamination after spin filtration. Since pMHC is prone to aggregation at lower 
concentrations, small pMHC aggregates in the reaction mixture could also account for 
a lower availability of functionalized protein complexes to react to these polymers. 
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With these measurements, it was demonstrated that pMHCs can be conjugated to PICs 
to create antigen-specific filamentous synthetic DCs. This synthetic strategy is 
applicable to both human HLA*0201 complexes with NY-ESO-I and MART-1 peptides, 
and for mouse H2-Kb complexes presenting an OVA-derived peptide. This approach 
can also be extended to other HLA types and additional peptide antigens.
Stimulation of NY-ESO-I-specific T cells using pMHC-presenting sDCs. After successfully 
synthesizing NY-ESO-I-specific sDCs, these PIC conjugates were assessed for their 
ability to stimulate T cells. For this, CD8+ T cells were transfected with mRNA encoding 
for an NY-ESO-I-specific TCR with over 80% efficiency (Figure 2a). As a control, mock 
transfected T cells were used to evaluate non-specific T-cell activation. Both NY-ESO-I-
specific and mock-transfected T cells were stimulated with unbound NY-ESO-I-MHC 
or PIC-conjugated NY-ESO-I-MHC, either alone or in combination with anti-CD28 
antibody. Additionally, cells were stimulated with the combined NY-ESO-I-MHC/
CD28-PIC. After 24 hours, no IFNy could be detected for pMHC-PIC-stimulated cells. 
Unbound pMHC did induce low levels of IFNy secretion, indicating that polymer-bound 
stimulation was not efficient within the first 24 hours (Figure 2b). After 72 hours 
however, IFNy secretion of pMHC-PIC-stimulated was markedly increased, while 
unbound pMHC did not induce further secretion (Figure 2c). These observations are 
consistent with long-term stimulations that were done with anti-CD3-presenting PICs 
in chapter 2 [30]. These anti-CD3-sDCs were also able to induce sustained signalling 
and IFNy secretion over multiple days, whereas effects induced by unbound anti-CD3 
where much shorter [30]. Strikingly, co-conjugation of pMHC and anti-CD28 showed a 
marked release of IFNy over 24 hours, which was 2.5-fold higher than IFNy secretion 
from mock-transfected cells, indicating an antigen-specific effect. Also, these levels 
were greatly increased after 72 hours, again demonstrating a long-term effect on T-cell 
activation of PIC-based sDCs. Although stimulation of NY-ESO-I-specific T cells clearly 
exhibited increased IFNy secretion compared to mock-transfected cells when 
stimulated with pMHC/CD28-PICs, conjugation of anti-CD28 to PICs also induced 
non-specific activation of T-cells. For other scaffolds, such as magnetic microbeads and 
iron-dextran nanoparticles, this effect was absent [35,41]. In contrast, PIC-conjugated 
anti-CD28 can induce low levels of early activation, as was observed for some 
PIC-antibody conjugates in chapter 4. Natural ligands for CD28, such as B7, or antibodies 
with lower affinity, could be used to further optimize PIC-aAPCs. Nonetheless, a great 
enhancement in IFNy secretion was observed for TCR-transfected T cells. With this, a 
first demonstration was given of functional PIC-based sDCs capable of antigen-specif-
ic human T cell activation. So far, the stimulatory capacity of NY-ESO-I-presenting PICs 
was established on T cells from two donors. To further establish reproducibility and 
modularity of our approach, these experiments should be extended to more donors 
and additional antigens such as MART-1 should be used for T-cell stimulation as well. 
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MART-1 could also be used to expand non-transfected T-cells through multiple 
 re-stimulations over several weeks [42]. The results presented here are the first 
demonstration of the antigen-specific stimulatory capacity of PIC-based sDCs.
In vitro stimulation of OVA-specific mouse T cells. To apply antigen-specific sDCs in 
an in vivo model, mouse OVA-Kb-presenting PICs were synthesized using the same 
method as was applied for human pMHC-PICs. To test the synthesized OVA-Kb-con-
taining PICs, purified OT-1 T cells were stimulated with OVA-Kb or with P-OVA-Kb. 
After 24 hours, CD69 expression was measured to evaluate the stimulatory capacity of 
the different PIC-protein conjugates. OVA-Kb-PICs were capable of inducing high levels 
of CD69, comparable to levels induced with unbound Kb-OVA, indicating a high 
potential to activate T cells (Figure 3a). After three days, proliferation was assessed 
through Celltrace Violet dilution, which revealed that Kb-stimulated T cells proliferated 
extensively (Figure 3b). For human T cells, presentation of signal 1 on PICs led to 
increased activation compared to stimulation with unbound anti-CD3 or pMHC, 
whereas activation of OT-1 T cells was not increased when OVA-Kb was conjugated 
onto PICs (Figure 3c-d).
Figure 2  NY-ESO-I-specific in vitro stimulation of human CD8+ T cells (A) Histogram of 
TCR-transfected CD8+ T cells stained with NY-ESO-I-MHC tetramers (red). CD8+ T cells were 
isolated from healthy donor peripheral blood lymphocytes and mRNA transfection was 
done by electroporation. After this, cells were stained with APC-labelled NY-ESO-I-MHC 
tetramers and measured by flow cytometry. Staining of mock-transfected cells is shown in 
grey. (B) IFNy secretion 24h and (C) 72h after stimulation of TCR-transfected CD8+ T cells. 
TCR-transfected CD8+ T cells were stimulated with 100 ng/mL pMHC. Duplicate stimulation 
of T cells from one healthy donor is shown.
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It is important to note that Kb-OVA densities conjugated onto the PICs was not 
determined. P-Kb-OVA conjugates with higher densities may be able to further 
increase T cell activation beyond levels of unbound Kb-OVA. Generally, monomeric 
pMHC complexes do not induce activation of CD8 T cells [43]. However, it is possible 
that interactions of OVA-Kb with the T cell surface or transfer of peptides to T cell MHC 
can explain the stimulatory capacity of monomeric OVA-Kb [36]. For stimulation with 
soluble dimers or tetramers of OVA-Kb, some induction of OT-1 T cell activation has also 
been reported [44,45]. Possibly, linking recombinant pMHC complexes to proteins like 
Figure 3  OVA-specific in vitro stimulation of mouse OT-1 cells. (A) Percentage of CD69- 
expressing OT-1 T cells 24h after in vitro stimulation with Kb-OVA or PIC-Kb-OVA. (B) Histro- 
grams of Celltrace Violet dilution to determine proliferation of OT-I T cells after stimulation 
with Kb-OVA or PIC-Kb-OVA (C) Percentage of live OT-1 T cells that are proliferating after 
stimulation with Kb-OVA or PIC-Kb-OVA as determined by flow cytometry analysis of 
Celltrace Violet dilution. (D) Mean proliferation cycle of live OT-1 T cells after stimulation 
with Kb-OVA or PIC-Kb-OVA  as determined by flow cytometry analysis of Celltrace Violet 
dilution. Representative experiment from two independent stimulations is depicted.
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immunoglobulins and streptavidin could increase their stability, decrease interactions 
with cell membranes and decrease aggregation. This could help to limit stimulation in 
unbound form. In addition, cells that were stimulated with PICs containing a second 
stimulatory molecule, such as anti-CD28 or IL-2, did not further increase their 
activation compared to stimulation with unconjugated anti-CD28 (Figure S2a-b) or 
IL-2 (Figure S2c-d). OT-1 cells are highly sensitive to antigen-specific stimulation, as is 
apparent from the observed proliferation cycles OVA-Kb-stimulated cells undergo. 
Since these cells may be maximally stimulated with just this first signal, we could not 
observe an effect of additional co-stimuli or cytokines. In recent literature, elevated 
responses have been reported for OT-1 stimulation with microsized aAPCs presenting 
multiple signals [45–48], indicating that our PIC-pMHC conjugates could be further 
optimized to allow for optimal co-stimulation. Still, we have established that OVA-Kb 
does not lose its stimulatory capacity when conjugated to PICs. This confirms that 
PIC-pMHC conjugates can be efficient aAPCs for antigen-specific stimulation of mouse 
T cells. 
In vivo treatment with PIC sDCs induces antigen-specific T-cell activation. After 
having established that OVA-Kb-bearing PICs are capable of inducing potent T-cell 
responses in vitro, their capacity for in vivo antigen-specific T-cell stimulation was 
tested. For this, isolated OT-1 T cells were labelled with Celltrace Violet and adoptively 
transferred in C57/BL6J mice (Figure 4a). The following day, mice were vaccinated 
intravenously with OVA-Kb or OVA-Kb-PIC together with IL-2 and 2 days later, T cell 
activation was assessed by Celltrace dilution (Figure 4b). While OVA-Kb-stimulated 
cells showed some proliferation (approximately 20%), this was increased almost 3-fold 
when OT-1 T cells were stimulated with PIC-conjugated OVA-Kb (Figure 4c). 
Furthermore, PIC-OVA-Kb-stimulated T cells showed more rounds of proliferation 
compared to stimulation with the unbound complex (Figure 4d). This clearly 
demonstrates the potential of using PIC-based sDCs for in vivo T-cell stimulation. 
Thus, intravenously injected pMHC-PICs can stimulate T cells in the spleen and deliver 
Figure 4  in vivo stimulation of OT-1 T cells in C57/BL6J mice (A) Schematic representation of 
in vivo stimulation of OT-1 T cells with Kb-OVA-PICs. CD8+ T cells are isolated from an OT-1 
mouse, stained with Celltrace Violet dye and injected into C57/BL6J mice. After 1 day, 240 ng 
OVA-Kb-containing samples and 380 ng IL-2 are injected and after another two days, cells 
are harvested from spleens to measure proliferation (B) Histograms showing Celltrace 
Violet dye dilution to indicate proliferation of OT-1 T cells retrieved from spleens of treated 
mice. (C) Percentage of proliferating OT-1 T cells as determined by Celltrace Violet dye 
dilution. (D) Mean proliferation cycle of OT-1 T cells as determined by Celltrace Violet dye 
dilution. Stimulations were done on two mice per condition.
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a stronger signal compared to unbound OVA-Kb, whereas no difference in effect was 
observed in vitro
 Taken together, our results signify that pMHC conjugation to PICs can both 
improve their bio-distribution and increase their antigen-specific stimulatory 
capacity in vivo. Furthermore, injection of OVA-Kb/IL-2-PIC was performed to test the 
effect of co-conjugating this cytokine in an in vivo setting. However, stimulation with 
PIC-conjugated IL-2 did not markedly change T-cell proliferation compared to unbound 
IL-2 stimulation. This further highlights the need for optimizing MHC/IL-2 ratios in 
these multiple-signal conjugates, as protein densities of conjugates used in these 
experiments were not determined (Figure S3). As demonstrate in chapter 6, IL-2 
densities should be tightly controlled to obtain a potent stimulatory effect of cyto-
kine-presenting sDCs. Optimal pMHC and IL-2 densities still has to be determined for 
stimulation of mouse T cells. To further track the full effect of PIC-conjugated IL-2 in 
vivo, it may be necessary to assess effects of stimulation over longer periods of time 
and to make use of a less sensitive model for T-cell stimulation, that is more reflective 
of physiological activation. Nonetheless, these experiments demonstrated that PIC 
scaffolds are highly suitable for in vivo stimulation of antigen-specific T-cells.
Conclusions
Cancer immunotherapy has significantly improved clinical outcomes in patients with 
advanced disease, but can be limited by their non-specific side effects. Therefore, anti-
gen-specific immunotherapies are being developed that show great promise towards 
both reducing these side effects and greatly improving potency of anti-cancer 
immune responses. With these therapies, antigen-specific T cells can be induced that 
accurately and potently target and kill cancer cells. However, many of these therapies 
are based on adoptive cell transfer, and require culture of immune cells ex vivo. This 
makes these strategies laborious and difficult to apply on a wide-spread clinical level. 
To circumvent the use of ACT, aAPCs can be used as cell-free systems to efficiently 
stimulate T cells.
 In chapters 2-6 of this thesis, PICs have been established as potent artificial 
 antigen-presenting cells for polyclonal stimulation of T cells by triggering CD3. Here, 
we have demonstrated that, instead of conjugating anti-CD3 antibodies, we can 
effectively produce pMHC-PIC conjugates. To this end, PIC-protein conjugates were 
demonstrated to be capable to act as potent aAPCs for antigen-specific stimulation 
of human T cells. Importantly, pMHC-PICs can also stimulate antigen- specific T cells 
in vivo. 
 The use of multiple antigens in addition to both human and mouse MHC 
complexes shows that these aAPCs are highly modular. To further broaden the scope 
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of cancers that can be targeted with this therapy, PIC-conjugates should be synthesized 
using additional HLA types and antigens. Furthermore, ratios with co-stimulatory 
molecules and cytokines can be further optimized to induce more potent stimulation 
of T-cells. These optimized pMHC-PICs need to be tested for T-cell stimulation in models 
that may be more biologically relevant than TCR- transfected T cells or OT-1 T cells used 
here. Instead, expansion of both naïve and intratumoral antigen-specific T cells, 
present within large populations of cells not specific for these antigens, could give a 
better idea of the clinical potency of these aAPCs. In conclusion, the preliminary 
experiments presented in this chapter have demonstrated the promise of semi-flexible 
filamentous PIC scaffolds as aAPCs for antigen-specific immunotherapy. More 
experiments on non-transgenic T cells and application of sDCs in in vivo tumor models 
are needed to further establish their potency.
Experimental Procedures
Materials and mice. OT-1 and C57/BL6J mice (female, 5-8 weeks old) were purchased 
from Charles River. DNA encoding b2m and mouse H2-Kb heavy chain were a kind gift 
from the Ton Schumacher lab. DNA for human HLA-A2 heavy chain was obtained 
from Thermofisher geneart. Amicon Ultra 30 kDa cut-off spin filters were obtained 
from Merck. Micro BCA assay kit, M-450 tosylactivated dynabeads, one Shot BL21(DE3) 
chemically competent E. Coli, human IFNy ELISA kit, RPMI, AlexaFluor-NHS esters and 
CellTrace Violet Cell Proliferation kit were from Thermofisher. Human and mouse 
CD8+ T cell isolation kits were purchased from Miltenyi Biotec. DBCO-4EG-NHS ester 
was from Jenabioscience. Atto488-NHS ester was from atto-tec. Human anti-CD28 
(Clone 9.3) and mouse anti-CD28 (clone 37.51) were obtained from BioXCell. Recombinant 
IL-2 was purchased from cell sciences. X-vivo 15 medium was from Lonza. NY-ESO-I 
mRNA was a kind gift from Ugur Sahin, BioNTech AG (Mainz, Germany). NY-ESO-I 
tetramer (APC-A2/Kb Chimeric SLLWITQV-loaded) was from Proimmune. Mouse 
anti-CD69-PE antibody was from Biolegend.
Biotin-azido PIC synthesis. The polyisocyanopeptides (PICs) used in this study were 
synthesized according to literature procedures [29,31]. Briefly, non-functional methoxy 
and functional azide terminated monomers were reacted in a 30:1 ratio using a nickel 
catalyst (Figure S1a), statistically yielding a polymer with every 3.5 nm a functional 
azide group. Next, 60 % of the azide were converted to biotin using DBCO-4EG-biotin 
as described in literature [40]. The resulting azide biotin PICS were analyzed with 
Atomic Force Microscopy (Nanoscope III, digital instruments) operating in tapping 
mode in air, using NSG10 tips. For this, the polymer (10 ug/ml) was dropcasted on 
freshly cleaved mica for 5 minutes after which the substrate was dried under a 
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nitrogen flow (Figure S1b). From these images the polymer length could be established 
with imageJ, yielding an average length of 383 nm.   
Production of pMHC complexes. Class I MHC refolding reactions were performed as 
described in literature [32,33]. Briefly, human HLA-A2, human b2m and mouse H2-Kb 
(sequences in figure S1) were produced by expression in Escherichia Coli and isolated as 
inclusion bodies. Proteins were denatured in 8M urea in 100mM Tris-HCl buffer (pH 8). 
For refolding reactions, short peptide antigens (MART-126-35: ELAGIGILTV, NY-ESO-I157-
165: SLLMWITQV, OVA257-264: SIINFEKL) were dissolved in 50 mL of cold refolding buffer 
to a final concentration of 60 µM. To this solution, denatured b2m and class I MHC 
were added dropwise to a final concentration of 2 µM and 1 µM, respectively. Refolding 
reactions were incubated on a rotator at 4 °C overnight. Addition of denatured proteins 
and overnight incubation was repeated twice, after which the reaction mixtures were 
incubated on a rotator at 4 °C for 48 hours. After removal of aggregates, refolding 
reactions were concentrated on Amicon 30 kDa cut-off spin filters to a volume of 1-2 
mL and pMHC complexes were purified using a Bio-Rad Enrich SEC70 size exclusion 
column in Bio-rad NGC medium-pressure liquid chromatography system. Fractions 
were collected with a Biofrac fraction collector, and analyzed for presence of pMHC 
using SDS-PAGE gel electrophoresis. Pooled fractions containing refolded pMHC 
complexes were concentrated over Amicon 30 kDa cut-off spin filters. Absorbance at 
280 nm was used to calculate protein concentrations using the molar extinction 
coefficient of the pMHC complexes (99930 M-1cm-1 for human HLA-A2 complexes, 
94770 M-1cm-1 for mouse H2-Kb-complexes). This method was verified using a micro 
BCA protein assay. For later use, the produced protein complexes, samples were 
snap-freezed in liquid nitrogen and stored at -80 °C. 
Conjugation of pMHC to microbeads. To test whether the newly refolded pMHC 
complexes were functional when conjugated to conventional artificial APCs, 4.5 µm 
beads were coated with these complexes. For this, 8*107 M-450 tosyl-activated 
dynabeads were dissolved in 200 µL PBS and 12.5 µg or 4.2 µg of NY-ESO-I-MHC complex 
was added to obtain beads with two different pMHC densities. The reaction mixture 
was incubated overnight at 4 °C on an rotator, after which beads were washed on 
Dynal MPC-L Magnetic Particle Concentrator (3x PBS+0.1%BSA+2mM EDTA, 3x PBS). 
pMHC-beads were used for functional experiments immediately after synthesis.
Functionalization of pMHC complexes. To functionalize pMHC with DBCO and 
Atto488 dyes, between 200-1000 ug of protein complexes were mixed with 
DBCO-4EG-NHS ester and Atto488-NHS ester in PBS in 1:4:4 ratios. After incubation for 
2h at 4 °C on a rotator, functionalized pMHC was purified over a 2 mL 7K Zeba spin 
column. To determine the degree of DBCO and Atto488 labelling, the purified 
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complexes were analyzed by measuring their absorbance at 280, 309 and 501 nm on a 
nanodrop 200c spectrophotometer. After correcting for overlap of absorbance spectra 
of the individual molecules, protein, DBCO and Atto488 concentrations were calculated 
using molar extinction coefficients of the individual molecules (12000 M-1cm-1 for 
DBCO, 90000 M-1cm-1 for Atto488). Protein concentrations determined by nanodrop 
were verified using a micro BCA protein assay. Protein yields were typically around 
30-70%.
Conjugation of pMHC to PICs. To develop antigen-specific PIC-based aAPCs, DBCO/At-
to488-functionalized pMHC (0.5 equivalents with respect to azide groups on the PICS), 
DBCO/AlexaFluor350-functionalized anti-CD28 (0.2 equivalents) and/or DBCO/Al-
exaFluor647-functionalized IL-2 (0.5 equivalents) were added to 60 ug of azide-biotin 
functionalized PICs (1 mg/mL in PBS) and incubated overnight at 4 °C on a rotator. 
PIC-protein conjugates were purified over magnetic monoavidin beads as described in 
literature [40]. For this, reaction mixtures were incubated with 1mL of magnetic 
monoavidin bead solution for 2 hours at 4 °C, after which they were washed with 
PBS+0.1%tween-20 (2x) and PBS (4x) on a Dynal MPC-L Magnetic Particle Concentrator. 
Polymers were eluted from beads by incubation with PBS containing 2 mM biotin for 
2 hours at 4 °C on a rotator. Concentrations of proteins conjugated to PICs were 
determined as described in previous chapters using a Tecan Spark 10M fluorescence 
plate reader. For human pMHC-PICs, polymer concentration was measured using 
circular dichroism (CD) (JASCO J-810).
Antigen-specific stimulation of NY-ESO-I TCR-expressing CD8 T cells. pMHC-PIC 
performance as antigen-specific aAPCs was tested on CD8 T cells expressing NY-ESO-
I-specific T cell receptors (TCRs). For this, human peripheral blood lymphocytes were 
isolated from buffy coats obtained from healthy donors using ficoll density 
centrifugation. CD8+ T cells were isolated from peripheral blood lymphocytes using 
the Miltenyi CD8+ T cell isolation kit. After isolation, mRNA transfection using a 
Bio-rad gene pulser was done to induce expression of an NY-ESO-I-specific TCR. As a 
control, a mock transfection was performed. Transfection efficiency was determined 
by flow cytometry after cells were stained with NY-ESO-I-MHC-tetramers. 50.000 
TCR-transfected CD8+ T cells were stimulated with 50-100 ng/mL pMHC or 
25.000-50.000 protein-coated microbeads in X-Vivo medium containing 2% human 
serum at 37 °C. After 24h and 72h, supernatant was collected for ELISA measurement 
of IFNγ concentrations.
In vitro stimulation of mouse OT-1 T cells. For stimulation of OVA-specific mouse T 
cells (OT-1 T cells), PIC-Kb-OVA conjugates were produced using the same method as 
described for human PIC-MHC-peptide conjugates. OT-1 CD8 T cells were isolated from 
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spleen and lymph nodes of OT-1 mice using the Miltenyi CD8 isolation kit. Cells were 
labelled with 5 uM Celltrace Violet to monitor proliferation, after which 30.000 OT-1 T 
cells were stimulated with varying concentrations of H2-Kb-OVA. Stimulations were 
done either in complete RPMI medium containing 10% FCS in presence of 2 µg/mL 
stimulatory anti-CD28 antibody or with addition of IL-2 amounts matching PIC-bound 
IL-2 concentrations. After 1 day, CD69 expression was determined using a FACSVerse 
flow cytometer and after 3 days, proliferation was analyzed by measuring Celltrace 
Violet dilution on the FACSverse flow cytometer. 
In vivo stimulation of mouse OT-1 T cells. Preliminary experiments on two mice per 
stimulation were done to establish the in vivo stimulatory capacity of our 
 antigen-specific PIC-based aAPCs. CD8+ T cells were isolated from an OT-I mouse and 
labelled with Celltrace Violet as described before. C57/BL6J mice (5-8 week-old females 
from Charles River) were injected with 105 Celltrace-labelled OT-I cells. After 24h, 240 
ng of Kb-OVA or PIC-Kb-OVA were injected intravenously together with 380 ng of IL-2. 
Furthermore, one mouse was injected with PIC-Kb-OVA/IL-2 (240 ng Kb-OVA and 380 
ng IL-2 bound to PICs). Two days after injection, splenocytes were collected, stained for 
CD8 expression and T-cell proliferation of OT-I T cells was analyzed using a FACSverse 
flow cytometer.
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Supplementary figures
   HLA-A2 Heavy Chain
MGSHSMRYFF TSVSRPGRGE PRFIAVGYVD DTQFVRFDSD AASQRMEPRA PWIEQEGPEY 
WDGETRKVKA HSQTHRVDLG TLRGYYNQSE AGSHTVQRMC GCDVGSDWRF LRGYHQYAYD 
GKDYIALKED LRSWTAADMA AQTTKHKWEA AHVAEQLRAY LEGTCVEWLR RYLENGKETL 
QRTDAPKTHM THHAVSDHEA TLRCWALSFY PAEITLTWQR DGEDQTQDTE LVETRPAGDG 
TFQKWAAVVV PSGQEQRYTC HVQHEGLPKP LTLRLPETGG LE
   H2-Kb Heavy chain
MGPHSLRYFV TAVSRPGLGE PRYMEVGYVD DTEFVRFDSD AENPRYEPRA RWMEQEGPEY        
WERETQKAKG NEQSFRVDLR TLLGYYNQSK GGSHTIQVIS GCEVGSDGRL LRGYQQYAYD  
GCDYIALNED LKTWTAADMA ALITKHKWEQ AGEAERLRAY LEGTCVEWLR RYLKNGNATL  
LRTDSPKAHV THHSRPEDKV TLRCWALGFY PADITLTWQL NGEELIQDME LVETRPAGDG  
TFQKWASVVV PLGKEQYYTC HVYHQGLPEP LTLRWELPET GG
   Human β2m
MARSVTLVFL VLVSLTGLYA IQKTPQIQVY SRHPPENGKP NILNCYVTQF HPPHIEIQML
KNGKKIPKVE MSDMSFSKDW SFYILAHTEF TPTETDTYAC RVKHASMAEP KTVYWDRDM
Figure S1  Protein sequences of (A) HLA-A*0201 heavy chain, (B) H2-Kb heavy chain and 
(C) human β2m. Heavy chains also contain C-terminal sortase tag motives (LPETGG) for optional 
site-specific modifications.
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Figure S2  Proliferation after in vitro stimulation of mouse OT-1 cells. (A) OT-1 T cells were 
labelled with Celltrace Violet, stimulated with different concentrations of OVA-Kb or 
PIC-OVA-Kb in presence of unbound anti-CD28, or with PIC-OVA-Kb/aCD28, and after three 
days percentage of proliferating cells and (B) mean proliferation cycle was determined by 
Celltrace Violet dye dilution measurement. (C) OT-1 T cells were labelled with Celltrace 
Violet, stimulated with different concentrations of OVA-Kb or PIC-OVA-Kb in presence of 
unbound IL-2, or with PIC-OVA-Kb/IL-2, and after three days percentage of proliferating cells 
and (B) mean proliferation cycle was determined by Celltrace Violet dye dilution 
measurement.
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Figure S3  in vivo stimulation of OT-1 T cells in C57/BL6J mice with 240 ng OVA-Kb and 380 
ng IL-2 (A) Histograms showing Celltrace Violet dye dilution to indicate proliferation of OT-1 
T cells retrieved from spleens of treated mice. (C) Percentage of proliferating OT-1 T cells as 
determined by Celltrace Violet dye dilution. (D) Mean proliferation cycle of OT-1 T cells as 
determined by Celltrace Violet dye dilution.
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8.1  Summary
Artificial antigen-presenting cells for improved immunotherapy. During the past 
decade, immunotherapy has been established as a promising novel cancer treatment 
option. The important role of the immune system in supporting and reducing tumor 
growth has triggered development of therapies targeting different aspects of 
immunity. In particular, the clinical success of immune check-point blockade anti - 
bodies has sparked a renewed interest for immune modulation in cancer. By binding 
to overexpressed inhibitory molecules on tumor cells or suppressive/suppressed 
immune cells, these antibodies can restore anti-tumor immunity by releasing the 
brakes that were put in place by cancer. Alternatively, cytokine therapies have induced 
objective clinical responses through direct stimulation of immune cells. This approach 
directly induces immune responses, rather than targeting inhibitory mechanisms. To 
this end, also monoclonal anti- bodies that can trigger costimulatory receptors have 
been applied in clinical trials. Although these non-specific cytokine and antibody 
treatments have induced potent anti- tumor immunity, application of these therapies 
is limited by their severe toxicity.
 To gain more direct control over immune cells, several cell-based therapies have 
been developed. These approaches make use of ex vivo-cultured autologous immune 
cells, and are generally more specific towards tumor antigens. In T-cell based therapies, 
tumor-infiltrating lymphocytes can be expanded and re-infused to induce potent and 
long-lasting tumor regression. To further increase potency, affinity and antigen-spec-
ificity of these cells, genetically modified T cells have induced potent and durable 
clinical responses, especially for hematologic malignancies. Alternatively, dendritic 
cells have been applied in vaccination strategies to successfully induce tumor 
regression in a number of patients with advanced cancer. These dendritic cells can be 
loaded with antigens and stimulated ex vivo to give them the ability to properly 
stimulate specific T cells in vivo. The unprecedented clinical success stories of these 
cell-based therapies have further established cancer immunotherapy as a promising 
approach to treat a wide variety of malignancies. 
 However, the need for tailor-made personalized vaccines using ex vivo cell culture 
make these strategies costly and highly laborious, also due to the large investments in 
infrastructure needed for these therapies. Therefore, there is a great need for cell-free 
immunotherapies that can match the anti-tumor immunity induced by cell-based 
vaccines. To provide such a system, artificial  Antigen-Presenting Cells (aAPCs) are 
being developed as synthetic mimics of dendritic cells. Besides offering an off-the-shelf 
approach, aAPCs allow for more direct control over the signals that are presented to T 
cells compared to cell-based approaches. 
 As was discussed in chapter 1, several different types of aAPCs have been 
developed to this point, which has revealed design parameters important to properly 
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activate T cells. As was reported for in vitro T cell stimulations, size, shape, ligand 
density, ligand clustering and surface flexibility of aAPC scaffolds all play a role to 
optimize T cell activation. Experiments with rigid bead-based scaffolds demonstrated 
that a sizes over several micrometers and a high aspect ratio (stretched shape) are 
more favorable for proper stimulation. When the size of scaffolds was reduced, 
increasing ligand densities were needed on these beads to maintain their stimulatory 
potential [1]. Furthermore, aAPCs with softer surfaces have been demonstrated to 
enhance expansion of T cells, as was shown for PDMS surfaces and supported lipid 
bilayers (SLBs) with different fluidities. Pre-clustering ligands on beads or SLBs can 
further increase their stimulatory capacity, as this creates a high local density of 
stimulatory molecules on aAPCs. 
 To apply aAPCs in vivo, several additional (and sometimes conflicting) character-
istics have to be taken into account. Especially the size and shape of the synthetic 
scaffolds were shown to be important parameters for optimal bio distribution. 
Scaffolds with stretched shapes have a more favorable distribution in vivo, since they 
can reach lymphoid organs better and show lower uptake into phagocytic cells. 
Conveniently, stretched particles with higher aspect ratios are also better at 
multivalently interacting with and stimulating T cells in vitro, which makes particle 
shape one of the most important parameters to optimize for in vivo T cell activation. 
Predictably, the biodistribution of smaller particles is more effective than that of large, 
microsized particles. Although the latter particles are better T cell stimulators, they do 
not move far from injection points and cannot access lymphoid organs. 
 Thus, for in vivo aAPC therapy, scaffolds need to be nano-sized and preferably 
have a high aspect ratio. Additionally, a certain degree of flexibility to allow for 
receptor rearrangements is favorable for these scaffolds. To incorporate these 
properties in a single aAPC design, we have developed aAPCs making use of polyiso-
cyanopeptides (PICs) as scaffolds, called synthetic Dendritic Cells (sDCs). PICs can be 
made with lengths of 100 – 1000 nm and have a filamentous shape. These polymers 
are thought to be excellent aAPC scaffolds due to their high aspect ratio and semi-flex-
ibility. Importantly, these polymers are biocompatible and presence of azide-function-
alities in their side chains allow for straightforward and controlled modification with 
biomolecules. In the experiments described in chapter 2, these azides were used for 
streptavidin conjugation to PICs. By binding of biotinylated antibodies to these 
streptavidin-coated PICs, the first PIC-based sDCs were developed [2,3]. 
Polyisocyanopeptides as synthetic dendritic cells. To establish proof of principle of 
PIC-based sDCs, 200 nm-long streptavidin-coated PICs were coated with stimulatory 
antibodies against CD3. These anti-CD3-PICs were more effective than PLGA 
microparticles with similar ligand densities [3]. Conjugation of a stimulatory 
anti-CD28 antibody to provide costimulation was able to further enhance immune 
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responses. Again, anti-CD3/CD28-PICs were more potent than corresponding PLGA 
microparticles [2]. Although these initial experiments demonstrated that PICs can be 
effective sDCs, design parameters responsible for their efficient T cell stimulation 
could be further analyzed and optimized. As described in chapter 2 of this thesis, 
anti-CD3 multivalency on the semi-flexible scaffolds is essential for optimal T cell 
stimulation. With increasing length and antibody density, PICs induced more effective 
activation and prolonged TCR signaling. Because polymer length was found to be an 
important parameter, in the work described in the following chapters longer PICs 
(~400 nm) were used. Furthermore, anti-CD3 density (relative distances between 
antibodies) has a significant influence on T cell activation, and needs to be tightly 
controlled when analyzing the effect of conjugating additional stimulatory molecules 
to PICs. 
 Because the purification with spin filtration used for the PIC-streptavidin- 
antibody conjugates used in chapter 2 was inefficient and gave low yields, direct 
measurement of anti-CD3 density was difficult. Therefore, streptavidin densities were 
determined by Atomic Force Microscopy and to determine antibody spacing it is 
assumed that each streptavidin molecule binds to one anti-CD3. To increase yields of 
purified PIC-protein conjugates, in chapter 3 a novel affinity-based purification method 
was introduced for PICs. The increased yields and high purity of PIC-protein conjugates 
obtained using this method allowed for direct quantification of PIC concentrations 
using Circular Dichroism (CD). This method allows for more straightforward 
quantification of anti-CD3/PIC-ratios compared to the AFM method described before. 
Furthermore, the streptavidin linker was replaced by a short PEG to make sDCs 
synthesis even more straightforward. Due to the removal of streptavidin (which has 4 
binding sites), the anti-CD3/PIC-ratios are directly correlated to the anti-CD3 density 
on PICs. Taken together, the simplified design and improved purification introduced in 
chapter 3 led to increased yields and more straightforward synthesis and analysis, 
thereby allowing for more rapid development of higher numbers of PIC-protein 
conjugates. This higher synthetic throughput was essential to develop the sDCs 
presented in chapters 4-7.
 The introduction of simple PEG linkers instead of streptavidin paved the way for 
the development of sDCs containing a wide variety of co-stimulatory antibodies. In 
chapter 4, the synthesis of PIC-antibody conjugates was optimized to obtain a modular 
strategy that can rapidly produce a wide variety of sDCs. Screening of plate-bound 
co-stimulatory antibodies revealed that the speed of differentiation of CD8 T cells can 
be controlled through co-stimulatory antibodies. CD27 co-stimulation of naïve cells 
and 4-1BB co-stimulation of pre-stimulated cells resulted in more rapid differentiation 
compared to stimulation of CD28, OX40 and CD150. Conjugates of PICs and 
co-stimulatory antibodies can stimulate T cells, especially when anti-CD3 and 
co-stimulatory antibodies are co-conjugated to one and the same polymer. 
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Optimization of co-stimulatory sDCs using the modular synthetic strategy presented 
in chapter 4 could lead to nanofilaments that can control the differentiation and 
functionality of T cells.
 The same modular synthetic strategy also allowed for incorporation of DNA-based 
linkers into PIC-antibody conjugates, as was described in chapter 5. Antibodies were 
efficiently conjugated to PICs through DNA hybridization, which resulted in sDCs that 
could efficiently stimulate T cells. By anchoring complementary DNA strands in 
different geometries to PICs and anti-CD3, linkers were developed that could act as 
tension gauge tethers when forces are applied on the sDCs by T cells. In this way, the 
force-responsive behavior of T cell activation can be studied and forces that rupture 
the DNA duplexes between antibodies and PICs can be measured. The small size and 
multivalent binding of sDCs allows for measurement of forces that regulate relative 
movement and segregation of receptors on the T cell surface.
 In chapters 2-5, only antibodies were conjugated to PICs. It was demonstrated in 
chapter 6 that cytokines can also be conjugated to the same polymers using a similar 
strategy. Cytokines are essential in T cell biology and have been applied in a variety of 
immunotherapeutic approaches. However, their application is limited by their toxic 
side effects, highlighting that there is a need for targeting cytokines to T cells. 
Conjugation of cytokines onto PICs allowed for the development of sDCs that can be 
used to target immobilized cytokines IL-2 and IFNα directly to T cells. It was 
demonstrated that conjugation of IL-2 to PICs resulted in diminished cytokine activity. 
However, when IL-2-PICs were targeted to T cells by co-conjugation of anti-CD3 to one 
and the same polymer, cytokine activity of the PIC-immobilized IL-2 was increased 
compared to unbound cytokines. Anti-CD3/IL-2-PICs and anti-CD3/IFNα-PICs could 
thus be used as a potent tool to lower the side effects and increase the potency of 
cytokine-based immunotherapy.
 Side effects of sDC-based immunotherapies, such as the cytokine-sDCs, could be 
further diminished with antigen-specific T cell stimulation. As was demonstrated in 
chapters 2-6, potent polyclonal T cell activation could be achieved through conjugation 
of stimulatory anti-CD3 antibodies to PICs. The use of anti-CD3 provided a straight-
forward method to activate T cells, and the OKT3 clone provides a good model to 
simulate peptide-MHC (pMHC) binding of TCRs. However, for safe in vivo application, 
monoclonal antigen-specific T cell stimulation should be achieved. In chapter 7, 
pMHCs are produced and conjugated onto PICs instead of anti-CD3 antibodies to 
provide antigen-specific stimulation of T cells. sDCs were generated that were specific 
for cancer germline antigen NY-ESO-I, and human T cells transfected with a TCR that 
can recognize this antigen were efficiently and specifically activated with these sDCs. 
Co-conjugation of anti-CD28 onto the same PIC resulted in a synergistic enhancement 
of T cell activation, although some non-antigen-specific stimulation was also 
observed. In addition, OVA-specific pMHC-complexes were generated that could be 
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recognized by the OT-1 mouse T cell clone. In vitro activation of OT-1 T cells with the 
produced sDCs was similar to activation of cells stimulated with unbound pMHC. 
Importantly, in vivo stimulation of OT-1 T cells with i.v. injected pMHC-PIC conjugates 
resulted in a markedly enhanced T cell activation compared to unbound pMHCs. 
Although additional experiments are needed to show that sDCs can stimulate natural 
antigen-specific T cells, these initial results clearly demonstrate the great potential of 
using sDCs as an ‘off-the-shelf’ approach for active in vivo immunization in cancer 
immunotherapy. An overview of the developed PIC-conjugates used in this thesis is 
depicted in figure 1.
8.2   Manipulation of T cell activation mechanisms  
with sDCs
T cell activation is initiated upon recognition of specific pMHC complexes on the 
surface of antigen presenting cells. To induce potent T cell responses while avoiding 
auto-immunity, this process needs to be highly selective. In this regard, T cells have to 
be able to respond to very low numbers of foreign peptide antigens in a sea of 
self-peptides. In addition, the TCR repertoire is highly diverse due to somatic 
Figure 1  Molecular structure, linkers and biomolecules used in PIC-bioconjugates in the 
work presented in this thesis.
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recombination that occurs in the thymus, which means that pMHC-TCR interactions 
need to span a range of affinities. Because the peptides presented by MHCs are short, 
TCRs need to differentiate between self-pMHC and agonists based on minimal 
differences in affinity. Therefore, several mechanisms are in place to translate small 
differences in affinity to strong TCR signaling [4,5]. Since sDCs mimic the function of 
antigen-presenting cells, their interactions with T-cells should also impact these 
mechanisms. In addition, sDCs can be used to further study molecular mechanisms of 
T cell activation.
1. Kinetic proofreading with serial engagement
Interactions between pMHCs and TCRs are generally much weaker than other recep-
tor-ligand pairs. Nonetheless, T cells can readily detect small differences in affinity 
and the weak interactions of these ligands are sufficient to induce strong downstream 
signaling [4,6,7]. Mechanisms in which TCR binding by pMHC directly leads to 
downstream signaling are not able to properly explain the high selectivity of T cells 
[8]. Thus, T cell activation is not proportional to the number of occupied TCRs, because 
such a mechanism would not account for the ability of T cells to differentiate between 
foreign and self-antigens. 
 Instead, pMHC recognition is more consistent with a kinetic proofreading model 
(Figure 2) [8,9]. This model states that T cell activation is initiated after a minimal 
number of TCRs has been bound by pMHCs for the minimal duration it takes to trigger 
a downstream signal. This means that there is a time delay in between the initial 
Figure 2  Kinetic proofreading model of TCR triggering. In the kinetic proofreading model, 
pMHC (P) binding to TCRs (T) requires a series of biochemical transformations to form 
intermediates (C), before downstream signaling can occur. The signaling-competent TCR 
state (CN) is depicted in red. Each modification can be reversed completely after dissociation 
of pMHC. Adapted with permission from [8].
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binding event and signaling output. In other words, TCRs can be ‘turned on’, which is 
dependent on the off-rate of the pMHC-TCR interaction [10]. After dissociation of the 
pMHC, the TCR will remain in an active state for a certain time, in which other TCRs 
can be triggered as well. This allows a small number of pMHCs to trigger multiple 
TCRs and in this way T cells can discriminate between peptides based on their 
dissociation times from TCRs [8,9,11]. Indeed, it has been observed that a small number 
or even a single pMHC can be sufficient to induce cytokine production in T cells [12].
 Although the molecular players in initial TCR signaling are known, it is still 
difficult to completely explain kinetic proofreading using the described signaling 
cascades. During interactions of TCRs with self pMHCs, T cells are already primed to 
rapidly respond upon encounter of agonist peptides [13]. During the short interactions 
between TCRs and self (non-agonist) pMHCs, co-receptors CD4 and CD8 can 
dynamically interact with the (shortly) bound MHC. Active Lck that is bound to 
intracellular tails of these co-receptors can in this way phosphorylate ITAMs of 
CD3-ζ-chains present in the TCR complex (Figure 3) [14]. CD3-ζ-phophorylation can 
recruit ZAP70 from the cytosol, which is bound to CD3 in an inactive state. Subsequent 
phosphorylation of ZAP70 would initiate productive downstream TCR signaling, but 
the short self pMHC-TCR interaction time does not allow for this to happen. Upon 
ligation of an agonist pMHC, which is bound to the TCR for a sufficient duration, 
ZAP70 is phosphorylated by co-receptor bound Lck [15]. Thus, in this way the 
TCR-CD3-ZAP70 complex is ‘turned on’ [4,5,14]. Because the TCR has two CD3 chains, 
the active, phosphorylated state of ZAP70 is probably stabilized through trans- 
Figure 3  Lck initiation of TCR-bound ZAP-70 signalling. In resting T cells, inactive ZAP70 is 
bound to TCRs. Lck initiates TCR signalling through phosphorylation (red dots) of ZAP70, which 
stabilizes binding of Lck. This leads to a positive feedback loop in which Lck and ZAP70 can 
phosphorylate nearby proteins. Conversely, unbound Lck may also initiate signalling in absence 
of CD4/CD8 co-receptors. Adapted with permission from [5].
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autophosphorylation by ZAP70 bound to a neighboring CD3 chain [16,17]. As a result, 
proximity of Lck is no longer required and ZAP70 will remain active even after 
dissociation of pMHC, which is enhanced by temporary protection from constitutively 
active phosphatases [5]. To promote further signal stabilization, ZAP70 can bind Lck 
and keep it in close proximity to the TCR. Alternatively, the co-receptor-Lck complex 
can dissociate from MHC, with which it was weakly interacting, and find a nearby 
pMHC-TCR interaction to repeat this sequence of events [5]. Accumulation of 
phosphorylated ZAP70 can then form a starting point for LAT phosphorylation and 
the formation of LAT signalosomes [18]. 
 Although this model for the initiation of TCR signaling works well for natural 
DC-T cell interactions, in case of polyclonal aAPC stimulations (using anti-CD3 
antibodies), there is no binding of CD4 or CD8 co-receptors to initiate ZAP70 
 phosphorylation. Therefore, co-receptor binding of Lck does not play an essential role 
in the initiation of TCR signaling, but helps to increase sensitivity [19]. In case of 
anti-CD3 aAPC stimulation, free Lck that is present in the cytoplasm is important to 
initiate signaling, which may also be the essential in natural T-cell-DC interactions 
[20]. Although kinetic proofreading fits well with most literature on pMHC-TCR 
interactions, to this point there is no consensus on how signaling mechanisms can 
provide kinetic proofreading for T-cell activation. TCR mechanosensing, spatial 
redistribution of phosphatases and cluster formation provide explanations on how 
increased sensitivity could be achieved [4].
 For sDC stimulation of T cells, kinetic proofreading may be achieved through 
multivalent ligand binding. Since a minimal number (or density) of anti-CD3 anti- 
bodies is essential for productive T cell activation (Chapter 2), serial engagement of 
anti-CD3 may be needed to trigger sufficient TCRs. Binding of the anti-CD3 clone we 
used, OKT3, is known to exhibit off-rates in the range of natural agonist pMHCs [21,22]. 
This off-rate, combined with a high on-rate, could allow for rapid rebinding of 
neighboring CD3 molecules.
2. Mechanosensing
Binding affinities of interacting molecules are often measured in solution. However, 
in nature pMHCs and TCR interact while both molecules are embedded in cell 
membranes. Also in aAPC stimulations, the interacting molecules are presented on a 
surface (two-dimensional interaction). A single soluble pMHC cannot induce TCR 
triggering, whereas a single immobilized pMHC can effectively trigger multiple TCRs 
[12]. This illustrates that interactions between membrane- bound receptors are 
fundamentally different from interactions of molecules in solution. Importantly, 
variability in on-rates of membrane-bound pMHC binding to TCRs is much greater 
than that of in solution pMHCs. These two-dimensional on-rates of pMHCs are 
correlate well with their stimulatory capacity [23]. In addition, off-rates of immobilized 
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pMHCs are generally faster, in part due to presence of mechanical forces between the 
interacting planes [24,25].
 During T cell-DC interactions, forces in the range of 10 to 100 pN per TCR are 
generated [4,26,27]. In part, this is caused by the small size of the interacting pMHC-TCR, 
which repels or compresses larger molecules and the glycocalyx in the contact area 
[28,29]. Furthermore, forces are actively induced by cytoskeletal movement of 
membrane-bound receptors [30]. The generated forces seem to play an important role 
in the induction of TCR signaling, and could help to increase sensitivity and selectivity 
of antigen recognition by T cells. Both F-actin flow and myosin II contractility, 
processes that put considerable strain on the pMHC-TCR interaction are essential for 
efficient force-dependent TCR triggering [31,32]. An externally applied force of 10 pN 
can induce triggering of a single TCR [33]. Interestingly, when forces are applied on 
non-agonist anti-TCR antibody coated beads, TCR signaling is also observed [34]. Thus, 
force generation and TCR mechanosensing both benefit TCR signaling. Possibly, these 
forces lead to release of CD3 ITAMs from the cell membrane, in this way exposing 
them for phosphorylation by Lck [35,36]. 
 Force generation can also contribute to ligand discrimination through formation 
of pMHC-TCR catch bonds [38–40]. Self-pMHC and TCRs form ‘slip bonds’, bonds that 
are destabilized by force application. As expected, exerting a force on self-pMHC-TCR 
interactions leads to a decrease in force lifetime. However, several agonist pMHC have 
been reported to form ‘catch bonds’. For these interactions, binding is stabilized when 
a (small) force is exerted on the two molecules [41]. pMHC-TCR catch bond formation 
was most effective at forces of ~10 pN, which is in the same range as the forces 
necessary for potent TCR signaling [26,40]. These findings are supported by single 
molecule force measurements suggesting that forces applied by agonist pMHCs lead 
to a conformational change in TCRs that stabilize pMHC-TCR interactions [42]. 
Although catch bonds have been reported for multiple antigens, it is unclear whether 
Figure 4  Force generation between pMHCs and TCRs. Movement of TCRs, regulated by retrograde 
actin flow, is responsible for catch bond formation, conformational change and mechanotrans-
duction in TCRs. Adapted with permission from [37] and [5].
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catch bond formation is a general mechanism needed for productive TCR signaling 
[41]. 
 The ability of TCRs to sense force also impacts their interactions with aAPCs. As 
mentioned in the introduction, surface properties of aAPC scaffolds play an important 
role in their efficacy. In general, providing a certain level of rigidity by immobilization 
on a surface is essential, but aAPCs with a softer surfaces seem to be more efficient 
[43,44]. Therefore, the semi-flexibility of PICs could be important for their signal 
transduction. To confirm the role of substrate stiffness of filamentous polymers, 
interactions of T cells and PICs with different rigidities should be tested. Since PIC 
rigidity is directly related to intramolecular hydrogen bonding, these polymers can be 
synthesized through variation of amino acids in the PIC side chains [45,46]. To further 
understand the role of forces in T cell activation, sDCs containing force-sensitive 
linkers, such as those generated in chapter 5, could be used. 
3. Spatial redistribution and segregation
The close contacts formed due to the small size of pMHC-TCR interactions also give rise 
to an additional mechanism for T-cell activation (Figure 5). In resting T cells, several 
kinases, including Lck, are present in active form and are therefore able to 
phosphorylate CD3-ζ and ZAP70 [47,48]. This kinase activity is balanced by 
membrane-bound phosphatases CD45 and CD148. Because these phosphatases contain 
large extracellular domains, they are segregated from TCRs during close-contact 
pMHC interactions [49,50]. Long-lasting spatial segregation of phosphatases stabilizes 
phosphorylation of CD3 and ZAP70, which contributes to propagation of TCR signaling. 
In the absence of TCR stimuli, artificial segregation of CD45 is sufficient to initiate TCR 
signaling [51]. Altogether, agonist pMHCs induce formation of close contacts between 
APCs and T cells to keep TCRs in an environment that favors Lck kinase activity over 
CD45 phosphatase activity. Similarly, CD148 can destabilize TCR signals, but acts 
further downstream in the signaling cascade [52]. 
 For several types of aAPCs, such as minimally sized bead-based scaffolds and an-
tibody-coated surfaces, phosphatase-excluded close contact zones might form and 
contribute to T cell activation [51]. Because of the filamentous shape of PICs, it is 
doubtful whether the close contact zones needed for spatial segregation of 
phosphatases are present in PIC-T cell interactions. Possibly, the (semi-)rigidity of PIC 
clusters with a high density of polymers could lead to a certain level of phosphatase 
exclusion. Presence of clustered PIC networks on the T cell membrane should be 
studied using high-resolution imaging to further clarify mechanisms of PIC-based T 
cell activation. Experiments with CD3/CD45-PIC indicate that CD3 signaling could still 
occur in proximity of CD45, although it was not confirmed whether these PICs indeed 
bind to CD45. Taken together, spatial segregation of phosphatases may not be a 
dominant mechanism for the activity of sDCs described in this thesis.
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4. TCR clustering and immune synapse formation
In resting T cells, TCRs are present in small linear 20-200 nm clusters, containing 1-20 
TCRs, that grow coalesce upon TCR stimulation [54–56]. This spatial organization of 
TCRs is important for T cell activation and also plays an important role in the previously 
mentioned mechanisms [57]. Proximity of TCRs allows for rapid rebinding of a single 
agonist pMHC, which can trigger multiple receptors in this way [58]. Furthermore, 
TCR clustering stabilizes close contacts that allow for force generation and phosphatase 
segregation [57]. In addition, nanodomain membrane organization allows for fast 
signaling kinetics and amplification. Many kinases involved in TCR signal trans -
duction, including LAT, Lck and ZAP70 may also reside in distinct nanoclusters in 
before T cell activation [59]. Size increase of TCR clusters after triggering further 
increases pMHC rebinding and T cell sensitivity. Indeed, larger TCR clusters can be 
triggered at lower agonist pMHC doses due to increased avidity and signal propagation 
[60]. The important role of TCR clustering is further highlighted by the observation 
that active clustering of nanoscale aAPCs in a magnetic field can lead to a marked 
increase in T cell activation [61,1]. 
 Thus, T cell activation is most efficiently initiated at TCR nanoclusters. TCR 
stimulation at nanoclusters leads to an increase of cluster size to form of TCR 
microclusters containing ~50-300 TCRs, transiently surrounded by a ring of adhesion 
molecules [62,63]. Simultaneously, clustering and phosphorylation of ZAP70 and LAT 
occur at these microclusters [64,65]. While initial TCR signals, such as LAT phosphory-
lation and calcium release, are generated within minutes, sustained signaling from 
microclusters is required to induce cytokine production and proliferation. Blockade of 
Figure 5  Kinetic segregation of TCR and CD45 phosphatases initiates signaling. Close contacts 
between T cells and APCs after pMHC-TCR binding lead to exclusion of large phosphatases, such 
as CD45. Reprinted with permission from [53].
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pMHC signals after microcluster formation inhibits TCR signaling from these clusters 
and blocks formation of newly formed clusters [66]. When T cells are strongly 
stimulated with high ligand densities, an immune synapse can be formed [67]. The 
classical synapse structure is characterized by accumulation of TCRs in a central area, 
called the central Supra Molecular Activation Cluster (cSMAC). The cSMAC is 
surrounded by a peripheral SMAC (pSMAC), containing adhesion molecules. Immune 
synapse formation is initiated when TCR microclusters start moving towards a central 
spot on the T cell membrane. At the periphery, this process is regulated by F-actin 
retrograde flow and is dynein-dependent closer to the cSMAC [68]. Movement of 
microclusters leads to strong TCR signaling, possibly due to force generation. In the 
center of the cSMAC, TCR signaling is abrogated and TCRs are endocytosed to dampen 
their stimulatory action. However, on the borders of the cSMAC and pSMAC, a 
signaling cSMAC is formed where TCR signaling is maintained (Figure 6) [62].
 Experiments with nanosized beads demonstrate that aAPCs need to be able to 
target nanoclusters to induce efficient activation [1]. Since PICs are ~400 nm in length, 
they may be able to efficiently bind to and trigger TCR nanoclusters. Possibly, the 
filamentous shape of our sDCs is particularly suitable to target these clusters, since EM 
measurements indicate that nanoclusters consist of linear TCR arrangements, 
meaning that short rows of TCRs are present on the T cell surface [56]. Binding to a TCR 
in these clusters could allow for rapid release and rebinding of nearby TCRs to ligands 
presented on PICs. Movement of TCRs is important for the formation of microclusters, 
generation of signals from microclusters and formation of a signaling cSMAC. aAPCs 
Figure 6  TCR microcluster movement and immune synapse formation. TCR triggering leads to 
formation of TCR microclusters, containing TCRs, CD28, kinases and adaptors. With continued 
stimulation, these microclusters start moving towards a central spot on the T cell membrane, 
which leads to force-induced signaling. In the centre of this immunological synapse (cSMAC), 
TCRs are recycled and signaling is abrogated, while CD28 remains at the edge of the cSMAC and 
may continue signaling. During stimulation, TCRs are continuously transported from the 
periphery towards the cSMAc, leading to maintained TCR signaling. Adapted with permission 
from [62].
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that allow for a certain level of TCR movement due to scaffold flexibility may be able 
to better accommodate these changes in the T cell membrane. However, to this point 
these mechanisms of PIC-based TCR triggering are speculative. High resolution 
microscopy experiments should be performed to reveal PIC binding to TCR 
microclusters and the formation of different immune synapse-like structures for PICs 
or aAPCs with different stiffness. In addition, electron microscopy measurements of 
PIC-T-cell interactions could be done to shed light on nanocluster binding of sDCs.
 Each of the mechanisms mentioned above can be sufficient to initiate T cell 
activation. Thus, by artificially inducing one of these mechanisms, signaling cascades 
are triggered. Either applying force to receptors, or inducing phosphates-kinase 
segregation, or inducing TCR clustering activates T cells. In nature, all of these 
mechanisms are probably contributing to enhance selectivity and sensitivity of TCR 
signaling. To induce optimized T cell responses with novel sDCs, these mechanisms 
should be considered in sDC designs.
Co-stimulation at TCR microclusters further potentiates T cell activation
TCR triggering by itself does not produce potent T cell activation, but leads to T cell 
anergy. When dendritic cells are activated due to the presence of danger signals, 
co-stimulatory ligands are upregulated. Together with TCR stimulation, co-stimulation 
leads to productive T cell activation, characterized by high levels of cytokine 
production and proliferation [69]. CD28, being the most studied and one of the most 
essential costimulatory molecules expressed by T cells, is also present in signaling TCR 
microclusters. During immune synapse formation, CD28 moves to the edge of the 
cSMAC (between the cSMAC and pSMAC), where it delivers sustained co-stimulatory 
signaling [70]. Co-stimulation through CD28 can both enhance TCR signaling and 
induce distinct signaling cascades [71]. 
 PKCθ recruitment is directly regulated through CD28, as it binds to the CD28 
cytoplasmic tail via Lck. In resting T cells, cytoplasmic tails of CD28 are bound to the 
plasma membrane, and therefore unable to interact with Lck. Triggering by CD80 or 
CD86 leads to release of these tails, which allows for a stabile interaction with Lck [72]. 
CD28 stimulation does not significantly contribute to microcluster formation. Instead, 
CD28 signaling could be potentiated by the microcluster environment that favors Lck 
activity [73]. In addition, the high affinity of Lck for the CD28 cytoplasmic tail may 
assist the induction of TCR signaling [72]. Thus, TCR and co-stimulatory signaling are 
co-localized and synchronized in microclusters. In addition to synergy in early 
signaling, downstream pathways may also be enhanced by CD28, for example due to 
PKCθ recruitment [74]. The synergistic signaling of CD3 and CD28, together with their 
colocalization in microclusters explains the enhanced T cell activation observed when 
co-presenting anti-CD3 and anti-CD28 on one and the same PIC. For these polymers, 
both the enhanced CD28 binding (due to CD3 targeting) in microclusters, as well as 
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simultaneously triggering synergistic signaling pathways in close proximity, could 
contribute to the observed activation boost. 
 For other co-stimulatory molecules, such as the TNF receptor superfamily 
receptors used in chapter 4, localization in relation to signaling has not been studied 
extensively. Proximal signaling molecules of this receptor family appear to be 
different from TCR and CD28 kinases [69]. Nonetheless, more downstream signaling 
pathways are overlapping and may account for the observed synergy with TCR 
signaling [75]. CD70, the ligand for CD27, is recruited to the immune synapse in DCs 
together with MHCII and CD27 may thus signal in close proximity to TCRs [76]. 
Furthermore, 4-1BB stimulation can lead to phosphorylation of CD3, Lck and LAT [77]. 
Co-localization of TCR signals and co-stimulation could be a general mechanism to 
avoid antigen-independent co-stimulatory signaling. Also cytokine receptors are can 
be recruited to the immune synapse, and possibly to signaling microclusters. 
Experiments in chapers 4 and 6 indicate that co-triggering receptors in close proximity 
to each other may be a general mechanism to enhance signaling of T cell stimulatory 
signals 2 and 3. Multiple co-stimulatory molecules and cytokines exhibit some level of 
synergy when co-presented on one and the same PIC, which allows for closely spaced 
signal induction. This characteristic of PIC-based sDCs makes them particularly 
promising for clinical application, since it allows for the delivery of immunostimula-
tory factors with less off-target toxicity.
8.3  Further pre-clinical development of sDCs
The small size and filamentous shape of sDCs make them a particularly attractive 
option for active in vivo immunization. This could lead to potent ‘off-the-shelf’ cancer 
immunotherapies that could possibly replace or augment cell-based therapies. To 
develop these novel therapies, it is essential that sDCs can induce antigen-specific T 
cell activation. Therefore, it was first demonstrated in chapter 7 that sDCs can induce 
antigen-specific T cell activation both in vitro and in vivo. Although these results 
established that monoclonal T cell stimulation is possible, efficient antigen-specific 
activation of natural T cells, rather than transfected or transgenic cells, is needed to 
fully exploit the potential of sDCs. This means that sDCs should be optimized to induce 
expansion a small number of antigen-specific T cells within a large mixed group of T 
cells. Importantly, additional in vivo experiments are needed to further demonstrate 
the applicability of sDCs in cancer immunotherapy. Although transgenic OT-1 T cells 
work well for initial proof of the in vivo activity of sDCs, tumor models in mice should 
also be explored without injections of antigen-specific T cell clones.
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Incorporation of stimulatory signals. To achieve antigen-specific stimulation of only 
a small population of T cells within a large group of cells with different specificities, 
specialized optimization of the signals presented on sDCs is needed. Similar to 
experiments using anti-CD3 antibodies (chapter 2/4), multivalent pMHC presentation 
dictates that a high density of pMHC molecules should also lead to potent activation 
of antigen-specific T cells. Furthermore, incorporation of signals 2 and/or 3 is essential 
to induce full-blown activation and anti-tumor activity, as was demonstrated in 
chapters 4 and 6 [2]. However, the same co-stimulatory molecules and cytokines could 
lead to off-target binding of sDCs in non-purified cell populations and because of this, 
high doses of conjugates may be needed to observe clinical responses. Especially the 
use of high affinity ligands, such as co-stimulatory antibodies, may lead to off-target 
binding. As a result, natural B7 ligands are generally used for active in vivo immunization 
using aAPCs [78,79]. Nonetheless, injection of anti-CD28-containing microbeads have 
been shown to induce antigen-specific anti-tumor responses [80], indicating that 
incorporation using anti-CD28 is a feasible approach. For use in human trials, caution 
is needed when using anti-CD28, as a stimulatory anti-CD28 antibody induced 
dangerous toxicity during a clinical trial in 2006 [81]. In contrast to antibodies used 
on aAPCs, this superagonist stimulated CD28 in the absence of TCR triggering. 
Taken together, the use of natural ligands may be more appropriate for in vivo 
application of sDCs.
 Alternatively, or simultaneously, cytokines can be conjugated onto PICs to induce 
anti-tumor T cell responses. In chapter 6 it was demonstrated that PIC-cytokine 
conjugates, PIC-IL-2 in particular, have reduced interactions with T cells compared to 
unbound cytokines. Because of this, cytokines can be targeted to T cells using other 
ligands, such as anti-CD3 antibodies or pMHC. Several cytokines, including IL-2 and 
IFNα, are already approved for treatment of a number of malignancies [82]. By using 
cytokines immobilized onto PICs, sDCs could be developed that may efficiently target 
and strongly stimulate specific T cell clones. To further demonstrate whether cytokine 
targeting can be used for cancer treatment, sDCs based on PIC-cytokine conjugates 
need to be applied in tumor models in mice. However, at this point it is not known 
whether efficient targeting of PIC-immobilized cytokines to mouse T cells is also 
possible. In vitro experiments with optimized sDCs should determine whether 
humanized mouse models are needed before testing this type of sDCs in vivo. 
Nonetheless, the experiments presented in chapter 6 indicate that cytokine-contain-
ing sDCs may allow for efficient antigen-specific immunotherapy through TCR 
targeting.
 
Immunotherapies should target a wide variety of antigens. To develop broadly 
applicable immunotherapies, commonly shared tumor antigens such as MART-1, 
GP100 and NY-ESO-1 have been widely studied as targets [83,84]. Cell-based vaccines 
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targeting these antigens have induced anti-melanoma immune responses in pre- 
clinical and clinical tests, which demonstrated the great promise of antigen-specific 
immunotherapy [85,86]. In chapter 7, we developed sDCs targeting MART-1 and 
NY-ESO-1. Optimization of these sDCs may allow for ‘off-the-shelf’ immunotherapies, 
since application of these synthetic constructs do not require to culture cells for each 
individual patient.
 However, targeting of these shared tumor-associated antigens have also shown 
several disadvantages. Some of these antigens may also be expressed by healthy cells, 
and can therefore induce tolerance of T cells, which may impede their anti-tumor 
activity. In addition, strong stimulation of some of these antigens can induce off-target 
toxicity of cells that express low levels of these antigens [87]. For example, treatments 
using high affinity MART-1-specific T cells can lead to skin rashes and hearing loss 
[88]. On-target off-tumor toxicity of high-affinity TCR immunotherapy has led to a 
search for more specific antigens. Analysis of the antigen repertoire of T cells induced 
by non-specific cancer immunotherapies, such as checkpoint blockade antibodies, has 
identified neo-antigens as another group of antigens that could be even more potent 
as targets of antigen-specific therapies [89]. Because these neo-antigens are peptides 
directly derived from mutated protein, they are specific only to the tumor tissue. 
Broadening the antigen repertoire of immunotherapies to include these neo-antigens 
could greatly benefit clinical responses and prevent recurrence of tumor growth 
[89,90]. Also in the development of sDCs, the use of multiple antigens, including 
neo-antigens, is an interesting approach that could lead to more complete tumor 
control.
A strategy for personalized sDC-based immunotherapy. Since neo-antigens stem 
from random mutations, these antigens are not shared between patients. Because of 
this, neo-antigen-specific therapies need to be personalized to each individual patient. 
sDCs that present neo-antigens are therefore difficult to produce as ‘off-the-shelf’ 
therapies, as this requires the production and conjugation of a wide variety of pMHCs. 
As a result, application of personalized sDCs would require several steps after diagnosis 
of a patient, and is not directly applicable. However, a strategy could be envisioned 
that could make personalized sDC treatments, while still partly retaining their ‘off-
the-shelf’ character. This proposed strategy contains several steps:
1. Determine (neo-)antigens in tumor biopsy. To determine antigens specifically 
expressed by tumor cells, whole exome sequencing of both normal and tumor 
cells can be done. HLA types of patients should then be determined and mutated 
peptides likely to be presented onto MHC complexes can be predicted using 
established HLA/peptide binding algorithms [87]. For peptide binding to the most 
common HLA types, prediction algorithms are fairly accurate. An alternative 
approach that circumvents the use of prediction algorithms makes use of mass 
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spectrometry. However, peptide purification and subsequent mass spectrometry 
may not be sensitive enough to detect all expressed antigens [91].
2. Peptide synthesis. After prediction of the expressed antigens, short peptides can be 
readily synthesized using standard solid-phase peptide synthesis. As peptide 
synthesis is cheap, fast and can be done under GMP conditions, this method is 
suitable to quickly yield short MHC-binding peptides. For the production of a 
neo-antigen-based vaccine consisting of long peptides and TLR ligands, this 
strategy (from exome sequencing up to long peptide synthesis) was successfully 
applied in a phase I clinical trial [92].
3. UV-induced MHC-bound peptide exchange. A straightforward method to produce a 
variety different PIC-pMHC conjugates will be essential to target neo-antigens 
using sDCs. A method that could facilitate this was developed by Schumacher et 
al. [93]. To produce a large library of MHC complexes containing different peptides, 
a strategy can be used in which MHC complexes are loaded with a UV-cleavable 
peptde. By applying UV light to cleave this conditional ligand in presence of 
another MHC-binding peptide, peptide exchange will occur with high efficiency, 
which facilitates rapid production of pMHC libraries. This method was shown 
successful for a wide variety of peptides and MHCs of different HLA types [93,94]. 
Possibly, peptide exchange could also be done for PIC-bound MHC complexes that 
contain UV-cleavable ligands, thereby facilitating production of sDCs with a 
variety of targets.
Taken together, sDCs could be either applied as ‘off-the-shelf’ therapy to target 
commonly shared tumor antigens, or in a personalized approach that includes the 
detection or prediction of neo-antigens to synthesize a variety of PIC-pMHC conjugates. 
These approaches need to be further developed in future pre-clinical studies.
8.4   Challenges for clinical application of sDCs  
in cancer therapy
Nanomedicines, such as sDCs, have paved the way to exploit novel targeted strategies 
to treat diseases. Nanoscale materials have proven to efficient scaffolds to target 
cancers in a variety of strategies, but their clinical translation has been relatively slow 
[95]. From a regulatory point of view, application of small molecule drugs and 
biologicals is easier, leading to faster clinical translation of these drugs [96]. For com-
mercialization of drugs, it is therefore often more attractive for industry to invest in 
less complex therapeutics. However, interest in nanotherapeutics is growing due to 
their limited side effects, but some major issues that slow down regulatory approval 
still remain [97]. Importantly, bio-distribution and resulting long-term safety profiles 
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are not comparable to most available drugs and nanomedicines often consist of hybrid 
structures that each need individual GMP-grade production and approval. For many 
nanomaterials it is currently unclear whether their bio-distribution in humans is 
comparable to pre-clinical animal models. Furthermore, they are often produced in a 
batch process, which can result in batch-to-batch variability, especially when 
production is scaled up for clinical use [96,97]. Nanomedicines often require more 
complex characterization and toxicity tests before they can be implemented in 
therapies. Many of these issues have resulted in lack of commercialization, although 
industry is now catching up and increasing numbers of nanotherapeutics are being 
approved because of this [98,99].
 Nanomedicines being developed for immunotherapy are facing similar issues 
[100]. Because of their more straightforward translation, non-specific immunothera-
pies, most notably checkpoint blockade antibodies, have become standard practice in 
cancer immunotherapy. These therapies have demonstrated the great potential of 
immunotherapy, but are still limited by dangerous side effects [101]. As targeted 
treatments, cell-based immunotherapies have been applied in successful clinical 
trials. Although some of these therapies have demonstrated great clinical benefits, 
widespread application of cell-based treatments is challenging because of their 
laborious personalized preparation. Despite their complexity, DC and CAR-T cell-based 
therapies have been approved for several clinical applications [102,103]. As discussed 
in this thesis, clinical translation of nanomedicines, such as sDCs, could give rise to 
targeted immunotherapies that do not require specialized cell culture facilities and 
are therefore less personalized and easier to scale up. Several challenges, that are also 
a problem for translation of nanomedicine in general, need to be addressed for clinical 
translation of sDCs.
 At this point, cell-free aAPCs have been used in clinical trials for ex vivo T cell 
stimulation, but not for active in vivo immunization. PIC-based sDCs may be used for 
this in the future, but extensive characterization of their toxicity profile is still needed 
for clinical translation. PIC filaments and PIC-antibody conjugates were determined to 
be non-toxic using cell culture [3], and also PIC-based hydrogels are non-toxic in vitro 
[104]. In addition, both seem to be well tolerated in initial in vivo experiments, but 
more extensive toxicity and bio-distribution studies need to be done. Some of the 
proteins that can be conjugated onto PICs, including cytokines and co-stimulatory 
antibodies, have been approved for clinical use. However, cytokines can give rise to 
dangerous side effects, and reduced toxicity profiles of PIC-cytokine conjugates need 
to be demonstrated in vivo to allow clinical translation. Importantly, production of 
these proteins is possible at clinical scale, which allows for rapid upscaling of sDC 
production. For preparation of GMP-grade (nano)therapeutics, it is essential that clean 
and highly pure products can be developed. As is described in chapter 3, the final step 
of our sDC production consists of affinity-based purification of PIC-conjugates. 
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Impurities and contaminants can easily be removed during this process, leading to a 
highly pure product. For clinical translation, it is essential to extensively characterize 
therapeutics, which can be more difficult for nanomedicines [105]. Analysis of our 
sDCs can be done in a more straightforward manner compared to other aAPCs through 
a combination of circular dichroism (CD) and protein assays. Particle-based aAPCs rely 
on indirect measurement of protein content, which is often less reproducible. Taken 
together, PICs still require extensive toxicological tests to allow for clinical translation, 
whereas their straightforward synthesis and analysis may facilitate approval. Due to 
their clinical benefit, complex cell-based immunotherapies are being applied and 
approved in clinical trials regularly. Continued multidisciplinary efforts leading to 
translation of nanomedicines are needed to supplement these cell-based therapies 
with ‘off-the-shelf’ strategies [105].
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Immuuntherapie met artificiële antigeen-presenterende cellen.
Immuuntherapie is in de afgelopen jaren opgekomen als een veelbelovende nieuwe 
therapievorm voor de behandeling van kanker. Klassieke therapieën, zoals chemo- 
therapie of bestraling, richten zich op het direct doden van kankercellen. In immuno-
therapieën wordt daarentegen geprobeerd om het immuunsysteem te moduleren, 
zodat dit zelf de kanker kan aanvallen. Immuuncellen kunnen een belangrijke rol 
spelen in zowel het bevorderen van kanker, als het opruimen van tumoren. Dit heeft 
geleid tot de ontwikkeling van verschillende immuuntherapieën die op deze kanker-
stimulerende en kankerremmende processen kunnen inspelen, en zich daarbij richten 
op verschillende onderdelen van het immuunsysteem. 
 De hernieuwde belangstelling voor kankerbehandeling door middel van  immuun - 
modulatie is met name aangewakkerd door het klinische succes van antilichamen die 
immuuncheckpoints kunnen blokkeren. Immuuncellen die aanwezig zijn in tumoren 
worden vaak door stimulatie van deze immuuncheckpoints (via de receptoren op 
tumorcellen of andere immuuncellen) geremd om een anti-tumor immuunreactie 
te voorkomen. Door deze interactie te blokkeren wordt deze remming op het 
immuunsysteem opgeheven, waardoor de tumor wel weer kan worden aangevallen 
door immuuncellen. Behalve via het opheffen van remmende mechanismes, kunnen 
kankerpatiënten ook baat hebben bij directe stimulatie van immuuncellen die 
kankercellen kunnen vernietigen. Dit kan bijvoorbeeld gedaan worden door injectie 
van hoge doses cytokinen of (co)stimulerende antilichamen. De hierboven genoemde 
antilichaam- en cytokine therapieën hebben laten zien dat modulatie van het 
immuunsysteem een veelbelovende methode kan zijn om kanker aan te pakken. 
Helaas zijn deze therapieën niet kankerspecifiek, maar zorgen ze voor stimulatie van 
het gehele immuunsysteem, wat kan zorgen voor ernstige bijwerkingen omdat het 
immuun - systeem niet alleen maar de tumor aanvalt. De toepasbaarheid en dosis van 
deze aspecifieke therapieën is daarom beperkt.
 Om meer controle over immuunreacties te krijgen, kunnen uit patiënten geïsoleerde 
immuuncellen in het lab worden gestimuleerd. Deze cellen kunnen vervolgens 
teruggeplaatst worden in de patiënt, en kan daarmee een meer gerichte immuun- 
respons opwekken vergeleken met eerder genoemde strategieën. Zo zijn er ver- 
schillende celtherapieën ontwikkeld die gebruik maken van T-cellen, omdat dit 
celtype gespecialiseerd is in herkennen en vernietigen van gevaarlijke lichaamseigen 
cellen, zoals geïnfecteerde cellen of tumorcellen. Om tumor- specifieke T-cellen in te 
zetten voor immunotherapie kunnen deze cellen worden geïsoleerd uit tumorbiopten, 
waarnaar ze worden geëxpandeerd en weer worden teruggeïnjecteerd in patiënten. 
Hier kunnen deze cellen zorgen voor een sterke en langdurige afname van tumoren. 
Genetische modificatie van T-cellen heeft verder geleid tot een hogere affiniteit en 
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specificiteit. Dit heeft geleid tot verder een verbeterde klinische respons van T-cel-
therapieën, met name in leukemie.
 Een ander celtype dat met succes is toegepast in vaccinatiestrategieën tegen 
kanker is de dendritische cel; een celtype dat gespecialiseerd is in het presenteren van 
stukjes eiwit (antigenen) aan T-cellen. Dendritische cellen kunnen worden geïsoleerd 
uit het bloed van patiënten, waarna ze worden gestimuleerd en beladen met specifieke 
tumorantigenen. Vervolgens zorgt dit ervoor dat deze dendritische cellen na injectie 
tumor-specifieke T-cellen kunnen stimuleren in het lichaam. Ook deze strategie heeft 
voor tumorregressie gezorgd in een aantal patiënten met vergevorderde kankers. 
De ongeëvenaarde klinische succesverhalen van deze celtherapieën hebben immuun-
therapie verder op de kaart gezet als een veel- belovende aanpak voor het behandelen 
van een groot aantal kankers.
 Hoewel celtherapieën goede resultaten laten zien, moeten deze vaccins persoonlijk 
geproduceerd worden voor elke patiënt door cellen in het lab op te kweken. Deze 
 arbeidsintensieve productie en hierdoor ook de kosten zijn vaak problematisch. Het 
stimuleren en kweken van cellen voor behandeling van patiënten moet gebeuren in 
gespecialiseerde laboratoria, en is daardoor niet overal mogelijk. Er is hierdoor een 
grote behoefte aan celvrije immunotherapieën die algemeen kunnen worden 
toegepast en vergelijkbare immuunreacties tegen tumoren kunnen opwekken als 
cellulaire therapieën. Om dit aan te pakken worden er daarom artificiële Antigen- 
Presenterende Cellen (aAPCs) ontwikkeld om de functie van dendritische cellen na te 
bootsen met een synthetisch construct. Deze aAPCs bieden een kant-en-klaar product 
dat direct kan worden toegepast om T-cellen in patiënten te stimuleren. Daarnaast 
zorgen aAPCs voor meer directe controle over signalen die aan T-cellen gepresenteerd 
worden vergeleken met beschikbare celtherapieën.
 Tot nu toe zijn er al een aantal verschillende soorten aAPCs ontwikkeld, zoals ook 
beschreven is in hoofdstuk 1. Deze eerste constructen hebben duidelijk gemaakt welke met 
welke parameters belangrijk zijn om een sterke activatie van T-cellen te induceren. Via 
celkweekexperimenten werd met deze biomaterialen aangetoond dat de grootte, vorm, 
dichtheid en rangschikking van liganderen, en de flexibiliteit op het oppervlak van aAPCs 
allemaal een rol hebben om optimale T-celactivatie te realiseren. Op deze manier werd 
duidelijk dat rigide bolvormige deeltjes met een minimale diameter van enkele micrometers 
en een meer uitgestrekte ovaalvormige vorm voor betere stimulatie zorgen. Wanneer 
kleinere deeltjes worden gebruikt, bleek er een hogere dichtheid aan stimulerende liganden 
nodig te zijn op deze bolletjes om hun effectiviteit te behouden. Met behulp van 
zowel PDMS-bedekte materialen, als deeltjes die bedekt zijn met lipidemembranen van 
verschillende flexibiliteit, is daarnaast aangetoond een meer flexibel oppervlak zorgt voor 
betere expansie van T-cellen. T-celstimulatie kan nog verder verbeterd worden door 
liganden geclusterd vast te zetten op membranen of rigide bolletjes, omdat dit zorgt voor 
een hoge gelokaliseerde dichtheid van stimulerende moleculen.
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Om aAPCs direct in het lichaam toe te passen moet men rekening houden met een 
aantal extra (en soms conflicterende) karakteristieken. Zo zijn vooral de afmetingen 
en de vorm van de gebruikte synthetische constructen belangrijk voor een optimale 
biodistributie na injectie. Ook materialen met een meer uitgestrekte ovaalvormige 
vorm laten een betere verspreiding en beschikbaarheid zien in vivo, omdat meer van 
deze deeltjes lymfoïde organen (waar immuun - cellen zich bevingen) bereiken en 
minder worden opgenomen door fagocyterende cellen. Dit is gunstig, aangezien 
uitgerekte deeltjes ook in celkweekexperimenten beter bleken in het maken van 
directe multivalente contacten met T-cellen. De vorm van aAPCs is daarom een van de 
belangrijkste parameters om te optimaliseren voor een goede activatie van T cellen in 
het lichaam. Grote deeltjes beter zijn in het stimuleren van T-cellen dan kleinere 
structuren, maar kunnen niet ver van de injectieplaats komen. Deze microdeeltjes 
komen daardoor niet in lymfoïde organen terecht, waardoor ze slecht bruikbaar zijn 
voor directe T-celstimulatie in het lichaam.
 Voor het toepassen van aAPC-therapie in vivo is het dus gebleken dat de gebruikte 
constructen nano-afmetingen moeten hebben. Daarnaast biedt gebruik van 
materialen met een langwerpige vorm betere distributie en activatie dan het gebruik 
van bolvormige deeltjes. Verder is een zeker mate van flexibiliteit, wat beweging van 
receptoren op het T-celmembraan mogelijk maakt, ook gunstig voor het activerende 
vermogen van deze constructen. Om deze eigenschappen samen te laten komen in het 
ontwerp van één enkel construct, hebben wij gebruik gemaakt van polyisocyanopep-
tides (PICs) als fundament voor de ontwikkeling van nieuwe aAPC: De synthetische 
Dendritische Cel (sDC). PICs zijn dunne filament vormige polymeren die gemaakt 
kunnen worden met lengtes van 100-1000 nm. Door hun langgerekte vorm en se-
mi-flexibiliteit zouden deze polymeren uitermate geschikt moeten zijn voor het 
ontwikkelen van aAPCs. PICs zijn biocompatibel en kunnen relatief eenvoudig en 
gecontroleerd worden gemodificeerd met biomoleculen door de aanwezigheid van 
azidefunctionaliteiten in hun zijketens. In hoofdstuk 2 zijn deze azides gebruikt voor 
het conjugeren van streptavidine aan de PICs. De eerste sDCs werden gemaakt door 
biotine-gefunctionaliseerde antilichamen aan deze streptavidine-PICs te binden.
Polyisocyanopeptides als synthetische Dendritische Cellen. Om het principe te 
bewijzen dat op PICs kunnen werken als sDCs zijn 200-nm-lange streptavidine- PICs 
bedekt met stimulerende antilichamen tegen CD3. Deze anti-CD3-PICs stimuleerden 
T-cellen beter dan PLGA microdeeltjes met vergelijkbare liganddichtheid. 
Immuunreacties konden verder worden versterkt via additionele conjugatie van 
stimulerend antilichamen tegen CD28, wat voor een co-stimulerend signaal zorgt. 
Deze eerste experimenten toonden aan dat PICs effectief kunnen zijn als sDCs, maar 
ontwerpfactoren die zorgen voor deze goede stimulatie van T-cellen kon nog 
uitgebreider worden geanalyseerd en verbeterd. In hoofdstuk 2 laten we daarom zien 
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dat de multivalentie van anti-CD3 op deze semi-flexibele polymeren essentieel is voor 
optimale stimulatie van T-cellen. Hier werd duidelijk dat PICs zorgen voor betere 
activatie en langdurige T-cel receptor (TCR) signalering in T-cellen wanneer langere 
constructen worden gebruikt, en wanneer meerdere anti-CD3 antilichamen dichter 
bij elkaar geplaatst zijn. Omdat de polymeerlengte belangrijk is, hebben we in de 
latere hoofdstukken langere PICs (~ 400 nm) gebruikt. De dichtheid van anti-CD3 (de 
relatieve afstand tussen de antilichamen) heeft een significante invloed op activatie 
van T-cellen en moet daarom goed gecontroleerd worden wanneer we het effect van 
conjugatie van andere PIC- geconjugeerde stimulerende moleculen analyseren. 
De in hoofdstuk 2 gebruikte zuivering van antilichaam-streptavidine-PICs via 
spinfiltratie was erg inefficiënt en leidde tot erg lage opbrengst van gezuiverd product. 
Hierdoor was het moeilijk om de anti-CD3-dichtheid direct te meten en werden in 
plaats daarvan de streptavidinedichtheid bepaald met behulp van Atomic Force 
Microscopy. Om de opbrengst van gezuiverde PIC-eiwitconjugaten te verhogen hebben 
we een nieuwe affiniteitzuivering geïntroduceerd voor PICs in hoofdstuk 3. Omdat 
deze methode zorgt voor een hoge zuiverheid en opbrengst van PIC-eiwitconjugaten, 
was het vervolgens mogelijk om PIC-concentraties direct te kwantificeren met behulp 
van Circular Dichroism (CD). Met behulp van deze methode werd het gemakkelijker 
om anti-CD3/PIC-ratios te bepalen. De synthese van sDCs kon verder worden 
vereenvoudigd door streptavidine te vervangen door een conjugatiestrategie waarin 
alleen een korte PEG werd gebruikt als linker. Omdat antilichaambinding aan PICs 
hierdoor niet meer via streptavidine (wat vier bindingsplaatsen heeft) plaatsvindt, 
was de anti-CD3/PIC-ratios in deze constructen zich direct gekoppeld aan de relatieve 
afstand tussen antilichamen op deze PICs. Uiteindelijk hebben de vereenvoudigde 
structuur en de verbeterde zuivering gezorgd voor een verhoogde synthese opbrengst 
en een eenvoudigere syntheseroute en karakterisatie van de geproduceerde 
conjugaten. Hierdoor konden sneller grote hoeveelheden van verschillende PIC- 
eiwitconjugaten geproduceerd worden. Deze verbeterde syntheseomzet was essentieel 
voor het ontwikkelen van de sDCs die worden beschreven in hoofdstukken 4 t/m 7.
 Het gebruik van eenvoudige PEG linkers in plaats van streptavidine maakte het 
mogelijk om een grote verzameling aan sDCs met verschillende co-stimulerende 
antilichamen te ontwikkelen. In hoofdstuk 4 is beschreven hoe de synthese van 
PIC-antilichaamconjugaten verder is geoptimaliseerd, waardoor snel een groot aantal 
verschillende functionele sDCs geproduceerd kon worden. Het screenen van 
plaatgebonden co-stimulerende antilichamen liet zien dat de snelheid van T-cel-
differentiatie kan worden gestuurd door verschillende co-receptoren op T-cellen te 
stimuleren. Co-stimulatie van naïve CD8+ T-cellen met anti-CD27, of van voor-
gestimuleerde cellen met anti-4-1BB resulteerde in een snellere differentiatie in 
verhouding tot cellen die gestimuleerd waren met anti-CD28, anti-OX40 of anti-CD150. 
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Stimulatie van T-cellen met deze conjugaten van anti-CD3 en co-stimulerende 
antilichamen zorgt met name voor verhoogde activatie wanneer anti-CD3 en co- 
stimulerende antilichamen beide op hetzelfde polymeer zitten. Het optimaliseren 
van deze co-stimulerende sDCs zou kunnen leiden tot nanofilamenten waarmee de 
differentiatie en functionaliteit van T-cellen bestuurd kan worden.
 Dezelfde modulaire synthesestrategie heeft het ook mogelijk gemaakt om, zoals 
beschreven in hoofdstuk 5, DNA-linkers in te bouwen in PIC-antilichaamconjugaten. 
Antilichamen konden efficiënt aan PICs geconjugeerd worden via het hybridiseren 
van twee DNA-strengen. sDCs die op deze manier werden gemaakt konden efficient 
T-cellen stimuleren. Door twee complementaire DNA-strengen in verschillende 
oriëntaties aan PICs en anti-CD3 te conjugeren werd een eerste stap gezet naar de 
ontwikkeling van sDCs met ingebouwde krachtsensoren. Deze sDCs kunnen 
vervolgens worden ingezet om te bestuderen welke krachten door T-cellen worden 
gegenereerd tijdens hun activatie. Door het breken van de DNA-duplexen tussen 
antilichamen en PICs te meten kan de grootte van deze krachten worden gemeten. 
Omdat PICs multivalent binden aan T-cellen en relatief klein zijn ten opzichte van 
klassieke aAPCs, kunnen deze DNA-sDCs mogelijk gebruikt worden voor het meten 
van relatieve beweging en afscheiding van receptoren op T-cellen.
 In hoofdstukken 2-5 zijn alleen antilichamen aan PICs geconjugeerd voor de 
synthese van sDCs. In hoofdstuk 6 lieten we zien dat ook cytokinen met dezelfde 
 synthesestrategie aan deze polymeren geconjugeerd kunnen worden. T-cellen zijn 
afhankelijk van cytokinen voor hun overleving, proliferatie en veel van hun andere 
functies. Deze signaleringsmoleculen worden daarom ook toegepast in verschillende 
immunotherapieën. Helaas gaat injectie van cytokinen vaak gepaard met gevaarlijke 
bijwerkingen die de toepassing van deze therapieën limiteren. Het is daarom nodig 
om ervoor te zorgen dat deze cytokinen zich meer specifiek op T-cellen richten. 
Door cytokinen aan PICs vast te maken konden sDCs ontwikkeld worden waarmee 
geïmmobiliseerd IL-2 en IFNα meer specifiek aan T-cellen konden binden. Hierbij werd 
aangetoond dat conjugatie van IL-2 aan PICs zorgt voor een verminderde bioactiviteit 
van het cytokine. Wanneer daarentegen deze IL-2-PICs naar specifiek naar T-cellen 
worden gestuurd door anti-CD3 aan hetzelfde polymeer vast te maken, zorgt dit voor 
een verhoogde cytokine-activiteit, ook vergeleken met cytokinen die niet aan PICs 
zijn gebonden. Anti-CD3/IL-2-PICs en anti-CD3/IFNα-PICs kunnen daarom krachtige 
wapens zijn om de bijwerkingen van deze cytokinen te verminderen en de werking 
van cytokinetherapieën te verbeteren.
 Potentiële bijwerkingen van het gebruik van sDCs (zoals cytokine-sDCs) voor 
immunotherapie, kunnen verder worden verminderd door alleen T-cellen te 
stimuleren die specifieke antigenen herkennen. In hoofdstukken 2-6 hebben we 
gezien dat conjugatie van stimulerende antilichamen tegen CD3 aan PICs kan zorgen 
voor sterke activatie van polyklonale T-cellen. Het gebruik van anti-CD3 is een relatief 
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eenvoudige manier om T-cellen te activeren. Hierbij worden interacties tussen 
peptide-MHC (pMHC) en TCRs goed gesimuleerd met behulp van de OKT3 antili-
chaamkloon. Om sDCs veilig in vivo toe te kunnen passen is het daarentegen belangrijk 
om niet alle T-cellen, maar alleen T-cellen die bepaalde (tumor)antigenen herkennen 
te stimuleren. In hoofdstuk 7 is daarom beschreven hoe pMHCs worden geproduceerd 
en geconjugeerd aan PICs in plaats van anti-CD3, om hiermee antigeen-specifieke 
stimulatie van T-cellen te bewerkstelligen. Hiervoor werden sDCs geproduceerd die 
specifiek zijn voor kankerantigeen NY-ESO-I. Menselijke T-cellen waarin een 
NY-ESO-I-specifieke TCR tot expressie was gebracht konden effectief en specifiek 
geactiveerd worden met deze sDCs. Ook hier zorgde co-conjugatie van pMHC en 
anti-CD28 aan dezelfde PIC is een synergistische verhoging van activatie van T-cellen, 
hoewel hierdoor ook wat aspecifieke stimulatie werd geïnduceerd. Daarnaast werden 
ook ovalbumine-specifieke geproduceerd die herkend kunnen worden door de T-cellen 
uit OT-1-muizen. Celkweekstimulatie-experimenten wezen uit dat de geproduceerde 
sDCs deze T-cellen even goed konden activeren als ongebonden pMHC. Wanneer deze 
sDCs echter geïnjecteerd werden in het bloed van muizen, werden dezelfde OT-1 
T-cellen aanzienlijk beter geactiveerd vergeleken met ongebonden pMHC. Hoewel er 
meer experimenten gedaan moeten worden om te laten zien dat sDCs ook natuurlijke 
antigeen-specifieke T-cellen kan stimuleren, laten deze eerste resultaten duidelijk het 
potentieel van sDCs voor directe in vivo-vaccinatie zien. In de toekomst kan het 
gebruik van sDCs daarom mogelijk een strategie bieden voor een kant-en-klare 
immunotherapie die direct in patiënten geïnjecteerd kan worden zonder ingewikkelde 
en dure celkweekprocedures. In figuur 1 is een overzicht weergegeven van de 
verschillende PIC-conjugaten die zijn ontwikkeld in dit proefschrift.
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Figuur 1  Moleculaire structuur, linkers en biomoleculen die gebruikt zijn in de PIC-bio-
conjugaten die in dit proefschrift zijn beschreven.
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Dankwoord
Met dit proefschrift komt er een eind aan vier jaar promotieonderzoek. Gelukkig stond 
ik hier niet alleen voor, want het afronden van mijn promotie en het schrijven van dit 
proefschrift was niet mogelijk geweest zonder de hulp en steun van een groot aantal 
mensen. Ik wil hier dan ook iedereen bedanken die een bijdrage heeft geleverd aan het 
tot stand komen van dit boekje.
Als eerste wil ik graag mijn promotor, Carl, bedanken. Terwijl ik zelf nog bezig was 
met optimaliseren van de PICs, dacht jij altijd een paar stappen vooruit. Hierdoor 
hadden we altijd een duidelijk doel voor ogen. Verder waardeer ik de vrijheid die je 
me gaf om de verschillende projecten ook zelf richting te geven. Je leerde mij om in een 
vroeg stadium een opzet te maken voor thesishoofdstukken en publicaties, wat essentieel 
was voor de afronding van mijn promotie. Jouw immunologische kennis en jouw 
enthousiasme voor het samenwerken met andere disciplines zullen zeker leiden tot 
mooie nieuwe immunotherapieën.
Ook mijn co-promotoren zijn erg belangrijk geweest tijdens mijn PhD. Jurjen, jij zorgde voor 
regelmatige immunologische input en jouw enthousiasme en positieve instelling was 
altijd goed om de motivatie vast te houden, vooral als de resultaten tegen zaten. Jouw 
tips voor het opbreken van verschillende projecten waren ook zeer waardevol, met 
name om tot publicatie van het cytokineproject te komen. Verder wil ik je bedanken 
voor de gezellige barbecues tijdens de vierdaagse en bij jullie nieuwe huis. Veel succes 
met je eigen onderzoeksgroep en het opzetten van immunoengineering in Eindhoven. 
Roel, er wordt vaak gezegd dat immunologen en scheikundigen maar moeilijk met 
elkaar konden praten. In onze samenwerking heb ik daar nooit last van gehad. Vanaf 
het begin hadden we een goede discussies en konden we urenlang over polymeren en 
T-cellen praten. Nog steeds gaan onze WhatsAppvergaderingen onophoudend door en 
zijn deze een soort tweede labjournaal geworden. Zonder jouw polymeerexpertise en 
samenwerking had ik het niet gered, en ik was daarom ook erg blij dat je besloot om 
als postdoc bij TIL verder te gaan, zodat we onze projecten konden doorzetten. Ik denk 
dat het niet meer dan terecht is dat je bent toegevoegd als mijn co-promotor!
Jorieke en Dion, bedankt dat jullie mijn paranimfen willen zijn! Jorieke, we hebben 
lang samen een U’tje gedeeld en dat beviel me altijd erg goed. Ik kon altijd bij jou 
terecht voor goede wetenschappelijke discussies, immunologische input of gewoon 
een goed gesprek, bedankt daarvoor! Hopelijk kunnen we in de toekomst blijven 
samenwerken. Dion, bij jou kon ik vaak terecht om het over de chemische kant van het 
verhaal te hebben. Samen konden we een aantal mooie projecten met nieuwe soorten 
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sDCs opzetten, waarvan de afronding nu dankzij jouw doorzettingsvermogen in de 
chemie steeds dichterbij komt.
Tijdens mijn promotie heb ik het geluk gehad een aantal studenten te mogen begeleiden 
die een belangrijke bijdrage hebben geleverd aan mijn onderzoek. Sigrid, jij bent begonnen 
met het opzetten van het co-stimulatieproject dat is beschreven in hoofdstuk 4. Dit bleek 
toch ingewikkelder te zijn dan gedacht, maar jouw vele experimenten waren essentieel 
voor het begrijpen van de functie van deze moleculen. Anne, ook jouw werk was 
belangrijk om erachter te komen hoe we co-stimulerende antilichamen op polymeren 
konden krijgen en je hebt hier een goede start mee gemaakt. Bedankt daarvoor! 
Carla, thank you for your contributions to my thesis! You also continued working on 
the co-stimulation project and contributed to chapter 4, but your help in starting up 
the MHC project, which is described in chapter 7, was probably even more important. 
I enjoyed your critical scientific attitude, which will definitely help you in your future 
career.
Hiernaast wil ik een aantal studenten bedanken die ook een bijdrage hebben geleverd 
aan het werk in deze thesis. Ruben, ondanks dat de uitkomst van je experimenten 
tegenvielen, bleef je altijd enthousiast over de volgende stappen. Jouw resultaten 
waren belangrijk om duidelijk te maken dat er een zuiveringsmethode nodig was voor 
het vervolg van het onderzoek. Bob, jij hebt de scheikunde achter de polymeer synthese 
onderzocht om meerdere PICs aan elkaar vast te knopen. Helaas hebben we maar 
een paar kleine immunologische testen kunnen doen tijdens jouw stage en kon ik je 
niet overhalen om weer te gaan volleyballen. Veel succes met je carrière als DJ of 
scheikundige! Tuur, jij bedacht je eigen project tijdens een bachelorvak en je begon 
samen met Dion dit ook uit te voeren tijdens je stage. Hoewel het een moeilijk project 
was, bleef je steeds nieuwe methoden proberen, wat uiteindelijk belangrijk was voor 
ons om de PICs beter te begrijpen. Marjolein, helaas had ik door het schrijven van dit 
proefschrift niet veel tijd om je te helpen bij het immunologische deel van je stage. 
Gelukkig had je hier al ervaring in, wat heeft gezorgd voor mooie resultaten. Ik ben er 
van overtuigd dat de projecten die ik ben begonnen in goede handen zijn bij jou!
Furthermore, I would like to thank all (former) TILlers for the great atmosphere inside 
and outside of the lab, as well as the legendary (christmas) parties. Martijn, ik wil 
jou ook graag in het bijzonder bedanken. Toen we nog een U’tje deelden kon je me 
altijd goed vertellen welke vogels er langs vlogen. Bedankt ook voor je kritische blik! 
Wanneer er input nodig was, had je er geen probleem mee om er met gestrekt been in 
te komen, wat ik zeker kon waarderen! Bas, door jouw aanwezigheid wordt het nooit 
saai op het lab. Bedankt voor de hulp bij eiwitproductie en de gezelligheid en succes 
met het afronden van je promotie! Eric, of het nu om computerproblemen ging of om 
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het produceren van MHC-complexen of particles, jij stond altijd klaar om te helpen. 
De feestjes die je tijdens de vierdaagse organiseert zijn altijd weer goed! Mika and 
Yusuf, your vast knowledge and experience on mouse vaccination studies were 
essential for chapter 7 of this thesis. Thank you for the great collaboration in the in vivo 
projects. Iris, bedankt voor de goede sfeer in ons U’tje en voor de potjes tafeltennis! 
Daar moeten we er zeker meer van gaan doen de komende tijd. Camille, it was a 
pleasure writing the nature materials feature with you. Good luck with you PhD! 
I also want to thank the other members of the targeting DLM, Duco, Felix, Edyta, 
Eliézer, Floris, Koen, Mangala, Massis, Olga Ilina, Olga Koshkina and Oya for the 
discussions during and outside of meetings. 
Subhra and Leonie, thank you for helping me to get started with my PhD. Angela, 
thank you for your initial work on the hydrogel project. Florian, your help with setting 
up multi-color flow cytometry panels was greatly appreciated. I always enjoyed our 
discussions, especially when combined with some good cheese and wine. Good luck 
and have fun in California! Marcella, I am thankful for your help in setting up 
antigen- specific T cell stimulation protocols. I wish you a lot of happiness with your 
family in Italy. Lotte, bedankt voor de hulp bij de Rubicon. Ook wil ik graag Jeanette, 
Ilja en Sandy bedanken voor alle ondersteuning!
During my PhD I had the privilege of being a member of the legendary TIL-band 
for several years. I would like to thank all the past members, Christian, Ben, Martijn, 
Svenja, Jonas and Koen, and present members, Laurent, Glenn, Iris, Yusuf and 
Danielle, for the great time rehearsing and playing music in the knowledge square 
and old cave. Thank you for accepting my mediocre keyboard skills and for giving me 
reason to play the piano again! 
I also would like to thank some people from other departments. Kerstin, you put a lot 
of effort in improving the manuscripts Roel and I sent out for publication. Thanks to 
your supervision of Roel’s PhD, we received a lot of valuable input in our research! 
Alan en Jan, bedankt voor jullie inbreng tijdens de meetings die we aan het begin 
van mijn promotie hebben gehad. Joep, ondanks wat interessante resultaten is ons 
gezamenlijke project nooit helemaal van de grond gekomen. Onze samenwerking 
heeft wel gezorgd voor goede discussies en voor het testen van verschillende mogelijke 
conjugatiemethoden, wat erg belangrijk was voor mijn promotieonderzoek. Bedankt 
daarvoor! Abbas, thank you for the synthesis of a cleavable peptide. Hopefully we will 
be able to use it soon so that we can finally publish a nice paper on it!
Ook wil ik mijn studiegenoten Tim en Ralph graag bedanken. We kwamen elkaar 
weer tegen tijdens de PhD introductiecursus (the sky is the limit) en het was in de 
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jaren daarop altijd gezellig om weer samen een biertje te drinken tijdens de PhD 
retreats en op Tims promotiefeestje. 
Behalve binnen de wetenschap, zijn ook een aantal mensen buiten de wetenschap 
belangrijk geweest voor de ondersteuning en de nodige afleiding tijdens het soms 
stressvolle promotietraject. Om te beginnen wil ik de paarse coños van VoCASA heren 
2, Artem, Dennis, Julian, Lars, Michiel, Mick, Niels, Pieter, Roan en Teun, bedanken 
voor alle gezellige trainingen en wedstrijden. Vooral in de afgelopen twee seizoenen 
hebben we mooie prestaties neergezet, zoals het winnen van de beker en het behalen 
van de vijfde plaats in de tweede divisie afgelopen jaar. De feestjes met jullie waren 
ook onvergetelijk, met als hoogtepunten natuurlijk de teamuitjes naar Budapest en 
Warschau. Veel succes komend seizoen! Davai!
Tom, ik ben blij dat we na 10 jaar nog steeds beachvolleybalpartners zijn! Door elke 
zomer hard te trainen en zoveel mogelijk toernooien af te gaan staan is ons niveau elk 
jaar weer wat beter geworden. Hierdoor staan we tegenwoordig niet meer bekend als 
Tommieboy en Loeloeman, maar als Beachteam Eggermont/Van de Grift. Vooral het 
weekend op Ameland is elk jaar weer een groot succes!
Sjoerd, het valt niet mee om tegelijkertijd een promotie te halen, frontman te zijn van 
onze binnenkort wereldberoemde band en toch de 28 te halen, maar jij doet het alsof 
het niets is. Het is mooi hoe je je blijft inzetten voor de acceptatie van de snoekbaars 
zonder een idee te hebben van de prijs van een pot pindakaas. Bedankt voor je mooie 
teksten en onze hoogstaande potjes pool!
Verder wil ik graag mijn vrienden van de middelbare school, Ali, Bas, Daan, Martijn 
en Walter bedanken. Het is mooi dat we elkaar nog altijd regelmatig zien, en dat het 
dan steeds toch weer (bar) gezellig is. Jullie zorgden voor de nodig afleiding en 
motivatie tijdens mijn promotie, bijvoorbeeld door samen bier te drinken in de polder 
of de stad, maar ook door een schitterprachtige en ellendige fietstocht naar Rome te 
maken. Hierbij werd maar al te duidelijk dat die vrije tijd eigenlijk totaal geen pretje is, 
en dat er niets mooier is dan werken met een kopje koffie en een gevulde koek erbij.
Jan, Anja, Oma, Sidney en Robin, bedankt voor de gezelligheid als we weer in de 
achterhoek zijn! Het is heel fijn dat ik meteen in de familie ben opgenomen. Ik heb 
jullie interesse in mijn werk tijdens het gourmetten of bij een kopje koffie met een stuk 
taart altijd op prijs gesteld. Sidney en Robin, veel geluk gewenst bij het spannende 
nieuwe hoofdstuk in jullie leven!
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Lieve familieleden, ik ben blij dat ik in een gelukkige familie ben opgegroeid die mij 
altijd hebben gestimuleerd en hebben gesteund om mezelf te ontwikkelen en te doen 
wat ik leuk vind. Ik kijk er altijd weer naar uit om naar Kekerdom te gaan en iedereen 
weer te zien. Ook alle aanhangers wil ik graag bedanken. Naud, mijn (inmiddels niet 
meer zo) kleine broertje, het is mooi dat je ondertussen ook bijna bent afgestudeerd en 
bent gesetteld met Lisa, samen met Stewie en Susie. Laten we binnenkort weer eens 
een biertje drinken of samen gaan eten! Wieneke, jij bent er altijd goed in om te 
regelen dat de hele familie weer bij elkaar komt. Het is altijd gezellig als jij er met 
Casper weer bij bent, of het nou in Kekerdom of bij een volleybalfeestje is! Florieke, 
bedankt voor het goede voorbeeld dat je als grote zus altijd voor mij geweest bent. Het 
is altijd erg leuk om bij jou en Rob over de vloer te komen. Ook mijn kleine neefje Jens 
wil ik graag bedanken! Verder heeft Daantje mijn promotie gesteund met een hoop 
enthousiasme als ik weer in Kekerdom was. Papa en mama, jullie staan altijd voor ons 
klaar. Het was misschien niet altijd even duidelijk waar ik nou mee bezig was, maar 
hopelijk maakt dit boekje iets meer duidelijk. Bedankt voor jullie steun!
Lieve Colet, ondanks dat we het heen en weer reizen tussen Amsterdam en Nijmegen 
goed vol hebben gehouden, is het heel fijn om nu samen te wonen met jou! Het 
schrijven van dit boek werd een stuk makkelijker doordat we samen in hetzelfde 
traject zaten. Het heeft ontzettend veel geholpen dat we samen konden schrijven en 
samen konden klagen over schrijven. Met jouw promotie heb ik alvast een (veel te) 
goed voorbeeld gehad voor mijn eigen verdediging. Bedankt dat ik altijd op je liefde en 
steun kan rekenen! Ik kijk uit naar alle avonturen die we samen nog gaan beleven in 
de VS en daarna!

